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Foreword 
The COVIPENDIUM was an initiative of the Institute for the Future of the Rega Institute (KU Leuven, Belgium). It was 
created at the start of the COVID-19 epidemic in February 2020, as a living paper on the new coronavirus disease. The 
project aimed at providing a structured compilation of available scientific data about the virus, the disease and its 
control. Its objective was to help scientists identify the most relevant publications on COVID-19 in the wealth of 
information published every day.  
The COVIPENDIUM was also expected to foster a global understanding of disease control and stimulate 
transdisciplinary initiatives. To this end, special attention was given to the development of a broad table of contents, 
addressing the widest spectrum of publications related to the disease and its consequences.  
This living paper has been updated on a weekly basis until mid-September. Due to the huge amount of information 
published by that time, it had become more and more difficult to maintain the COVIPENDIUM up-to-date. The authors 
therefore decided to put an end to this initiative. The latest version of the document, dated October 20, is meant to 
provide to the reader the information gathered over the 9-month period of the project, and illustrate the benefits of 
organizing available information using both a living paper approach and a wide multi-disciplinary dimension. 
Introduction  
Coronaviruses are common human pathogens, causing generally-mild acute respiratory illnesses known as the 
common cold (Wu Euro Surv 2020, see below). Prior to December 2019 when clusters of pneumonia cases with 
unknown aetiology were detected in Wuhan, China, only two additional strains of coronaviruses had caused outbreaks 
of severe acute respiratory disease in humans: the severe acute respiratory syndrome coronavirus (SARS-CoV) and 
Middle East respiratory syndrome coronavirus (MERS-CoV). On 9 January 2020, a novel coronavirus, 2019-nCoV 
(temporary name), was officially identified as the cause of an outbreak of viral pneumonia in Wuhan 
(https://www.who.int/china/news/detail/09-01-2020-who-statement-regarding-cluster-of-pneumonia-cases-in-
wuhan-china). The timeline of medical and scientific events up to June 2020 has been described by Carvalho (Nat Med 
2020, see below).  
The virus spread rapidly within China, and an increasing number of cases appeared in other countries. On January 30th 
2020, the outbreak was said to constitute a Public Health Emergency of International Concern 
https://www.who.int/publications/m/item/covid-19-public-health-emergency-of-international-concern-(pheic)-
global-research-and-innovation-forum). The disease was named COVID-19 by WHO on February 11 2020 
(https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-
11-february-2020), and the virus named SARS-CoV-2 by the International Committee on Virus Taxonomy on the same 
day (Coronaviridae Study Group of the International Committee on Taxonomy of Viruses Nat Microbiol 2020, see 
below). Subsequently, a group of virologists in China suggested renaming SARS-CoV-2 as human coronavirus 2019 
(HCoV-19), considering that such a name would distinguish the virus from SARS-CoV and keep it consistent with the 
WHO name of the disease it causes, COVID-19 (Jiang Lancet 2020, see below). Virus naming long remained 
controversial (Voice from China Chin Med J 2020, see below) and in the scientific literature, the virus can be referred 
to by these different names, even though Wu, Ho et al. (Lancet 2020, see below) suggested keeping SARS-CoV-2 as its 
name. 
On March 11 2020, WHO characterised COVID-19 as a pandemic (https://www.who.int/dg/speeches/detail/who-
director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020). 
Despite the wide implementation of a number of public health measures, the epidemic continued to progress in the 
months that followed this announcement. As of October 20 2020, 12:00 CET, according to WHO, a total of 40 114 293 
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cases has been confirmed globally, including 1 114 692 deaths. The vast majority of the cases has been reported by 
other countries than China (e.g. U.S.A. 8 065 615, India 7 597 063, Brazil 5 235 34, Russian Federation 1 415 316, vs. 
China 91 546). 
The virus   
Coronaviruses 
Coronaviruses (CoVs) are enveloped, positive-sense, single-stranded RNA viruses that belong to the subfamily 
Coronavirinae, family Coronavirdiae, order Nidovirales. The virion has a nucleocapsid composed of genomic RNA and 
phosphorylated nucleocapsid (N) protein, which is buried inside phospholipid bilayers and covered by spike proteins 
(Li J Med Virol 2020, see below). The membrane (M) protein (a type III transmembrane glycoprotein) and the envelope 
(E) protein are located among the spike (S) proteins in the virus envelope. CoVs were given their name based on a 
characteristic crown-like appearance. 
There are four genera of CoVs, namely, Alphacoronavirus (αCoV), Betacoronavirus (βCoV), Deltacoronavirus (δCoV), 
and Gammacoronavirus (γCoV) (Chan Em Micr Inf 2020, see below). Evolutionary analyses have shown that bats and 
rodents are the gene sources of most αCoVs and βCoVs, while avian species are the gene sources of most δCoVs and 
γCoVs. CoVs have repeatedly crossed species barriers and some have emerged as important human pathogens.  
The genomic RNA is used as template to directly translate polyprotein (pp) 1a/1ab, which encodes non-structural 
proteins to form the replication-transcription complex (RTC) in a double-membrane vesicles (Chen J Med Vir 2020, see 
below). Subsequently, a nested set of subgenomic RNAs are synthesized by the RTC in a manner of discontinuous 
transcription. The first ORFs (ORF1a/b), about two-third of the whole genome length, encode 16 non-structural 
proteins (nsp1-16). Other ORFs on the one-third of the genome near the 3’-terminus encodes the main structural 
proteins: S, M, E, and N proteins. Besides these four main structural proteins, CoVs encode special structural and 
accessory proteins. All the structural and accessory proteins are translated from the subgenomic RNAs of CoVs. 
Prasad (Ind J Med Res 2020, see below) presented electron microscopy images of the virus (Figure 1). The images 
revealed the presence of stalk-like projections ending in round peplomeric structures typical of a coronavirus particle. 
Figure 1 Transmission electron microscopy imaging of SARS-CoV-2 (from Prasad Ind J Med Res 2020) 
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Transmission electron microscopy imaging of COVID-19. (A) A representative negative-stained COVID-19 particle showing morphodiagnostic features of family 
Coronaviridae. (B) Defocussed image of the same particle resolving the virus envelope glycoprotein morphology in finer details. The boxed area A shows a 
tetramer-like aggregate of four distinct peplomers, arrows shown by B show a more orthodox morphology of coronavirus surface projections. M indicates the 
matrix of the virus particle. C shows a distinct 'peplomer head' with negative stain silhouette. The area D is interesting as possible linear projections could be 
imaged. Five distinct peplomers could be imaged as shown by the arrows. (C) A highly magnified processed image for pixel corrections shows a distinct evidence 
of direct 'stalk' connecting the peplomer to the virion surface. The peplomers are shown with asterisk and the stalk with an arrow. Magnification bars are built 
into the micrographs. 
SARS-CoV-2 is a betacoronavirus  
On January 3, 2020, the first complete genome of the novel β genus coronaviruses (2019-nCoV, subsequently named 
SARS-CoV-2) was identified in samples of bronchoalveolar lavage fluid from a patient from Wuhan 
(http://weekly.chinacdc.cn/en/article/id/a3907201-f64f-4154-a19e-4253b453d10c and  Wu Nature 2020, see below). 
A viral genome sequence was released via the community online resource virological.org on 10 January (Wuhan-Hu-
1, GenBank accession number MN908947 (http://virological.org/t/novel-2019-coronavirus-genome/319). Additional 
sequences were rapidly obtained by other groups and complete genomes were submitted to GISAID (see for instance, 
Zhu New Engl J Med 2020 below). 
SARS-CoV-2 falls into the genus betacoronavirus, which includes CoVs discovered in humans, bats, and other wild 
animals (SARS-CoV, bat SARS-like CoV, and others). As illustrated in Table 1 below, additional studies, based on 
subsequent virus isolates, confirmed that the virus is phylogenetically closest to bat SARS-like CoV (SL-ZC45 and SL-
CoVZXC21). 
Table 1 SARS-CoV-2 sequence similarity with other coronaviruses 
% similarity with 
reference 
SARS  MERS bat SARS-like CoV* BatCoV RaTG13 
N.R. N.R. 89.1% N.R. Wu Nature 2020, see below 
79.0% 51.8% 87.6-87.7% N.R. Ren Chinese Med J 2020, see below 
82% N.R. 89% N.R. Jiang Em Micr Inf 2020, see below 
82% N.R. 89% N.R. Chan Em Micr Inf 2020, see below 
79% 50% 88% N.R. Lu Lancet 2020, see below 
N.R. N.R. N.R. 96.3% Paraskevis Infect Genet Evol 2020, see below 
<80% N.R. N.R. 96.2% Zhou Nature 2020, see below 
79.7% N.R. 87.9% N.R. Chen Em Micr Inf 2020, see below 
* bat-SL-CoV-ZC45 and/or bat-SL-CoV-ZXC21 
The observation that SARS-CoV-2 isolates have a single intact open reading frame gene 8 is a further indicator of bat-
origin CoVs. In addition, although closely related to BatCoV RaTG13 sequence throughout the genome (sequence 
similarity 96.3%), SARS-CoV-2 shows discordant clustering with the Bat_SARS-like coronavirus sequences (Paraskevis 
Infect Genet Evol 2020, see below; Lu Lancet 2020, see below). Specifically, in the 5'-part spanning the first 11,498 
nucleotides and the last 3'-part spanning 24,341-30,696 positions, SARS-CoV-2 and RaTG13 formed a single cluster 
with Bat_SARS-like coronavirus sequences, whereas in the middle region spanning the 3'-end of ORF1a, the ORF1b 
and almost half of the spike regions, SARS-CoV-2 and RaTG13 grouped in a separate distant lineage within the 
sarbecovirus branch. Consequently, the levels of genetic similarity between SARS-CoV-2 and RaTG13 suggest that the 
latter does not provide the exact variant that caused the outbreak in humans, but the hypothesis that SARS-CoV-2 has 
originated from bats is very likely.  
Genome structure 
Similar to other βCoVs, the SARS-CoV-2 genome contains two flanking untranslated regions and a single long open 
reading frame encoding a polyprotein (Chan Em Micr Inf 2020, see below). The SARS-CoV-2 genome is arranged in the 
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order of 5’-replicase (orf1/ab)-structural proteins [S-E-M-N]−3’ and lacks the hemagglutinin-esterase gene which is 
characteristically found in lineage A β-CoVs, as illustrated in Figure 2.  
The genome of SARS-CoV-2 encodes four major structural proteins [spike (S), envelope (E), membrane (M), and 
nucleocapsid (N)], approximately 16 nonstructural proteins (nsp1–16), and five to eight accessory proteins (Jiang 
Trends Imm 2020, see below). Among them, the S protein plays an essential role in viral attachment, fusion, entry, 
and transmission. It comprises an N-terminal S1 subunit responsible for virus-receptor binding and a C-terminal S2 
subunit responsible for virus-cell membrane fusion. The S1 subunit contains a signal peptide, followed by an N-
terminal domain (NTD) and receptor-binding domain (RBD), while the S2 subunit contains conserved fusion peptide, 
heptad repeat 1 and 2, transmembrane domain, and cytoplasmic domain.  
Figure 2 Genome organization of the SARS-CoV-2 genome compared to other betacoronaviruses (from Chan Em Micr Inf 2020) 
 
Remarkably, orf3b encodes a completely novel short protein. Furthermore, new orf8 likely encodes a secreted protein 
with an alpha-helix, following with a beta-sheet(s) containing six strands. 
Using direct RNA sequencing and sequencing-by-synthesis methods, Kim (Cell 2020, see below) provided a high-
resolution map of the SARS-CoV-2 transcriptome and epitranscriptome. In addition to viral genomic RNA and 9 
canonical subgenomic RNAs, SARS-CoV-2 produces transcripts encoding unknown ORFs with fusion, deletion, and/or 
frameshift (Figure 3). The authors also found at least 41 RNA modification sites on viral transcripts, with the most 
frequent motif, AAGAA.  
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Figure 3 Graphical presentation of the data by Kim (Cell 2020) 
 
Origin of the virus 
Phylogenetic and likelihood-mapping analyses of 12 genome sequences of the virus with known sampling date (24 
December 2019 and 13 January 2020) and geographic location (primarily Wuhan city, Hubei Province, China) suggested 
a potentially large ‘first generation’ human-to-human virus transmission. Li, Zai et al. (J Med Virol 2020, see below) 
estimated that SARS-CoV-2 likely originated in Wuhan on 9 November 2019 (95% credible interval: 25 September 2019 
and 19 December 2019). Li, Wang et al. (J Med Vir 2020, see below) confirmed the recent and rapid human-to-human 
transmission, with estimates of virus emergence ranging from 15 October to 10 November 2019 or 16 November to 
22 December 2019 depending on the calculation method. 
Paraskevis (Infect Genet Evol 2020, see below) described the lack of a mosaic relationship of SARS-CoV-2 to the closely 
related sarbecoviruses, indicating the lack of a recombination event in the emergence of SARS-CoV-2. Hence, SARS-
CoV-2 likely emerged from the accumulation of mutations responding to altered selective pressures or from the 
infidelity of RNA polymerase perpetuated as replication-neutral mutations (Fahmi Infect Genet Evol. 2020, see below). 
Patino-Galindo (manuscript on bioRxiv: https://www.biorxiv.org/content/10.1101/2020.02.10.942748v2) suggested a 
two-hit scenario in the emergence of the SARS-CoV-2 virus whereby the virus ancestors in bats first acquired genetic 
characteristics of SARS by incorporation of a SARS-like RBD through recombination before 2009, and subsequently, 
the lineage that led to SARSCoV-2 accumulated further, unique changes specifically in the RBD. 
Gu (Virus Evol 2020, see below) reported that the amino acid usage pattern of SARS-CoV-2 was generally found similar 
to bat and human SARSr-CoVs. He also found greater synonymous codon usage distance between SARS-CoV-2 and its 
phylogenetic relatives on S and M genes, suggesting these two genes of SARS-CoV-2 are subjected to different 
evolutionary pressures. 
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Based on an analysis of the 4 structural genes, Kandeel (J MedVir 2020, see below) further reported that SARS-CoV-2 
prefers pyrimidine rich codons to purines. Most high-frequency codons were found to end with A or T, while the low 
frequency and rare codons were ending with G or C. SARS-CoV-2 structural proteins showed 5-20 lower ENc values, 
compared with SARS, bat SARS and MERS-CoVs. This implies higher codon bias and higher gene expression efficiency 
of SARS-CoV-2 structural proteins. SARS-CoV-2 encoded the highest number of over biased and negatively biased 
codons. Pangolin β-CoV showed little differences with SARS-CoV-2 ENc values, compared with SARS, bat SARS and 
MERS CoV. 
A manuscript by Zhang (on medRxiv: https://www.medrxiv.org/content/10.1101/2020.02.25.20027953v2) provided a 
hypothesis to explain the initial spread of the disease. Based on the analysis of 169 virus sequences, the authors were 
able to propose a classification of current SARS-CoV-2 isolates into two main types, with three sources of transmission, 
namely Type IA, Type IB, and Type II. Among them, Type IA corresponded to the earliest transmission source, which 
did not occur in the Huanan Market, indicating that the original transmission source was not from the Huanan Market. 
Type II came from the Huanan Market. As most samples detected belong to Type II, it was speculated that a Type II 
virus was the major outbreak source. By analysing the three genomic sites distinguishing Type I and Type II strains, it 
was found that the synonymous changes at two of the three sites conferred higher protein translational efficiencies 
to Type II strains. The authors speculated that this observation may be related to higher transmissibility of Type II 
strains. 
Tang (preprint on National Science Review: https://academic.oup.com/nsr/advance-
article/doi/10.1093/nsr/nwaa036/5775463?searchresult=1) presented additional data on the origin and evolution of 
SARS-CoV-2. Although the authors found only 4% variability in genomic nucleotides between SARS-CoV-2 and the bat 
SARSr-CoV RaTG13, the difference at neutral sites was 17%, suggesting the divergence between the two viruses was 
much larger than previously estimated. The report also suggested that new variations in functional sites in the 
receptor-binding domain (RBD) of the spike seen in SARS-CoV-2 and viruses from pangolin SARSr-CoVs are likely caused 
by mutations and natural selection besides recombination. Based on the analyses of 103 SARS-CoV-2 genomes, the 
authors confirmed the publication by Zhang (on medRxiv: 
https://www.medrxiv.org/content/10.1101/2020.02.25.20027953v2) indicating that these viruses evolved into two 
major types. These 2 types were here designated L and S, with the L type (~70%) being more prevalent than the S type 
(~30%), and the S type representing the ancestral version. Of note, both types of virus were detected outside China. 
Yi (Clin Inf Dis 2020, see below) used a different approach to the analysis of 84 sequences in GISAID to provide evidence 
for genetic recombination underlying the evolution of the virus. 
While comparing ORF1ab polyprotein with other βCoVs, Cárdenas-Conejo (J Med Vir 2020, see below) found a 42 
amino acid signature that is only present in SARS-CoV-2. Members from clade 2 of sarbecoviruses have traces of this 
signature. The amino acid signature located in the acidic-domain of papain-like protein of SARS-CoV2 and bat-SL-
RatG13 guided the authors to suggest that SARS-CoV-2 probably emerged by genetic drift from bat-SL-CoV-RaTG13. 
Lau, Luk et al. (Em Inf Dis 2020, see below) noted that despite the close relatedness of SARS-CoV-2 to bat and pangolin 
viruses, none of the existing SARS-related CoVs represents its immediate ancestor. Most of the genome region of SARS-
CoV-2 is closest to SARSr-Ra-BatCoV-RaTG13 from an intermediate horseshoe bat in Yunnan, whereas its RBD is closest 
to that of pangolin viruses. Potential recombination sites were identified around the RBD region, suggesting that SARS-
CoV-2 might be a recombinant virus, with its genome backbone evolved from Yunnan bat virus-like SARS-related CoVs 
and its RBD region acquired from pangolin virus-like SARS-related CoVs. 
Divergence dates between SARS-CoV-2 and the bat sarbecovirus reservoir were subsequently estimated as 1948 (95% 
highest posterior density (HPD): 1879–1999), 1969 (95% HPD: 1930–2000) and 1982 (95% HPD: 1948–2009), indicating 
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that the lineage giving rise to SARS-CoV-2 had been circulating unnoticed in bats for decades (Boni Nat MIcrob 2020, 
see below). 
Among the hypotheses to explain the origin of SARS-CoV-2, Xia (Mol Biol Evol 2020, see below) observed that SARS-
CoV-2 has the most extreme CpG deficiency in all known βCovs genomes. This suggests that SARS-CoV-2 may have 
evolved in a new host (or new host tissue) with high zinc finger antiviral protein expression. This observation allowed 
for an alternative hypothesis for the origin of SARS-CoV-2. The ancestor of SARS-CoV-2 and BatCoV RaTG13 might have 
infected the intestine of a mammalian species (e.g., canids). Then the presumably strong selection against CpG in the 
viral RNA genome in canid intestine may have resulted in rapid evolution of the virus, with many CpG→UpG mutations 
leading to reduced genomic ICpG and GC%. The licking of anal regions in canids during mating and other circumstances 
may facilitate viral transmission from the digestive system to the respiratory system. Finally, the reduced viral genomic 
ICpG may have allowed the virus to evade human zinc finger antiviral protein-mediated immune response and become 
a severe human pathogen. 
In spite of these considerable research advancements, the origin of the virus remains ambiguous. Zhang (J Inf 2020, 
see below) indicated that the source of the virus might be tracked in the following ways: 
 Tracing back the viral emergence at the Huanan seafood market. It has been that the market has been closed 
for more than two months, but the government can list all merchants in the market and clarify which animals 
they sold, and what were the purchase channels of the animals. Thus, sampling the animals from their 
purchase channels appears feasible. 
 Detection of the SARS-CoV-2-like virus in wild animals. 
 Detection of serum antibody in clinical samples collected before December 2019 in Hubei Province, especially 
in Wuhan. 
Additional important research is also focused on the identification of putative intermediate animal hosts, as presented 
in Host range & search for intermediate animal hosts below). Moreover, a report by J Cohen in July 2020 (Science 
Mag 2020, see: https://www.sciencemag.org/news/2020/07/who-led-mission-may-investigate-pandemic-s-origin-
here-are-key-questions-ask) indicated that a WHO-led international mission was under preparation, in order to 
investigate the pandemic’s origin.  
Multiple reasons to rule out a laboratory origin 
While speculations, rumours and conspiracy theories that SARS-CoV-2 is of laboratory origin circulate in social media, 
several publications point to the lack of credible evidence to support the claim that SARS-CoV-2 originated from a 
laboratory-engineered CoV.  
Liu (Emerg Micr Inf 2020, see below), for instance, pointed to the fact that evolution is stepwise and accrues mutations 
gradually over time, whereas synthetic constructs would typically use a known backbone and introduce logical or 
targeted changes instead of the randomly occurring mutations that are present in naturally isolated viruses such as 
bat CoV RaTG13. However, the sequence data irrefutably show that SARS-CoV-2 is not derived from any previously 
used virus backbone. Hao (Emerg Microbes Inf 2020, see below) ruled out a published claim that SARS-CoV-2 would 
have a unique inserted sequence (1378 bp) located in the middle of its S glycoprotein gene that had no match in other 
coronaviruses and that this unique sequence would be similar to some sequence in a common expression vector used 
in research laboratory. 
Andersen (Nature Med 2020, see below) added that while SARS-CoV-2 may bind human ACE2 with high affinity, 
computational analyses predict that the interaction is not ideal and that the RBD sequence is different from those 
shown in SARS-CoV to be optimal for receptor binding. Thus, the high-affinity binding of the SARS-CoV-2 S protein to 
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human ACE2 is most likely the result of natural selection on a human or human-like ACE2 that permits another optimal 
binding solution to arise. This is strong evidence that SARS-CoV-2 is not the product of purposeful manipulation. 
In theory, it is also possible that SARS-CoV-2 acquired RBD mutations during adaptation to passage in cell culture, as 
has been observed in studies of SARS-CoV (Andersen Nature Med 2020, see below). The finding of SARS-CoV-like 
coronaviruses from pangolins with nearly identical RBDs, however, provides a much stronger explanation of how SARS-
CoV-2 acquired these via recombination or mutation. The acquisition of both the polybasic cleavage site and predicted 
O-linked glycans also argues against culture-based scenarios. New polybasic cleavage sites have been observed only 
after prolonged passage of low-pathogenicity avian influenza virus in vitro or in vivo. Furthermore, a hypothetical 
generation of SARS-CoV-2 by cell culture or animal passage would have required prior isolation of a progenitor virus 
with very high genetic similarity, which has not been described. Subsequent generation of a polybasic cleavage site 
would have then required repeated passage in cell culture or animals with ACE2 receptors similar to those of humans, 
but such work has also not previously been described. Finally, the generation of the predicted O-linked glycans is also 
unlikely to have occurred due to cell-culture passage, as such features suggest the involvement of an immune system. 
Sequence diversity among isolates 
Initial observations in China 
Among the first data generated at the beginning of the outbreak, virus isolates from five patients with severe 
pneumonia (hospitalized from December 18 to December 29, 2019 at Jin Yin-tan hospital in Wuhan) revealed 99.8-
99.9% nucleotide identities (Ren Chinese Med J 2020, see below). Zhou (Nature 2020, see below) also reported more 
than 99.9% identity among isolates obtained from 7 patients, Lu (Lancet 2020, see below) more than 99.98% sequence 
identity among 10 genome sequences obtained from nine patients, and Ceraolo (J MedVir 2020, see below) >99% 
sequence similarity among 56 genomes. Of note, at least two hyper-variable genomic hotspots were detected, one of 
which responsible for a Serine/Leucine variation in the viral ORF8-encoded protein. Another study conducted on 32 
genomes of strains sampled from China, Thailand, and USA between 24 December 2019 and 23 January 2020 
suggested increasing tree-like signals from 0 to 8.2%, 18.2%, and 25.4%) overtime also provided early evidence of 
increasing genetic diversity of SARS-CoV-2 in human hosts (Li, Wang et al. J Med Vir 2020, see below).  
Following the analysis of 54 gene sequences, Wen (J Infect 2020, see below) noted the hyper-variable genomic hotspot 
to be established in the SARS-CoV-2 population at the nucleotide but not the amino acid level, suggesting that there 
beneficial mutations had not been acquired. Of note, nsp1, nsp3, and nsp15 of ORF1ab and gene S were found to carry 
significantly more mutations than other genes. Subsequently, Wang (J Med Vir 2020, see below) reported on the 
analysis of 95 full-length genomic sequences of SARS-CoV-2 strains from NCBI and GISAID databases. The homology 
among all viral strains was generally high, among them 99.99% (99.91%-100%) at the nucleotide level, 99.99% (99.79%-
100%) at the amino acid level. Although overall variation in ORF regions was low, 13 variation sites in 1a, 1b, S, 3a, M, 
8, and N regions were identified, among which positions nt28144 in ORF 8 and nt8782 in ORF 1a showed mutation 
rate of 30.53% (29/95) and 29.47% (28/95) respectively. 
Sequence-based surveillance and resources 
Monitoring the virus sequence diversity among the newest isolates remains an important component of COVID-19 
surveillance. The number of sequences deposited to GISAID increased rapidly after the first virus identification. By 
October 20 2020 12:00 CET, a total of 151 535 sequences has been reached (see https://www.gisaid.org/). 
In addition to GISAID, other resources became available for SARS-CoV-2 sequence analysis. The Nextstrain team 
analyzes virus sequence data on a global and continental level, and the Nextclade tool has been designed to compare 
new sequences to the SARS-CoV-2 reference sequence, assign them to clades, and see where they fall on a the SARS-
CoV-2 tree (https://nextstrain.org/sars-cov-2/). 
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The website of the China National Center for Bioinformation (https://bigd.big.ac.cn/ncov?lang=en), available in 
Chinese and English, constitutes another useful resource on SARS-CoV-2 sequences. Another resource described by 
Cleemput (Bioinform 2020, see below) is the Genome Detective Coronavirus Typing Tool, available at 
https://www.genomedetective.com/app/typingtool/cov, which can accurately identify SARS-CoV-2 sequences 
isolated in China and around the world.  
Intra-host variants of SARS-Cov-2 
Following metatranscriptome sequencing for the bronchoalveolar lavage fluid of SARS-CoV-2 patients, Shen (Clin Inf 
Dis 2020, see below) presented data suggesting that SARS-CoV-2 evolves in vivo after infection. The median number 
of intra-host variants was 1-4 in SARS-CoV-2 infected patients, ranging between 0 and 51 in different samples. The 
distribution of variants on genes was similar to those observed in the population data (110 sequences). However, very 
few intra-host variants were observed in the population as polymorphism, implying either a bottleneck or purifying 
selection involved in the transmission of the virus, or a consequence of the limited diversity represented in the current 
polymorphism data.  
Bal (Clin Microb Inf 2020, see below), characterized whole genome sequences of SARS-CoV2 isolated from an 
asymptomatic patient, in 2 clinical samples collected 1 day apart. Comparison of these sequences suggested viral 
evolution with development of quasispecies. The study also identified a new deletion in nsp2 (Asp268Del). The analysis 
of 571 whole genome sequences identified this deletion in 37 other viruses collected in England (February) and in 
Netherlands (March), suggesting the spread of this deletion in Europe. 
Viral mutations  
According to Rambaut (Nature Microb 2020, see below; https://cov-lineages.org/), the earliest lineage A viruses, such 
as Wuhan/WH04/2020 (EPI_ISL_406801), sampled on 5 January 2020, share two nucleotides (positions 8,782 in 
ORF1ab and 28,144 in ORF8) with the closest known bat viruses (RaTG13 and RmYN02). Different nucleotides are 
present at those sites in viruses assigned to lineage B, of which Wuhan-Hu-1 (GenBank accession no. MN908947) 
sampled on 26 December 2019 is an early representative. Hence, although viruses from lineage B happen to have been 
sequenced and published first, it is likely (based on current data) that the most recent common ancestor (MRCA) of 
the SARS-CoV-2 phylogeny shares the same genome sequence as the early lineage A sequences (for example, 
Wuhan/WH04/2020). 
Multiple mutations have been described in subsequent virus isolates. For instance, Benvenuto (J inf 2020, see below) 
found in more recent isolates the presence of two mutations affecting NSP6 and ORF 10 adjacent regions. Amino acidic 
change stability analysis suggests both mutations could confer lower stability of the protein structures. 
In another example, Sheikh (Infect Genet Evol. 2020, see below) observed the 5’ terminal of the genome to be more 
variable and prone to mutations, as compared to the 3’ terminal. ORF1ab, S, ORF3a and E appeared as key drivers of 
diversity among strains with RBD of S emerging as mutational hotspot.  
Using the epitope information along with variants of the virus, Koyama (Pathog 2020, see below) found several 
variants which might cause drifts. Among such variants, 23403A>G variant (p.D614G) in S protein B-cell epitope 
appeared to be observed frequently in European countries, such as the Netherlands, Switzerland, and France, but 
seldom observed in China. A subsequent analysis of over 1 225 SARS-CoV-2 genomes spanning from late December 
2019 to mid-March 2020 (Isabel Sci Rep 2020, see below). The D614G mutation was reported as a predominant clade 
in Europe (954 of 1449, i.e. 66%, sequences) and spreading worldwide (1237 of 2795, 44%, sequences). Molecular 
dating analysis estimated the emergence of this clade around mid-to-late January (10-25 January) 2020. 
Eaaswarkhanth (Int J Infect Dis 2020, see below) speculated that the S-G614 strains may be more virulent, increasing 
the severity in infected individuals, especially in Europe where this mutation is prominent. In line with this hypothesis, 
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Zhang (manuscript on bioRxiv: https://www.biorxiv.org/content/10.1101/2020.06.12.148726v1) observed that 
retroviruses pseudotyped with S-G614 infected ACE2-expressing cells markedly more efficiently than those with S-
D614. This greater infectivity was correlated with less S1 shedding and greater incorporation of the S protein into the 
pseudovirion. Similar results were obtained using the virus-like particles produced with SARS-CoV-2 M, N, E, and S 
proteins. However, S-G614 did not bind ACE2 more efficiently than S-D614, and the pseudoviruses containing these S 
proteins were neutralized with comparable efficiencies by convalescent plasma. S-G614 was shown more stable than 
S-D614, consistent with epidemiological data suggesting that viruses with S-G614 transmit more efficiently. Similarly, 
Daniloski (manuscript on bioRxiv: https://www.biorxiv.org/content/10.1101/2020.06.14.151357v2) produced SARS-
CoV-2-pseudotyped lentiviral particles (S-Virus) with variant and with S-D614. The authors showed that in multiple cell 
lines, including human lung epithelial cells, that pseudovirus carrying the S-G614 mutation was up to 8-fold more 
effective at transducing cells than wild-type pseudovirus. However, according to Isabel, in silico analyses on the S 
protein structure suggested that the mutation is most likely neutral to protein function as it relates to its interaction 
with the human ACE2 receptor (Sci Rep2020, see below). 
Benedetti (J Transl Med 2020, see below) identified SARS-CoV-2 genome sequences carrying a previously unknown 
deletion of 9 nucleotides in position 686-694 of nsp1, corresponding to AA position 241-243 (KSF). This deletion was 
found in different geographical areas. Structural prediction modelling suggests an effect on the C-terminal region of 
the protein, important for regulation of viral replication and negative effect on host’s gene expression. In addition, 
substitution of the two amino acids (KS) from nsp1 of SARS-CoV was previously reported to revert loss of IFN-α 
expression. This observation confirms that SARS-CoV-2 is undergoing profound genomic changes. 
Of note, a study by MacLean (manuscript on bioRxiv: https://www.biorxiv.org/content/10.1101/2020.05.28.122366v2) 
suggested that the vast majority of observed mutations occur at low frequency, with only ~10% of mutations observed 
in more than six of 15537 sequences. 
Clade nomenclatures for SARS-CoV-2 
Phylogenetic analyses soon identified the circulation of different clades of SARS-CoV-2. In a publication available online 
from April 24 2020, Sheikh (Infect Genet Evol. 2020, see below) already revealed at least five different clades 
circulating. Rambaut (Nature Microb 2020, see below; https://cov-lineages.org/) suggested a nomenclature system 
with the two major lineages of SARS-CoV-2 denoted as lineages A and B (see Viral mutations above).  
However, as reviewed by Alm (EuroSurv 2020, see below), alternative nomenclature systems have been proposed, 
including those by Nextstrain (https://nextstrain.org/sars-cov-2/) and GISAID 
(https://www.gisaid.org/references/statements-clarifications/clade-and-lineage-nomenclature-aids-in-genomic-
epidemiology-of-active-hcov-19-viruses/). Nextstrain and GISAID clade nomenclatures aim at providing a broad-brush 
categorisation of globally circulating diversity, while the lineages of Rambaut are meant to correspond to outbreaks. 
The relation between the three nomenclatures is illustrated in Figure 4. 
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Figure 4. Schematic comparison of the GISAID, Nextstrain and cov-lineages.org nomenclatures for SARS-CoV-2 sequences, February–July 
2020 (from Alm EuroSurv 2020) 
 
Sequence homology of the S gene  
The S gene of SARS-CoV-2 appears highly divergent to other CoVs, with less than 75% nucleotide sequence identity to 
all previously described SARS-CoVs, except a 93.1% nucleotide identity to RaTG13 (Zhou Nature 2020, see below). The 
S genes of SARS-CoV-2 and RaTG13 S gene are longer than other SARS-CoVs. The major differences in SARS-CoV-2 are 
three short insertions in the N-terminal domain, and 4/5 key residues changes in the receptor-binding motif, in 
comparison with SARS-CoV.  
At the level of amino acids, the S glycoprotein of SARS-CoV-2 was found to have 76.3% identity and 87.3% similarity 
with the S glycoprotein of SARS-CoV (Baruah J Med Virol 2020, see below). 
The S2 subunit of SARS-CoV-2 was found highly conserved, sharing 99% sequence identity with those of the two bat 
SARS-like CoVs (SL-CoV ZXC21 and ZC45) and human SARS-CoV (Chan Em Micr Inf 2020, see below). This observation 
suggests that broad spectrum antiviral peptides against S2 may be considered as therapeutic candidates.  
The S1 subunit of SARS-CoV-2 shares around 70% identity to that of the two bat SARS-like CoVs and human SARS-CoV. 
The core domain of the receptor binding domain (RBD) (excluding the external subdomain) is highly conserved, but 
the external subdomain of the SARS-CoV-2 RBD (which is responsible for the direct interaction with the host receptor) 
shares only 40% amino acid identity with other SARS-related coronaviruses. Of note, homology modelling in another 
study revealed that SARS-CoV-2 has a similar RBD structure to that of SARS-CoV, despite amino acid variation at some 
key residues (Lu Lancet 2020, see below). Moreover, several critical residues in SARS-CoV-2 RBD (particularly Gln493) 
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provide favourable interactions with human ACE2, consistent with SARS-CoV-2's capacity for human cell infection 
(Wan J Virol 2020, see below). Several other critical residues in SARS-CoV-2 RBD (particularly Asn501) are compatible 
with, but not ideal for, binding human ACE2. 
Structure of S and interactions with the ACE2 receptor 
Wrapp (Science 2020, see below) disclosed the 3.5 Å-resolution cryo-EM structure of the SARS-CoV-2 S trimer in the 
prefusion conformation. The predominant state of the trimer has one of the three receptor-binding domains (RBDs) 
rotated up in a receptor-accessible conformation. He also showed biophysical and structural evidence that SARS-CoV-
2 S binds ACE2 with higher affinity than SARS-CoV S. Additionally he tested several published SARS-CoV RBD-specific 
monoclonal antibodies and found that no appreciable binding to SARS-CoV-2 S, confirming previous conclusions from 
sequence analyses that antibody cross-reactivity may be limited between the two virus RBDs.  
Yan (Science 2020, see below) presented the cryo-EM structures of full-length human ACE2, in the presence of a 
neutral amino acid transporter B0AT1, with or without the receptor binding domain (RBD) of the surface S  
glycoprotein (S protein) of SARS-CoV-2, both at an overall resolution of 2.9 Å, with a local resolution of 3.5 Å at the 
ACE2-RBD interface. The ACE2-B0AT1 complex is assembled as a dimer of heterodimers, with the Collectrin-like 
domain (CLD) of ACE2 mediating homo-dimerization (see Figure 5). The RBD is recognized by the extracellular 
peptidase domain (PD) of ACE2 mainly through polar residues. 
Figure 5 Interactions between SARS-CoV-2-RBD and ACE2 (from Yan Science 2020). 
 
(A) The PD of ACE2 mainly engages the α1 helix in the recognition of the RBD. The α2 helix and the linker between β3 and β4 also contribute to the interaction. 
Only one RBD-ACE2 is shown. (B to D) Detailed analysis of the interface between SARS-CoV-2-RBD and ACE2. Polar interactions are indicated by red dashed lines. 
NAG, N-acetylglucosamine. 
The structural basis of ACE2 receptor recognition by SARS-CoV-2 was further investigated by Shang (Nature 2020, see 
below) and Lan (Nature 2020, see below). Compared with the SARS-CoV RBD, a human ACE2-binding ridge in SARS-
CoV-2 RBD was found to take a more compact conformation; moreover, several residue changes in SARS-CoV-2 RBD 
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stabilize two virus-binding hotspots at the RBD/hACE2 interface. These structural features of SARS-CoV-2 RBD enhance 
its hACE2-binding affinity. The same observation was made by Wang (Cell 2020, see below). 
Letko (Nature Microb 2020, see below) confirmed previous observations in terms of receptor usage of the virus, and 
suggested that SARS-CoV-2 is capable of using human ACE2 efficiently, which may help to explain human-to-human 
transmissibility. The experiments were based on the use of pseudotypes and investigated the mechanism of entry of 
a whole set of lineage B βCoVs. 
Ibrahim (J Inf 2020, see below) developed predictions of the COVID-19 S binding site to the cell-surface receptor 
(Glucose Regulated Protein 78 (GRP78)). The study revealed that binding is more favourable between regions III (C391-
C525) and IV (C480-C488) of the spike protein model and GRP78. Region IV was found the main driving force for GRP78 
binding with the predicted binding affinity of -9.8 kcal/mol. These nine residues could be used to develop therapeutics 
specific against COVID-19. 
Of note, Xia (Cell Mol Immunol 2020, see below) published a report on the fusion mechanism of SARS-CoV-2 and fusion 
inhibitors targeting HR1 domain in S protein. 
Watanabe (Science 2020, see below) revealed the glycan structures on a recombinant SARS-CoV-2 S immunogen. This 
analysis enabled mapping of the glycan-processing states across the trimeric viral S. Shielding of the receptor binding 
sites on the SARS-CoV-2 spike by proximal glycosylation sites (N165, N234, N343) could be observed. The shielding of 
receptor binding sites by glycans is a common feature of viral glycoproteins (observed for instance on SARS-CoV-1 S). 
While the oligomannose-type glycan content (28%) was found above that observed on typical host glycoproteins, it 
was lower than that of other viral glycoproteins. Overall, this glycosylation analysis of SARS-CoV-2 offers a detailed 
benchmark of site-specific glycan signatures characteristic of a natively folded trimeric S. 
Other SARS-CoV-2 genes and proteins 
A manuscript by Alam (Front Cell Infect Microbiol 2020, see below) showed the conservation of the E gene, differing 
between SARS and SARS-Cov2 with a difference of single amino acid substitution and a single amino acid insertion 
present in SARS but absent from SARS-CoV-2. The authors recommended diagnosis to be based on this protein. 
The RNA-dependent RNA polymerase (RdRp, also named nsp12) is the central component of coronaviral 
replication/transcription machinery. Gao (Science 2020, see below) reported the cryo-EM structure of the full-length 
viral nsp12 in complex with cofactors nsp7 and nsp8 at 2.9-Å resolution. In addition to the conserved architecture of 
the polymerase core of the viral polymerase family, nsp12 possesses a newly identified β-hairpin domain at its N 
terminus. The structure provides a basis for the design of new antiviral therapeutics targeting viral RdRp.  
Immunity to SARS-CoV-2 infection  
While information pertaining to immune responses to SARS-CoV-2 remained scarce in the first months of the epidemic, 
an increasing amount of data is now available to characterize both innate and adaptive immune responses to the virus 
(see for instance Vabret Immunity 2020 below). Such knowledge can be expected to facilitate vaccine development 
as well as specific immunotherapy against COVID-19.  
Epitope predictions 
Immune-informatics approaches targeting identification of T and B cell epitopes of SARS-CoV-2 have been described 
by numerous authors. For instance: 
 Baruah (J Med Virol 2020, see below) predicted five CTL epitopes, three sequential B cell epitopes and five 
discontinuous B cell epitopes in the S glycoprotein. Simulations suggested that the CTL epitopes bind MHC 
class I peptide-binding grooves via multiple contacts, with continuous hydrogen bonds and salt bridge anchors, 
Delivered by Ingenta
IP: 157.193.240.2 On: Fri, 04 Jun 2021 12:29:12
Copyright Leuven University Press
 
Authors: Martine Denis, Valerie Vandeweerd, Rein Verbeke, Anne Laudisoit, Tristan Reid, Emma Hobbs, Laure Wynants, Diane 
Van der Vliet  
COVIPENDIUM version: 20 OCT 2020  Transdisciplinary Insights - Living Paper | 24 
supporting their potential in generating immune responses. Of note, the study found only one overlapping 
CTL epitope between MERS-CoV and SARS-CoV-2 with one gap and one mismatch (Y-LQPRTFLL/YKLQPLTFLL), 
and no comparable epitopes with SARS-CoV.  
 Kumar (manuscript on Preprints: https://www.preprints.org/manuscript/202002.0071/v1) predicted 8 B cell 
epitopes in the S protein based on the antigenicity score by using Vaxigen 2.0, some of which displayed overlap 
with those predicted by Baruah.  
 Bojin (on Preprints : https://www.preprints.org/manuscript/202002.0102/v1) identified multiepitope 
peptides that can potentially trigger both CD4+ and CD8+ T cell immune responses.  
 The approach selected by Ahmed (Vir 2020, see below) focused on one side on S and N epitopes conserved 
across isolates and T cell epitopes offering broad coverage. 
 Fast (on bioRxiv: https://www.biorxiv.org/content/10.1101/2020.02.19.955484v2) reported the use of 
various computational tools from structural biology and machine learning to identify SARS-CoV-2 epitopes 
based on viral protein antigen presentation and antibody binding properties. The study identified two 
potential neutralizing B-cell epitopes near the spike protein RBD (positions 440-460 and 494-506) and a whole 
set of potential MHC I and II epitopes. 
 Additional epitope predictions were also reported by Bhattacharya (J Med Virol 2020, see below). 
 Grifoni (Cell Host & Micr 2020, see below) identified multiple specific regions in SARS-CoV-2 that have high 
homology to SARS-CoV. Parallel bioinformatic predictions identified a priori potential B and T cell epitopes for 
SARS-CoV-2. The authors suggested that independent identification of the same regions using two approaches 
reflects the high probability that these regions are promising targets for immune recognition of SARS-CoV-2. 
In this study, 10 B cell epitopes were identified with high sequence similarity between SARS-CoV and SARS-
CoV-2. Five of these epitopes were found in the S protein, two in the membrane protein, and three in the 
nucleocapsid (N) protein. T cell epitopes were mostly found in the S protein and N protein. 
 Using the concept of nullomer and introducing a distance from human self, Santoni (J Imm Meth 2020, see 
below) provided a list of peptides that could deserve experimental investigation. 
 Tilocca (Microbes Infect 2020, see below) analysed SARS-CoV-2 N protein epitopes in taxonomically related 
coronaviruses. 
 Using a Q-UEL system to access relevant literature, Robson (Comput Biol Med 2020, see below) found the 
KRSFIEDLLFNKV epitope to be particularly well conserved 
 Adding to an already long list of SARS-CoV-2 predicted epitopes, Joshi (Inform Med Unlocked 2020, see below) 
proposed an epitope, ITLCFTLKR, for use as a potential vaccine candidate against SARS-COV-2. This epitope 
was found to have a 99.8% structural favourability as per Ramachandran-plot analysis and suitable population 
coverage. 
 Kiyotani (J Hum Genet. 2020, see below) authors found that four epitopes, S1060-1068, S1220-1229, N222-
230, and N315-324 of SARS-CoV-2, have exactly same sequences reported as immunogenic SARS-CoV-derived 
epitopes for HLA-A*02:01, that correspond to S1042-1050, S1203-1211, N223-231, and N317-325 of SARS-
CoV, respectively. Two epitopes in ORF1ab, ORF1ab2168-2176, and ORF1ab4089-4098 (which is conserved in 
SARS-CoV) were predicted to have a strong affinity to HLA-A*24:02 as well as HLA-A*02:01 and HLA-A*02:06. 
Based on their allele frequency, these epitopes could cover 83.8% of the Japanese individuals. Since no 
mutation was identified in these epitope sequences, these were considered to possibly contribute to the 
development of rationally designed vaccines against SARS-CoV-2. 
 More recently, Oladipo, in an effort to develop a multiepitope vaccine, also predicted T cells and B cells 
epitopes, based on in silico analyses (Oladipo Inform Med Unlocked 2020, see below). 
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Observations in COVID-19 patients 
Thevarajan (Nat Med 2020, see below) reported the kinetics of the immune response in relation to clinical and 
virological features of a patient with mild-to-moderate COVID-19 requiring hospitalisation. Increased antibody-
secreting cells, follicular T-helper cells, activated CD4+ and CD8+ T-cells and IgM/IgG SARS-CoV-2-binding antibodies 
(immunofluorescence assay using SARS-CoV-2-infected Vero cells) were detected in blood, prior to symptomatic 
recovery. These immunological changes persisted for at least 7 days following full resolution of symptoms. Of note, 
the authors detected reduced frequencies of CD16+ CD14+ monocytes in peripheral blood at day 7-9, which might 
indicate efflux of CD16+CD14+ monocytes from blood to the site of infection. Low levels of activated HLA-DR+ CD3- 
CD56+ NK cells were found in both the COVID-19 patient and healthy controls. 
Comparisons between symptomatic and asymptomatic subjects 
Carsetti (manuscript on medRxiv, see https://www.medrxiv.org/content/10.1101/2020.06.22.20137141v1) 
performed a longitudinal follow-up analysis of innate and adaptive immunity in 64 adults with a spectrum of clinical 
presentations (28 healthy SARS-CoV-2-negative contacts of COVID-19 cases; 20 asymptomatic SARS-CoV-2-infected 
cases; 8 patients with mild COVID-19 disease and 8 cases of severe COVID-19 disease). The data showed that high 
frequency of NK cells and early and transient increase of specific IgA and, to a lower extent, IgG were associated to 
asymptomatic SARS-CoV-2 infection. By contrast, monocyte expansion and high and persistent levels of IgA and IgG, 
produced relatively late in the course of the infection, characterized severe disease. Modest increase of monocytes 
and rapidly declining antibodies were detected in mild COVID-19. 
Similarly, Long (Nature Med 2020, see below) studied 37 asymptomatic individuals who were diagnosed with RT-PCR-
confirmed SARS-CoV-2 infection. The asymptomatic group had a significantly longer duration of viral shedding than 
the symptomatic group. The virus-specific IgG levels in the asymptomatic group (median S/CO, 3.4; IQR, 1.6–10.7) 
were significantly lower (P = 0.005) relative to the symptomatic group (median S/CO, 20.5; IQR, 5.8–38.2) in the acute 
phase. Of asymptomatic individuals, 93.3% (28/30) and 81.1% (30/37) had reduction in IgG and neutralizing antibody 
levels, respectively, during the early convalescent phase, as compared to 96.8% (30/31) and 62.2% (23/37) of 
symptomatic patients. Forty percent of asymptomatic individuals became seronegative and 12.9% of the symptomatic 
group became negative for IgG in the early convalescent phase. In addition, asymptomatic individuals exhibited lower 
levels of 18 pro- and anti-inflammatory cytokines. These data suggest that asymptomatic individuals had a weaker 
immune response to SARS-CoV-2 infection. 
Antibody response 
In the first weeks of the epidemic, various studies characterized the kinetics, antigen specificity and isotype profile of 
the humoral response raised by SARS-CoV-2 infections.  
By using an ELISA based assay using the recombinant viral nucleocapsid, Guo (Clin Inf Dis 2020, see below) examined 
the host humoral response against SARS-CoV-2 including IgA, IgM and IgG responses. A total of 208 plasma samples 
were collected from 82 confirmed and 58 probable cases. The diagnostic value of IgM was evaluated in this cohort. 
The median times of IgM and IgA antibody detection were 5 days (IQR 3-6), while IgG was detected on 14 days (IQR 
10-18) after symptom onset, with a positive rate of 85.4%, 92.7% and 77.9% respectively. In confirmed and probable 
cases, the positive rates of IgM antibodies were 75.6% and 93.1%, respectively. The detection efficiency by IgM ELISA 
was higher than that of qPCR method after 5.5 days of symptom onset. The positive detection rate was significantly 
increased (98.6%) when combined IgM ELISA assay with PCR for each patient compare with a single qPCR test (51.9%). 
Yu (Eur Respir J 2020, see below) analysed SARS-CoV-2 S protein-specific IgA, IgM and IgG antibodies by 
chemiluminescent immunoassay in 183 samples from 37 patients. The positive rate of antibodies was 98.9%, 93.4% 
and 95.1%, for IgA, IgM and IgG, respectively. The seroconversion rate for IgA, IgM or IgG was 100% 32 days after 
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symptom onset, and the median conversion time for IgA, IgM and IgG was 13, 14 and 14 days, respectively. The relative 
levels of IgA and IgG were significantly higher in severe patients compared to non-severe patients. 
Padoan (Clin Chim Acta 2020, see below) evaluated the kinetics of IgM, IgA and IgG SARS-CoV-2 antibodies in COVID-
19 patients with confirmed (rRT-PCR) infection. The authors found that the IgA response appears and grows early, 
peaks at week 3, and it is stronger and more persistent than the IgM response. 
Immunology testing was also performed in 16 patients in Hong Kong using serum samples collected 14 days or longer 
after symptom onset (To Lancet Inf Dis 2020, see below). The following rates of seropositivity were reported: 94% for 
anti-N IgG (n=15), 88% for anti-N IgM (n=14), 100% for anti-RBD IgG (n=16), and 94% for anti-RBD IgM (n=15). Anti-
SARS-CoV-2-N or anti-SARS-CoV-2-RBD IgG levels correlated with virus neutralization titre (R2>0·9). Of note, Pecora 
(Clin Lab Med 2020, see below)  observed that there are conflicting reports regarding the kinetics of anti-N and anti-S 
antibody detection. Some reports have shown detection of anti-N slightly earlier than anti-S antibodies, whereas 
others have shown the contrary, possibly because of differences in assay format 
An early report by Xiao (J Inf 2020, see below) presented the kinetics of IgM and IgG responses in 34 patients (Figure 
6).  
Figure 6 Timeline of IgM and IgG antibodies level to SARS-CoV-2 from onset of symptoms (from Xiao J Inf 2020) 
 
Wu (non-peer-reviewed manuscript on medRxiv: 
https://www.medrxiv.org/content/10.1101/2020.03.30.20047365v1) characterized antibody responses in a  larger 
cohort of 175 COVID-19 recovered patients with mild symptoms. The levels and the time course of SARS-CoV-2-specific 
neutralizing antibodies (NAbs) (pseudotyped-lentiviral-vector-based neutralization assay) and the S-binding antibodies 
(ELISA using RBD, S1, and S2 proteins) were monitored in parallel. SARS-CoV-2-specific NAbs were detected in patients 
from day 10-15 after the onset of the disease and remained thereafter. No cross-reactivity with SARS-CoV was 
observed. The NAb titers correlated with the S-binding antibodies targeting S1, RBD, and S2 regions. Elderly and 
middle-age patients had significantly higher plasma NAb titers (P<0.0001) and S-binding antibodies (P=0.0003) than 
young patients. The NAb titers were positively correlated with plasma CRP levels but negatively correlated with the 
lymphocyte counts of patients at the time of admission, indicating an association between humoral response and 
cellular immune response.  
Another study, by Klein (J Clin Invest 2020, see below) reported substantial heterogeneity in the antibody response 
among potential convalescent plasma donors. Interestingly, sex, age and hospitalization emerged as factors that can 
be used to identify individuals with a high likelihood of having strong antiviral antibody levels. 
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Catalan-Dibene (Nature Reviews Immunology 2020, see below) described a preprint by Ju, who demonstrated the 
existence of virus-specific memory B cells recognizing the RBD of SARS-CoV-2 S protein in infected patients. They 
observed cross-reactivity of antibodies from these patients against S proteins, but not against the RBD, of SARS-CoV-
1 and MERS-CoV. Through single-cell sorting and BCR sequencing, they generated 206 SARS-CoV-2 RBD-specific 
monoclonal antibodies. Antibodies were from diverse families of immunoglobulin genes, without any apparent 
enrichment for specific families. Two clones showed 98-99% blocking of viral entry, which correlated with high 
competing capacity against ACE2 receptor. 
Neutralizing antibody responses 
Van der Heide (Nat Rev Imm 2020, see below) referred to a very interesting manuscript on medRxiv reporting robust 
induction of SARS-CoV-2-specific neutralizing antibodies in 94% of 175 patients with clinically mild COVID-19. 
Compared with young patients, middle-aged and older patients in this cohort had higher titres of neutralizing and 
binding antibodies. As older patients are generally considered at greater risk of severe disease, the robust humoral 
responses in this cohort was interpreted as possibly explaining their apparent protection. Of note, 10 of 175 patients 
recovered without developing detectable neutralizing antibody titres, suggesting that antiviral binding antibodies and 
cellular immune responses can both result in convalescence. 
Importantly, as demonstrated by Tan (Front Med 2020, see below) using samples collected at 6-7 months post-
infection in a pseudovirus assay, antibodies show no difference in blocking the cell-entry of the 614D and 614G variants 
of SARS-CoV-2. These data suggest that immunity developed from a 614D variant of SARS-CoV-2 may offer protection 
from the currently predominant 614D variant. 
Persistence of antibodies 
As presented above, Long (Nature Med 2020, see below) described a decline in antibody titers in the convalescent 
phase of the disease, suggesting that antibodies to SARS-CoV-2 may fade quickly. Other reports confirmed this 
observation. 
Prévost (manuscript on bioRxiv, see below) performed a cross-sectional study on 98 SARS-CoV-2-infected individuals 
to evaluate humoral responses against SARS-CoV-2 S. The vast majority of infected individuals elicited anti-S antibodies 
within 2 weeks after the onset of symptoms. The levels of receptor-binding domain (RBD)-specific IgG persisted 
overtime, while the levels of anti-RBD IgM decreased after symptoms resolution. While most of individuals developed 
neutralizing antibodies within the first two weeks of infection, the level of neutralizing activity was significantly 
decreased over time.  
Using sequential serum samples collected up to 94 days post onset of symptoms (POS) from 65 RT-qPCR confirmed 
SARS-CoV-2-infected individuals, Seow (manuscript on medRxiv, see 
https://www.medrxiv.org/content/10.1101/2020.07.09.20148429v1) showed seroconversion in >95% of cases and 
nAb responses when sampled beyond 8 days POS. The authors observed that the magnitude of the nAb response is 
dependent upon disease severity, but this was not found to affect the kinetics of the nAb response. Declining nAb 
titres were observed during the follow-up period. Whilst some individuals with high peak response (>10 000) 
maintained titres >1000 at >60 days POS, some with lower peak had titres approaching baseline within the follow up 
period. A similar decline in nAb titres was also observed in a cohort of seropositive healthcare workers from 2 hospitals. 
Iyer (manuscript on medRxiv, see https://www.medrxiv.org/content/10.1101/2020.07.18.20155374v1) measured the 
kinetics of early antibody responses to the RBD of the S protein of SARS-CoV-2 in a cohort of 259 symptomatic North 
American patients (up to 75 days after symptom onset) compared to antibody levels in 1548 individuals whose blood 
samples were obtained prior to the pandemic. Between 14-28 days from onset of symptoms, IgG, IgA, or IgM antibody 
responses to RBD were all accurate in identifying recently infected individuals, with 100% specificity and a sensitivity 
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of 97%, 91%, and 81% respectively. Although the estimated median time to becoming seropositive was similar across 
isotypes, IgA and IgM antibodies against RBD were short-lived with most individuals estimated to become seronegative 
again by 51 and 47 days after symptom onset, respectively. IgG antibodies against RBD lasted longer and persisted 
through 75 days post-symptoms. IgG antibodies to SARS-CoV-2 RBD were highly correlated with nAbs targeting the S 
protein. 
Tan (Front Med, see below) confirmed these data by showing that 14 samples available at 6–7 months post-infection 
all showed significant neutralizing activities in a pseudovirus assay.  
Cellular responses 
Flow cytometry analyses 
A study of the dynamic changes of lymphocyte subsets and cytokines profiles of 40 COVID-19 patients has been 
reported by Liu (EBioMed 2020, see below). Significant decreases in the counts of T cells, especially CD8 + T cells, were 
observed as well as increases in IL-6, IL-10, IL-2 and IFN-γ levels in the peripheral blood in the severe cases compared 
to those in the mild cases. T cell counts and cytokine levels in severe COVID-19 patients who survived the disease 
gradually recovered at later time points to levels that were comparable to those of the mild cases. 
Wang (J Inf Dis 2020, see below) measured peripheral blood lymphocyte subsets in 60 hospitalized COVID-19 patients 
before and after treatment. Total lymphocytes, CD4+ T cells, CD8+ T cells, B cells and NK cells decreased in COVID-19 
patients, and severe cases had a lower level than mild cases. The subsets (especially CD8+ T cells and CD4+/CD8+ ratio) 
showed a significant association with the inflammatory status. After treatment, 37 patients (67%) reached clinical 
response, with an increase of CD8+ T cells and B cells. In multivariate analysis, a post-treatment decrease of CD8+ T 
cells and B cells and an increase of CD4+/CD8+ ratio were indicated as independent predictors for poor efficacy. 
Liao (Nat Med 2020, see below) characterized the lung immune microenvironment with the bronchoalveolar lavage 
fluid (BALF) from 3 severe and 3 mild COVID-19 patients. The data show that monocyte-derived FCN1+ macrophages, 
but not FABP4+ alveolar macrophages that represent a predominant macrophage subset in BALF from patients with 
mild diseases, overwhelm in the severely damaged lungs from patients with acute respiratory distress syndrome 
(ARDS). These cells are highly inflammatory and enormous chemokine producers implicated in cytokine storm. 
Furthermore, the formation of tissue resident, highly expanded clonal CD8+ T cells in the lung microenvironment of 
mild symptom patients suggests a robust adaptive immune response. 
Zheng, Zhang et al. (Cell Mol Imm 2020, see below) provided a detailed analysis of the immunological characteristics 
of peripheral blood leukocytes from 16 patients, incl. 10 mild cases and 6 severe cases. The levels of IFN-γ and TNF-α 
in CD4+ T cells were lower in the severe group than in the mild group, whereas the levels of granzyme B and perforin 
in CD8+ T cells were higher in the severe group than in the mild group. The activation molecules showed no differences 
in CD4+ T cells, whereas the levels of HLA-DR and TIGIT in CD8+ T cells were higher in the severe group than in the 
mild group. These data indicate that COVID-19, similar to some chronic infections, damages the function of CD4+ T 
cells and promotes excessive activation and possibly subsequent exhaustion of CD8+ T cells. Compared with the 
healthy control and mild group, the frequency of multi-functional CD4+ T cells (positive for at least two cytokines) 
decreased significantly in the severe group. In CD8+ T cells, the frequency of the non-exhausted (PD-1−CTLA-4−TIGIT−) 
subset in the severe group was found significantly lower than that in the other two groups, an observation confirming 
a report by Zheng, Gao et al. (Cell Mol Imm 2020, see below). 
Virus-specific responses 
Pia (Nat Rev Imm 2020, see below) referred to a manuscript by Braun on medRxiv (subsequently published in Nature, 
see below), which reported the characterization of CD4+ T cell responses to SARS-CoV-2 in 18 patients with COVID-
19 and 68 seronegative healthy donors. Peripheral blood mononuclear cells from patients and HDs were stimulated 
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with peptide pools derived from the SARS-CoV-2 S protein. S protein-specific CD4+ T cells could be detected in 83% of 
COVID-19 patients, as well as in 34% of healthy donors, albeit at lower frequencies. CD4+ T cells from patients with 
COVID-19 had a phenotype of recent activation in contrast to those from healthy donors. The authors suggest that S 
protein-specific T cells in healthy donors may be cross-reactive clones developed following a previous exposure to 
human endemic coronaviruses. 
Using HLA class I and II predicted peptide ‘megapools’, Grifoni (Cell 2020, see below) identified circulating SARS-CoV-
2−specific CD8+ and CD4+ T cells in ~70% and 100% of COVID-19 convalescent patients, respectively. CD4+ T cell 
responses to S were robust and correlated with the magnitude of the anti-SARS-CoV-2 IgG and IgA titers. The M, spike 
and N proteins each accounted for 11-27% of the total CD4+ response, with additional responses commonly targeting 
nsp3, nsp4, ORF3a and ORF8, among others. For CD8+ T cells, spike and M were recognized, with at least eight 
SARSCoV-2 ORFs targeted. Confirming the data reported by Pia, the authors detected SARS-CoV-2−reactive CD4+ T 
cells in ~40-60% of unexposed individuals, suggesting cross-reactive T cell recognition between circulating ‘common 
cold’ coronaviruses and SARS-CoV-2.  
Transcriptional changes  
Ong (Cell Host Microbe 2020, see below) profiled the transcriptional changes in a panel of immune genes in 3 COVID-
19 patients and 10 healthy volunteers.  Attenuated cytokine expression associated with mild infection was suggested 
to possibly delay T cell immunity against SARS-CoV-2, which would prolong infection, leading to the possibility that 
afebrile and undifferentiated COVID-19 cases may drive virus spread in the community. 
Blanco-Melo (Cell 2020, see below) compared the transcriptional response of SARS-CoV-2 to that of seasonal influenza 
A virus and respiratory syncytial virus in lung epithelium and transformed lung alveolar cells. The authors observed a 
significant lack of type I and III interferon (IFN-I and IFN-III) expression as compared to other respiratory viruses. 
Previous reports also demonstrated that coronaviruses hold mechanisms to evade host innate immune responses, in 
particular type I IFN signalling.  
The data can be analysed in light of another publication by Hackbart (PNAS 2020, see below), who demonstrated that 
a coronavirus endoribonuclease (EndoU) delays the activation of the host sensor system, by a mechanism where 
EndoU cleaves the 5-polyuridines from negative-sense viral RNA, which would otherwise be recognized by the 
cytosolic RNA sensor MDA5. Taken together, these findings suggest that SARS-CoV-2 can evade or delay antiviral 
immunity, ultimately leading to a dysregulated immune response and increased immunopathogenesis. 
Wen (Cell Discov 2020, see below) depicted a high-resolution transcriptome landscape of blood immune cell subsets 
during the recovery stage of COVID-19. It revealed that, compared to that in the healthy controls (HCs), monocytes 
containing high inflammatory gene expression and IL1β+ subsets predominated, whereas CD4+ T cells decreased 
remarkably in patients in the early recovery stage of COVID-19. We found that T and B cell clones were highly expanded 
during the recovery stage in COVID-19 patients. 
Persistence of SARS-CoV-2-specific memory lymphocytes 
Rodda (manuscript on medRxiv, see https://www.medrxiv.org/content/10.1101/2020.08.11.20171843v2) performed 
a longitudinal assessment of individuals recovered from mildly symptomatic COVID-19 to determine if they develop 
and sustain immunological memory against the virus. The authors found that recovered individuals developed virus-
specific memory B and T cells that not only persisted, but in some cases increased numerically over three months 
following symptom onset. Furthermore, the SARS-CoV-2-specific memory lymphocytes exhibited characteristics 
associated with potent antiviral immunity: memory T cells secreted IFN-γ and expanded upon antigen re-encounter, 
while memory B cells expressed receptors capable of neutralizing virus when expressed as antibodies. These findings 
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demonstrated that mild COVID-19 elicits memory lymphocytes that persist and display functional hallmarks associated 
with antiviral protective immunity. 
Tan (Front Med 2020, see below) also suggested that a durable anti-SARS-CoV-2 cell-mediated immunity is common 
in the convalescent population. The authors found in 10 blood samples from cases at 6–7 months post-infection used 
for memory T-cell tests, that IFN- γ-producing CD4+ and CD8+ cells were increased upon SARS-CoV-2 antigen 
stimulation.  
Immunity to other coronaviruses and cross-reactivity 
Data pertaining to immunity against other coronaviruses could be very relevant to the understanding of immune 
responses to (and pathogenesis of) SARS-CoV-2. For instance, Wang (Virol Sin 2018, see below) found antibodies 
against bat SARS-related coronavirus in people living near caves inhabited by bats in China. Serology testing against 
common human CoV strains was conducted in a prospective study of 200 subjects evaluated for respiratory infections 
in the U.S. (Gorse J Med Vir 2020, see below). Interestingly, a publication by Chan (J Clin Virol 2009, see below) 
presented the seroprevalence of HCoV HKU1 according to age, showing steadily increasing seroprevalence in 
childhood and early adulthood, from 0% in the < 10 years age group to a plateau of 21.6% in the 31-40 years age group 
in Hong Kong. More recently, Mateus (Science 2020, see below) demonstrated that SARS-CoV-2 cross-reactive T-cell 
responses could be induced by infection with any of the circulating HCoVs: OC43, 229E, HKU1 or NL63.1 
To what extent such pre-existing immunity may impact immune responses to SARS-CoV-2 remains to be better 
understood. De Vries (Signal Transd Targ Ther 2020, see below) noted that pre-existing cross-reactive immunity may 
impact COVID-19 disease heterogeneity in different ways. At the moment it is unclear whether this is a positive or 
negative contribution, pre-existing cross-reactive immunity could either ameliorate or worsen COVID-19. As illustrated 
by Figure 7, different pre-exposure history could lead to different cross-reactive responses and different disease 
severity. 
Figure 7. Pre-existing cross-reactive T-cell immunity could impact COVID-19 disease severity (from de Vries Signal Transd Targ Ther 2020). 
 
Of note, Kumakamba (manuscript on bioRxiv : https://doi.org/10.1101/2020.07.20.211664) reported the circulation 
of diverse α and βCoVs in Congo basin wildlife. Lacroix (Viruses 2020, see below) in Guinea in frugivorous and 
insectivorous bats species and Maganga (Sci Rep 2020 , see below) found α and βCoVs in cave-dewelling bats of Gabon ; 
all αCoVs sequences grouped with human CoV 229E (HCoV-229E). These findings suggest that CoVs are widely spread 
in Africa and their circulation should be assessed to evaluate the risk of exposure of potential zoonotic CoVs to humans. 
The exposure to and the consumption of wild animals infected with multiple strains of coronaviruses could also 
Delivered by Ingenta
IP: 157.193.240.2 On: Fri, 04 Jun 2021 12:29:12
Copyright Leuven University Press
 
Authors: Martine Denis, Valerie Vandeweerd, Rein Verbeke, Anne Laudisoit, Tristan Reid, Emma Hobbs, Laure Wynants, Diane 
Van der Vliet  
COVIPENDIUM version: 20 OCT 2020  Transdisciplinary Insights - Living Paper | 31 
potentially build a baseline level of immunity in communities relying on such a diet and explain to some extent the 
poor percolation of SARS-CoV-2 in human population in some countries.  
Cross-reactivity of antibodies 
In silico work and samples from immunized animals 
Based on structure analyses, Tian (Em Inf Dis 2020, see below) predicted potent binding of SARS-CoV-2 S protein by 
SARS-specific human monoclonal antibody CR3022. Yuan (Science 2020, see below) determined the crystal structure 
of CR3022 in complex with the receptor-binding domain (RBD) of the SARS-CoV-2 S protein. CR3022 was found to 
target a highly conserved epitope, distal from the receptor-binding site, that enables cross-reactive binding between 
SARS-CoV-2 and SARS-CoV. However, in vitro experiments subsequently indicated the inability of CR3022 to neutralize 
SARS-CoV-2 (Manenti J Med Vir 2020, see below). 
Using MLV-based pseudotypes neutralization assays, Walls (Cell 2020, see below) investigated the ability of plasma 
from four mice immunized with a stabilized SARS-CoV S to inhibit SARS-CoV-2 S- and SARS-CoV S-mediated entry into 
target cells. All sera tested completely inhibited transduction of SARS-CoV S-MLV and reduced SARS-CoV-2 S-MLV 
transduction to ∼10% of control in Vero E6 cells. The elicitation of a heterotypic response blocking SARS-CoV-2 S-
mediated entry into host cells concurred with the sequence and structural conservation of SARS-CoV-2 S and SARS-
CoV S along with their comparable glycans shields and suggested that immunity against one virus of the sarbecovirus 
subgenus can potentially provide protection against related viruses. 
Ou (Nature Comm 2020, see below) also investigated antibody cross-reactivity between SARS-CoV-2 S and SARS-COV 
S. Polyclonal anti-SARS S1 antibodies T62 inhibited entry of SARS-CoV S- but not SARS-CoV-2 S-pseudovirions.  
Human samples 
Further studies by Ou (Nature Comm 2020, see below) using recovered SARS and COVID-19 patients’ sera showed 
limited cross-neutralization. Similarly, a serosurvey of a small number of healthy donors who provided samples prior 
to the emergence of SARS-CoV-2 indicated that pre-existing antibodies to common human CoVs show very little cross-
reactivity to SARS-CoV-2 (St John J Immunol 2020, see below). One preliminary study of a small cohort of SARS-CoV-2 
immune individuals showed that there was no cross-reactivity of their Abs against the RBD of S protein from SARS-
CoV or MERS-CoV, and no cross-neutralization of the viruses. Most cross-reactive Abs were directed at the S2 domain 
of S protein and the NP protein. However, a study on 98 SARS-CoV-2-infected individuals found that some of the 
elicited antibodies cross-reacted with other human coronaviruses in a genus-restrictive manner (Prévost, manuscript 
on bioRxiv, see below). 
Cross reactive T cells 
Studies dissecting the human immune response against SARS-CoV-2 concluded that 20-50% of people who had not 
been exposed to SARS-CoV-2 had significant T cell reactivity directed against peptides corresponding to SARS-CoV-2 
sequences (Le Bert Nature 2020, see below; Grifoni Cell 2020, see below; Meckiff on bioRxiv, see below; Weiskopf Sci 
Immunol 2020, see below; Braun Nature 2020, see below). The studies were from geographically diverse cohorts (USA, 
Netherlands, Germany, Singapore, and UK), and the general pattern observed was that the T cell reactivity found in 
unexposed individuals was predominantly mediated by CD4+ T cells. Using human blood samples derived before the 
SARS-CoV-2 virus was discovered in 2019, Mateus (Science 2020, see below) mapped 142 T cell epitopes across the 
SARS-CoV-2 genome and demonstrated a range of pre-existing memory CD4+ T cells that are cross-reactive with 
comparable affinity to SARS-CoV-2 and the common cold coronaviruses HCoV-OC43, HCoV-229E, HCoV-NL63, or HCoV-
HKU1. 
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Innate immunity  
Type I interferon 
Lei (Nature 2020, see below) showed that SARS-CoV-2 induces overt but delayed type-I interferon (IFN) responses. By 
screening 23 viral proteins, the authors found that SARS-CoV-2 NSP1, NSP3, NSP12, NSP13, NSP14, ORF3, ORF6 and M 
protein inhibit Sendai virus-induced IFN-β promoter activation, whereas NSP2 and S protein exert opposite effects. 
Further analyses suggested that ORF6 inhibits both type I IFN production and downstream signalling, and that the C-
terminus region of ORF6 is critical for its antagonistic effect. 
Zhang (Science 2020, see below) provided strong evidence of the importance of type I IFN in the control of SARS-CoV-
2, by showing that inborn errors of TLR3- and IRF7-dependent type I IFN immunity can underlie life-threatening COVID-
19 pneumonia in patients with no prior severe infection. The authors indeed found an enrichment in rare variants 
predicted to be loss-of-function (LOF) at the 13 human loci known to govern TLR3- and IRF7-dependent type I 
interferon (IFN) immunity to influenza virus, in 659 patients with life-threatening COVID-19 pneumonia, relative to 534 
subjects with asymptomatic or benign infection. By testing these and other rare variants at these 13 loci, LOF variants 
were defined in 23 patients (3.5%), aged 17 to 77 years, underlying autosomal recessive or dominant deficiencies. 
Human fibroblasts with mutations affecting this pathway were shown to be vulnerable to SARS-CoV-2. A report by 
Bastard (Science 2020, see below) further supported the role of type I IFN, as it described the presence of neutralizing 
auto-antibodies against type I in other patients with life-threatening COVID-19 pneumonia. At least 101 of 987 patients 
with life-threatening COVID-19 pneumonia had neutralizing IgG auto-Abs against IFN-ω (13 patients), the 13 types of 
IFN-α (36), or both (52), at the onset of critical disease; a few also had auto-Abs against the other three type I IFNs. 
The auto-Abs neutralize the ability of the corresponding type I IFNs to block SARS-CoV-2 infection in vitro. These auto-
Abs were not found in 663 individuals with asymptomatic or mild SARS-CoV-2 infection and were present in only 4 of 
1227 healthy individuals. 
NK cells 
NK cell count reduces remarkably during SARS-CoV-2 infection, predominantly in critically ill patients (Masselli Adv Biol 
Regul 2020, see below). This is consistent with previous findings in SARS and it is conceivable that this finding is due 
to NK sequestration into target organs, e.g. the lung. However, it is unclear at this time if this decrease is due to NK 
cell redistribution in infected sites or cell death. In addition, a very interesting mechanism of T and NK cell exhaustion 
has been hypothesized by Zheng, Gao et al. (Cell Mol Imm 2020, see below). In their work, the authors observed that 
the NK group 2 member A (NKG2A) receptor, which transduces inhibitory signalling and suppresses T-cell and NK 
cytokine secretion and cytotoxic function, is overexpressed in COVID-19 patients as compared to healthy controls, 
while the percentage of T and NK cells expressing the activation markers CD107a, IFNɣ, IL-2, and TNFɑ was significanly 
lower. Taken together, these data indicate that patients with severe COVID-19 have a severely compromised innate 
immune response likely due to a functional exhaustion of peripheral CD8+ T and NK cells. 
Immune evasion mechanisms 
As a member of the βCoV genus, SARS-CoV-2 can be expected to stimulate immune evasion mechanism potentially 
similar to those of SARS-CoV and MERS-CoV (Prompetchara Asia Pac J All Imm 2020, see below). The mechanisms of 
how SARS-CoV and MERS-CoV modulate host immune responses were extensively studied. In brief, most mechanisms 
rely on the inhibition of innate immune responses, especially type I interferon recognition and signalling. The viral 
proteins including membrane (M) or nonstructural (NS) proteins (eg. NS4a, NS4b, NS15) are the key molecules in host 
immune modulation. 
Type I interferon 
Xia, Cao et al. (Cell Rep 2020, see below) identified SARS-CoV-2 proteins that antagonize type I interferon (IFN-I) 
response: nsp6 binds TANK binding kinase 1 (TBK1) to suppress interferon regulatory factor 3 (IRF3) phosphorylation, 
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nsp13 binds and blocks TBK1 phosphorylation, and ORF6 binds importin Karyopherin α 2 (KPNA2) to inhibit IRF3 
nuclear translocation. The authors identified two sets of viral proteins that antagonize IFN-I signalling through blocking 
signal transducer and activator of transcription 1 (STAT1)/STAT2 phosphorylation or nuclear translocation. Remarkably, 
SARS-CoV-2 nsp1 and nsp6 were found to suppress IFN-I signalling more efficiently than SARS-CoV and MERS-CoV. 
Interferon stimulated genes 
To identify the molecular effectors that govern interferon control of SARS-CoV-2 infection, Martin-Sancho (manuscript 
on bioRxiv, see below) conducted a large-scale gain-of-function analysis that evaluated the impact of human interferon 
stimulated genes (ISGs) on viral replication. A limited subset of ISGs were found to control viral infection, including 
endosomal factors that inhibited viral entry, nucleic acid binding proteins that suppressed viral RNA synthesis, and a 
highly enriched cluster of ER and Golgi-resident ISGs that inhibited viral translation and egress. These included the 
type II integral membrane protein BST2/tetherin, which was found to impede viral release, and is targeted for immune 
evasion by SARS-CoV-2 Orf7a protein. 
RNAi 
As explained by Mu (Sci China Life Sci 2020, see below), viral infection generates virus-derived dsRNA (vi-dsRNA), which 
could be recognized and cleaved by the host endoribonuclease Dicer into virus-derived siRNAs (vsiRNAs). These 
vsiRNAs are integrated into the Argonaute protein within the RNA-induced silencing complex (RISC) to direct the 
destruction of cognate viral RNAs in infected cells in a sequence-specific manner. As a countermeasure, viruses encode 
viral suppressors of RNAi (VSRs) to antagonize the RNAi pathway at different steps. Previous study has reported that 
SARS-CoV nucleocapsid (N) protein displayed a VSR activity in mammalian cells via a cellular reversal-of-silencing assay. 
Mu showed that SARS-CoV-2 can act as a VSR in cells in both initiation and effector steps of RNAi, thereby probably 
representing a key immune evasion factor of SARS-CoV-2 and contributing to the pathogenicity of the virus. 
NKG2A expression and NK and CD8+ T cells 
Zheng, Gao et al. (Cell Mol Imm 2020, see below) showed that the total number of NK and CD8+ T cells was decreased 
markedly in patients with SARS-CoV-2 infection, and further observed that NKG2A expression is upregulated on NK 
cells and CTLs in patients, with a reduced ability to produce CD107a, IFN-γ, IL-2, granzyme B, and TNF-α. Also, the 
percentage of NKG2A+ cytotoxic lymphocytes was found decreased in recovered patients infected with SARS-CoV-2, 
which strongly suggests that NKG2A expression may be correlated with functional exhaustion of cytotoxic 
lymphocytes and disease progression in the early stage of COVID-19. 
Clinical disease   
Initial observations in Wuhan 
In December, 2019, a series of pneumonia cases of unknown cause emerged in Wuhan, Hubei, China, with clinical 
presentations greatly resembling viral pneumonia (http://www.who.int/csr/don/12-january-2020-novel-coronavirus-
china/en/). By Jan 2, 2020, 41 admitted hospital patients had been identified as having laboratory-confirmed COVID-
19 (Huang Lancet 2020, see below). Most of the infected patients were men (30 [73%] of 41); less than half had 
underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease 
(six [15%]). Median age was 49.0 years (IQR 41.0-58.0). 27 (66%) of 41 patients had been exposed to Huanan seafood 
market. One family cluster was found. Common symptoms at onset of illness were fever (40 [98%] of 41 patients), 
cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 
39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38). Dyspnoea developed 
in 22 (55%) of 40 patients (median time from illness onset to dyspnoea 8·0 days [IQR 5.0-13.0]). 26 (63%) of 41 patients 
had lymphopenia. All 41 patients had pneumonia with abnormal findings on chest CT. Complications included acute 
respiratory distress syndrome (12 [29%]), RNAaemia (six [15%]), acute cardiac injury (five [12%]) and secondary 
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infection (four [10%]). 13 (32%) patients were admitted to an ICU and six (15%) died. Compared with non-ICU patients, 
ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFα. 
Incubation period 
Among the first 425 patients with confirmed COVID-19-pneumonia, the mean incubation period was 5.2 days (95% 
confidence interval, 4.1 to 7.0), with the 95th percentile of the distribution at 12.5 days (Li New Engl J Med 2020, see 
below). This observation was confirmed by other datasets as illustrated in Table 2 below. 
Table 2 Incubation period as reported by different studies 
 
Mean incubation period and 95% 
confidence interval 
Other information 
Li NewEngl J Med 2020 5.2 days (95% CI, 4.1 to 7.0) 
95th percentile of the distribution at 
12.5 days 




median 7 days (no more than 14 days 
for 92% patients) 
Backer EuroSurv 2020  6.4 days (95% CI, 5.6 - 7.7) 
ranging from 2.1 to 11.1 days (2.5th to 
97.5th percentile) 
Guan NEJM 2020   
median of 3 days; ranging from 0 to 24 
days 
Xu BMJ 2020  
median 4 days (interquartile range 3-5 
days) 
Jia Disaster Med Public Health Prep 2020 6.28 days  
Leung Infect Control Hosp Epidemiol 2020 1.8 days (95% CI, 1.0 to 2.7) For travellers to Hubei 
Leung Infect Control Hosp Epidemiol 2020 7.2 days (95% CI, 6.1  to 8.4) For non-travellers 
 
Lauer (Ann Intern Med 2020, see below) assessed the incubation period using a compilation of 181 published cases 
with identifiable exposure and symptom onset windows. A median incubation period of 5.1 days (95% CI, 4.5 to 5.8 
days) was found, with 97.5% of those who develop symptoms doing so within 11.5 days (CI, 8.2 to 15.6 days) of 
infection. These estimates imply that, under conservative assumptions, 101 out of every 10,000 cases will develop 
symptoms after 14 days of active monitoring or quarantine. Whether this risk is acceptable will depend on the 
underlying risk of infection and consequences of missed cases.  
Similar results were obtained by Linton (J Clin Med 2020 see below), who found the incubation period to falls within 
the range of 2–14 days with 95% confidence and to have a mean of around 5 days. Based on the 95th percentile 
estimate of the incubation period, she recommended that the length of quarantine should be at least 14 days. 
A systematic review of COVID-19 epidemiology by Park (J Clin Med 2020, see below), which included 41 studies, 
indicated an estimated incubation period of 4-6 days. 
Interestingly, based on reports collected in China, Han (manuscript on medRxiv: 
https://www.medrxiv.org/content/10.1101/2020.02.24.20027474v1) found that the incubation periods of groups of  
individuals with age ≥40 years and age <40 years demonstrated a statistically significant difference. The former group 
had a longer incubation period and a larger variance than the latter. Cai (Clin Inf Dis 2020, see below) reported an 
incubation period in children of about two days usually, with a range of 2-10 days. 
Description of clinical disease  
Shi (Cell Death Diff 2020, see below) described SARS-CoV-2 infection as a 3-stage process: stage I, an asymptomatic 
incubation period with or without detectable virus; stage II, non-severe symptomatic period with the presence of virus; 
stage III, severe respiratory symptomatic stage with high viral load. 
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Clinical disease in China 
Individual reports 
A large number of reports provide descriptions of the clinical signs associated with COVID-19 in Wuhan and other cities 
in China. The disease ranges from mild infection to severe acute respiratory infection. Table 3 illustrates the signs and 
symptoms detected in a selection of early reports describing the disease as observed in hospitalized patients. 
Table 3 Clinical presentation in different cohorts of patients with COVID-19 pneumonia (frequency of reported symptoms) 
 
Chen Lancet 2020  
(n=99*) 
Song Radiol 2020 
(n=51) 
Chang JAMA 2020 
(n=13) 
Guan NEJM 2020 
(n=1099**) 
Wang JAMA 2020  
(n=138) 
fever 83% 96% 92.3% 88.7% 98.6% 
cough 82% 47% 46.3% 67.8% 59.4% 
shortness of breath (dyspnoea) 31%   18.7% 31.2% 
muscle ache (myalgia) 11% 
31% 
23.1% 14.9% 34.8% 
fatigue   38.1% 69.6% 
confusion 9%     
headache 8% 16% 23.1% 13.6%  
sore throat 5%   13.9%  
rhinorrhoea 4%     
chest pain 2%     
diarrhoea  2% 10%  3.8% 10.1% 
nausea and vomiting 1%   5% 10.1% 
acute respiratory distress syndrome 17%   3.4%  
*   Among the 99 patients, 76% patients received antiviral treatment, including oseltamivir (75 mg every 12 h, orally), ganciclovir (0.25 g every 
12 h, intravenously), and lopinavir and ritonavir tablets (500 mg twice daily, orally). The duration of antiviral treatment was 3-14 days (median 3 
days) 
** Patients with laboratory-confirmed COVID-19 acute respiratory disease from 552 hospitals in 31 provinces/provincial municipalities through 
January 29th, 2020; see https://www.medrxiv.org/content/10.1101/2020.02.06.20020974v1 
Additional data were also made available in the reports listed below (non-exhaustive): 
 Zhang (Virol Sin 2020, see below) described 2 cases of COVID-19 in Wuhan 
 Huang (Trav Med Inf Dis 2020, see below) described 34 cases in Wuhan 
 Chen (on MedRxiV: https://www.medrxiv.org/content/10.1101/2020.02.16.20023903v1) described 21 
patients with COVID-19 
 Li (on medRxiv: https://www.medrxiv.org/content/10.1101/2020.02.11.20022053v1) described 17 patients 
outside Wuhan 
 Cai (on MedRXiv : https://www.medrxiv.org/content/10.1101/2020.02.17.20024018v1) described 298 
confirmed cases in Shenzhen, from January 11, 2020 to February 6, 2020 
 Zhang (Allergy 2020, see below) described 140 patients in Wuhan, aged 25 to 87 years 
 Liu (Chin Med J 2020, see below) described 78 patients in Wuhan 
 Yang (Lancet Resp Med 2020, see below) described 52 critically ill patients  
 Liu (on medRxiv https://www.medrxiv.org/content/10.1101/2020.02.17.20024166v3) described 109 patients, 
including 53 severe disease cases. 
 Xu (BMJ 2020, see below) described 62 hospitalized patients with confirmed infection in seven hospitals in 
Zhejiang province. 
 Wu (Clin Inf Dis 2020, see below) described 80 cases in Jiangsu Province. 
 Yang (on medRxiv: https://www.medrxiv.org/content/10.1101/2020.02.28.20028068v1) analysed 55 
hospitalized cases in Beijing. 
 Zhou (Lancet 2020, see below) provided details on 191 patients with laboratory-confirmed disease in Wuhan. 
 Qian (QJM 2020, see below) described 91 hospitalized patients with COVID-19 in Zhejiang. 
 Lian (Influenza Other Respir Viruses 2020, see below) analyzed 465 confirmed cases in Zhejiang province. 
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Metaanalyses 
A meta-analysis by Sun (J Med Vir 2020, see belowbelow) covered ten of these studies1, including a total number of 
50 466 patients. It confirmed that fever and cough are the most common symptoms in patients with SARS-CoV-2 
infection, and that a vast majority of these patients (96.6%) have abnormal chest CT examination. The incidence of 
fever was estimated at 89.1%, the incidence of cough 72.2%, and the incidence of muscle soreness or fatigue 42.5%. 
In this analysis, the incidence of acute respiratory distress syndrome (ARDS) reached 14.8%. ARDS is the most severe 
form of acute lung injury (Cheng, Wang et al. J Med Vir 2020, see below). It is characterized mainly by increased 
pulmonary vascular permeability and pulmonary oedema. It is often induced by sepsis, aspiration, and pneumonia 
(including that caused by SARS coronavirus and human influenza viruses). It is a clinical, high-death-rate disease. 
Diarrhoea, haemoptysis, headache, sore throat, shock, and other symptoms were reported to occur only in a small 
number of patients. 
Of note, Sun (J Med Vir 2020, see below) reported a definition of fever as temperature ≥ 37.3°C. He did not provide 
details on the method of temperature recording (e.g. axillary, forehead or sublingual). By contrast, Guan (NEJM 2020, 
see below) mentioned a definition of fever as an axillary temperature of 37.5°C or higher. Such discrepancies can be 
expected to result in some variability across hospitals with regard to the detection of this symptom.  
Another meta-analysis by Li (J Med Vir 2020, see below), including a somewhat different set of ten studies2 found the 
main clinical symptoms of COVID-19 patients to be fever (88.5%), cough (68.6%), myalgia or fatigue (35.8%), 
expectoration (28.2%), and dyspnoea (21.9%). In addition to common respiratory symptoms, the symptoms of 
headache or dizziness (12.1%), diarrhoea (4.8%), nausea, and vomiting (3.9%) were also obvious in some patients. 
A third meta-analysis by Rodriguez-Morales (Trav Med Inf Dis 2020, see below) found that in 656 patients, fever (88.7%, 
95%CI 84.5-92.9%), cough (57.6%, 40.8-74.4%) and dyspnea (45.6%, 10.9-80.4%) were the most prevalent 
manifestations. Among the patients, 20.3% (95%CI 10.0-30.6%) required intensive care unit (ICU), 32.8% presented 
with ARDS (95%CI 13.7-51.8), 6.2% (95%CI 3.1-9.3) with shock. Some 13.9% (95%CI 6.2-21.5%) of hospitalized patients 
had fatal outcome. 
Borges do Nascimento (J Clin Med 2020, see below) provided another meta-analysis of available clinical data, covering 
a total of 61 studies (59,254 patients). The most common disease-related symptoms were fever (82%, 95% confidence 
interval (CI) 56%–99%; n = 4410), cough (61%, 95% CI 39%–81%; n = 3985), muscle aches and/or fatigue (36%, 95% CI 
18%–55%; n = 3778), dyspnoea (26%, 95% CI 12%–41%; n = 3700), headache in 12% (95% CI 4%–23%, n = 3598 patients), 
sore throat in 10% (95% CI 5%–17%, n = 1387) and gastrointestinal symptoms in 9% (95% CI 3%–17%, n = 1744). 
A relevant feature of COVID-19, not addressed by the meta-analyses, is the absence of dyspnoea, observed even in 
the most severe cases, in which subjects present tachypnoea and tachycardia (Bertran Recasens Eur J Neurol 2020, 
see below). In the Wuhan cohort, 62.4% of severe cases and 46.3% of those who ended up intubated, ventilated or 
dead did not present dyspnoea. 
Less frequent observations 
Hu (Eur Heart J, see below) presented a COVID-19 case with fulminant myocarditis with cardiogenic shock. This clinical 
presentation had initially been reported to be rare, but was subsequently better recognized. A review by Bansal 
                                                          
1 Huang Lancet 2020; Wang JAMA 2020 ; Chen Lancet 2020; Guan NEJM 2020 ; Chen Zhonghua Jie He He Hu Xi Za Zhi.; Sun, 
Lancet 2020;  Yang medRxiv 2020 (manuscript subsequently withdrawn); Li medRxiv 2020; The Novel Coronavirus Pneumonia 
Emergency Response Epidemiology Team, Chinese Center for Disease Control and Prevention. Zhong Hua Liu Xing Bing Xue Za 
Zhi 2020; Xu BMJ 2020. 
2 Huang Lancet 2020; Chang JAMA 2020; Guan NEJM 2020; Wang JAMA 2020; Li N Engl J Med 2020; Chen Lancet 2020; Wang 
Biosci Trends 2020; Kui Chin Med J 2020; Lei Chin J Tuberc Resp Dis 2020; Mingqiang Chin Med J 2020. 
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(Diabetes Metab Syndr 2020, see below) indicated that acute cardiac injury, defined as significant elevation of cardiac 
troponins, is the most commonly reported cardiac abnormality in COVID-19. It occurs in approximately 8-12% of all 
patients. Direct myocardial injury due to viral involvement of cardiomyocytes and the effect of systemic inflammation 
appear to be the most common mechanisms responsible for cardiac injury. 
Of note, while expression of the ACE2 receptor in kidney and bladder had suggested the possibility of renal 
involvement in COVID-19, Wang (manuscript on medRxiv: 
https://www.medrxiv.org/content/10.1101/2020.02.19.20025288v1)  analysed data from 116 hospitalized patients, 
and concluded that acute renal impairment was uncommon in COVID-19, and that there was no aggravation of chronic 
renal failure observed in this cohort. 
Although abnormalities of liver function indexes are common in COVID-19 patients, based on a retrospective study 
conducted on 115 confirmed cases, the impairment of liver function was not found by Zhang (Liver Int 2020, see below) 
to be a prominent feature of COVID-19. 
A report by Zhao (Lancet Neurol 2020, see below) described a case of SARS-CoV-2 infection associated with Guillain-
Barré syndrome. 
Clinical disease outside China 
Descriptions of cases that occurred outside China are also available. For instance:  
 Ki (Epidemiol Health 2020, see below) described the early cases identified in Korea,  
 Holshue the first case in the United States of America (USA) (New Engl J Med 2020, see below), and Harcourt 
(Emerg Infect Dis  2020, see below) the virus isolation from this patients and its characterization, 
 Arentz (JAMA 2020, see below) 21 critically Ill patients with COVID-19 in Washington State, USA, 
 Bastola (Lancet Inf Dis 2020, see below) and Shrestha (J Travel Med 2020, see below) the first case in Nepal, 
 Silverstein (Lancet 2020, see below) and Marchand-Senecal (Clin Inf Dis 2020, see below) described the first 
imported case in Canada, 
 Van Cuong (Lancet Inf Dis 2020, see below) the first case in Vietnam,  
 Cheng (J Formos Med Assoc 2020, see below) described the first case in Taiwan, and Huang (J Micr Imm Inf 
2020, see below) 2 cases in Taiwan, 
 Lillie (J Inf 2020, see below) described 2 cases in the UK with person to person transmission, 
 Young (JAMA 2020, see below) described the case series of the first 18 patients with PCR-confirmed SARS-
CoV-2 infection at 4 hospitals in Singapore from January 23 to February 3, 2020, 
 The COVID-19 National Emergency Response Center (Osong Public Health Res Perspect 2020, see below) 
presented 28 cases in South Korea, 
 Bernard Stoecklin (Euro Surv 2020, see below) and Lescure (Lancet Inf Dis 2020, see below) presented the first 
cases in France, 
 Pongpirul (Emerg Infect Dis. 2020, see below) described 11 cases in Thailand, 
 Goyal (NEJM 2020, see below) described the key characteristics of 393 patients in New York.  
Spiteri (Euro Surv 2020, see below) described the first cases detected in Europe, excluding cases reported in the United 
Kingdom (UK), as at 21 February 2020. The analysis included both sporadic cases among travellers from China (14 
cases) and cases who acquired infection due to subsequent local transmission in Europe (21 cases). The clinical 
presentation observed in the cases in Europe is that of an acute respiratory infection. However, of the 31 cases with 
information on symptoms, 20 cases presented with fever and nine cases presented only with fever and no other 
symptoms. 
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Tostmann (Euro Surv 2020, see below) reported data from a Dutch study in which all 1247 HCW tested between 10 
and 29 March 2020 received an email with a link to an online questionnaire on the symptoms they experienced before 
their test. Test-positive HCW most frequently reported headache (71%), general malaise (63%) and muscle ache (63%). 
A systematic review by Grant (PLoS One 2020, see below) determined the prevalence of symptoms associated with 
COVID-19 worldwide. The most prevalent symptoms were fever (78% [95% CI 75%-81%]; 138 studies, 21,701 patients; 
I2 94%), a cough (57% [95% CI 54%-60%]; 138 studies, 21682 patients; I2 94%) and fatigue (31% [95% CI 27%-35%]; 78 
studies, 13,385 patients; I2 95%). Overall, 19% of hospitalised patients required non-invasive ventilation (44 studies, 
6513 patients), 17% required intensive care (33 studies, 7504 patients), 9% required invasive ventilation (45 studies, 
6933 patients) and 2% required extra-corporeal membrane oxygenation (12 studies, 1486 patients). 
A Cochrane review undertaken on 27 April 2020 identified 16 studies including 7706 participants (Struyf Cochrane 
Database Syst Rev 2020, see below). Prevalence of COVID-19 varied from 5% to 38% with a median of 17%. The authors 
found data on 27 signs and symptoms, falling into four different categories: systemic, respiratory, gastrointestinal and 
cardiovascular. No studies assessed combinations of different signs and symptoms and results were highly variable 
across studies. Most had very low sensitivity and high specificity; only six symptoms had a sensitivity of at least 50% in 
at least one study: cough, sore throat, fever, myalgia or arthralgia, fatigue, and headache. Of these, fever, myalgia or 
arthralgia, fatigue, and headache could be considered red flags (defined as having a positive likelihood ratio of at least 
5) for COVID-19 as their specificity was above 90%, meaning that they substantially increase the likelihood of COVID-
19 when present. 
Non-respiratory symptoms 
Cardiac manifestations 
A meta-analysis by Li (Prog Cardiovasc Dis 2020, see below), based on a systematic literature search across Pubmed, 
Embase and pre-print from December 1, 2019 to March 27, 2020, found acute cardiac injury more frequent in those 
with severe, compared to milder, disease (risk ratio 5.99, 3.04 to 11.80; p < 0.001). Meta-regression suggested that 
cardiac injury biomarker differences of severity are related to a history of hypertension (p = 0.030). In addition, 
COVID19-related cardiac injury was associated with higher mortality (summary risk ratio 3.85, 2.13 to 6.96; p < 0.001). 
hsTnI and NT-proBNP levels increased during the course of hospitalization only in non-survivors. 
More recent reviews confirmed these observations. For instance, a narrative literature review by Cruz Rodriguez (J 
Invest Med, see below) indicated that myocardial injury has been reported in 20%-30% of patients hospitalized due to 
COVID-19 and is associated with a worse prognosis and high mortality (~50%-60%). Proposed mechanisms of 
myocardial injury include inflammation within the myocardium (due to direct viral infection or cytokine storm), 
endotheliitis, coronary vasculitis, myocarditis, demand ischemia, plaque destabilization and right ventricular failure. 
The right ventricle is particularly vulnerable to injury and failure in COVID-19-infected patients, given the hypoxic 
pulmonary vasoconstriction, pulmonary microthrombi or pulmonary embolism. 
Gastrointestinal symptoms 
A U.S. case-control study among the 278 COVID-19 positive patients showed 35% of patients had gastrointestinal 
symptoms (Nobel Gastroenterology 2020, see below) 
Skin disorders 
Searching for evidence of skin involvement of COVID-19, Recalcati (J Eur Acad Dermatol Venereol 2020, see below) 
retrospectively analysed 88 patients, of which 18 patients (20.4%) developed cutaneous manifestations: 8 patients 
developed cutaneous involvement at the onset, 10 patients after the hospitalization. Cutaneous manifestations were 
erythematous rash (14 patients), widespread urticaria (3 patients) and chickenpox-like vesicles (1 patient). This was 
the first report of this kind. Joob (J Am Acad Dermatol 2020, see below) also provided a case report from Thailand 
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where the patient presented a skin rash with petechiae. Other common virus infections that might cause fever, rash 
and respiratory problem were ruled out by laboratory investigation and the final diagnosis of COVID-19 infection was 
by RT-PCR.  
Zulfiqar (NEJM 2020, see below) described a case of thrombocytopenic purpura in a female patient with COVID-19. 
The temporal sequence in this case suggested, but did not prove, that COVID-19 was a causal factor. 
Kolivras (JAAD Case Rep. 2020, see below) presented a case report of COVID-19 induced chilblains. Other reports of 
such symptom had appeared before in social media and in scientific literature. This case was interesting as a punch 
biopsy was obtained. Histopathologic findings resembled chilblain lupus with an absence of significant papillary dermal 
oedema. There was a superficial and deep lymphoplasmacytic infiltrate. 
Subsequent reports confirmed these observations, and various review papers were made available (see for instance 
Wollina (Dermatol Ther 2020, see below). As recently summarized by Singh (Adv Wound Care New Rochelle 2020, see 
below) cutaneous manifestations have been found in people of all age groups, including children. The cutaneous 
manifestations of COVID-19 are varied and include maculopapular, chilblain-like, urticarial, vesicular, livedoid, and 
petechial lesions. In addition, rashes are common in multisystem inflammatory syndrome in children, a new and 
serious health condition that shares symptoms with Kawasaki disease and is likely related to COVID-19. In addition, 
personal protective equipment-related skin wounds are of serious concern since broken cutaneous barriers can create 
an opening for potential COVID-19 infections. 
Ocular manifestations 
A recent systematic review and meta-analysis by Cao (Biomed Res Int 2020, see below) included a total of 12 studies 
with 1930 participants. The pooled prevalence rate of conjunctivitis/conjunctival congestion was 8% (95% CI: 5%-12%). 
1% (95% CI: 1%-4%) of COVID-19 patients were diagnosed with conjunctivitis/conjunctival congestion as the initial 
symptom. The pooled positive rate of conjunctival swab samples was 3% (95% CI: 2%-5%). The authors also assessed 
other ocular symptoms, including foreign body sensation, increased secretion, and eye itching. The pooled prevalence 
rates were 6% (95% CI: 3%-10%), 10% (95% CI: 8%-12%), and 9% (95% CI: 7%-10%), respectively. 
Venous thromboembolism 
While alterations of the coagulation pathways had soon been detected by clinical laboratory analyses, reports of 
thromboembolism related to COVID-19 appeared a few weeks later in the scientific literature.  
 Davoodi (preprint available at Research Square: https://www.researchsquare.com/article/rs-21602/v1) 
reported a case of deep vein thrombosis in a 57-year-old woman presenting with pain, redness, and leg 
swelling, who was then diagnosed with COVID-19.  
 Cui (J Thromb Haemost. 2020, see below) found an incidence of 25% (20/81) venous thromboembolism among 
patients with severe disease; 8 of these patients with venous thromboembolism events died. The venous 
thromboembolism group was different from the non-venous thromboembolism group in age, lymphocytes 
counts, activated partial thromboplastin time (APTT), D-dimer, etc. If 1.5 µg/mL was used as the D-dimer cut-
off value to predicting venous thromboembolism, the sensitivity was 85.0%, the specificity was 88.5% and the 
negative predictive value (NPV) was 94.7%.  
 The incidence of thrombotic complications (composite outcome of symptomatic acute pulmonary embolism, 
deep-vein thrombosis, ischemic stroke, myocardial infarction or systemic arterial embolism) was studied in 
184 ICU patients with proven COVID-19 pneumonia at 3 Dutch hospitals (Klok Thrombosis Res 2020: 
https://www.sciencedirect.com/science/article/pii/S0049384820301201). All patients received at least 
standard dose thromboprophylaxis. The cumulative incidence of the composite outcome was 31% (95%CI 20-
41), of which CT pulmonary angiography and/or ultrasonography confirmed venous thromboembolismin 27% 
(95%CI 17-37%) and arterial thrombotic events in 3.7% (95%CI 0-8.2%). Acute pulmonary embolism was the 
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most frequent thrombotic complication (n = 25, 81%). In this study, age (adjusted hazard ratio (aHR) 1.05/per 
year, 95%CI 1.004-1.01) and coagulopathy, defined as spontaneous prolongation of the prothrombin time > 3 
s or activated partial thromboplastin time > 5 s (aHR 4.1, 95%CI 1.9-9.1), were independent predictors of 
thrombotic complications. 
 A retrospective study conducted in France evaluated 26 consecutive patients with severe COVID-19 (Llitjos J 
Thromb Haemost 2020, see below). Eight of these patients (31%) were treated with prophylactic 
anticoagulation whereas 18 patients (69%) were treated with therapeutic anticoagulation. The overall rate of 
venous thromboembolic events in patients was 69%. The proportion of venous thromboembolic events was 
significantly higher in patients treated with prophylactic anticoagulation when compared to the other group 
(100% vs. 56%, respectively, p=0.03). Surprisingly, the authors found a high rate of thromboembolic events in 
COVID-19 patients treated with therapeutic anticoagulation, with 56% of venous thromboembolic events and 
6 pulmonary embolisms. 
Kermani-Alghoraishi (Curr Probl Cardiol 2020, see below) reviewed venous thromboembolism phenomena in COVID-
19 patients and the importance of their timely diagnosis. A systematic review by Divani (J Stroke Cerebrovasc Dis, see 
below) provided more insights into the clinical manifestations and pathophysiological mechanisms of stroke in COVID-
19 patients. SARS-CoV-2 can down-regulate ACE2 and, in turn, overactivate the classical renin-angiotensin system (RAS) 
axis and decrease the activation of the alternative RAS pathway in the brain. The consequent imbalance in vasodilation, 
neuroinflammation, oxidative stress, and thrombotic response may contribute to the pathophysiology of stroke during 
SARS-CoV-2 infection. 
Neurological manifestations  
A few months into the epidemic, Asadi-Pooya (J Neurol Sci 2020, see below) found highly likely that some patients, 
particularly those who suffer from a severe illness, have CNS involvement and neurological manifestations, even 
though such evidence was scarce and of low quality. More solid data on this topic accumulated in the following months; 
the number of recognized neurologic manifestations of SARS-CoV-2 infection increased rapidly. These neurologic 
manifestations may result from a variety of mechanisms, including virus-induced hyperinflammatory and 
hypercoagulable states, direct virus infection of the CNS, and postinfectious immune mediated processes (Koralnik 
Ann Neurol 2020, see below). Numerous review papers documented the various neurological symptoms and 
complications associated with the infection (see for instance Azim Cureus 2020, see below; Paterson Brain 2020, see 
below; Nepal Crit Care 2020, see below; Correia Neurol Psychiatry Brain Res 2020, see below; Almqvist Ann Clin Transl 
Neurol 2020, see below). A recent meta-analysis by Chua (Brain Inj 2020, see below) based on 48 studies reported on 
70 patients with 73 neurological manifestations. 39 (53.4%) patients had stroke, 18 (24.7%) had Guillain-Barré 
syndrome and variants, 11 (15.1%) had meningitis, encephalitis, encephalopathy, or myelitis, and five (6.8%) had 
seizures. They had a mean age of 61.9 ± 17.7 years (60.6% male). Neurological disease occurred 8.1 ± 6.8 days from 
initial symptoms. Average mortality rate was 17.8%. Stroke has a mortality rate of 25.6%. Olfactory and gustatory 
dysfunction occurred in 59.9% and 57.5%, respectively. 
Taste and olfactory disorders 
In March 2020, multiple reports in the media started to associate anosmia and dysgeusia with COVID-19 (see for 
instance, https://www.sciencealert.com/mild-covid-19-might-cause-a-lost-of-smell-or-taste; or 
https://edition.cnn.com/2020/03/23/health/coronavirus-symptoms-smell-intl/index.html). Giacomelli (Clin Inf Dis 
2020, see below) performed a cross-sectional survey of the prevalence of olfactory and taste disorders in the context 
of SARS-CoV-2 infection. Twenty (33.9%) reported at least one taste or olfactory disorder and 11 (18.6%) both. Twelve 
patients (20.3%) presented the symptoms before the hospital admission, whereas 8 (13.5%) experienced the 
symptoms during the hospital stay. Taste alterations were more frequently (91%) before hospitalization, whereas after 
hospitalization taste and olfactory alteration appeared with equal frequency. Mao (JAMA Neurol 2020, see below) 
Delivered by Ingenta
IP: 157.193.240.2 On: Fri, 04 Jun 2021 12:29:12
Copyright Leuven University Press
 
Authors: Martine Denis, Valerie Vandeweerd, Rein Verbeke, Anne Laudisoit, Tristan Reid, Emma Hobbs, Laure Wynants, Diane 
Van der Vliet  
COVIPENDIUM version: 20 OCT 2020  Transdisciplinary Insights - Living Paper | 41 
reported hypogeusia in 12 [5.6%]) and hyposmia in 11 out of 214 patients [5.1%]). A study by Lechien (Eur Arch 
Otorhinolaryngol 2020, see below) involved 417 mild-to-moderate COVID-19 patients. Face pain and nasal obstruction 
were the most disease-related otolaryngological symptoms in this cohort. 85.6% and 88.0% of patients reported 
olfactory and gustatory dysfunctions, respectively. There was a significant association between both disorders 
(p < 0.001). Olfactory dysfunction appeared before the other symptoms in 11.8% of cases. Among the 18.2% of 
patients without nasal obstruction or rhinorrhoea, 79.7% were hyposmic or anosmic. The early olfactory recovery rate 
was 44.0%. Females were significantly more affected by olfactory and gustatory dysfunctions than males (p = 0.001). 
Eliezer (JAMA Otolaryngol Head Neck Surg 2020, see below) presented a case where the main symptom expressed by 
the patient infected by SARS-CoV-2 was the sudden and complete loss of the olfactory function without nasal 
obstruction. CT scan of the nasal cavity that showed bilateral inflammatory obstruction of the olfactory clefts that was 
confirmed on magnetic resonance imaging of the nasal cavity. There were no anomalies of the olfactory bulbs and 
tracts. Similarly, Galougahi (Acad Radiol 2020, see below) found normal olfactory bulb volume without abnormal signal 
intensity in the olfactory bulb and tract and no sign of nasal congestion by magnetic resonance. This finding is 
consistent with prior reports of SARS-CoV-induced anosmia, where olfactory bulb MRI similarly did not demonstrate 
abnormal findings. The authors suggested further investigations incl. longitudinal MRI both in the acute and in follow-
up phases of the disease. 
Of note, Gane (Rhinology 2020, see below) reported a case characterized by sudden onset anosmia in a COVID-19 
confirmed patient who did not develop any further symptoms. Based on a survey of 2428 patients reporting new onset 
anosmia during the COVID-19 pandemic, Hopkins (Rhinology 2020, see below) concluded that 1 in 6 patients with 
recent onset anosmia reports this as an isolated symptom. COVID-19 testing was not performed in this study, but the 
authors recommended additional studies to further investigate the link between this symptom and the virus. 
In a Stockholm, Sweden, hospital, where 19.1% of the medical staff (N=2149) were seropositive for SARS-CoV-2 (IgG 
antibodies, as tested by multiplex assay displaying 99.4% sensitivity and 99.1% specificity), the symptoms with the 
strongest correlation to seroprevalence were anosmia and ageusia, indicating that both disorders be included in 
screening guidance and in the recommendations of self-isolation to reduce further spread of SARS-CoV-2 (Rudberg 
Nature Comm 2020, see below). 
Spinato (JAMA 2020, see below) found that an altered sense of smell or taste was more frequent among 105 women 
(72.4%; 95% CI, 62.8%-80.7%) than among 97 men (55.7%; 95% CI, 45.2%-65.8%; P = .02). 
Menni (Nature Med 2020, see below) investigated whether loss of smell and taste is specific to COVID-19 in 2 618 862 
individuals who used an app-based symptom tracker. Among the 18 401 who had undergone a SARS-CoV-2 test, the 
proportion of participants who reported loss of smell and taste was higher in those with a positive test result (4668 of 
7178 individuals; 65.03%) than in those with a negative test result (2436 of 11223 participants; 21.71%) (odds 
ratio = 6.74; 95% confidence interval = 6.31–7.21).  
Encephalopathy and/or encephalitis  
Encephalopathy and/or encephalitis are reported by an increasing number of studies (Almqvist Ann Clin Transl Neurol 
2020, see below). Nepal (Crit Care 2020, see below) reviewed 6 cases of encephalitis reported from China, Switzerland, 
Japan, and from America. The age of the patients ranged from early 20s to late 60s. All of them had preceding 
symptoms of fever and cough followed by a rapidly deteriorating level of consciousness. Meningeal irritability in the 
form of nuchal rigidity, Kernig’s, and Brudzinski’s was reported in two out of the six cases. Where lumbar puncture 
was performed, it showed lymphocytic pleocytosis typical of a viral meningo-encephalitis. SARS-CoV-2 was detected 
in the cerebrospinal fluid (CSF) in only one Chinese patient and Japanese patient.  
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An observational case series from France reported on neurological complications in intensive care unit patients: 13/58 
of patients (22%) presented with encephalopathic features (Almqvist Ann Clin Transl Neurol 2020, see below). Brain 
MRI showed that 8/13 patients displayed leptomeningeal enhancement on post‐contrast T1‐weighted and fluid‐
attenuated inversion recovery (FLAIR) sequences – a sign of leptomeningeal inflammation. Another French study 
found that 7/26 patients (27%) showed EEG/MRI changes suggestive of encephalopathy. Also, several cases of acute 
necrotizing encephalopathy (ANE) or posterior reversible encephalopathy syndrome (PRES) have been described. A 
Turkish study showed that 12/27 patients (44%) showed abnormalities on brain MRI with signs suggestive of ischemia 
or menigoencephalitis. Of note, only minimal evidence points to direct infection of neurons/glial cells by SARS-CoV-2 
viral particles, as shown by mostly negative RT-PCR analyses from CSF. Nevertheless, CSF from a small subset of 
patients with encephalitic features did test positive for SARS-CoV-2 RNA. 
Cases of COVID-19-associated acute disseminated encephalomyelitis (ADEM) have also been reported (see for 
instance Parsons (J Neurol 2020, see below) or de Miranda Henriques-Souza (Neuroradiol 2020, see below). 
Guillain-Barre Syndrome 
Toscano (NEJM 2020, see below) examined five patients who had Guillain-Barré syndrome after the onset of COVID-
19. The findings were generally consistent with an axonal variant of Guillain-Barré syndrome in three patients and with 
a demyelinating process in two patients. The authors reported that they could not determine whether severe deficits 
and axonal involvement are typical features of COVID-19–associated Guillain-Barré syndrome. An additional case 
observed in Iran was reported by Sedaghat (J Clin Neurosci 2020, see below), and a case in the U.S.A. presented by 
Virani (IDCases 2020, see below). Subsequently, a review by Brouwer (Brouwer Infez Med 2020, see below) identified 
a total of 9 cases of Guillain-Barré syndrome. Two Guillain-Barré syndrome variants have also been described in a case 
series from Spain. Specifically, one case of Miller Fisher syndrome and one case of polyneuritis cranialis associated 
with COVID-19 was described (Nepal Crit Care 2020, see below). A similar review of case reports by Carrillo-Larco 
(Wellcome Open Res 2020, see below) identified 12 cases of Guillain-Barré syndrome and COVID-19; one was a Miller 
Fisher case. The age ranged between 23 and 77 years, and there were more men (9/102). Guillain-Barré symptoms 
started between 5 and 24 days after those of COVID-19. The protein levels in cerebrospinal fluid samples ranged 
between 40 and 193 mg/dl. None of the cerebrospinal fluid samples tested positive for COVID-19. 
Acute myelitis 
Several authors documented acute myelitis in COVID-19 patients. The first of these cases  was a 66-year-old male, 
from Wuhan, with a 5-day history of fever, who was admitted to the hospital and found positive for SARS-CoV-2 
(reviewed by Nepal Crit Care 2020, see below). After a night of high fever, he developed bilateral weakness of his 
lower limbs, with urinary and bowel incontinence, rapidly progressing to flaccid lower extremity paralysis and 
paraesthesia and numbness below T10. Planters were down going bilaterally. A clinical diagnosis of post-infectious 
acute myelitis was made. He received treatment with ganciclovir, lopinavir/ritonavir, moxifloxacin, dexamethasone, 
IVIG, and mecobalamin. His bilateral lower extremity paralysis ultimately improved. Subsequent reports of acute 
myelitis associated with COVID-19 included those by AlKetbi (Radiol Case Rep 2020, see below), Durrani (Clin Pract 
Cases Emerg Med 2020, see below), Sotoca (Neurol Neuroimmunol Neuroinflamm. 2020, see below) and Águila-Gordo 
(J Clin Neurosci 2020, see below).  
Chow (BMJ Case Rep 2020, see below), Chakraborty (BMJ Case Rep 2020, see below) and Munz (J Neurol 2020, see 
below) described cases of acute transverse myelitis. A case of acute necrotizing myelitis (ANM) and acute motor axonal 
neuropathy (AMAN), a rare variant of Guillain-Barré syndrome, was also described by Maideniuc (J Neurol 2020, see 
below). 
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Clinical imaging  
Chest computed tomography 
A number of early reports provided a detailed description of chest computed tomography (CT) scan findings of patients 
with COVID-19 pneumonia. For instance: 
 Kong Radiol 2020 (https://pubs.rsna.org/doi/full/10.1148/ryct.2020200028);   
 Li Radiol 2020 (https://pubs.rsna.org/doi/full/10.1148/ryct.2020200026);  
 Ng Radiol 2020 (https://pubs.rsna.org/doi/full/10.1148/ryct.2020200034);  
 Song Radiol 2020, see below; 
 Chung Radiol 2020, see below; 
 Bernheim Radiol 2020, see below; 
 Yoon Korean J Radiol 2020, see below; 
 Xu Eur J Nucl Med Mol Imaging 2020, see below; 
 Yang (J Inf 2020, see below) presented clinical imaging data from 149 RT-PCR confirmed positive patients in 
three tertiary hospitals of Wenzhou; 
 Shi Lancet Inf Dis 2020, see below; 
 Xu (J Inf 2020, see below) described data from 50 patients, including mild type, common, severe and critically 
severe cases; 
 Albarello (Int J Infect Dis 2020, see below) presented the CT findings in 2 cases in Italy; 
 Li and Xia (AJR Am J Roentgenol 2020, see below) described 51 cases in Wuhan; 
 Zhou (AJR Am J Roentgenol 2020, see below) described CT findings in 62 patients in Wuhan; 
 Xiong (Invest Radiol 2020, see below) described 42 cases in Wuhan including cases with progressive disease 
features; 
 Zhu (J Inf 2020, see below) described 6 cases in Guangzhou; 
 Li (Ped Radiol 2020, see below) presented CT findings from 5 children at a large tertiary-care hospital in China 
with positive RT-PCR for COVID-19; 
 Xia (Pedriatr Pulmonol 2020, see below) described 20 paediatric patients , of which 6 presented with unilateral 
pulmonary lesions (6/20, 30%), 10 with bilateral pulmonary lesions (10/20, 50%), and 4 showed no 
abnormality on chest CT (4/20, 20%);  
 Zhao (Clin Radiol 2020, see below) presented chest CT images of 80 patients in China. 
Guan (NEJM 2020, see below) found that on admission ground-glass opacity (see Figure 8) was the typical radiological 
finding on chest CT (50.00%, in a dataset of 1 099 patients with laboratory-confirmed disease). The typical radiological 
imaging of COVID-19 pneumonia demonstrated destruction of the pulmonary parenchyma including interstitial 
inflammation and extensive consolidation, similar to SARS (Pan Radiol 2020, see below). However, some patients with 
COVID-19 pneumonia consistently demonstrated no hypoxemia or respiratory distress during the course of 
hospitalization. A study in 21 patients recovering from COVID-19 pneumonia (without severe respiratory distress 
during the disease course) showed that lung abnormalities on chest CT showed greatest severity approximately 10 
days after initial onset of symptoms. Dai (Can Assoc Radiol 2020, see below) also discussed the difference between 
COVID-19 and other lung diseases. 
Zhang (Int Care Med 2020, see below) observed white “Septal Lines” in a 75-year-old male confirmed with severe 
COVID-19 pneumonia, suggesting that cellulosic exudation occurred at the surface of lung lobes. 
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Figure 8 CT lung imaging from a 41-year-old woman who tested positive for COVID-19. This 3-D reconstruction shows multifocal ground 
glass opacities without consolidation (from https://www.itnonline.com/content/radiologists-describe-coronavirus-ct-imaging-features). 
 
Salehi (AJR Am J Roentgenol 2020, see below) published a systematic review of imaging findings in 919 patients. The 
authors found the characteristic patterns and distribution of CT manifestations: ground glass opacification (GGO) 
(88.0%), bilateral involvement (87.5%), peripheral distribution (76.0%), and multilobar (more than one lobe) 
involvement (78.8%) (Table 4). Isolated GGO or a combination of GGO and consolidative opacities were some of the 
most common CT findings. Other CT findings included interlobular septal thickening, bronchiectasis, pleural thickening, 
and subpleural involvement, with various rates across the studies. Pleural effusion, pericardial effusion, 
lymphadenopathy, cavitation, CT halo sign, and pneumothorax were less common or rare. 
Table 4 Common Patterns and Distribution on Initial CT Images of 919 Patients With COVID-19 (from Salehi AJR AM J Roentgenol 2020) 
 
Thirteen studies (2738 participants, with 2386 having abnormal CT imaging features) were included in a meta-analysis 
by Bao (J Am Coll Radiol, see below), which was aimed at providing a more precise estimate of detection of COVID-19 
by chest CT and reporting on the most common imaging findings on chest CT imaging. The pooled positive rate of the 
CT imaging was 89.76% and 90.35% when only including thin-section chest CT. Typical CT signs were ground glass 
opacities (83.31%), ground glass opacities with mixed consolidation (58.42%), adjacent pleura thickening (52.46%), 
interlobular septal thickening (48.46%), and air bronchograms (46.46%). Other CT signs included crazy paving pattern 
(14.81%), pleural effusion (5.88%), bronchiectasis (5.42%), pericardial effusion (4.55%), and lymphadenopathy (3.38%). 
The most anatomic distributions were bilateral lung infection (78.2%) and peripheral distribution (76.95%). The 
incidences were highest in the right lower lobe (87.21%), left lower lobe (81.41%), and bilateral lower lobes (65.22%). 
The right upper lobe (65.22%), right middle lobe (54.95%), and left upper lobe (69.43%) were also commonly involved. 
The incidence of bilateral upper lobes was 60.87%. A considerable proportion of patients had three or more lobes 
involved (70.81%). 
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Qin (Eur J Nucl Med Mol Imaging 2020, see below) described for the first time the 18F-FDG PET/CT findings of four 
patients with COVID-19. The data confirmed previous observations of peripheral ground-glass opacities and/or lung 
consolidations (in more than two pulmonary lobes). Lung lesions were characterized by a high 18F-FDG uptake and 
there was evidence of lymph node involvement. Conversely, disseminated disease was absent, a finding suggesting 
that COVID-19 has pulmonary tropism.  
Following the evaluation of 80 patients, Wu (Invest Radiol 2020, see below) suggested significant correlations between 
the degree of pulmonary inflammation and the main clinical symptoms and laboratory results. Similarly, Zhao (AJR Am 
J Roentgenol 2020, see below) investigated the relationship between chest CT findings and the clinical condition of 
101 patients with COVID-19 pneumonia in Hunan, China, and found that architectural distortion, traction 
bronchiectasis, and CT involvement score aided in the evaluation of the severity and extent of the disease. 
Based on a retrospective analysis of 27 consecutive patients, Yuan (PLoS One 2020, see below) found that a simple CT 
scoring method was able to predict mortality. 
Lung ultrasound 
Chest CT has thus acquired a pivotal role for the diagnosis and assessment of lung involvement in COVID-19, and CT 
protocols are used to estimate the pulmonary damage. Unfortunately, CT scanning is not available in all emergency 
departments. Lung ultrasound is a surface imaging technique greatly developed in the last decades and strongly 
recommended for acute respiratory failure. Poggiali (Radiol 2020, see below) presented preliminary data from 12 
patients suggesting the feasibility of using bedside ultrasound for the early diagnosis of COVID-19 pneumonia. A 
recommendation for more studies on this topic was also made by Soldati (J Ultrasound Med 2020, see below), who 
presented data from 2 additional cases. However, a study by Lu (Ultraschall Med 2020, see below) showed moderate 
agreement (Kappa = 0.529) between bedside ultrasound for lung lesions and CT in patients with COVID-19. The 
ultrasound scores to evaluate mild, moderate and severe lung lesions exhibited sensitivity of 68.8 % (11/16), 77.8 % 
(7/9), 100.0 % (2/2), specificity of 85.7 % (12/14), 76.2 % (16/21), 92.9 % (26/28), and diagnostic accuracy of 76.7 % 
(23/30), 76.7 % (23/30), 93.3 % (28/30), respectively. 
A standardized approach has been proposed to optimize the use of lung ultrasound in COVID-19 patients (Soldati, 
Smargiassi et al. J Ultrasound Med 2020, see below). Moreover, a panel of international experts evaluated the position 
of ultrasound in the management of COVID-19 and summarized benefits, open questions and challenges in the setting 
of the COVID-19 epidemic (Ultraschall Med 2020, see below). 
Laboratory finding & biomarkers 
A number of reports present the laboratory observations associated with COVID-19. Various studies addressed the 
search for a prognostic marker of severe infection, while others focused on understanding pathological mechanisms.  
Virus shedding & virus load 
A large number of studies analysed the virus load in respiratory secretions of COVID-19 patients (mostly using RT-PCR). 
Key findings related to virus detection in patients are illustrated below.  
Virus load and infectivity 
The correlation of RNA-based viral load in the respiratory tract with infectivity, as measured in cell culture, even though 
limited, has been established by several studies. Wölfel (Nature 2020, see below) provided a detailed virological 
analysis of 9 COVID-19 cases in Germany. Pharyngeal virus shedding was very high during the first week of symptoms 
(peak at 7.11 × 108 RNA copies per throat swab, day 4). Infectious virus was readily isolated from throat- and lung-
derived samples, but not from stool samples, in spite of high virus RNA concentration. Blood and urine never yielded 
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virus. Active replication in the throat was confirmed by viral replicative RNA intermediates in throat samples. 
Sequence-distinct virus populations were consistently detected in throat and lung samples from the same patient, 
proving independent replication. 
Virus load and disease severity 
The viral load detected from the respiratory tract of patients was soon positively linked to lung disease severity (Liu 
Sci China Life Sci 2020, see below), and subsequent studies confirmed this observation. Liu (Lancet Inf Dis 2020, see 
below) presented data from 76 patients suggesting that the viral load of SARS-CoV-2 might be a useful marker for 
assessing disease severity and prognosis. The mean viral load of severe cases was indeed around 60 times higher than 
that of mild cases. However, Lescure (Lancet Inf Dis 2020, see below) observed high nasopharyngeal virus load within 
the first 24 h of illness onset (5.2 and 7.4 log10 copies per 1000 cells, respectively), in 2 patients with few symptoms. 
Virus load by age 
Older age was correlated with higher viral load (Spearman's ρ=0·48, 95% CI 0·074-0·75; p=0·020) in a study by To 
(Lancet inf Dis 2020, see below), but a study by Zhou (Clin Infect Dis 2020, see below) did not reach the same conclusion 
when comparing patients <65 yrs [31.0 (IQR: 23.5-40.5) days] to those ≥65 yrs [31.0 (IQR: 24.3-38.0) days)]. 
Various studies also investigated the virus load in paediatric cases of infection. For instance, in a cohort of patients 
with mild to moderate illness within 1 week of symptom onset, Heald-Sargent (JAMA Ped 2020, see below) compared 
3 groups: young children younger than 5 years (n = 46), older children aged 5 to 17 years (n = 51), and adults aged 18 
to 65 years (n = 48). The authors found similar median (interquartile range) CT values for older children (11.1 [6.3-
15.7]) and adults (11.0 [6.9-17.5]). However, young children had significantly lower median (interquartile range) CT 
values (6.5 [4.8-12.0]), indicating that young children have equivalent or more viral nucleic acid in their upper 
respiratory tract compared with older children and adults. The topic was also addressed by Jones (manuscript on 
medRxiv: https://www.medrxiv.org/content/10.1101/2020.06.08.20125484v1). In this study, viral loads of at least 
250 000 copies, a threshold previously established by the authors for the isolation of infectious virus in cell culture at 
more than 5% probability, were present across the study period in 29.0% of kindergarten-aged patients 0-6 years old 
(n=38), 37.3% of those aged 0-19 (n=150), and in 51.4% of those aged 20 and above (n=3153). The authors concluded 
that a considerable percentage of infected people in all age groups, including those who are pre- or mild-symptomatic, 
carry viral loads likely to represent infectivity. 
Virus load in different types of specimens 
Presence of the virus in different types of clinical specimens was also analysed. Pan (Lancet Inf Dis 2020, see below) 
for instance, reported such analysis from 82 infected individuals. The data can be summarized as follows: 
 In 2 patients monitored daily, the viral loads in throat swab and sputum samples peaked at around 5-6 days 
after symptom onset, ranging from around 10⁴ to 10⁷ copies per mL during this time.  
 In individuals at different stages of infection, viral loads ranged from 641 copies per mL to 1.34×10¹¹ copies per 
mL, with a median of 7.99 × 10⁴ in throat samples and 7.52 × 10⁵ in sputum samples.  
 A sputum sample collected on day 8 post-onset from a patient who died had a very high viral load (1·34 × 10¹¹ 
copies per mL).  
 Notably, two individuals, who were under active surveillance because of a history of exposure to infected 
patients showed positive results on RT-PCR a day before onset, suggesting that infected individuals can be 
infectious before them become symptomatic. 
 From 17 confirmed cases with available data (representing days 0–13 after onset), stool samples from nine 
(53%; days 0–11 after onset) were positive on RT-PCR analysis, but with lower viral loads than respiratory 
samples. 
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Another study by Chen, Lan et al. (Em Micr Inf 2020, see below) found detectable SARS-CoV-2 RNA in the blood of 6 
of 57 patients. Importantly, all of these 6 patients progressed to severe symptom stage, indicating a strong correlation 
of serum viral RNA with disease severity (p-value = 0.0001). 
Kinetic studies 
SARS-CoV-2 shedding kinetics has significant implications for hospital infection prevention and control, discharge 
management, and public health. Various early reports describing cases observed in China therefore covered this 
important topic. In the cohort of 191 patients with laboratory-confirmed disease described by Zhou (Lancet 2020, see 
below), duration of viral shedding ranged between 8 and 37 days. The median duration of viral shedding was 20·0 days 
(IQR 17·0–24·0) in survivors, but continued until death in fatal cases. 
In the study by Liu (Lancet Inf Dis 2020, see below), the viral load of severe cases remained significantly higher for the 
first 12 days after onset than those of corresponding mild cases. Mild cases were also found to have an early viral 
clearance, with 90% of these patients repeatedly testing negative on RT-PCR by day 10 post-onset. By contrast, all 
severe cases still tested positive at or beyond day 10 post-onset. 
From a small series of 8 patients with mild to moderate disease, Ma (J Microbiol Immunol Infect 2020, see below) 
suggested that stool specimens of children may remain PCR-positive for a longer time than those of adults. 
Chang (Am J Respir Crit Care Med 2020, see below) determined the time kinetics of viral clearance in reference to the 
resolution of symptoms in 16 patients treated in Beijing, China, and showed that half of the patients with COVID-19 
were viral positive even after resolution of their symptoms.  
A study by To (Lancet inf Dis 2020, see below) in 23 patients with COVID-19 showed a median viral load in posterior 
oropharyngeal saliva or other respiratory specimens at presentation of 5·2 log10 copies per mL (IQR 4·1-7·0). Salivary 
viral load was highest during the first week after symptom onset and subsequently declined with time (slope -0·15, 
95% CI -0·19 to -0·11; R2=0·71). In one patient, viral RNA was detected 25 days after symptom onset.  
Yuan (Inflamm Res 2020, see below) presented a kinetic view of viral load, cell count and biochemical parameters in 
patients with mild/moderate and severe disease. The authors also observed that COVID-19 mRNA clearance ratio was 
significantly correlated with the decline of serum creatine kinase (CK) and lactate dehydrogenase (LDH) levels, which 
may then predict a favourable response to treatment.  
Additional data were reported by Perera (Em Inf Dis 2020, see below), who investigated 68 respiratory specimens from 
35 coronavirus disease patients in Hong Kong, of whom 32 had mild disease. Culturable SARS-CoV-2 and subgenomic 
RNA were rarely detectable beyond 8 days after onset of illness. By contrast, virus RNA was detectable for many weeks 
by reverse transcription PCR. 
Wölfel (Nature 2020, see below) provided a detailed virological analysis of 9 COVID-19 cases in Germany. Pharyngeal 
virus shedding was very high during the first week of symptoms (peak at 7.11 × 108 RNA copies per throat swab, day 
4). Shedding of viral RNA from sputum outlasted the end of symptoms. Of note, seroconversion occurred after 7 days 
in 50% of these patients (14 days in all), but was not followed by a rapid decline in viral load. 
Fontana (Inf Contr Hosp Epi 2020, see below) provided a review of available data on October 20 2020. Seventy-seven 
studies on SARS-CoV-2 were included. All studies reported PCR-based testing and 12 also included viral culture data. 
The overall pooled median duration of RNA shedding from respiratory sources was 18.4 days (95% CI: 15.5 days - 21.3 
days; I2=98.87%, p<0.01) among 28 studies. When stratified by disease severity, the pooled median duration of viral 
RNA shedding from respiratory sources was 19.8 days (95% CI: 16.2 days – 23.5 days; I2=96.42%, p<0.01) among 
severely ill patients and 17.2 days (95% CI: 14.0 days - 20.5 days; I2=95.64%, p<0.01) in mild/moderate illness. Viral 
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RNA was detected up to 92 days after symptom onset. Viable virus was isolated by culture from -6 days to 20 days 
relative to symptom onset. The authors concluded that SARS-COV-2 RNA shedding can be prolonged, even though 
high heterogeneity has been observed. Detection of viral RNA may not correlate with infectivity since available viral 
culture data suggested shorter durations of shedding of viable virus. Additional data is still needed to determine the 
duration of shedding of viable virus and the implications for risk of transmission. 
Cell counts 
Various early reports characterized the changes in cell counts in COVID-19 patients. Among these publications, a 
manuscript by Liu (on medRxiv: https://www.medrxiv.org/content/10.1101/2020.02.10.20021584v1) based on the 
monitoring of 61 patients suggested the neutrophil/lymphocyte ratio as a predictive marker of severe illness. This 
biomarker proved superior to the MuLBSTA score that had been suggested before for COVID-19 patients monitoring. 
A subsequent report from data in 40 patients confirmed this conclusion (Liu EBioMed 2020, see below). 
Chen (J Clin Invest 2020, see below) reported significantly lower lymphocyte counts in severe cases (0.7 × 109 125 /L) 
than moderate cases (1.1 × 109/L). Absolute number of T lymphocytes, CD4+T and CD8+T cells decreased in nearly all 
the patients, and were markedly lower in severe cases (294.0, 177.5 and 89.0 × 106/L) than moderate cases (640.5, 
381.5 and 254.0 × 106/L). The expressions of IFN-γ by CD4+T cells tended to be lower in severe cases (14.1%) than 
moderate cases (22.8%). 
A study by Zheng (manuscript on medRxiv: https://www.medrxiv.org/content/10.1101/2020.02.19.20024885v1)  
investigated differences in laboratory parameters between 103 COVID-19 and 22 non-COVID-19 pneumonia cases. The 
lymphocyte subsets counts were found to exhibit a significant negative correlation with biochemical indices relating 
to organ injury in the COVID-19 infected patients. 
Similarly, Zeng (manuscript on medRxiv: https://www.medrxiv.org/content/10.1101/2020.03.08.20031229v2) 
described a phenomenon of lymphocyte depletion (PLD) observed in 100% severe or critical cases (ICU). As the disease 
progressed and clinical status deteriorated, levels of lymphocytes were found progressively decreased before death.  
A study by Tan (Signal Transduct Target Ther 2020, see below) confirmed the observation of lymphopenia.  
Lymphocyte counts in severe patients were found to decrease initially and then increase to higher than 10% until 
discharge. In contrast, the lymphocyte count of moderate patients fluctuated very little after disease onset and was 
higher than 20% upon discharge. These results suggest that lymphopenia is a predictor of prognosis in COVID-19 
patients. 
Based on the observation that eosinopenia is frequently observed in COVID-19 patients (79% in SARS-CoV-2 positive 
patients vs. 36% in SARS-CoV-2 negative patients, Li (on medRxiv: 
https://www.medrxiv.org/content/10.1101/2020.02.13.20022830v1) suggested an alternative, simple, approach to 
facilitate triage of patients. The approach led to a diagnosis sensitivity and specificity of 79% and 64%, respectively. 
Zhang (Allergy 2020, see below) also reported eosinopenia in most patients, but the frequency of the observation 
(52.9%) does not support the diagnostic value of this marker. 
Qin (Clin Inf Dis 2020, see below) described 452 patients who underwent laboratory examinations on admission. 
Similar to previous reports, the authors reported that severe cases tend to have lower lymphocytes counts, higher 
leukocytes counts and neutrophil-lymphocyte-ratio (NLR), as well as lower percentages of monocytes, eosinophils, 
and basophils. Most of severe cases demonstrated elevated levels of infection-related biomarkers and inflammatory 
cytokines.  Lymphocyte subsets were analyzed in 44 patients with COVID-19 on admission. The total number of B cells, 
T cells and NK cells were significantly decreased in patients with COVID-19, and particularly in severe cases. The 
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percentage of naïve helper T cells (CD3+CD4+CD45RA+) increased and memory helper T cells (CD3+CD4+CD45RO+) 
were found decreased in severe cases.  
Chong (Br J Haematol 2020, see below) found reactive lymphocytes in 23/32 confirmed COVID-19 cases (72%) (Figure 
9). This is in stark contrast to the 2003 SARS where reactive lymphocytes of this type were not present in a review of 
185 cases in Singapore and were present in only 15.2% of 138 cases in Hong Kong. 
Similarly, Foldes (Am J Hematol 2020, see below) reported atypical lymphocytes that appeared reactive in a patient. 
Prominent among these were lymphoplasmacytoid lymphocytes with an eccentric nucleus, deeply basophilic 
cytoplasm and a prominent paranuclear hof. 
Figure 9 Reactive lymphocyte in COVID-19 patients (from Chong Br J Haematol 2020) 
  
The most common reactive lymphocyte subtype seen in COVID-19 patients displayed a distinctive abundant pale blue cytoplasm that often 
abuts adjacent red blood cells (top left and right). Lymphoplasmacytoid lymphocytes were present in 16 out of 23 patients (bottom images: left, 
right and centre). 
Biochemistry 
Elevated C-reactive protein (CRP) is an important feature of COVID-19 (Zhang Lancet Resp Med 2020, see below). A 
study in 12 patients (Liu Sci China Life Sci 2020, see below) found blood biochemistry indexes, albumin (ALB), CRP, 
lactate dehydrogenase (LDH), may be predictors of disease severity. Similarly, Liu (Chin Med J 2020, see below) 
found CRP to be significantly elevated in a progression group compared to another group of patients with 
improvement/stabilization (38.9 [14.3, 64.8] vs. 10.6 [1.9, 33.1] mg/L, U = 1.315, P = 0.024). Albumin was 
significantly lower in the progression group than in the improvement/stabilization group (36.62 ± 6.60 vs. 41.27 ± 
4.55 g/L, U = 2.843, P = 0.006). 
In a cohort of 132 COVID-19 patients, Li (J Infect 2020, see below) observed significantly increased serum amyloid A 
(SAA) and CRP levels. As disease progressed from mild to critically severe, SAA and CRP gradually increased, while 
lymphocyte counts decreased; a ROC curve analysis suggested that SAA/lymphocyte counts, CRP, SAA, and lymphocyte 
counts are valuable in evaluating the severity of COVID-19 and distinguishing critically ill patients from mild ones; 
patients with SAA consistently trending down during the course of disease had better prognosis, compared with 
patients with SAA continuously rising. Patient with higher initial SAA level were also more likely to have poor CT 
imaging. 
Delivered by Ingenta
IP: 157.193.240.2 On: Fri, 04 Jun 2021 12:29:12
Copyright Leuven University Press
 
Authors: Martine Denis, Valerie Vandeweerd, Rein Verbeke, Anne Laudisoit, Tristan Reid, Emma Hobbs, Laure Wynants, Diane 
Van der Vliet  
COVIPENDIUM version: 20 OCT 2020  Transdisciplinary Insights - Living Paper | 50 
Fan (Clin Gastroenterol Hepatol 2020, see below) described a cohort of 148 patients, of which (50.7%) showed 
abnormal liver function at admission, characterized by increased ALT, AST, GGT, AKP.  
Alanine aminotransferase, LDH levels, high-sensitivity CRP and ferritin were significantly higher in severe cases (41.4 
U/L, 567.2 U/L, 135.2 mg/L and 1734.4 ug/L) than moderate cases (17.6 U/L, 234.4 U/L, 51.4 mg/L and 880.2 ug /L) 
(Chen on medRxiv: https://www.medrxiv.org/content/10.1101/2020.02.16.20023903v1). IL-2R, TNF-α and IL-10 
concentrations on admission were significantly higher in severe cases (1202.4 pg/mL, 10.9 pg/mL and 10.9 pg/mL) 
than moderate cases (441.7 pg/mL, 7.5 pg/mL and 6.6 pg/mL).  
Moreover, the angiotensin II level in the plasma sample from COVID-19 patients has been found markedly elevated 
and linearly associated to viral load and lung injury (Liu Sci China Life Sci 2020, see below). 
A meta-analysis by Lippi (Clin Chim Acta 2020, see below) showed that increased  procalcitonin  values  are associated 
with a nearly 5-fold higher risk of severe SARS-CoV-2 infection (OR, 4.76; 95%  CI,  2.74-8.29).  The heterogeneity 
among the different studies was found to be modest (i.e., 34%). As the synthesis of this biomarker is inhibited by INF-
γ, whose concentration is expected to increase during viral infections, the authors speculate that increased 
procalcitonin could reflect bacterial superinfection in severe disease cases. However, more investigations are still 
needed to identify the origin of the biomarker. 
Another meta-analysis by Lippi (Prog Cardiovasc Dis 2020, see below) assessed cardiac troponin I (cTnI) in patients 
with COVID-19. Although the heterogeneity was considerably high, the values of cTnI were found to be significantly 
increased in patients with severe disease than in those without (SMD, 25.6 ng/L; 95% CI, 6.8–44.5 ng/L). 
A meta-analysis by Henry (Clin Chem Lab Med. 2020, see below) identified IL-6, IL-10 and serum ferritin as strong 
discriminators for severe disease. 
Aziz (J Med Virol 2020, see below) evaluated IL6 as a marker of severe disease. A total of 9 studies were included in 
the systematic review and meta-analysis. Patients with severe COVID-19 had significantly higher serum IL-6 levels 
compared to non-severe patients (mean difference (MD): 38.6 pg/mL, 95% CI: 24.3 - 52.9 pg/mL, p <0.001, I2 = 98.5%). 
On meta-regression, increasing mean IL-6 level was associated with increased mortality in patients (Coefficient (Q): 
0.01, 95% CI: 0.01-0.03, p = 0.03). 
A nice review by Terpos (Am J Hematol 2020, see below) provided a clear picture of the laboratory findings associated 
with COVID-19. Evidence was presented to support that various parameters have potential as predictive parameters 
for severity: lymphopenia, thrombocytopenia and neutrophilia (raised neutrophils) not only predict ARDS, but also 
cardiovascular complications. Raised procalcitonin, ferritin, LDH, IL-6 and CRP and the coagulation disorders (D-dimer, 
increased fibrin degradation, PTT and aPT) were also highlighted. 
Coagulation parameters 
Tang (J Thromb Haemost 2020, see below) described the coagulation data of 183 consecutive patients with confirmed 
COVID-19 pneumonia. The non-survivors revealed significantly higher D-dimer and fibrin degradation product (FDP) 
levels, longer prothrombin time and activated partial thromboplastin time compared to survivors on admission 
(P<0.05). 71.4% of non-survivors and 0.6% survivors met the criteria of disseminated intravascular coagulation during 
their hospital stay. 
Zhou (Lancet 2020, see below) found increasing odds of in-hospital death associated with D-dimer levels greater than 
1·0 μg/L (18·42, 2·64–128·55; p=0·0033) on admission. Gao (J Med Vir 2020, see below) found that IL-6 and D-Dimer 
were closely related to the occurrence of severe COVID-19 in adult patients, and their combined detection had the 
Delivered by Ingenta
IP: 157.193.240.2 On: Fri, 04 Jun 2021 12:29:12
Copyright Leuven University Press
 
Authors: Martine Denis, Valerie Vandeweerd, Rein Verbeke, Anne Laudisoit, Tristan Reid, Emma Hobbs, Laure Wynants, Diane 
Van der Vliet  
COVIPENDIUM version: 20 OCT 2020  Transdisciplinary Insights - Living Paper | 51 
highest specificity and sensitivity for early prediction of the severity of disease. In this study in 43 patients, the 
specificity of predicting the severity of COVID-19 during IL-6 and D-Dimer tandem testing was up to 93.3%, while the 
sensitivity of such testing reached 96.4%.  
A meta-analysis by Lippi (Clin Chim Acta 2020, see below) included 1779 COVID-19 patients, of whom 399 (22.4%) had 
severe disease. The pooled analysis revealed that platelet count was significantly lower in patients with more severe 
COVID-19 (WMD -31×109/L; 95% CI, from -35 to -29×109/L). A subgroup analysis comparing patients by survival, found 
an even lower platelet count observed with mortality (WMD, -48×109/L; 95% CI, -57 to -39×109/L. In the four studies 
which reported data on rate of thrombocytopenia (n=1427), a low platelet count was associated with over five-fold 
enhanced risk of severe COVID-19 (OR, 5.1; 95% CI, 1.8-14.6). 
Time from illness onset to death 
In an analysis of early published data, Linton (J Clin Med 2020, see below) found a median time delay of 13 days from 
illness onset to death (17 days with right truncation). However, the WHO-China Joint Mission on Coronavirus Disease 
2019 Mortality, which analysed data on 2114 COVID-19 related deaths among 55 924 laboratory-confirmed cases in 
China, reported that the time between symptom onset and death ranged from about 2 weeks to 8 weeks 
(https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf). 
Asymptomatic infections 
As illustrated by multiple reports, significant proportion of SARS-CoV-2 infections is not associated with any symptom 
of the disease.  For instance, Zhou (Clin Microb Inf 2020, see below) monitored a cohort of 13 patients who were 
asymptomatic at the time of diagnosis. 12/13 presented with radiographic abnormalities from the time of diagnosis; 
4/13 presented signs of radiographic progression; only 3/13 developed symptoms of the disease from 2 days after 
diagnosis. All patients became negative by PCR by day 18 at the latest.  
Day (BMJ 2020, see below) reported data from approx. 3000 individuals in an Italian village and showed that a majority 
of people infected with SARS-CoV-2 (50-75%) were asymptomatic. Similarly, Kimball (MMWR 2020, see below) 
reported facility-wide testing in long-term care facility, which identified a 30.3% prevalence of infection among 
residents. Approximately half of the residents with positive test results did not have any symptoms at the time of 
testing. 
In some cases, apparent asymptomatic infections may actually correspond to presymptomatic patients. In another 
example, Hu (Sci China Life Sci 2020, see below) presented the clinical characteristics of 24 cases with asymptomatic 
infection screened from close contacts in Nanjing, China. None of the 24 asymptomatic cases reported any obvious 
symptoms when nucleic acid screening was performed. Five cases (20.8%) developed symptoms (fever, cough, fatigue, 
etc.) during hospitalization. Twelve (50.0%) cases showed typical CT images of ground-glass chest and 5 (20.8%) 
presented stripe shadowing in the lungs. The remaining 7 (29.2%) cases showed normal CT image and had no 
symptoms during hospitalization. These 7 cases were younger (median age: 14.0 years; P=0.012) than the rest.  
A number of studies aimed at quantifying the proportion of asymptomatic infections. As indicated by Nishiura (Int J 
Inf Dis 2020, see below), the asymptomatic ratio is conventionally estimated using sero-epidemiological data. However, 
such data were not available at the beginning of the epidemic. Instead, the authors estimated the asymptomatic ratio 
by using information on Japanese nationals that were evacuated from Wuhan, China on chartered flights. Based on 
this very small sample size, the asymptomatic ratio was estimated at 30.8% (95% confidence interval (CI): 7.7%, 53.8%) 
among evacuees. Mizumoto (Euro Surveill 2020, see below) derived the delay-adjusted asymptomatic proportion of 
infections cases on board the Diamond Princess cruise ship. The estimated asymptomatic proportion reached a 
somewhat lower value of 17.9% (95% credible interval (CrI): 15.5-20.2%), overlapping the confidence interval of the 
estimate of Nishiura. 
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In a more recent publication, Han (Int J Biol Sci 2020, see below) indicated that the proportion of asymptomatic 
individuals among all confirmed cases widely differed (from 1.95% to 87.9%) according to the study setting and the 
populations studied. 
Re-infections 
A key question for COVID-19 has long been whether true re-infection occurs (To, Hung et al. Clin Inf Dis 2020, see 
below). Although neutralizing antibody develops rapidly after infection, antibody titers start to decline as early as 1-2 
months after the acute infection. Due to prolonged viral shedding at low levels near the detection limit of RT-PCR 
assays, patients tested negative and discharged from hospitals are often having recurrence of positive results. A case 
report suggested that re-infection may occur, but viral genome analysis was not performed to confirm this conclusion. 
According to the media, additional re-infection cases have been found in Europe, but the observations not published 
in a scientific journal (https://www.euronews.com/2020/08/25/two-cases-of-covid-19-reinfection-reported-in-
europe). These reported cases couldn’t put an end to the controversy between persistent virus shedding and re-
infection. However, on Aug 25th 2020, To, Hung et al. (Clin Inf Dis 2020, see below) reported on a 33-year old male 
residing in Hong Kong with a second episode of infection which occurred 4.5 months after the first episode. Re-
infection was confirmed using whole genome analysis to discriminate re-infection from prolonged viral shedding, and 
was also supported by epidemiological, clinical and serological data. The authors noted that this confirmation of re-
infection has important implications. In particular, herd immunity appears less likely to eliminate SARS-CoV-2, 
although it is possible that subsequent infections may be milder than the first infection as observed for this patient. 
Of note, re-infection is common for “seasonal” coronaviruses 229E, OC43, NL63 and HKU1. In some instances, re-
infection occurs despite a static level of specific antibodies. These data also have implications on vaccine development. 
Another case of re-infection was reported two days later by Tillett (Lancet Inf Dis, see below), who described the data 
from an investigation of two instances of SARS-CoV-2 infection in a same twenty-five year old individual in the US. 
Through nucleic acid sequence analysis, the viruses associated with each instance of infection were found to possess 
a degree of genetic discordance that cannot be explained reasonably through short-term in vivo evolution. 
Interestingly, in this case, symptoms consistent with COVID-19 were associated with both infections. The 
generalizability of this finding remains unknown. 
A subsequent publication from the European CDC on September 21 2020 described a total of 6 cases of re-infection, 
including both symptomatic and asymptomatic infections (https://www.ecdc.europa.eu/en/publications-data/threat-
assessment-brief-reinfection-sars-cov-2). An additional case of reinfection with a new strain harbouring the S variant 
D614G was reported by Goldman (manuscript on medRxiv, see below). 
Case fatality rate 
Case fatality rate in China 
Early data from China yielded an estimated mortality of the COVID-19 of approximately 2.84%, based on 1 975 
infections and 56 deaths reported in 26 days following the first official announcement of the epidemic (Wang, Tang et 
al. J Med Virol 2020, see below). Data available by October 20 2020 12:00 CET pointed towards a higher value (91 546 
confirmed cases and 4746 deaths in China, corresponding to 5.18%) (WHO dashboard at https://covid19.who.int/). At 
global level (40 114 293 confirmed cases and 1 114 692 deaths) the same day, the estimate reached 2.78%. 
Obviously, this type of estimate has to be taken with a lot of caution. As indicated by Kobayashi (J Clin Med 2020, see 
below), the observed dataset of reported cases represents only a proportion of all infected individuals and there can 
be a substantial number of asymptomatic and mildly infected individuals who are never diagnosed. Several authors 
suggested that the number of reported cases of the disease, in China as well as in other countries, is likely to be 
underestimated (see for instance De Salazar on medRxiv: 
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https://www.medrxiv.org/content/10.1101/2020.02.13.20022707v1). Battegay (Swiss Med Wkly 2020, see below), 
like Kobayashi (J Clin Med 2020, see below ) or Baud (Lancet Inf Dis 2020, see below), also pointed to the fact that 
diagnosis of COVID-19 infection will precede recovery or death by days to weeks and that the number of deaths should 
therefore be compared to the past case counts. Lack of a standardized case definition also affects estimates of case 
fatality rates (see Case definition below). 
Other authors, like Spychalski (Lancet Infect Dis 2020, see below) showed that the case fatality rate calculated per 
total cases seems to remain the best tool to express the fatality of the disease, even though it might underestimate 
this figure in the initial phase of an outbreak. 
Ji, Ma et al. (Lancet 2020, see below) highlighted the difference in mortality rates between Hubei and other Chinese 
provinces. The authors postulated that this difference is likely to be related to the rapid escalation in the number of 
infections around the epicentre of the outbreak, which has resulted in an insufficiency of health-care resources, 
thereby negatively affecting patient outcomes in Hubei, while this has not yet been the situation for the other parts 
of China. 
A similar observation was made by Mizumoto (Em Inf Dis 2020, see below), who estimated the time-delay adjusted 
risk for death from COVID-19 as of February 28, 2020 in China. The estimates of the risk for death in Wuhan reached 
values as high as 12% in the epicenter of the epidemic and ≈1% in other, more mildly affected areas. Comparable 
results were obtained by Wilson (Em Inf Dis 2020, see below), who reported case-fatality risks, when adjusted for a 
13-day lag time from reporting to death, of 3.5% in China and 0.8% in China, excluding Hubei Province. 
Nevertheless, according to the large retrospective study reported by the Novel Coronavirus Pneumonia Emergency 
Response Epidemiology Team (Zhonghua Liu Xing Bing Xue Za Zhi 2020, see below; and Wu JAMA 2020, see below), 
based on the 72 314 reports received through February 11 2020 by the Chinese Centre for Disease Control and 
Prevention in mainland China,  1023 deaths were observed out of a total of 44 672 confirmed cases, corresponding to 
a case-fatality rate of 2.3%. This analysis also showed that the case-fatality rate is largely influenced by the age of the 
patients (Table 5). 
Of note, the WHO-China Joint Mission on Coronavirus Disease 2019 Mortality, which presented data on 2114 COVID-
19 related deaths among 55 924 laboratory-confirmed cases in China, also reported the highest mortality among 
people over 80 years of age, with a case fatality rate of 21.9% (https://www.who.int/docs/default-
source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf). 
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Table 5 Patients, deaths, and case fatality rates, as well as observed time and mortality for n=44,672 confirmed COVID-19 cases in Mainland 
China as of February 11, 2020 (from The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team Zhonghua Liu Xing Bing 
Xue Za Zhi 2020). 
 
A study by Wu (Nat Med 2020: https://www.nature.com/articles/s41591-020-0822-7) provided somewhat lower 
estimates of the case fatality rate in Wuhan, of 0.3% (0.1–0.7%), 0.5% (0.3–0.8%) and 2.6% (1.7–3.9%) for those aged 
<30 years, 30–59 years and >59 years, respectively. 
Using a different approach, and based on early data, Wu (Eurosurv 2020, see below) also estimated the risk of fatality 
among hospitalised cases at 14% (95% confidence interval: 3.9-32%). This estimate of the hospital fatality risk 
remained fairly stable over the 10-day period since the first death was announced on 11 January. Subsequently, Leung 
(Rev Med Vir 2020, see below) calculated that as of 2 February 2020, over 17 000 cases were confirmed in China, with 
a hospital fatality rate of 2.1%; in Hubei province, the hospital fatality rate reached 3.1%, significantly above the rest 
of China (Figure 10). 
Figure 10 Trends of hospital fatality rates in Hubei province and the rest of China with 95% CI (from Leung Rev Med Vir 2020) 
 
Case fatality rate outside China 
Based on data up to Feb 8th, Verity found estimates of case fatality ratio from international cases stratified by age to 
be consistent with those from China (Lancet Inf Dis 2020, see below).  
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Wilson (on medRxiv:  https://www.medrxiv.org/content/10.1101/2020.02.15.20023499v1) considered symptomatic 
cases outside of China (countries/settings with 20+ cases) and the proportion who are in intensive care units (4.0%, 
14/349 on 13 February 2020). Given what is known about case fatality rates for intensive care unit patients with severe 
respiratory conditions from a meta-analysis, he estimated a case fatality rate of 1.37% (95%CI: 0.57% to 3.22%) for 
COVID-19 cases outside of China. Using data as of as of March 5 2020, Wilson (Em Inf Dis 2020, see below) also 
reported a case fatality estimate in 82 countries, territories, and areas reaching 4.2%.  
Rajgor (Lancet Inf Dis 2020, see below) acknowledged the level of variability of COVID-19 case fatality rate estimates, 
and noted that a unique situation has arisen for estimating the case fatality rate with the outbreak onboard the 
Diamond Princess cruise ship. This scenario provided a population living in a defined territory without most other 
confounders, such as imported cases, defaulters of screening, or lack of testing capability. 3711 passengers and crew 
were onboard, of whom 705 became sick and tested positive for COVID-19 and seven died, giving a case fatality rate 
of 0.99%. If the passengers onboard were generally of an older age, the case fatality rate in a healthy, younger 
population could be lower. 
The systematic review of COVID-19 epidemiology by Park (J Clin Med 2020, see below), which included 41 studies, 
indicated that current model-based estimates ranged from 0.3% to 1.4% for outside China. 
In June, another systematic review and meta-analysis by Grant (PLoS One 2020, see below) found a hospital fatality 
rate of 7% (73 studies, 10 402 patients). 
Italy 
Based on the first 888 cases confirmed in Italy, Porcheddu (J Infect Dev Ctries 2020, see below) noted that the case 
fatality rate in China and Italy were identical at 2.3%.  Livingston (JAMA 2020, see below) provided a case fatality rate 
per age group in Italy. It was found to increase with age, up to 22.7% in subjects 90 years of age and older.  A 
subsequent report by Onder (JAMA 2020, see below) mentioned an overall fatality rate of persons with confirmed 
COVID-19 of 7.2% (calculated as number of deaths/number of cases), and a case fatality rate of 20.2% in subjects >80 
years of age in Italy. Deaths were said to be mainly observed among older, male patients with multiple comorbidities. 
However, the data presented by Onder remained limited, and derived from the first month of documented COVID-19 
cases in Italy.  
Barone-Adesi (Disaster Med Public Health Prep 2020, see below) commented on the higher case-fatality rate observed 
in Italy compared to China, and suggested that the Italian testing strategy could explain an important part of the 
observed difference. The majority of patients that are currently tested in Italy have severe clinical symptoms that 
usually require hospitalization. Indeed, the proportion of positive cases that are admitted to the hospital in Italy is 
about 40% (and used to be much higher in previous weeks), while it was about 10-20% in China. As the positive cases 
resulting from this testing strategy are so skewed towards more serious conditions, it is not surprising that a higher 
case fatality rate is observed. 
Another study rejected the possibility that social habits and intergenerational contacts contribute to explain the 
number of deaths observed in Italy (Giangreco J Trav Med 2020, see below) 
U.S.A. 
Preliminary reports from 4226 patients with COVID-19 in the United States indicated that fatality was highest in 
persons aged ≥85, ranging from 10% to 27%, followed by 3% to 11% among persons aged 65–84 years, 1% to 3% 
among persons aged 55-64 years, <1% among persons aged 20–54 years, and no fatalities among persons aged ≤19 
years (CDC COVID-19 Response Team MMWR Morb Mortal Wkly Rep 2020, see below). 
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McMichael (NEJM 2020, see below) described an outbreak linked to a long-term care facility in the U.S. (Washington 
state). Case-fatality rate among residents (median age 83 years, ranging from 51 to 100) reached 35%. 
India 
As of July 3, 2020, India reported a fatality rate of 2.8%, among the lowest in the world (Samaddar Front Genet 2020, 
see below). Also, the severity of the disease was found much less among Indians as evidenced by the low rate of ICU 
admission (15.3%) and the need for mechanical ventilation (4.16%). Samaddar hypothesized that several factors might 
have some role in reducing the susceptibility of Indians to COVID-19. Data available by October 20 2020 12:00 CET still 
point towards a relatively low value (7 597 063 cases and 115 197 deaths in India, corresponding to 1.52% (WHO 
dashboard at https://covid19.who.int/). Most recent data from the Indian states of Tamil Nadu and Andhra Pradesh 
provided more detailed estimates of mortality in India (Laxminarayan Science 2020, see below). Case fatality ratios 
spanned 0.05% at ages of 5 to 17 years to 16.6% at ages of 85 years or more. 
Special populations  
Elderly 
In the study reported by Chen (Lancet 2020, see below), COVID-19 was found more likely to affect older males with 
comorbidities. The impact of age as well as gender and comorbidities is described in the section Risk factors below. 
Haemodialysis patients 
A manuscript by Ma depicted 42 cases of disease in a cohort of 230 haemodialysis patients in Wuhan 
(https://www.medrxiv.org/content/10.1101/2020.02.24.20027201v3). Despite the death of 10 patients with COVID-
19 vs. 3 without COVID-19 during the study, the symptoms reported for most of the patients were mild, and there 
were only 3 cases admitted to ICU. 
Cancer patients 
Data are available to show that cancer patients seem to be at increased risk of COVID-19 and increased risk of severe 
events (see section Error! Reference source not found. below). 
Immunocompromised patients 
Minotti (J Inf 2020, see below) identified 16 publications with 110 immunosuppressed patients, mostly presenting 
cancer, along with transplantation and immunodeficiency. Cancer was more often associated with a more severe 
course, but not necessarily with a bad prognosis. The data showed that both children and adults with 
immunosuppression seemed to have a favourable disease course, as compared to the general population. The authors 
indicated that this observation might be explained by a hypothetical protective role of a weaker immune response, 
determining a milder disease presentation and thus underdiagnosis.  
More recently, a review by Cajamarca-Baron (Reumatol Clin 2020, see below) confirmed that patients with cancer and 
recent cancer treatment (chemotherapy or surgery) and SARS-CoV-2 infection have a higher risk of worse outcomes. 
In transplant patients (renal, cardiac and hepatic), with neurological pathologies (multiple sclerosis, neuromyelitis 
optica [NMODS], myasthenia gravis [MG]), primary immunodeficiencies and infection with human immunodeficiency 
virus (HIV) in association with immunosuppressants, studies have shown no tendency for worse outcomes. 
Primary Antibody Deficiencies patients 
Quinti (J Allergy Clin Immunol 2020, see below) identified seven Primary Antibody Deficiencies (PAD) patients with 
COVID-19 infection: five affected with Common Variable Immune Deficiencies (CVIDs) and two affected with 
Agammaglobulinemia, one with X-linked Agammaglobulinemia (XLA) and one with Autosomal Recessive 
Agammaglobulinemia (ARA). All PAD patients have defective antibody production. Patients with Agammaglobulinemia 
lack B lymphocytes whereas patients with Common Variable Immune Deficiency have dysfunctional B lymphocytes. In 
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patients affected with agammaglobulinemias, the COVID-19 course was characterized by mild symptoms, short 
duration, with no need of treatment with the immune-modulating drug blocking IL-6, and had a favourable outcome. 
In contrast, patients affected with Common Variable Immune Deficiencies presented with a severe form of the disease 
requiring multiple drug treatment, including antiretrovirals agents and IL-6 blocking drugs, and mechanical ventilation. 
The strikingly different clinical course of COVID-19 in patients with agammaglobulinemia compared to CVIDs cannot 
be explained by the level of serum immunoglobulins which were similarly low in all PAD patients at diagnosis. 
Children 
Paediatric data from China 
The first confirmed paediatric case of SARS-CoV-2 infection is said to have been reported in Shenzhen on January 20 
(Cao J Formos Med Assoc 2020, see below). By January 30, there were 28 children (1 month to 17 years) with confirmed 
infection in China (Shen World J Pediatr 2020, see below). The clinical features appeared variable. Several patients 
displayed no obvious clinical symptoms at diagnosis, and they were found by screening because of close contacts with 
confirmed patients; and further chest imaging suggested pneumonia. Several gradually presented with fever, fatigue, 
dry cough, accompanied by other upper respiratory symptoms including nasal congestion, runny nose, and seldom 
gastrointestinal symptoms such as nausea, vomiting and diarrhoea. Laboratory examination in paediatric patients 
showed that blood routine was often normal, and C-reactive protein was normal or transiently elevated. Lung imaging 
examination revealed mild increase of lung markings or ground-glass opacity or pneumonia. Most paediatric patients 
had mild symptoms, without fever or pneumonia. They had good prognosis and recovered within 1-2 weeks after 
disease onset. Only a few patients had lower respiratory tract infections. No severe cases or deaths have been reported 
in the paediatric population up to now. 
With the progression of the outbreak, the first infant case was reported from Xiaogan, Hubei province. This was a 3-
month-old female infant who had fever for one day and as discharged uneventfully 2 weeks later (Cao J Formos Med 
Assoc 2020, see below). A subsequent retrospective study described 9 cases in children (7 females/2 males) aged 1 to 
11 months (Wei JAMA 2020, see below). Four patients were reported to have fever, 2 had mild upper respiratory tract 
symptoms, 1 had no symptoms but tested positive for COVID-19 in a designated screening because of exposure to 
infected family members, and 2 had no information on symptoms available. None of the 9 infants required intensive 
care or mechanical ventilation or had any severe complications.  
Liu (NEJM 2020, see below) retrospectively reported 6 paediatric cases treated in Wuhan hospitals in January 2020. 
One of the 6 children was admitted to the paediatric intensive care unit. All the patients recovered after hospitalization 
for a median of 7.5 days (range, 5 to 13). 
Xia (Pedriatr Pulmonol 2020, see below) presented the clinical, laboratory, and chest CT features of 20 paediatric 
inpatients with COVID-19 in Wuhan. Fever (12/20, 60%) and cough (13/20, 65%) were the most common symptoms. 
Procalcitonin elevation was found frequently (16/20, 80%).  
A case in a 55 day-old infant was reported in detail by Cui (J Infect Dis 2020, see below). The patient initially presented 
with mild dry cough and no fevers. However, symptoms became gradually worse from day 7 to day 11 of illness, and 
symptomatic support was strengthened. This case highlighted that infants with COVID-19 can also present with 
multiple organ damage and rapid disease changes. 
The retrospective Chinese study involving COVID-19 cases reported through February 11, 2020, and corresponding to 
44672 confirmed cases, 549 cases were identified in the 10-19 years age group (1%) and 416 cases among children 
less than 10 years (1%) (Wu JAMA 2020, see below).  
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Lu (NEJM 2020, see below) tested 1391 children from January 28 through February 26, 2020 in Wuhan, of whom a 
total of 171 (12.3%) were confirmed to have SARS-CoV-2 infection. The median age of the infected children was 6.7 
years. Fever was detected in 41.5%. Other common signs and symptoms included cough and pharyngeal erythema. A 
total of 27 patients (15.8%) did not have any symptoms of infection or radiologic features of pneumonia. A total of 12 
patients had radiologic features of pneumonia but did not have any symptoms of infection. During the course of 
hospitalization, 3 patients required intensive care support and invasive mechanical ventilation; all had coexisting 
conditions (hydronephrosis, leukemia, and intussusception). Lymphopenia was present in 6 patients (3.5%). The most 
common radiologic finding was bilateral ground-glass opacity (32.7%). As of March 8, 2020, there was one death: a 
10-month-old child with intussusception had multiorgan failure and died 4 weeks after admission. 
Another large paediatric cohort in China was reported by Dong (Pediatrics 2020, see below). There were 731 (34.1%) 
laboratory-confirmed cases and 1412 (65.9%) suspected cases. The median age of all patients was 7 years 
(interquartile range: 2-13). Over 90% of all patients were asymptomatic, mild, or moderate cases.  
From a systematic review of COVID-19 in children, Ludvigsson (Acta Paediatr 2020, see below) identified 45 relevant 
scientific papers and letters describing mostly paediatric cases from China. The data showed that children have so far 
accounted for 1-5% of diagnosed COVID-19 cases, that they often have milder disease than adults and deaths have 
been extremely rare. Diagnostic findings have been similar to adults, with fever and respiratory symptoms being 
prevalent, but fewer children seem to have developed severe pneumonia. Elevated inflammatory markers were less 
common in children and lymphocytopenia seemed rare.  
Paediatric data from other countries 
In an early report, Wong (JAMA 2020, see below) mentioned 3 confirmed paediatric cases in Singapore. The patients 
were very young (6 months, 1 year and 2 years) and had very mild symptoms. 
Park (J Korean Med Sci 2020, see below) reported the first paediatric case of COVID-19 in Korea, a 10-year-old girl who 
presented mild clinical course of her pneumonia that did not require antiviral treatment. 
Shekerdemian (JAMA Ped 2020, see below) presented the outcome of a cross-sectional study that included children 
positive for COVID-19 admitted to 46 North American PICUs between March 14 and April 3, 2020 with follow-up to 
April 10, 2020.  Of the 48 children with COVID-19 admitted, 25 (52%) were male, and the median (range) age was 13 
(4.2-16.6) years. Forty patients (83%) had significant preexisting comorbidities; 35 (73%) presented with respiratory 
symptoms and 18 (38%) required invasive ventilation. Eleven patients (23%) had failure of 2 or more organ systems. 
Extracorporeal membrane oxygenation was required for 1 patient (2%). Targeted therapies were used in 28 patients 
(61%), with hydroxychloroquine being the most commonly used agent either alone (11 patients) or in combination (10 
patients). At the completion of the follow-up period, 2 patients (4%) had died and 15 (31%) were still hospitalized, 
with 3 still requiring ventilatory support and 1 receiving extracorporeal membrane oxygenation.  
Mahase (BMJ April 28 2020, see below) described a rising number of children presenting with a multisystem 
inflammatory state in the UK. The cases had in common “overlapping features of toxic shock syndrome and atypical 
Kawasaki disease with blood parameters consistent with severe COVID-19 in children. Kawasaki disease is a rare 
vasculitis of childhood that can cause coronary-artery aneurysms. Similar reports circulated in French media (see for 
instance https://www.connexionfrance.com/French-news/France-warns-of-child-illness-similar-to-Kawasaki-disease-
that-may-be-Covid-19-linked). A cluster of eight children with hyperinflammatory shock, showing features similar to 
atypical Kawasaki disease, Kawasaki disease shock syndrome, or toxic shock syndrome (typical number is one or two 
children per week) has been described by Riphagen (Lancet 2020, see below). All children were previously fit and well. 
Six of the children were of Afro-Caribbean descent, and five of the children were boys. All children except one were 
well above the 75th centile for weight. All children progressed to warm, vasoplegic shock, refractory to volume 
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resuscitation and eventually requiring noradrenaline and milrinone for haemodynamic support. Most of the children 
had no significant respiratory involvement, although seven of the children required mechanical ventilation for 
cardiovascular stabilisation. Other notable features (besides persistent fever and rash) included development of small 
pleural, pericardial, and ascitic effusions, suggestive of a diffuse inflammatory process. One child developed 
arrhythmia with refractory shock, requiring extracorporeal life support, and died from a large cerebrovascular infarct. 
On May 15, a WHO publication mentioned the need to characterize this syndrome and its risk factors, to understand 
causality, and describe treatment interventions. To that end, a preliminary case definition and case report form for 
multisystem inflammatory disorder in children and adolescents was issued (https://www.who.int/news-
room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19). 
Feldstein (NEJM 2020, see ) conducted targeted surveillance for multisystem inflammatory syndrome - from March 15 
to May 20, 2020, in paediatric health centres across the United States, and reported on 186 patients. The median age 
was 8.3 years, 115 patients (62%) were male, 135 (73%) had previously been healthy, 131 (70%) were positive for 
SARS-CoV-2 by RT-PCR or antibody testing, and 164 (88%) were hospitalized after April 16, 2020. Organ-system 
involvement included the gastrointestinal system in 171 patients (92%), cardiovascular in 149 (80%), hematologic in 
142 (76%), mucocutaneous in 137 (74%), and respiratory in 131 (70%). The median duration of hospitalization was 7 
days (interquartile range, 4 to 10); 148 patients (80%) received intensive care, 37 (20%) received mechanical 
ventilation, 90 (48%) received vasoactive support, and 4 (2%) died. Coronary-artery aneurysms (z scores ≥2.5) were 
documented in 15 patients (8%), and Kawasaki’s disease-like features were documented in 74 (40%). Most patients 
(171 [92%]) had elevations in at least four biomarkers indicating inflammation. The use of immunomodulating 
therapies was common: intravenous immune globulin was used in 144 (77%), glucocorticoids in 91 (49%), and 
interleukin-6 or 1RA inhibitors in 38 (20%). Multisystem inflammatory syndrome in children associated with SARS-CoV-
2 therefore appeared as serious and life-threatening illness. 
Andina (Pediatr Dermatol. 2020, see below) presented a series of 22 cases of chilblains in children and adolescents in 
the setting of COVID-19 seen in a very short period of time in the Emergency Department of a children’s hospital in 
Madrid. Chilblains, aka pernio, perniosis, or kibes, is a localized inflammatory skin disorder characterized by 
erythrocyanotic skin lesions induced by non-freezing cold exposure. Chilblains associated with COVID-19 became 
increasingly described in the medical literature. More details on this cutaneous manifestation can be found in the 
narrative review by Ladha (J Cut Med Surg 2020, see below). 
Systematic reviews and meta-analyses 
A systematic review by Castagnoli (JAMA Pediatr 2020, see below) identified seventeen studies conducted in China 
and one in Singapore, including a total of 1065 paediatric cases of SARS-CoV-2 infection. Data from this review showed 
that most children and adolescents who were infected by SARS-CoV-2 (i.e., tested positive by nasopharyngeal swab) 
presented with mild symptoms. Frequent clinical manifestations included fever, dry cough, and fatigue accompanied 
by other upper respiratory symptoms, such as nasal congestion and runny nose. Moreover, the main gastrointestinal 
symptoms were nausea, vomiting, and diarrhoea, which were reported in a few cases, particularly in a newborn and 
infants. In this analysis, only one paediatric case presented with severe lower respiratory tract infection (COVID-19 
pneumonia), complicated by shock and kidney failure, and fortunately, it was successfully treated with intensive care. 
The review by Hasan (Cureus 2020, see below) provided a summary of laboratory and clinical imaging data in children. 
A systematic review by Meena (Indian Ped 2020, see below) included 27 studies (4857 patients). It found that about 
half of the patients had each of fever and cough, 11% (6-17%) had fast breathing, and 6-13% had gastrointestinal 
manifestations. Most of the patients had mild to moderate disease, and only 4% had a severe or critical illness. 
Leukopenia was the commonest reported laboratory abnormality. 
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A more recent publication by Kharoud (on medRxiv, see below), including 37 studies (668 children in total) conducted 
between January 1, 2020, and July 15, 2020, provided other estimates of the pooled prevalence of various symptoms 
and laboratory findings of COVID-19 in the paediatric population. The most prevalent symptom of COVID-19 in children 
was 46.17% (95%CI 39.18-53.33%), followed by cough (40.15%, 95%CI 34.56-46.02%). Less common symptoms were 
found to be dyspnoea, vomiting, nasal congestion/rhinorrhoea, diarrhoea, sore throat/pharyngeal congestion, 
headache, and fatigue. The prevalence of asymptomatic children was 17.19% (95%CI 11.02-25.82%). The most 
prevalent laboratory findings in COVID-19 children were elevated Creatinine Kinase (26.86%, 95%CI 16.15-41.19%) and 
neutropenia (25.76%, 95%CI 13.96-42.58%). These were followed by elevated LDH, thrombocytosis, lymphocytosis, 
neutrophilia, elevated D Dimer, Elevated CRP, elevated ESR, leucocytosis, elevated AST and leukopenia. There was a 
low prevalence of elevated ALT and lymphopenia in children with COVID- 19. 
A retrospective analysis by Wang (Sci Rep 2020, see below) focused on gastrointestinal symptoms and faecal nucleic 
acid detection in paediatric COVID-19 patients from January 1, 2020 to August 10, 2020. The authors found that the 
most common gastrointestinal symptoms in children with COVID-19 were vomiting and diarrhoea, with a total 
incidence of 17.7% (95% Cl 13.9-21.5%). However, the prevalence of gastrointestinal symptoms in other countries 
(21.1%, 95% CI 16.5-25.7%) was higher compared to China (12.9%, 95% CI 8-17.7%). In Wuhan, the pooled prevalence 
was much higher (41.3%, 95% CI 3.2-79.4%) compared to areas outside Wuhan in China (7.1%, 95% CI 4.0-10.3%). 
Kaushik (Pediatr Infect Dis J 2020, see below) provided a systematic review of the multisystem inflammatory syndrome 
associated with SARS-CoV-2 infection in children. A total of 328 articles published from January 1, 2020, to July 31, 
2020 were identified. Sixteen studies with 655 participants (3 months-20 years of age) were included in the final 
analysis. Most of the children in reported studies presented with fever, gastrointestinal symptoms, and Kawasaki 
Disease-like symptoms. Sixty-eight percent of the patients required critical care; 40% needed inotropes; 34% received 
anticoagulation; and 15% required mechanical ventilation. More than two-thirds of the patients received intravenous 
immunoglobulin and 49% received corticosteroids. Remdesivir and convalescent plasma were the least commonly 
utilized therapies. Left ventricular dysfunction was reported in 32% of patients. Among patients presenting with 
Kawasaki Disease-like symptoms, 23% developed coronary abnormalities and 26% had circulatory shock. The majority 
recovered; 11 (1.7%) children died. 
Risk of infection in children 
While the disease seems to have a milder course in children than adults, a manuscript by Qifang Bi on medRxiv 
(https://www.medrxiv.org/content/10.1101/2020.03.03.20028423v1) suggested that children are at a similar risk of 
infection as the general population. This conclusion was driven from 391 cases and 1286 close contacts identified by 
the Shenzhen CDC. However, other lines of evidence pointed to a different attack rate of the disease in children 
compared to adults. In Iceland, Gudbjartsson (NEJM 2020, see below), carried out both targeted testing of persons at 
high risk for infection and population screening by RT-PCR. Children under 10 years of age were less likely to be found 
positive than were persons 10 years of age or older (6.7% vs. 13.7% for targeted testing; 0% vs. 0.8% in the population 
screening). In China, a household cohort study found a secondary attack rate in children of 4% comparing with 17.1% 
in adults (Li, Zhang et al. Clin Inf Dis 2020, see below). 
Pregnancy and newborns 
In general, pregnancy is a physiological state in which women are more susceptible to respiratory pathogens and 
severe pneumonia, due to an immunosuppressive state and various physiological adaptive changes (e.g., diaphragm 
elevation, increased oxygen consumption, and oedema of respiratory tract mucosa).  It is therefore reasonable to 
predict that pregnant women might be at greater risk for severe illness. Previous epidemics of other CoVs have 
typically resulted in severe complications during pregnancy such as maternal morbidity and mortality, perinatal 
infections and death (Wong Am J Obstet Gynecol 2004, see below; Alfaraj J Microbiol Immunol Infect 2019, see below). 
However, unlike CoV infections of pregnant women caused by SARS and MERS, pregnant women are not more 
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susceptible to COVID-19, nor are they at risk of more severe disease than the non-pregnant population. There is no 
clear evidence of vertical transmission of COVID-19 from the mother to the foetus. Several recent publications 
reviewed available information on COVID-19 in pregnant women (see for instance Diriba Eur J Med Res 2020, see 
below; Yee Sci Rep 2020, see below).  
Clinical characteristics of pregnant woman with COVID-19 infection 
Multiple studies have observed the clinical characteristics of COVID-19 pneumonia in pregnant women. Most early 
data stemmed from case reports and small case series3, but a higher level of evidence soon became available (Li Clin 
Inf Dis 2020, see below; Zaigham Acta Obstet Gynecol Scand 2020, see below; Qiancheng Int J Infect Dis 2020, see 
below; Yang J Matern Fetal Neonatal Med 2020, see below). The clinical characteristics of COVID-19 pneumonia in 
pregnant women seem to be similar to those reported for non-pregnant adults with COVID-19 pneumonia. Briefly, the 
most commonly reported symptoms are fever and cough, followed by fatigue, diarrhoea, dyspnoea, sore throat, and 
myalgia (Yang J Matern Fetal Neonatal Med 2020, see below). 
Reports on asymptomatic COVID-19 infected pregnant women have been made available, following the 
implementation of screening practices. In March 2020, Chen, Liao et al. (J Med Virol 2020, see below) reported that 
SARS-CoV-2 infection could asymptomatically occur during gestation, but was diagnosed after delivery. Another study 
by Sutton (NEJM 2020, see below) described 33 pregnant women who tested positive for COVID-19, of whom 29 
(87,9%) showed no symptoms of the disease. The authors recommended universal testing for all pregnant women 
admitted to the labour unit. 
A few pregnant women afflicted with severe respiratory morbidity have been reported in relation to COVID-19 (for 
instance, Hong Case Rep Womens Health 2020, see below). Two studies reported a total of three cases of maternal 
ICU admission (Breslin, Baptiste , Miller et al. Am J Obst & Gynecol MFM 2020, see below; Alzamora Am J Perinatol 
2020; see below).  All mothers had obesity class II or more and type 2 diabetes mellitus. A recent multicenter study 
reported nine pregnant women with severe COVID-19 infection (Hantoushzadeh Am J Obstet Gynecol 2020, see 
below). At the time of reporting 7 of 9 died, 1 of 9 remained critically ill and ventilator-dependent, and 1 of 9 recovered 
after prolonged hospitalization. Complications of COVID-19, such as cardiomyopathy and thromboembolism, have also 
been seen in the pregnant population (for instance, Juusela Am J Obst Gynecol MFM 2020, see below; Martinelli  
Thromb Res 2020, see below). 
Perinatal complications 
Pregnancy may not increase susceptibility to COVID-19 infection or influence the severity of the disease, but SARS-
CoV-2 infection does seem to influence pregnancy. Severe pneumonia during pregnancy (regardless of the causative 
agent) increases the risk of preterm delivery, foetal growth restriction, low birth weight and low Apgar score at birth. 
Regarding perinatal outcomes, most authors did not report adverse events (Chen Guo Lancet 2020, see below; Zhang 
Zhonghua Fu Chan Ke Za Zhi 2020, see below; Wang Clin Inf Dis 2020, see below; Yu Lancet Inf Dis 2020, see below; 
Liu AJR Am J Roentgenol 2020, see below; Yan Am J Obstet Gynecol 2020, see below). However, a meta-analysis on 
pregnancy outcome in COVID-19 patients found preterm birth to be the most common adverse pregnancy outcome 
(Di Mascio Am J Obst & Gynecol MFM 2020, see below). Li (Clin Inf Dis 2020, see below) found a higher incidence rate 
of premature delivery in confirmed cases (18,8%) compared to two control groups (5%), but none was due to severe 
maternal respiratory failure.  
                                                          
3 See for instance Chen Guo Lancet 2020; Liu, Chen J Inf 2020; Chen Huang Zhonghua Bing Li Xue Za Zhi 2020; Fan Clin Inf Dis 
2020; Yu Lancet Inf Dis 2020 
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Zhu (Transl Ped 2020, see below) presented the clinical features and outcomes of ten neonates, born to mothers with 
confirmed SARS-CoV-2 infection.  One newborn died from multiple organ failure and disseminated intravascular 
coagulation (DIC).  
A recent meta-analysis by Yee (Sci Rep 2020, see below) including 11 studies involving 9032 pregnant women with 
COVID-19 and 338 infants, found around 30% preterm delivery. Foetal death and detection of SARS-CoV-2 were 
observed in about 2%, whereas neonatal death was found to be 0.4%. 
Perinatal COVID-19 infection may have adverse effects on both neonate and mother. Though less serious than SARS-
CoV, in which adverse outcomes were reported in 10 out of 12 pregnancies, COVID-19 pregnancy seems not to be 
without risk. COVID-19 has been shown to be associated with a cytokine-storm (Huang Lancet 2020, see below). 
Abnormally elevated levels of TNF-α in maternal peripheral blood can be toxic to early embryo development and have 
been shown to induce preterm labour in non-human primate models (Yockey Immunity 2018, see below). Furthermore, 
maternal inflammation as a result of viral infection during pregnancy can affect several aspects of foetal brain 
development and may lead to a wide range of neuronal and behavioural dysfunctions in postnatal life (Mor Nat Rev 
Immunol 2017, see below). 
Vertical transmission 
In the first months of the epidemic, there was no evidence of vertical transmission of COVID-19. Repetitive negative 
samples of amniotic fluid, cord blood, neonatal throat swabs, placental tissue, genital fluid and breastmilk samples 
from COVID-19 infected mothers were reported in multiple studies (Chen Guo Lancet 2020, see below; Chen Huang 
Zhonghua Bing Li Xue Za Zhi 2020, see below; Yu Lancet Inf Dis 2020, see below; Wang Guo Clin Inf Dis 2020, see below; 
Zhu Transl Ped 2020, see below; Yang Ultrasound Obstet Gynecol 2020, see below; Khan Inf Contr Hosp Epi 2020, see 
below; Liu Front Med 2020, see below). However, more recent studies are now implying that vertical transmission 
may occur, although the proportion of pregnancies affected and the significance to the neonate has yet to be 
determined. 
A cohort study by Zeng (JAMA Pediatr 2020, see below) described 33 neonates born to mothers infected with COVID-
19. Of these 33 neonates, 3 (9%) showed positive nasopharyngeal swabs on day 2 of life. Strict infection control and 
prevention measures were implemented during the delivery. Zhang (Eur Respir J 2020, see below) described three 
cases of COVID-19 positive neonates delivered through caesarean section and under level III protection. No mother-
child contact or breastfeeding had occurred and all newborn babies were at isolation when symptoms occurred. 
Alzamora (Am J Perinatol 2020; see below) reported a case of a newborn who tested positive on RT-PCR of 
nasopharyngeal swab as soon as 16 hours after delivery. As in the cases mentioned above, there was a low probability 
of infection during the caesarean section or postnatally, due to sterility of the procedure and isolation measures 
implemented immediately after birth. Taken together, these findings strongly raised the suspicion of in utero 
transmission of SARS-CoV-2. 
Furthermore, two articles from separate research teams in China presented 3 cases of neonates who may have been 
infected with COVID-19 in utero (Zeng JAMA 2020, see below; Dong JAMA 2020, see below). In these three newborns, 
elevated IgM and IgG antibodies were found following birth, while nasopharyngeal swabs tested negative on RT-PCR. 
IgG is passively transferred across the placenta from mother to foetus. IgM is too large to cross the placenta; thus, IgM 
must have been produced by the infant when the virus crossed the placenta. However, IgM assays can be prone to 
false-positive and false-negative results, along with cross-reactivity and testing challenges (Wang J Clin Microb 2020, 
see below). Additionally, antibody levels decreased dramatically in the following weeks. Alzamora (Am J Perinatol 2020; 
see below) also evaluated neonatal immunoglobulins in a SARS-CoV-2 positive neonate. The authors reported negative 
serology in both mother and neonate on the day of birth, with seroconversion of the mother on day 5. In contrast, 
neonatal serology remained negative. This could be explained by the immaturity of the adaptive immunity in the 
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neonatal period. The challenges with false-positive IgM test results, along with a rapid decline in IgM concentration 
and the fact that an immature immune system in the neonatal period may not be capable of developing IgMs, raises 
the possibility that the laboratory findings in the 3 infants in the first case reports are not evidence of true congenital 
infection but rather could represent artifact. 
Zheng (Reprod Dev Med 2020: http://www.repdevmed.org/preprintarticle.asp?id=278679) described a very low 
expression of ACE2 in almost all human cell types of the early maternal-foetal interface, suggesting the placenta had 
virtually no susceptible cells to the virus. In contrast, Li, Chen et al. (PLoS One 2020, see below) evaluated cell specific 
expression of ACE2 at the maternal-foetal interface as well as in multiple foetal organs. The authors found a high 
expression of ACE2 in maternal-foetal cells (stromal cells, perivascular cells of decidua, cytotropho- and 
syncitiotrophoblast in placenta). ACE2 expression was also found in specific cell types of human foetal heart, liver and 
lung, but not in kidney. They concluded that both the vertical transmission and the placenta dysfunction/abortion 
caused by SARS-CoV-2 need to be further carefully investigated in clinical practice. 
All studies above described pregnancies in their third trimester, therefore the time interval from clinical manifestation 
of SARS-CoV-2 infection to delivery was short. The placental barrier is capable of delaying the transfer of the virus from 
mother to foetus; therefore, it remains uncertain whether there could be a risk of vertical transmission when SARS-
CoV-2 infection occurs earlier in the pregnancy. A study on SARS-CoV-2 infected pregnant women in early pregnancy 
was reported by Yu (Lancet Inf Dis 2020, see below). Two pregnant women were diagnosed with COVID-19 in the first 
trimester of pregnancy. In the second trimester, both patients tested positive for SARS-CoV-2 total antibodies in serum, 
while nasopharyngeal swabs were negative. The results of RT-PCR tests of the patients' amniotic fluid were negative, 
and tests for SARS-CoV-2 IgM and IgG in amniotic fluid were also negative. However, RNA is much less stable in 
amniotic fluid than is DNA and the virus might have been undetectable in amniotic fluid because of insufficient 
gestational age. Therefore, although SARS-CoV-2 was not detected in the amniotic fluid, the possibility of vertical 
transmission could not be ruled out.  
Intrapartum / post-partum infections 
Since COVID-19 is transmitted mainly through respiratory droplets and by close contact, neonates could acquire the 
infection during delivery or post-partum. A study by Fan (Clin Inf Dis 2020, see below) explored the topic of intrapartum 
transmission by testing vaginal secretions of COVID-19 infected mothers. They found vaginal swabs to be negative in 
all cases. Ferrazzi (BJOG 2020, see below) investigated the possibility of transmission during vaginal delivery in 24 
women. Of these 24 cases, only one newborn tested positive for the virus, presumably due to post-partum 
contamination. Liao (Int J Gynaecol Obstet 2020, see below) found similar reassuring results. These findings may 
indicate that vaginal delivery does not increase the risk of viral transmission. The CDC therefore stated that COVID-19 
infection is not an indication for delivery and states that vaginal delivery can be pursued in the event of spontaneous 
labour and good maternal condition. 
Due to possible post-partum transmission of the disease, there has been discussion on whether or not to separate 
mother and newborn. Consensus guidance from China recommended routine separation of neonates from mothers 
infected by COVID-19 for at least 14 days (Chen Int J Gyn Obstetr 2020, see below). During this period, direct 
breastfeeding was not recommended. However, routine precautionary separation of a mother and a healthy baby 
should not be undertaken lightly, given the potential detrimental effects on feeding and bonding. Furthermore, 
breastmilk contains specific antibodies with the capability of modulating an eventual SARS-CoV-2 infection in the 
newborn. In a document dated June 23 2020, WHO recommended that mothers with suspected or confirmed COVID-
19 should be encouraged to initiate or continue to breastfeed (https://www.who.int/news-
room/commentaries/detail/breastfeeding-and-covid-19). Mothers should be counselled that the benefits of 
breastfeeding substantially outweigh the potential risks for transmission. Mother and infant should be enabled to 
remain together while rooming-in throughout the day and night and to practice skin-to-skin contact, including 
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kangaroo mother care, especially immediately after birth and during establishment of breastfeeding, whether they or 
their infants have suspected or confirmed COVID-19.  
Case definition 
Interim case definitions based on the current information available have been issued by WHO 
(https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-
ncov)). The latest version of the document is dated August 7. The case definitions for suspected and probable cases 
have been revised as compared to earlier versions, to account for updated evidence on the most common or predictive 
symptoms and clinical and radiographic signs present in COVID-19 as well as known transmission dynamics. The 
current case definition integrates recent knowledge on signs and symptoms of COVID-19 issued from: 
 publications describing the clinical spectrum of COVID-19 among hospitalized (e.g., Guan NEJM 2020, see 
below; Menni 2020, see below) and non-hospitalized (e.g., Spinato JAMA 2020, see below; Tostamnn 2020, 
Struyf Cochrane Database Syst Rev 2020, see below) COVID-19 patients and WHO Clinical management of 
COVID-19 
 WHO’s and partners’ analysis of sensitivity, specificity and predictive value of most described signs and 
symptoms using surveillance data 
 expert consultations with clinicians, radiologists and laboratory scientists connected to global expert networks 
who supported validation of the definition. 
Of note, it has been recognized that countries may need to adapt COVID-19 case definitions depending on their local 
epidemiological situation and other factors.  
Suspected case 
A. A person who meets the clinical AND epidemiological criteria: 
Clinical criteria: 
1. Acute onset of fever AND cough; 
OR 
2. Acute onset of ANY THREE OR MORE of the following signs or symptoms: fever, cough, general weakness/fatigue1, 
headache, myalgia, sore throat, coryza, dyspnoea, anorexia/nausea/vomiting, diarrhoea, altered mental status. 
AND 
Epidemiological criteria: 
1. Residing or working in an area with high risk of transmission of the virus: for example, closed residential settings and 
humanitarian settings, such as camp and camp-like settings for displaced persons, any time within the 14 days prior to 
symptom onset; 
OR 
2. Residing in or travel to an area with community transmission2 anytime within the 14 days prior to symptom onset; 
OR 
3. Working in health setting, including within health facilities and within households, anytime within the 14 days prior 
to symptom onset. 
B. A patient with severe acute respiratory illness (SARI: acute respiratory infection with history of fever or measured 
fever of ≥ 38 C°; and cough; with onset within the last 10 days; and who requires hospitalization). 
Probable case 
A. A patient who meets clinical criteria above AND is a contact of a probable or confirmed case, or epidemiologically 
linked to a cluster of cases which has had at least one confirmed case identified within that cluster. 
B. A suspected case (described above) with chest imaging showing findings suggestive of COVID-19 disease* 
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* Typical chest imaging findings suggestive of COVID-19 include the following (Manna 2020): 
• chest radiography: hazy opacities, often rounded in morphology, with peripheral and lower lung distribution 
• chest CT: multiple bilateral ground glass opacities, often rounded in morphology, with peripheral and lower lung 
distribution 
• lung ultrasound: thickened pleural lines, B lines (multifocal, discrete, or confluent), consolidative patterns with or 
without air bronchograms. 
C. A person with recent onset of anosmia (loss of smell) or ageusia (loss of taste) in the absence of any other identified 
cause. 
D. Death, not otherwise explained, in an adult with respiratory distress preceding death AND who was a contact of a 
probable or confirmed case or epidemiologically linked to a cluster which has had at least one confirmed case identified 
within that cluster. 
Confirmed case 
A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms. 
Death due to COVID-19 
A COVID-19 death is defined for surveillance purposes as a death resulting from a clinically compatible illness in a 
probable or confirmed COVID-19 case, unless there is a clear alternative cause of death that cannot be related to 
COVID-19 disease (e.g. trauma). There should be no period of complete recovery between the illness and death. 
Definition of severe disease 
While WHO has not provided a definition of severe cases of COVID-19, various publications have classified disease 
cases according to severity. For instance, Zhang (Allergy 2020, see below) designated severe COVID-19 when the 
patients had one of the following criteria: 1) Respiratory distress with respiratory frequency ≥ 30/min; 2) Pulse 
Oximeter Oxygen Saturation ≤ 93% at  rest; 3) Oxygenation index (artery partial pressure of oxygen/inspired oxygen 
fraction, PaO2/FiO2) ≤ 300 mmHg. Critical cases have also been defined as having respiratory failure, septic shock, 
and/or multiple organ dysfunction or failure (with fatal cases reported only in the last group) (Wu JAMA 2020, see 
below). 
Pathophysiology of COVID-19  
The pathogenesis of COVID-19 is under investigation. Of note, a review on the comparative pathogenicity of the 
different human coronaviruses was published by Liu (J Med Vir 2020, see below). 
Viral tropism  
The S protein is responsible for coronavirus entry into the cell after by binding to a cell receptor and membrane fusion, 
two key steps in viral infection and pathogenesis (Benvenuto J Med Vir 2020, see below). Virus infectivity studies using 
HeLa cells expressing or not expressing ACE2 proteins from humans, Chinese horseshoe bats, civet, pig, and mouse 
showed that SARS-CoV-2 is able to use all but mouse ACE2 as an entry receptor in ACE2-expressing cells, but not cells 
without ACE2. ACE2 therefore appears as the likely cell receptor of SARS-CoV-2 (Zhou Nature 2020, see below). It was 
also demonstrated that SARS-CoV-2 does not use other coronavirus receptors, aminopeptidase N and dipeptidyl 
peptidase 4. 
However, cell entry of coronaviruses depends not only on binding of the viral S proteins to cellular receptors but also 
on S protein priming by host cell proteases. Hoffmann (Cell 2020, see below) demonstrated that SARS-CoV-2 uses the 
SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. 
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ACE2 is expressed in a variety of cells of different organs (endothelium, liver, lungs, etc.) and is part of the renin-
angiotensin blood pressure regulation system. In the respiratory tract, it is expressed on the apical face of respiratory 
epithelial cells via which infection may be mediated. Along the respiratory tract, ACE2 has been detected in the trachea, 
main bronchus and alveoli, and occasionally also in the small bronchi. An expression study found that ACE2 was mostly 
(83%) expressed by type II alveolar cells (AT2), and that this cell population also highly expressed other genes that 
positively regulate viral reproduction and transmission (Zhao Am J Respir Crit Care Med 2020, see below). 
By single cell sequencing, Weng (on bioRxiv: https://www.biorxiv.org/content/10.1101/2020.02.08.926006v3.full) 
found a strong co-expression between ACE2 and TMPRSSs, especially TMPRSS1 and TMPRSS2, in lung AT2 cells, which 
was also the main infected cell type in SARS-CoV pneumonia. Moreover, he found the endocytosis-associated genes 
were highly expressed in AT2 cells, implying that endocytosis may also facilitate the entry of SARS-CoV-2 into host cells. 
As the alveolar stem-like cells, AT2 cells promote surfactant biosynthesis, self-renewal and immunoregulation. Thus, 
SARS-CoV-2 appears to not only damage the AT2 cells leading to the direct injury to alveoli, but also raise alveolar 
surface tension to induce dyspnoea. 
Lukassen (EMBO J 2020, see below) investigated virus infection in the respiratory tract. SARS-CoV-2 was reported to 
enter cells via binding to ACE2, followed by its priming by TMPRSS2. ACE2 was found predominantly expressed in a 
transient secretory cell type in the subsegmental bronchial branches. Interestingly, these transiently differentiating 
cells show an enrichment for pathways related to RHO GTPase function and viral processes suggesting increased 
vulnerability for SARS-CoV-2 infection. 
Based on the public single-cell RNA-Seq datasets, Wu 
(https://www.medrxiv.org/content/10.1101/2020.02.11.20022228v2) found ACE2 expression in nasal epithelial cells. 
The size of this population of ACE2-expressing nasal epithelial cells appeared comparable with the size of the 
population of ACE2-expressing AT2 cells. 
Using bulk RNA-seq profiles from two public databases and single-cell transcriptomes from an independent dataset 
generated in-house, Xu (Int J Oral Sci 2020, see below) found evidence of ACE2 expression in the oral cavity and 
suggested enrichment in epithelial cells. Moreover, among different oral sites, ACE2 expression was found higher in 
tongue than buccal and gingival tissues. 
ACE2 and TMPRSSs are also highly co-expressed in absorptive enterocytes and upper epithelial cells of oesophagus, 
implying that intestinal epithelium and oesophagus epithelium may also be the potential target tissues. Liang (Gut 
2020, see below) also reported that ACE2 mRNA was highly expressed in the healthy human small intestine. Besides, 
single-cell RNA sequencing data showed ACE2 to be significantly elevated in proximal and distal enterocytes. Zhou 
(Nat Med 2020, see below) demonstrated active replication of SARS-CoV-2 in human intestinal organoids and isolation 
of infectious virus from the stool specimen of a patient with diarrheal COVID-19. The robust SARS-CoV-2 replication in 
human intestinal organoids suggests that the human intestinal tract might be a transmission route of SARS-CoV-2. 
They also established the first expandable organoid culture system of bat intestinal epithelium and present evidence 
that SARS-CoV-2 can infect bat intestinal cells. 
In addition, a manuscript by Lin (https://www.biorxiv.org/content/10.1101/2020.02.08.939892v1) reported the use 
of published kidney and bladder cell atlas data and an independent unpublished kidney single cell RNA-Seq data to 
evaluate ACE2 gene expressions in all cell types in healthy kidneys and bladders. Results showed the enriched 
expression of all subtypes of proximal tubule cells of kidney and low but detectable levels of expression in bladder 
epithelial cells. The data suggest that the urinary system may be a potential target for infection. Fan (on medRxiv: 
https://www.medrxiv.org/content/10.1101/2020.02.12.20022418v1) also noted that ACE2 is highly expressed in renal 
tubular cells, Leydig cells and cells in seminiferous ducts in testis. The authors recommended renal function evaluation 
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and special care of patients, especially in case of therapy with drugs associated with renal toxicity, and suggested that 
clinicians should pay attention to the risk of testicular lesions in patients. However, this hypothesis was not supported 
by the observations by Wang (see Clinical disease in China above). 
Liu (manuscript on medRxiv: https://www.medrxiv.org/content/10.1101/2020.02.28.20029181v1), using public 
datasets (bulk RNA-seq and single-cell RNA-seq),  showed expression of ACE2 in pancreas (in both exocrine glands and 
islets), and related this observation to  clinical data suggesting mild pancreatitis in some patients. Among 67 severe 
cases, 11 patients (16.41%) showed elevated levels of both amylase and lipase, and 5 patients (7.46%) showed imaging 
alterations.  
To construct a risk map of different human organs, Zou (Front Med 2020, see below) analysed the single-cell RNA 
sequencing (scRNA-seq) datasets derived from major human physiological systems, including the respiratory, 
cardiovascular, digestive, and urinary systems, for ACE2 expression. Through scRNA-seq data analyses, the authors 
identified the organs at risk, such as lung, heart, oesophagus, kidney, bladder, and ileum, and located specific cell types 
(i.e., type II alveolar cells (AT2), myocardial cells, proximal tubule cells of the kidney, ileum and oesophagus epithelial 
cells, and bladder urothelial cells) as vulnerable to SARS-CoV-2 infection. 
Chen (manuscript available on Preprints: https://www.preprints.org/manuscript/202002.0258/v2) found that ACE2 
expression in the lung increases with age. A high viral load in elderly patients could therefore be associated not only 
with low immunity but also with high expression of the ACE2 receptor. This could explain the high degree of severe 
disease in older patients with SARS-CoV-2 (Chen and Li Lancet Inf Dis 2020, see below). 
Considering that a conserved RGD (403-405:Arg-Gly-Asp) motif is present in the receptor -binding domain of the S 
proteins of all SARS-CoV-2, Sigrist (Antivir Res 2020, see below) presented the hypothesis that SARS-CoV-2 acquired 
integrin-binding to promote virus entry into host cells. However, experimental proof of this is required. Binding to 
integrin may play a supplemental role to ACE2 binding, like facilitating endocytosis by signalling through the integrin. 
Alternatively, the virus could infect different target cells by binding to ACE2 or to integrins. 
Using SARS-CoV-2 S protein pseudovirus system, Ou (Nature Comm 2020, see below) confirmed that human ACE2 is 
the receptor for SARS-CoV-2, found that SARS-CoV-2 enters 293/hACE2 cells mainly through endocytosis, and that 
PIKfyve, TPC2, and cathepsin L are critical for entry.  
Of note, a review by Li (Pharmacol Res 2020, see below) provided an interesting summary on ACE2 expression. It 
presents for instance the influence of sex hormones, age, or diet on expression. 
Portal of entry 
Xu (J Dent Res 2020, see below) analysed the expression of ACE2 in human organs in the GTEx portal. The expression 
of ACE2 in minor salivary glands was higher than that in lungs, which suggests salivary glands could be potential target 
for COVID-19. In addition, SARS-CoV RNA has been detected in saliva before lung lesions appeared. A similar 
phenomenon could explain the presence of asymptomatic infections with COVID-19.  
Using ex vivo and in vitro culture systems, Hui (Lancet Respir Med 2020, see below) found that the conjunctival 
epithelium and conducting airways appear to be potential portals of infection for SARS-CoV-2. SARS-CoV-2 infected 
ciliated, mucus-secreting, and club cells of bronchial epithelium, type 1 pneumocytes in the lung, and the conjunctival 
mucosa. In the bronchus, SARS-CoV-2 replication competence was higher than SARS-CoV. In the lung, SARS-CoV-2 
replication was similar to SARS-CoV. In conjunctiva, SARS-CoV-2 replication was greater than SARS-CoV.  
Delivered by Ingenta
IP: 157.193.240.2 On: Fri, 04 Jun 2021 12:29:12
Copyright Leuven University Press
 
Authors: Martine Denis, Valerie Vandeweerd, Rein Verbeke, Anne Laudisoit, Tristan Reid, Emma Hobbs, Laure Wynants, Diane 
Van der Vliet  
COVIPENDIUM version: 20 OCT 2020  Transdisciplinary Insights - Living Paper | 68 
Determinants of pathogenicity 
While information pertaining to the replication of SARS-CoV-2, and the interactions between the virus and its host, is 
accumulating, available data to document the mechanisms involved during infection by other human CoVs may also 
be of use (see for instance, Fung Ann Rev Microbiol 2019 below or Chen J Med Virol 2020 below).  
S protein and interaction with ACE2 
The expression level and expression pattern of human ACE2 in different tissues might be critical for the susceptibility, 
symptoms, and outcome of SARS-CoV-2 infection. A single-cell RNA-sequencing (RNA-seq) analysis indicated that Asian 
males may have higher expression of ACE2. Cao (Cell Discov 2020, see below) analysed coding-region variants in ACE2 
and the expression quantitative trait loci (eQTLs) variants, which may affect the expression of ACE2, to compare the 
genomic characteristics of ACE2 among different populations. No direct evidence was identified genetically supporting 
the existence of S-protein binding-resistant ACE2 mutants in different populations. However, East Asian populations 
were found to have higher allele frequencies in the eQTL variants, associated with higher ACE2 expression in tissues, 
which may suggest different susceptibility or response to SARS-CoV-2 from different populations under similar 
conditions. 
Subsequently, Hussain (J Med Vir 2020, see below) found that ACE2 alleles, rs73635825 (S19P) and rs143936283 
(E329G) showed noticeable variations in their intermolecular interactions with the viral S protein. These data provide 
a structural basis of potential resistance against SARS-CoV-2 infection driven by ACE2 allelic variants.  
A manuscript by Meng (on bioRxiv: https://www.biorxiv.org/content/10.1101/2020.02.08.926006v3.full) suggested 
enhanced S protein cleavage with SARS-CoV-2 compared to SARS-CoV. A SPRR insertion in the S1/S2 protease cleavage 
sites of SARS-CoV-2 S protein was found to increase cleavage efficiency as assessed by protein sequence alignment 
and furin score calculation. Additionally, the insertion sequence facilitates the formation of an extended loop which 
was more suitable for protease recognition by homology modelling and molecular docking. Coutard (Antivir Res 2020, 
see below) and Wang (Virol Sin 2020, see below) also identified a peculiar furin-like cleavage site in the S protein of 
SARS-CoV-2, which is lacking in the other SARS-like CoVs. The authors hypothesised that this cleavage site may affect 
the viral cycle and pathogenicity. Shang (PNAS 2020, see below) subsequently confirmed that unlike SARS-CoV, cell 
entry of SARS-CoV-2 is preactivated by proprotein convertase furin, reducing its dependence on target cell proteases 
for entry. The high hACE2 binding affinity of the RBD, furin preactivation of S, and hidden RBD in S potentially allow 
SARS-CoV-2 to maintain efficient cell entry while evading immune surveillance. 
Through plaque purification of Vero-E6 cultured SARS-CoV-2, Lau (Em Micr Inf 2020, see below) found a virus variant 
with in-frame deletions in the S1/S2 cleavage site region (Del-mut-1), which is attenuated in its ability to cause disease 
in a SARS-CoV-2 hamster model. 
Increased receptor expression 
A study by Ziegler (Cell 2020, see below) demonstrated that the antiviral interferon response upregulates the 
expression of ACE2 in human nasal epithelia and lung tissue. This finding suggested that SARS-CoV-2 could exploit the 
interferon pathway, essential for host antiviral defence, to enhance infection. 
Infection of immune cells 
Xu (Int J Oral Sci 2020, see below) found ACE2 expression in lymphocytes within the oral mucosa, and reported similar 
expression in various organs of the digestive system and in lung, even though the proportion of ACE2-positive 
lymphocytes was quite small.  
Wang (Cell Mol Immunol. 2020, see below) showed that SARS-CoV-2 could infect T cells (MT-2 cell line) and that 
infection occurred through receptor-dependent, S protein-mediated membrane fusion. A very low expression level of 
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hACE2 was found; from these data, the authors concluded that a novel receptor might mediate SARS-CoV-2 entry into 
T cells. However, the relevance of these data obtained in cell line to primary T cells remains to be confirmed. 
In a study by Feng (manuscript on medRxiv: 
https://www.medrxiv.org/content/10.1101/2020.03.27.20045427v1.full.pdf+html), spleens and lymph nodes from 
six COVID-19 patients with post-mortem examinations were collected and inspected for viral presence in resident 
macrophages, B cells and T cells. Immunochemistry demonstrated that SARS-CoV-2 nucleoprotein could be detected 
in ACE2+, CD169+ macrophages in spleen and lymph nodes, while no viral infection could be found in T cells and B 
cells. Moreover, it was observed that SARS-CoV-2 infection induces severe tissue damage including lymph follicle 
depletion, splenic nodule atrophy, histiocyte hyperplasia and lymphocyte reductions. The authors suggest that 
lymphocytopenia that is prevalent in COVID-19 patients might be caused by viral infected macrophages inducing 
lymphocyte apoptosis, mediated by Fas/FasL signalling.   
Other observations 
Angeletti (J Med Vir 2020, see below) used sequence analysis and modelling to predict features of SARS-Cov-2 
pathogenicity. He suggested that the stabilizing mutation falling in the endosome-associated-protein-like domain of 
the nsp2 protein could account for COVID-19 high transmission capability, while the destabilizing mutation in nsp3 
proteins could suggest a potential mechanism differentiating COVID-19 from SARS. 
Fahmi (Infect Genet Evol. 2020, see below) showed that two non-structural proteins, NS7b and NS8, were exclusively 
conserved among SARS-CoV-2, βCoV_RaTG, and BatSARS-like Cov. NS7b and NS8 have previously been shown to affect 
immune response signalling in the SARS-CoV experimental model. Thus, the authors speculated that the properties of 
these accessory proteins, NS7b and NS8, in SARS-CoV-2 may affect its ability to infect humans. 
Pathological observations from biopsies and autopsies 
A manuscript by Tian (J Thorac Oncol 2020, see below) described examinations of biopsies of 2 asymptomatic cancer 
patients who underwent surgery and were later found to have been infected with SARS-CoV-2. The lungs of both 
patients exhibited oedema, proteinaceous exudate with globules, focal hyperplasia of pneumocytes with only patchy 
inflammatory cellular infiltration, and multinucleated giant cells. Hyaline membranes were not prominent. These 
observations likely represent an early phase of the lung pathology of COVID-19 pneumonia. 
Xu (Lancet Resp Med 2020, see below)  described for the first time pathology findings from biopsies collected at 
autopsy. The pathological features of COVID-19 greatly resemble those seen in SARS and MERS. In addition, the liver 
biopsy specimens of the patient with COVID-19 showed moderate microvascular steatosis and mild lobular and portal 
activity, indicating the injury could have been caused by either SARS-CoV-2 infection or drug-induced liver injury. There 
were a few interstitial mononuclear inflammatory infiltrates, but no other substantial damage in the heart tissue. 
Zhang (Ann Int Med 2020, see below) presented the histopathologic changes seen on post-mortem transthoracic 
needle biopsies from a patient with COVID-19 who had respiratory failure and radiographic bilateral ground-glass 
opacities. Nonspecific findings consistent with diffuse alveolar damage were observed. Immunostaining of lung 
sections with an antibody to the Rp3 N protein of SARS-CoV-2 revealed prominent expression on alveolar epithelial 
cells, including damaged, desquamated cells within the alveolar space. In contrast, viral protein expression was 
minimally detectable on blood vessels or in the interstitial areas between alveoli. 
Barnes (J Exp Med 2020, see below) studied the function of neutrophils and their ability to form neutrophil 
extracellular traps (NETs), which may contribute to organ damage and mortality in COVID-19. The authors showed 
lung infiltration of neutrophils in an autopsy specimen from a patient who succumbed to COVID-19. Prior reports 
extensively linked aberrant NET formation to pulmonary diseases, particularly ARDS. Intravascular NETs have been 
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shown to play a vital role in initiating and accreting thrombosis in arteries and veins. NETs may also be involved in the 
cytokine storm. 
Menter (Histopathology 2020, see below) reported autopsy findings of 21 COVID-19 patients hospitalised in 
Switzerland. The primary cause of death was respiratory failure with exudative diffuse alveolar damage with massive 
capillary congestion often accompanied by microthrombi despite anticoagulation. Ten cases showed superimposed 
bronchopneumonia. Further findings included pulmonary embolisms (n=4), alveolar haemorrhage (n=3) and vasculitis 
(n=1). Pathologies in other organ systems were predominantly attributable to shock; three patients showed signs of 
generalised thrombotic microangiopathy. Six patients were diagnosed with senile cardiac amyloidosis upon autopsy. 
Most patients suffered from one or more comorbidities (hypertension, obesity, cardiovascular diseases, diabetes 
mellitus). 
Mechanisms of enhanced disease 
Antibody-dependent enhancement (ADE) occurs when antibodies facilitate viral entry into host cells and enhance viral 
infection in these cells. ADE has been observed for a variety of viruses, most notably flaviviruses (e.g., dengue virus). 
ADE has been observed for coronaviruses. Several studies have shown that sera induced by SARS-CoV S enhance viral 
entry into Fc receptor-expressing cells, including monocytes, macrophages and B cells (Wan, Shang, Sun et al. J Vir 
2020, see below). One study demonstrated that unlike receptor-dependent viral entry, serum-dependent SARS-CoV 
entry does not go through the endosome pathway. Additionally, it has long been known that immunization of cats 
with feline coronavirus S leads to worsened future infection due to the induction of infection-enhancing antibodies. 
Wan et al. further studied the molecular mechanism of ADE using MERS-CoV and a monoclonal antibody as a model. 
As early as in February 2020, a publication by Tetro (Micr Inf 2020, see below) further described the hypothesis that 
ADE due to prior exposure to other coronaviruses could underlie the severity of cases in the Hubei province. In the 
context of identifying the priming coronavirus, the authors noted that as the introduction of SARS-CoV into humans 
has been suggested to have occurred in the Hubei Province. However, SARS-CoV is not likely to be a predominant 
priming virus for ADE to SARS-CoV-2. Seroprevalence studies have shown a very low level of SARS-CoV seroconversion 
in the population apart from workers with direct contact with animals such as traders. 
Alternatively, Fu (Virol Sin 2020, see below) speculated that a mechanism of ADE of viral infection occurs in some 
patients with early, sub-optimal antibody activity that cannot completely clear the virus, but instead leads to persistent 
viral replication and inflammation. 
A review by Iwasaki (Nature Rev Immunol 2020, see below) outlined the potential danger of suboptimal antibody 
responses against SARS-CoV-2 and ADE, as well as implications for vaccine development. The authors raised the point 
that ADE might not facilitate the spread of SARS-CoV in infected hosts, as infection of macrophages through ADE does 
not result in productive viral replication and shedding. Instead, based on prior evidence with SARS-CoV, they suggest 
that non-neutralizing antibodies can promote inflammation and tissue injury by activating myeloid cells via FcRs. 
Enhanced disease might occur when low quality, low quantity antibodies are present, activating molecular 
mechanisms (e.g., FcR activation, viral RNA detection in macrophages, complement activation) that result in pro-
inflammatory cytokine secretion, increased neutrophil and eosinophil lung infiltration, and more severe lung 
pathology. The conclusion of this paper referred to 2 manuscripts on medRxiv, which have associated higher titres of 
anti-S and/or anti-N IgG and IgM at all time points following the onset of symptoms with a worse disease outcome.  
Zohar (Nat Rev Imm 2020, see below) further described the possible role of complement in disease severity in COVID-
19. Over-activation of the complement cascade by SARS-CoV-2 N, via the lectin pathway, has been reported to result 
in enhanced lung injury in mice. This study also showed that adding N-directed neutralizing monoclonal antibodies 
reduced fatality rates and lung injury. In addition to FcR expression, nearly all innate immune cells also express 
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complement receptors, providing an additional avenue through which antibodies may activate and direct the immune 
system. However, whether elevated antibody titres in progressive disease drive or temper complement activation 
remains to be determined. 
Based on developing scientific data, ADE concerns with COVID-19 seem to have evolved over time. As noted by Yager 
(Clin Imm 2020, see below), concerns of ADE with SARS-related coronaviruses are based primarily on experimental 
data with limited clinical evidence. As aging is associated with T-cell dysfunction, a role for aberrant T cell responses 
in elderly patients with severe disease should not be excluded. Further, aging is characterized by heightened, low-
grade chronic inflammation. The presence of pre-existing antibodies against coronaviruses in patients is plausible. 
However, discordance between the epidemiology of severe COVID-19 cases and seroprevalence data for homologous 
βCoVs, and the fluctuating circulation patterns of analogous human coronaviruses, cast doubts on roles for cross-
reactive antibodies in pathology. In a PNAS news feature (see below), Peeples also noted that a pathogenic Th2 
memory response with eosinophil and immune complex formation may cause (vaccine) enhanced disease. 
Arvin (Nature 2020, see below) reviewed observations relevant to the risks of ADE of disease, and their potential 
implications for SARS-CoV-2 infection. At present, there are no known clinical findings, immunological assays or 
biomarkers that can differentiate any severe viral infection from immune-enhanced disease, whether by measuring 
antibodies, T cells or intrinsic host responses. In vitro systems and animal models do not predict the risk of ADE of 
disease, in part because protective and potentially detrimental antibody-mediated mechanisms are the same, and 
designing animal models depends on understanding how antiviral host responses may become harmful in humans. 
The authors suggested that comprehensive studies are urgently needed to define clinical correlates of protective 
immunity against SARS-CoV-2. Moreover, because ADE of disease cannot be reliably predicted after either vaccination 
or treatment with antibodies, it will be essential to depend on careful analysis of safety in humans as immune 
interventions for COVID-19 move forward. 
Hyperinflammation and acute respiratory distress syndrome 
Similar to patients with SARS-CoV and MERS-CoV, patients with COVID-19 have soon been observed to develop acute 
respiratory distress syndrome (ARDS) with characteristic pulmonary ground glass changes on imaging (Zumla Lancet 
2020, see below). COVID-19 is also associated with increases in IL-6, IL-10, IL-2 and IFN-γ levels in the peripheral blood 
in the severe cases compared to those in the mild cases (Liu EBioMed 2020, see below). Evidence has rapidly 
accumulated to indicate that part of the severe COVID-19 patients have an elevated cytokine profile resembling the 
cytokine storm described in SARS and MERS (Zhang Clin Imm, see below). The observations have been found consistent 
with the characteristics of the so called “primary cytokine” storm induced by viral infection which were mainly 
produced by alveolar macrophages, epithelial cells and endothelial cells, rather than those observed in “secondary 
cytokine” storm induced by different subsets of activated T lymphocytes in late stage of viral infection or a 
complication of T cell-engaging therapies. 
Fu (Virol Sin 2020, see below) explored the possible mechanisms of the inflammatory response observed in COVID-19 
pneumonia. Based on previous studies of SARS-CoV, he separated the inflammatory responses in SARS-CoV-2 infection 
into primary and secondary responses (Figure 11). Primary inflammatory responses occur early after viral infection, 
prior to the appearance of neutralizing antibodies (NAb). These responses are mainly driven by active viral replication, 
viral-mediated ACE2 downregulation and shedding, and host antiviral responses. Secondary inflammatory responses 
begin with the generation of adaptive immunity and NAb. The virus-NAb complex can also trigger FcR-mediated 
inflammatory responses and acute lung injury.  
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Figure 11 Possible mechanisms of SARS-CoV-2-mediated inflammatory responses (from Fu Virol Sin 2020). 
 
Interestingly, Ong (Cell Host & Microbe 2020, see below) found a highly dynamic expression of pro-inflammatory genes 
in COVID-19. Expression of most of these genes peaked after nadir of respiratory function, which questions a cytokine 
storm hypothesis. Instead the authors’ data hints at the possibility that the IL1 pathway may be a more suitable 
correlate of severe respiratory disease.  
The cytokine profile associated with COVID-19 disease severity has been reported as characterised by increased IL-2, 
IL-7, granulocyte-colony stimulating factor, interferon-γ inducible protein 10, monocyte chemoattractant protein 1, 
macrophage inflammatory protein 1-α, and tumour necrosis factor-α. Predictors of fatality have been found to include 
elevated ferritin and IL-6, suggesting that mortality might be due to virally driven hyperinflammation (Mehta Lancet 
2020, see below).  
A better description of how the immune cell landscape is perturbed in severe COVID-19 was recently provided by Xu 
(Cell Discov 2020, see below). Using single-cell RNA sequencing, the authors characterized the peripheral blood 
mononuclear cells (PBMCs) from uninfected controls and COVID-19 patients and cells in paired broncho-alveolar 
lavage fluid (BALF). They found a close association of decreased dendritic cells (DCs) and increased monocytes 
resembling myeloid-derived suppressor cells (MDSCs), which correlated with lymphopenia and inflammation in the 
blood of severe COVID-19 patients. Those MDSC-like monocytes were immune-paralyzed. In contrast, monocyte-
macrophages in BALFs of COVID-19 patients produced massive amounts of cytokines and chemokines, but secreted 
little interferons. The frequencies of peripheral T cells and NK cells were significantly decreased in severe COVID-19 
patients, especially for innate-like T and various CD8+ T cell subsets, compared to healthy controls. In contrast, the 
proportions of various activated CD4+ T cell subsets among the T cell compartment, including Th1, Th2, and Th17-like 
cells were increased and more clonally expanded in severe COVID-19 patients. Patients' peripheral T cells showed no 
sign of exhaustion or augmented cell death, whereas T cells in BALFs produced higher levels of IFNG, TNF, CCL4, CCL5, 
etc. Paired TCR tracking indicated abundant recruitment of peripheral T cells to the severe patients' lung.  
Ciceri (Crit Care Resusc 2020, see below) suggested “MicroCLOTS” (microvascular COVID-19 lung vessels obstructive 
thromboinflammatory syndrome) as a new name for severe pulmonary COVID-19. The authors hypothesised that, in 
predisposed individuals, alveolar viral damage is followed by an inflammatory reaction and by microvascular 
pulmonary thrombosis. This progressive endothelial thromboinflammatory syndrome may also involve the 
microvascular bed of the brain and other vital organs, leading to multiple organ failure and death. 
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Magro (Transl Res 2020, see below) examined skin and lung tissues from 5 patients with severe COVID-19 
characterized by respiratory failure (n=5) and purpuric skin rash (n=3) by light microscopy and immunohistochemistry. 
No viral cytopathic changes were observed and the diffuse alveolar damage with hyaline membranes, inflammation, 
and type II pneumocyte hyperplasia, hallmarks of classic ARDS, were not prominent. These pulmonary findings were 
accompanied by significant deposits of terminal complement components C5b-9 (membrane attack complex), C4d, 
and MASP2, in the microvasculature, consistent with sustained, systemic activation of the alternative and lectin-based 
complement pathways. The purpuric skin lesions similarly showed a pauci-inflammatory thrombogenic vasculopathy, 
with deposition of C5b-9 and C4d in both grossly involved and normally-appearing skin. In addition, there was co-
localization of COVID-19 spike glycoproteins with C4d and C5b-9 in the inter-alveolar septa and the cutaneous 
microvasculature of two cases examined. In conclusion, at least a subset of sustained, severe COVID-19 may define a 
type of catastrophic microvascular injury syndrome mediated by activation of complement pathways and an 
associated procoagulant state. 
Impact of age on disease severity 
Molloy (Pediatr Res 2020, see below) suggested that a possible reason for the disparity in severity between adults and 
children may relate to differences in receptors in the renin-angiotensin system and altered inflammatory responses to 
pathogens. The differences in immune responses to SARS-CoV-2 in hospitalized paediatric and adult patients were 
analysed by Pierce (Sci Transl Med 2020, see below) to identify potential contributing mechanisms. In the first week 
after hospitalization, circulating IL-17A and IFN-γ concentrations were inversely related to age. More than 3 weeks 
later, CD4+ T cell responses to S protein were higher in adult compared to younger patients. Neutralizing antibody 
titres were also higher in adults and correlated positively with age and negatively with IL-17A and IFN-γ. These findings 
suggest that the poor outcome in adults is not caused by a failure to generate adaptive immune responses. 
Influence of gender  
A review by Scully (Nat Rev Imm 2020, see below) introduced sex-differential features of immunity and highlighted 
the potential sex differences underlying COVID-19 severity. In one cohort of patients with COVID-19, severe respiratory 
failure was associated with a pattern of inflammation, macrophage activation and depletion of lymphocytes that was 
distinct from bacterial infection. There was a sex bias for severe COVID-19 not observed in the comparator group with 
bacterial infections. Sex-differential production of IL-6, monocyte transcriptional patterns and inflammatory set point 
could contribute to an enhanced risk of death in males. 
Mechanisms of myocardial injury 
Both Guo (JAMA Cardiol 2020, see below) and Shi (JAMA Cardiol 2020, see below) observed that myocardial injury is 
significantly associated with fatal outcome of COVID-19 in China. A review of the importance of myocarditis in COVID-
19 was published by Madjid (JAMA Cardiol 2020, see below), who suggested that myocardial injury is likely associated 
with infection-related myocarditis and/or ischemia, and provides an important prognostic factor in COVID-19. Bonow 
(JAMA Cardiol 2020, see below) further discussed the observation that patients with pre-existing cardiovascular 
disease are susceptible to the most adverse complications of COVID-19, and the fact that the mechanisms responsible 
for these outcomes remain largely unknown. Bonow also pointed to a mechanism of demand ischemia that devolves 
into myocardial injury or plaque disruption stimulated by intense systemic inflammatory stimuli. SARS-CoV-2 can elicit 
an intense release of multiple cytokines and chemokines that may lead not only to vascular inflammation and plaque 
instability but also to myocardial inflammation. Direct viral infection of the myocardium is another possible causal 
pathway of myocardial damage. The affinity of SARS-CoV-2 for the host ACE2 receptor also raises the possibility of 
direct viral infection of vascular endothelium and myocardium. It is thus possible that in some patients with or without 
pre-existing cardiovascular disease, COVID-19-associated myocardial injury could represent myocarditis.  
Chen (Cardiovasc Res 2020, see below) found that pericytes with high expression of ACE2 might act as the target 
cardiac cell of SARS-CoV-2. The pericytes injury due to virus infection may result in capillary endothelial cells 
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dysfunction, inducing microvascular dysfunction. Patients with basic heart failure disease showed increased ACE2 
expression at both mRNA and protein levels, meaning that if infected by the virus these patients may have higher risk 
of heart attack and critically ill condition. This study may explain the high rate of severe cases among COVID-19 patients 
with basic cardiovascular disease 
Signs of liver injury 
Guan (Zhonghua Gan Zang Bing Za Zhi 2020, see below) investigated the possible mechanism of liver injury in patients. 
ALT and AST are indeed abnormally elevated in some patients, especially in severe disease cases. The author assumed 
that in addition to the over-activated inflammatory response in patients with COVID-19 pneumonia, the up-regulation 
of ACE2 expression in liver tissue caused by compensatory proliferation of hepatocytes derived from bile duct 
epithelial cells may also be the possible mechanism of liver tissue injury. 
A publication by Xu (Liver Int 2020, see below) provided a summary of available information on SARS-CoV-2 and liver 
injury. The authors noted that the liver injury observed in COVID-19 patients might be caused by lopinavir/ritonavir, 
and that there is still a lack of reports that liver failure occurs in COVID-19 patients with chronic liver diseases. 
Neurotropism 
Li, Bai et Hashikawa (J Med Vir 2020, see below), considering the similarities of the disease with SARS-CoV and MERS-
CoV,  proposed a potential neuroinvasion of SARS-CoV-2 to be partially responsible for the acute respiratory failure of 
COVID-19 patients. A similar hypothesis has been raised by Steardo (Acta Physiol 2020, see below). 
Conde Cardona (J Neurol Sci 2020, see below) presented a series of arguments supporting the contention that that 
respiratory distress is not only the result of pulmonary inflammatory structural damage, but also due to the damage 
caused by the virus in the respiratory centers of the brain. These arguments included for instance the neurological 
symptoms observed in a subset of the patients (incl. anosmia and dysgeusia), detection of the virus genome in the 
cerebrospinal fluid of a patient, as well as presence of receptors of ACE2 in the cerebral vascular endothelium and its 
self-regulatory function, causing elevation of cerebral blood pressure. 
Co-infections 
Since the beginning of the epidemic, various authors have observed co-infections with SARS-CoV-2 and another 
pathogen.  For instance, a study by Wang (manuscript on medRxiv : 
https://www.medrxiv.org/content/10.1101/2020.02.12.20022327v2) analysed 613 patients with fever who 
underwent multiple tests for 13 respiratory pathogens. Interestingly, 5.8% of patients with SARS-CoV-2 infection were 
reported to be co-infected with coronavirus (3/104), influenza A virus (2/104), rhinovirus (2/104), and/or influenza A 
H3N2 (1/104). 
Similarly, respiratory virus, fungi and bacteria co-infections were reported by Ai (on medRxiv 
https://www.medrxiv.org/content/10.1101/2020.02.13.20022673v1). 
A case report on co-infection with SARS-CoV-2 and Influenza A Virus in a patient with pneumonia in China has also 
been presented (Wu Emerg Inf Dis 2020, see below). 
Lin (Sci China Life Sci 2020, see below) reported on the use of a multiplex RT-PCR method (multiplex rapid detection 
kit 2.0, Uni-MEDICA Tech, Shenzhen), which can simultaneously detect 15 respiratory tract infection pathogens 
including the SARS-CoV-2, was employed to screen the pathogen agents in the patients. These 15 respiratory 
pathogens are SARS-CoV-2, influenza A/B, coronavirus NL63, coronavirus, parainfluenza virus type 1/2/3(PIV1/2/3), 
adenovirus, rhinovirus (hRV), human bocavirus, coronavirus HKU1 (HKU1), coronavirus OC43, human 
metapneumovirus (hMPV) and respiratory syncytial virus (RSV). A total of 186 suspected COVID-19 cases were tested. 
In the 92 SARS-CoV-2 (49.46%) positive patients, the common respiratory viruses RSV, hRV, hMPV, PIV2 and HKU1 
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were also simultaneously detected in six patients (3.2%) respectively, of which four patients (2.2%) were positive for 
at least two detected viruses. The co-infections in these six patients were further verified in parallel testing using a 
second-day sampling from the same patients. 
Zhu (J Med Vir 2020, see below) reported on a severe case involving co-infection of SARS-CoV-2 and HIV. Unfortunately, 
the publication did not provide details as to the time of HIV diagnosis. 
Rawson (Clin Inf Dis 2020, see below) explored the current literature surrounding bacterial/fungal co-infection in 
patients with coronavirus infection. 62/806 (8%) COVID-19 patients were reported as experiencing bacterial/fungal 
co-infection during hospital admission. Secondary analysis demonstrated wide use of broad-spectrum antibacterials.  
More recently, Lai (J Microbiol Immunol Infect 2020, see below) reported that Aspergillus spp. can cause co-infections 
in patients with COVID-19, especially in severe/critical illness. 
Animal models  
Animal models are required to provide information on pathogenesis, host responses to infection, and to evaluate 
vaccines and other therapeutic targets (Cohen Science 2020b, see below).  In March 2020, Yuan (Em Micr Infect, see 
below) provided a clear review on the status of natural and experimental infection of SARS-COVs and MERS in animal 
models.  
On the basis of sequence analyses, Wan, Shang, Graham et al. (J Vir 2020, see below) predicted that either SARS-CoV-
2 or laboratory mice and rats would need to be genetically engineered before a robust mouse or rat model for COVID-
19 would become available. By contrast, the authors noted that pigs, ferrets, cats, and non-human primates contain 
largely favourable SARS-CoV-2 -contacting residues in their ACE2 and hence may serve as animal models for SARS-
CoV-2. Comparison of SARS-CoV and SARS-CoV-2 S proteins bound the ACE2 receptors showed that the SARS-CoV-2 S 
glycoprotein has adapted to bind the human, but not rodent, ACE2 with high affinity and that ferrets are the most 
suitable model for the study of inhibitory antibodies and small molecules targeting the SARS-CoV-2 S protein 
interaction with ACE2 (Brooke, manuscript on Research Square: https://doi.org/10.21203/rs.3.rs-29443/v1). In 
contrast, the authors did not detect species-specific adaptation for TMPRSS2. Bosco-Lauth (manuscript on bioRxiv: 
https://doi.org/10.1101/2020.05.28.120998) studied the pathogenesis and SARS-CoV-2 transmission in domestic cats 
and suggested they may be an animal model more relevant to study mild human disease. Additionally, the relatively 
high-titer viral shedding produced by cats and the rapidity of transmission may make them an ideal model for 
simulation of aerosols. As such, cat models may be quite useful for understanding the shed/spread kinetics of SARS-
CoV-2 furthering the development of vaccines and therapeutics. 
Transgenic mice 
Bao (Nature 2020, see below) presented data supporting the suitability of the SARS-CoV transgenic mouse model for 
SARS-CoV2. The hACE2 transgenic mice were inoculated intranasally at a dosage of 10^5 TCID50 per mouse. Weight 
loss of up to 5% was observed for 10 dpi only in the infected mice. Other clinical symptoms were not observed. The 
typical histopathology was interstitial pneumonia with significant inflammatory cells infiltration around the 
bronchioles and blood vessels, and viral antigens were observed in bronchial epithelial cells and alveolar epithelial 
cells. The phenomenon was not found in wild type mice infected with SARS-CoV-2.  
Sun (Cell Host Micr 2020, see below) generated a mouse model expressing human ACE2 (hACE2) by using CRISPR/Cas9 
knockin technology. In comparison with wild-type C57BL/6 mice, both young and aged hACE2 mice sustained high viral 
loads in lung, trachea, and brain upon intranasal infection. Although fatalities were not observed, interstitial 
pneumonia and elevated cytokines were seen in SARS-CoV-2 infected-aged hACE2 mice. Interestingly, intragastric 
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inoculation of SARS-CoV-2 was seen to cause productive infection and lead to pulmonary pathological changes in 
hACE2 mice. 
The limited global availability of hACE2 transgenic mice led Israelow (J Exp Med 2020, see below) to develop a mouse 
model of SARS-CoV-2 infection and pathogenesis by delivering human ACE2 (hACE2) into the respiratory tract of mice 
using adeno-associated virus (AAV). The AAV-hACE2 mice supported productive viral replication, mounted a significant 
antibody response, and developed acute inflammatory pulmonary pathology similar to that found in COVID-19 
patients and non-human primate models. Assessment of the AAV-hACE2 mice’s cytokine and interferon response to 
SARS-CoV-2 revealed clear signatures of cytokines and interferon stimulated genes (ISGs), but no upregulation of type 
I, II or III interferons. The majority (73%) of upregulated genes were ISGs, and a distinct subset of 45 genes elevated in 
the infected lung were specific to type I interferon signalling; this type of interferon signalling was responsible for 
recruitment of proinflammatory cells into the lungs and for ISG expression, but not for viral clearance. This was 
consistent with other reports of elevated interferon signatures in the lungs of COVID-19 patients, and suggests that 
these AAV-hACE2 mice represent a useful model for studies of SARS-CoV-2 infections in humans. 
Golden Syrian Hamsters 
Chan (Clin Infect Dis 2020, see below) established a readily available small animal model for COVID-19 using golden 
Syrian hamster (Mesocricetus auratus). The Syrian hamster could be consistently infected by SARS-CoV-2. Within the 
first week of challenge, the following observations were made: 
- Maximal clinical signs of rapid breathing, weight loss and postural changes 
- Histopathological changes from the initial exudative phase of diffuse alveolar damage with extensive apoptosis 
to the later proliferative phase of tissue repair, airway and intestinal involvement with virus nucleocapsid 
protein expression,  
- High lung viral load, with a titre between 105-107 TCID50/g, peaking on day 2 post-inoculation and remaining 
detectable beyond day 7. 
- Spleen and lymphoid atrophy associated with marked cytokine activation. 
Challenged index hamsters consistently infected naïve contact hamsters housed within the same cage, resulting in 
similar pathology but not weight loss. All infected hamsters recovered and developed mean serum neutralising 
antibody titre ≥1:427 fourteen days post-challenge. Immuno-prophylaxis with early convalescent serum achieved 
significant decrease in lung viral load but not in lung pathology.  
Contrastingly, a more recent study demonstrated that SARS-CoV-2 replicates efficiently in the lungs of both young and 
older Syrian hamsters and causes severe pathological lesions in the lungs of these animals (Imai 2020 PNAS, see below). 
By using in vivo X-ray microcomputed tomographic (micro-CT) imaging, they showed that severe lung injury occurs in 
infected hamsters and that the severity of the lung abnormalities is related to the infectious dose. Finally, they 
assessed whether primary infection or passive transfer of convalescent serum could suppress the replication of SARS-
CoV-2 in hamsters. The levels of virus titer reduction were substantial in animals treated with convalescent sera (i.e., 
nearly 1,000-fold virus titer reduction in the lungs of animals inoculated with convalescent sera 1 d post-infection and 
nearly 100-fold virus titer reduction in those inoculated on day 2 post-infection). 
Sia (Nature 2020, see below) made similar observations and reported that SARS-CoV-2 was transmitted efficiently 
from inoculated hamsters to naive hamsters by direct contact and via aerosols. Transmission via fomites in soiled cages 
was not as efficient. Although viral RNA was continuously detected in the nasal washes of inoculated hamsters for 14 
days, the communicable period was short and correlated with the detection of infectious virus but not viral RNA.  
The age-related effects of COVID-19 observed in elderly human patients led Osterreider (Viruses 2020, see below) to 
compare the effects of SARS-CoV-2 infections in younger (6 months of age) vs. older (32-34 months of age) golden 
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hamsters. Viral replication in the upper and lower respiratory tract of experimentally-inoculated hamsters was 
independent of age, however clear age-dependent differences were seen: older hamsters exhibited more pronounced 
and consistent weight loss, developed more conspicuous alveolar and perivascular oedema indicative of vascular 
leakage, and mounted a slower and weaker immune response in lung tissue than younger animals. In addition, younger 
animals demonstrated rapid lung recovery at 14 dpi, whereas older animals did not. The authors suggested that the 
age-dependent differences observed in Syrian hamsters, that appear to mirror those seen in human patients, may 
make them a valuable animal model for comparative assessments of COVID-19 vaccines and treatments (e.g. 
immunotherapies and antiviral drugs).  
Ferrets 
Kim (Cell Host Micr 2020, see below) and Beer (ProMed archive number: 20200407.7196506) reported ferret models 
of SARS-CoV-2 infection and transmission that recapitulate aspects of human disease. SARS-CoV-2 infected ferrets 
exhibited elevated body temperatures and efficient virus replication in the upper respiratory tract (nasal turbinates, 
soft palate and tonsils) from as early as two days post-infection. Although fatalities were not observed, SARS-CoV-2-
infected ferrets shed virus in nasal washes, saliva, urine and faeces for up to 8 days post-infection. At 2 days post-
contact, SARS-CoV-2 was detected in all naïve direct contact ferrets. Furthermore, a few naïve indirect contact ferrets 
were positive for viral RNA, suggesting airborne transmission. Viral antigens were detected in nasal turbinate, trachea, 
lungs, and intestine with acute bronchiolitis present in infected lungs. Infections in ferrets appear to resemble mild 
human infections; this and the fact that SARS-CoV-2 replicates efficiently in the upper respiratory tract of ferrets makes 
them a candidate animal model for evaluating antiviral drugs or vaccine candidates against COVID-19. 
As seen above, given their susceptibility to experimental infection and onward transmission via direct and indirect 
contact, ferrets have been proposed as an animal model to study SARS-CoV-2 transmission. However, interestingly, in 
a natural experiment where 29 ferrets in one home had prolonged, direct contact and constant environmental 
exposure to two humans with symptomatic COVID-19, no evidence of SARS-CoV-2 transmission into the household 
ferret population via RT-PCR and ELISA was observed. To better understand this discrepancy between experimental 
and natural infection in ferrets, Sawatzki (manuscript on bioRxiv : 
https://www.biorxiv.org/content/10.1101/2020.08.21.254995v2) compared SARS-CoV-2 sequences from natural and 
experimental mustelid infections. They analysed all currently available genomic sequences of SARS-CoV-2 viruses of 
naturally infected European minks and experimentally infected ferrets. Viral sequences available from the two natural 
reverse zoonotic events in European mink farms (see section Human to animal transmission and risk of reverse 
spillover for details) allowed to infer founder-effect mutations versus acquired mutations of relevance to spillover. 
The authors identified three mutations of interest in the S protein coding sequence: N501T, D614G and S686G 
associated with mustelids. While there is evidence that ACE2 provides a weak host barrier, one mutation only seen in 
ferrets is located in the novel S1/S2 cleavage site and is computationally predicted to decrease furin activity. The 
absence of transmission in the high-exposure home contrasts with multiple human-to-mink spillover events, 
suggesting additional host barriers specific to ferrets. To date, experimental ferret infections have been successful 
(6 × 105 and 105.5 TCID50), and at least one inoculum contained a minority of virus with the S686G variant. These 
limitations may negatively affect ferrets as a disease and/or transmission model and should be further investigated. 
Cynomolgus macaques 
Rockx (Science 2020, see below) compared the pathogenesis of COVID-19, MERS and SARS in cynomolgus or crab-
eating macaques, and showed that SARS-CoV-2 infection in cynomolgus macaques results in COVID-19-like disease 
with prolonged virus excretion from nose and throat in absence of clinical signs. SARS-CoV-2 was introduced via 
combined intratracheal and intranasal inoculation; no significant weight loss or overt clinical signs were detected in 
any of the 8 macaques except for a serous nasal discharge in an aged animal on day 14 post-infection, by which time 
all remaining animals had seroconverted as identified by the detection of specific antibodies against the S1 domain 
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and N proteins of SARS-CoV-2. Higher levels of viral RNA were detected in nasal swabs of aged animals compared to 
younger animals. Viral replication was highest in lung tissue, but was also detected in ileum and tracheo-bronchial 
lymph nodes. In contrast, macaques infected with MERS-CoV via the same method remained free of clinical signs and 
seroconverted by day 21 post-infection; low levels of viral RNA were detected in nasal, throat and rectal swabs. The 
authors concluded that cynomolgus macaques are permissive to SARS-CoV-2 infection, shed virus for pronged periods 
of time, and display COVID-19-like disease. Severity of disease appeared to be intermediate between SARS-CoV and 
MERS-CoV infections established by similar inoculation doses and routes. 
Rhesus macaques 
Lu (manuscript on bioRxiv: https://www.biorxiv.org/content/10.1101/2020.04.08.031807v2) compared experimental 
inoculation of three non-human primate species with SARS-CoV-2. The study indicated that rhesus macaques (Macaca 
mulatta) were the most susceptible to SARS-CoV-2 infection, followed by cynomolgus or crab-eating macaques 
(Macaca fascicularis) and lastly common marmosets (Callithrix jacchus). Increased body temperature was 
continuously recorded in 100% (12/12) of Rhesus macaques, 33.3% (2/6) of crab-eating macaques and 0% (0/6) of 
common marmosets. Weight loss and radiographic chest abnormalities were observed in rhesus macaques and crab-
eating macaques, but were not performed in common marmosets. Viral genome was detected in nasal, throat and 
anal swabs as well as in blood from all three monkey species, with viral shedding from the upper respiratory tract 
peaking between days 6 and 8 post-inoculation. Viral RNA was detectable in peripheral blood from day 2 post 
inoculation, until day 10 post inoculation. Severe gross lesions and histopathological changes were observed in lung, 
heart and stomach of infected animals. 
Callaway (Nature 2020, see below) provided a summary of the status of research on COVID-19 animal models in March 
2020. He pointed to the preprint by Chao Shan at the Chinese Academy of Sciences Wuhan Institute of Virology, who 
found that rhesus macaques infected with SARS-CoV-2 had a fairly mild illness. The study followed 6 rhesus macaques 
over a period of 14 days after intratracheal inoculation with SARS-CoV-2, no changes in body temperature or weight 
loss were observed. No obvious clinical signs were observed except for mild anorexia in one animal. Blood, and 
oropharyngeal, nasal and anal swabs were collected over the course of the study; no viral RNA was detectable by RT-
PCR in any of the blood samples, but was observed to peak in the oropharyngeal swabs on days 1 and 5 post inoculation, 
and was undetectable by day 9. Anal swabs tested positive in 3/6 animals on day 2, with one animal continuing to shed 
virus until day 11. Radiographs of their lungs showed signs of pneumonia similar to those in humans with COVID-19. 
Post-mortem examination showed gross pathology in the lower respiratory tract, including diffuse interstitial 
pneumonia. Two of the animals were observed for an extended period of three weeks; these monkeys lost some 
weight, but didn’t seem to have other serious symptoms. 
Munster (Nature 2020, see below) also showed that SARS-CoV-2 causes respiratory disease in infected rhesus 
macaques, with disease lasting 8-16 days. Pulmonary infiltrates, a hallmark of human disease, were visible in lung 
radiographs. High viral loads were detected in swabs from the nose and throat of all animals as well as in 
bronchoalveolar lavages; in one animal we observed prolonged rectal shedding. Taken together, the rhesus macaque 
was found to recapitulate moderate disease observed in the majority of human cases. 
Deng (Science 2020, see below) studied the possibility of reinfection in a rhesus macaque model. Following the initial 
intratracheal infection, interstitial pneumonia and systemic viral dissemination mainly in the respiratory and 
gastrointestinal tracts were observed. Rhesus macaques reinfected with the identical SARS-CoV-2 strain during the 
early recovery phase of the initial SARS-CoV-2 infection did not show detectable viral dissemination, clinical 
manifestations of viral disease, or histopathological changes. Comparing the humoral and cellular immunity between 
primary infection and rechallenge revealed notably enhanced neutralizing antibody and immune responses (Table 6).  
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Protection against rechallenge in rhesus macaques has also been reported by Chandrashekar (Science 2020, see 
below). 
Yu (Animal Model Exp Med. 2020, see below) found that SARS-CoV-2 caused more severe interstitial pneumonia in 
old monkeys than that in young monkeys. Monkeys developed typical interstitial pneumonia characterized by 
thickened alveolar septum accompanied with inflammation and oedema; notably, old monkeys exhibited diffuse 
severe interstitial pneumonia. Viral antigens were detected mainly in alveolar epithelial cells and macrophages.  
Deng (Nature Comm 2020, see below) also presented data suggesting that macaques can be infected with SARS-CoV-
2 via the conjunctival route. Viral load and distribution in the macaques infected by this route were comparatively high 
in the nasolacrimal system, while relatively mild and local in the lung compared with those in macaques inoculated via 
intratracheal routes. This publication refers to the contrasting observation that no SARS-CoV-2 could be detected by 
RT-PCR in 114 conjunctival swabs samples 28 from patients with COVID-19 pneumonia. 
 
Table 6 SARS-CoV-2 neutralizing antibody titers in infected monkeys (from Deng Science 2020) 
 
African Green Monkeys 
Totura (manuscript on Research Square: https://www.researchsquare.com/article/rs-21725/v1) experimentally 
inoculated 12 African Green or vervet monkeys (Chlorocebus aethiops) with aerosolised MERS-coronavirus and 
reported clinical signs similar to infected humans, with dose-dependent increases observed in respiratory disease signs 
and viral titres in serum and throat swabs of infected monkeys. The authors suggested that African green monkeys 
(AGM) may similarly provide a suitable animal model for COVID-19 studies. Woolsey (manuscript on bioRxiv: 
https://www.biorxiv.org/content/10.1101/2020.05.17.100289v1.full) reported that AGM support a high level of SARS-
CoV-2 replication and develop pronounced respiratory disease. SARS-CoV-2 was detected in mucosal samples and 
faeces of 6 AGM challenged with 5.0 x 105 PFU of the Italy isolate of SARS-CoV-2 (SARS-CoV-2/INMI1-Isolate/2020/Italy) 
by combined intratracheal and intranasal routes (dose divided equally) up to 15 days after virus exposure. Noteworthy 
is that virus replication and respiratory disease can be produced in AGM using a much lower and more natural dose of 
SARS-CoV-2 than has been employed in other non-human primate studies.  
Further experimental infection of young AGM (N=6) revealed - through two imaging methods (18F-fluoro-2-deoxy-D-
glucose positron emission tomography or 18F-FDG PET and computed tomography or CT) - pulmonary lesions at 4 
days post-infection (dpi) that resolved over time. Infectious virus was shed from both respiratory and gastrointestinal 
tracts in all 6 animals in a biphasic manner, first between 2-7 dpi followed by a recrudescence at 14-21 dpi. All animals 
seroconverted simultaneously for IgM and IgG, which has also been documented in human COVID-19 cases (Hartman, 
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preprint on bioRxiv : https://doi.org/10.1101/2020.06.20.137687). The authors emphasize that young AGMs are 
suitable species to study mild/subclinical COVID-19 and are ideally suited for preclinical evaluation of candidate 
vaccines and therapeutic interventions. 
Further data on the topic of reinfection were obtained from a longitudinal monitoring of nasopharyngeal swabs and 
serum of cohorts of AGM, one of which had been pre-exposed to SARS-CoV-2 (community-acquired exposure) prior 
to SARS-CoV-2 challenge. A dramatic increase from D1 to D18 in all diagnostic targets (RT-PCR, IgM and IgG) and 
neutralization (PRNT and microneutralization) across the entire NHP cohort was observed with the exception of the 
pre-infected animal. In this animal, a generally static level of neutralization was observed, IgG titers rose but 
interestingly IgM levels dropped over the course of the study (Ricks, manuscript on bioRxiv: 
https://doi.org/10.1101/2020.07.06.189803). 
Surrogate models 
Heegaard (Front Microbiol 2020, see below) noted that the pig is an interesting case, as its ACE2 protein was both 
predicted and demonstrated experimentally to bind SARS-CoV-2 S protein; however, SARS-CoV-2 was found to neither 
replicate nor cause disease in pigs after experimental infection. Using a ten-fold higher viral dose for oronasal 
inoculation, Pickering (manuscript on bioRxiv : https://doi.org/10.1101/2020.09.10.288548) could detect evidence of 
infection, but only in a small proportion of animals. Heegaard suggested the use of a surrogate model based on 
intranasal inoculation of porcine respiratory coronavirus (PRCV) in pigs with robust metabolic syndrome such as obese 
Ossabaw miniature pigs, which may increase the severity of disease, similar to patients with metabolic syndrome 
having severe COVID-19. 
Epidemiology  
Disease emergence 
On 31 December 2019, the Wuhan Municipal Health Commission announced a cluster of cases of viral pneumonia of 
unexplained aetiology (Wu Eurosurv 2020, see below). The Southern China Seafood Wholesale Market in Wuhan was 
suspected to be related to 27 pneumonia cases without identified pathogenic agents that were reported in late 
December 2019. Most of the early cases were reportedly either shop owners, largely in the West District of the 
Southern China Seafood Wholesale Market, or people who visited the market before symptom onset. This market is a 
large open complex including sections selling seafood, fresh meat, produce, other perishable goods, and a very wide 
variety of live wild animals for consumption. Environmental disinfection of the Southern China Seafood Wholesale 
Market was initiated on 30 December 2019 and the market was closed on 1 January 2020.  
Host range & search for intermediate animal hosts 
In both the SARS-CoV and MERS-CoV epidemics, the viruses have likely originated from bats and then jumped into 
another amplification mammalian host [the Himalayan palm civet (Paguma larvata) for SARS-CoV and the dromedary 
camel (Camelus dromedarius) for MERS-CoV] before crossing species barriers to infect humans (Chan Em Micr Inf 2020, 
see below). Bonilla-Aldana (manuscript on Preprints: https://www.preprints.org/manuscript/202003.0103/v2) 
performed a systematic literature review with meta-analysis, using three databases to assess MERS-CoV and SARS-
CoV infection in animals and its diagnosis by serological and molecular tests to calculate pooled prevalence. From 34 
studies (n=20,896 animals), the pool prevalence by RT-PCR for MERS-CoV was 7.2% (95%CI 5.6-8.7%), with 97.3% 
occurring in camels with a prevalence of 10.3% (95%CI 8.3-12.3). From 5 studies and 2,618 animals, for SARS-CoV, the 
RT-PCR pool prevalence was 2.3% (95%CI 1.3-3.3). Of those, 38.35% were reported on bats, in which the pool 
prevalence was 14.1% (95%CI0.0-44.6%). In this meta-analysis, camels and bats were found to be positive by RT-PCR 
in over 10% of the cases for both; thus, suggesting their relevance in the maintenance of wild zoonotic transmission.  
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While phylogenetic analysis indicates a bat origin of SARS-CoV-2, the virus also potentially recognizes the ACE2 
receptor from a diversity of animal species (except mice and rats), implicating these animal species as possible 
intermediate hosts or animal models for SARS-CoV-2 infections (Wan, Shang, Granham et al. J Virol 2020, see below). 
As explained by Andersen (Nature Med 2020, see below), detailed understanding of how an animal virus jumped 
species boundaries to infect humans so productively will help in the prevention of future zoonotic events. If SARS-CoV-
2 pre-adapted in another animal species, then there is the risk of future re-emergence events. In contrast, if the 
adaptive process occurred in humans, then even if repeated zoonotic transfers occur, they are unlikely to take off 
without the same series of mutations. Building on these gaps, the Wildlife Disease Surveillance Focus Group 
recommends the creation of a central, publicly accessible database for recording the characteristics of animal viruses 
to help monitor the risk of any crossover into people. This would allow scientists to see how the pathogens and their 
prevalence are evolving worldwide, helping them identify any potential vaccine targets or antiviral treatments before 
a major outbreak occurs (Gray Vet Record 2020, see below). 
Observations from genetic studies 
A study by MacLean (bioRxiv 2020, see below) revealed a low frequency of viral mutations among 15 537 SARS-CoV-2 
genome sequences circulating in humans, suggesting that significant SARS-CoV-2 evolution occurred prior to spillover 
in humans. The authors warned that the high diversity of sarbecoviruses and their generalist nature make future 
emergence of divergent viral strains from bats to humans likely. 
Ji (J Med Virol. 2020, see below) suggested that snake is the most probable wildlife animal reservoir for SARS-CoV-2 
based on its relative synonymous codon usage bias resembling snake compared to other animals. However, this 
hypothesis was received with skepticism (https://www.nature.com/articles/d41586-020-00180-8). It was not 
supported by the bioinformatics protein structure and sequence analyses by Zhang (manuscript on Arxiv: 
https://arxiv.org/abs/2002.03173). Lam (manuscript on bioRxiv : 
https://www.biorxiv.org/content/10.1101/2020.05.01.072371v6) modelled S-protein:ACE2 complexes from 215 
vertebrate species, calculated their relative energies, correlated these energies to COVID-19 infection data, and 
analysed structural interactions. They predicted that known mutations are more detrimental in ACE2 than TMPRSS2, 
demonstrate phylogenetically that human SARS-CoV-2 strains originated from animal, and suggested that SARS-CoV-
2 can infect a broad range of mammals, but not fish, birds or reptiles. 
Chinese researchers of the South China Agricultural University in Guangzhou found 99% sequence similarity in the S 
RBD region between SARS-CoV-2 isolated from infected human subjects and coronaviruses taken from pangolins 
(Manis javanica) (https://www.nature.com/articles/d41586-020-00364-2). Researchers had noted previously that 
coronaviruses are a possible cause of death in pangolins, and that SARS-CoV-2 and coronaviruses from pangolins use 
receptors with similar molecular structures to infect cells. Lam (Nature 2020, see below) also reported the 
identification of SARS-CoV-2-related coronaviruses in pangolins seized in anti-smuggling operations in southern China. 
Metagenomic sequencing identified pangolin-associated CoVs that belong to two sub-lineages of SARS-CoV-2-related 
coronaviruses, including one very closely related to SARS-CoV-2 in the RBD. Cyranoski (Nature 2020, see below) 
subsequently summarized the investigations pertaining to the animal source of SARS-CoV-2. He noted that the 
previously communicated 99% homology between SARS-CoV-2 and a pangolin virus only applied to the S RBD region. 
The homology with pangolin viruses when considering the whole genome did not exceed 92.4%. A subsequent report 
by Zhang (Current Biology 2020, see below) reached similar conclusions. By contrast, SARS-CoV shared 99.8% of its 
genome with a civet coronavirus. 
Xiao (Nature 2020, see below) reported the isolation of a coronavirus from a Malayan pangolin, which showed 100%, 
98.6%, 97.8% and 90.7% amino acid identity with SARS-CoV-2 in the E, M, N and S genes, respectively. In particular, 
the receptor-binding domain within the S protein of the Pangolin-CoV is virtually identical to that of SARS-CoV-2, with 
one noncritical amino acid difference. Results of comparative genomic analysis suggested that SARS-CoV-2 might have 
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originated from the recombination of a Pangolin-CoV-like virus with a Bat-CoV-RaTG13-like virus. The Pangolin-CoV 
was detected in 17 of 25 Malayan pangolins analyzed. Infected pangolins showed clinical signs and histological changes, 
and circulating antibodies against Pangolin-CoV reacted with the S protein of SARS-CoV-2. The data suggest that 
pangolins have the potential to act as the intermediate host of SARS-CoV-2. Noteworthy is the evidence of Malayan 
pangolin SARS-CoV-2-related coronavirus (SARSr-CoV-2) is closely related to SARS-CoV-2 infecting multiple organs in 
pangolins, with the lungs being the major target, with ACE2 and TMPRSS2 co-expression with viral RNA. Importantly, 
viral RNA and protein were detected in 3 foetuses providing evidence for vertical virus transmission in pangolins (Li, 
preprint on bioRxiv: https://doi.org/10.1101/2020.06.22.164442). 
Another prediction of the interaction between the RBD of the S protein and the ACE2 receptor surprisingly suggested 
that not only pangolins, but also turtles (C. picta bellii, C. mydas, and P. sinensis) might act as potential intermediate 
hosts transmitting SARS-CoV-2  to human (Liu, Xiao et al. J Med Vir 2020, see below). 
ACE2 contains at least five key amino acids critical for binding S protein of SARS-CoV-2. Based on these five amino 
acids, Luan (Biochem Biophys Res Commun 2020, see below) analysed the corresponding amino acids of different 
mammals to determine which mammalian ACE2 could interact with the SARS-CoV-2 S protein. The authors found that 
the ACE2 of Camelus dromedarius, Procyon lotor, Rhinolophus ferrumequinum, Rattus norvegicus, Mus musculus, 
Ornithorhynchus anatinus, Loxodonta africana, Erinaceus europaeus, Nyctereutes procyonoides, Suricata suricatta, 
Dipodomys ordii, and Cavia porcellus are not able to associate with S protein. The authors indicated cat/dog ACE2 may 
bind to S protein of SARS-CoV-2. The ACE2 proteins from Circetidae, incl. Mesocricetus auratus (golden hamster) and 
Cricetulus griseus (Chinese hamster). Similarly, a study by Luan (J Med Vir 2020, see below) also suggested that ACE2 
proteins from Cricetidae were able to associate with SARS-CoV-2 RBD. The authors found a similar result for Bovidae. 
Rodrigues (manuscript on bioRxiv: https://doi.org/10.1101/2020.06.05.136861) investigated the structural properties 
of several ACE2 orthologs bound to the SARS-CoV-2 S protein and found that species not susceptible to SARS-CoV-2 
infection have non-conservative mutations in several ACE2 amino acid residues which disrupt key polar and charged 
contacts with the viral spike protein. Their models predict affinity-enhancing mutations that could be used to design 
ACE2 variants for therapeutic purposes. 
Robins (manuscript on bioRxiv: https://doi.org/10.1101/2020.06.05.136887) examined the protein covariance-based 
on the conserved CoV proteins called 1a/1b, S, 3a, E, M, and N from a set of 850 viral genome networks of SARS 
coronaviruses revealing interactions important to their emergence as human pathogens. They state that 
recombination with other viruses in combination with new adaptive mutations important for entry into human cells is 
the likely evolutionary scenario that converted a bat virus into human pathogen. Analysing ± 9,000 SARS-CoV-2 
genomes from Africa, America, Asia, Europe, and Oceania, Jones (manuscript on bioRxiv: 
https://doi.org/10.1101/2020.06.05.135954) showed that the virus is a complex of slightly different genetic variants 
that are unevenly distributed on Earth, demonstrated that SARS-CoV-2 phylogeny is spatially structured and 
hypothesized this could be the result of founder effects occurring as a consequence of, and local evolution occurring 
after, long-distance dispersal. 
Of note, while controversies about the source of the virus and its intermediate host remain, Li (Infect Genet Evol 2020, 
see below) evaluated coronaviruses derived from five wild animals, including Paguma larvata, Paradoxurus 
hermaphroditus, Civet, Aselliscus stoliczkanus and Rhinolophus sinicus (Chinese rufous horseshoe bat). Genome and 
ORF1a homology analyses showed that SARS-CoV-2 is not the same coronavirus as the coronavirus derived from these 
five animals, whereas the authors confirmed the highest homology with Bat coronavirus isolate RaTG13. Latinne 
(Nature Comm 2020, see below) next studied bat-CoVs (including 630 novel CoV sequences) macroevolution, cross-
species transmission, and dispersal in China. Adopting a Bayesian approach the authors found inter-family and -genus 
switching is most common in Rhinolophidae bats and the genus Rhinolophus and present a phylogenetic analysis 
suggesting a likely origin for SARS-CoV-2 in Rhinolophus spp. bats. They further identify the host taxa and geographic 
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regions that define hotspots of CoV evolutionary diversity in China that could help target bat-CoV discovery for 
proactive zoonotic disease surveillance. Further bayesian evolutionary rate and divergence dates estimates were used 
to understand the role of reservoir species, the role of recombination and the time of SARS-CoV-2 divergence. As 
presented above (see Origin of the virus), Boni (Nature 2020, see below) showed that the sarbecoviruses—the viral 
subgenus containing SARS-CoV and SARS-CoV-2—undergo frequent recombination and exhibit spatially structured 
genetic diversity on a regional scale in China. SARS-CoV-2 itself is not a recombinant of any sarbecoviruses detected 
to date, and its receptor-binding motif, important for specificity to human ACE2 receptors, appears to be an ancestral 
trait shared with bat viruses and not one acquired recently via recombination. Boni and co-authors estimated that 
divergence time between SARS-CoV-2 and bat sarbecovirus reservoir were in 1948 (95% highest posterior density 
(HPD): 1879–1999), 1969 (95% HPD: 1930–2000) and 1982 (95% HPD: 1948–2009), indicating that the lineage giving 
rise to SARS-CoV-2 has been circulating unnoticed in bats for decades. 
Susceptibility of various animal species to SARS-CoV-2 
Field studies and laboratory challenge data remain important to conduct for better understanding the zoonotic 
transmission of SARS-CoV-2. One of these studies was conducted by Deng (Transbound Em Dis 2020, see below), who 
after confirming the specificity, sensitivity and suitability of SARS-CoV-2 ELISA kit  for different species of experimental  
animals, evaluated clinical serum samples from domestic livestock (pig, cow, sheep, horse), poultry (chicken, duck,  
goose), experimental animal (mice, rat, and rhesus monkey), companion animal (dog and cat), and wild animals  (camel, 
fox, mink, alpaca, ferret, bamboo rat, peacock, eagle, tiger, rhinoceros, pangolin, leopard, cat, jackal, giant panda,  
masked civet, porcupine, bear, yellow-throated marten, weasel, red pandas, and wild boar). All serum samples had 
negative results, which made the authors conclude that the animal species above can be excluded as intermediate 
host of SARS-CoV-2. Of note, no SARS CoV-2 specific antibodies were detected in all dogs and cats, even for the street 
dogs and cats in Wuhan City and the pet dog raised by a COVID-19 patient. 
Rabbit (Oryctolagus cuniculus) and livestock (cattle, Bos Taurus) susceptibility to SARS-CoV-2 have been experimentally 
tested in more recent studies. While the infection is asymptomatic in healthy New Zealand White rabbits, infectious 
virus with peak titers corresponding to ~103 TCID50 could be detected up to day seven post inoculation in the nose. 
The minimum dose to establish productive infection was 105 TCID50, indicating that virus transmission between 
rabbits may be less efficient compared to ferrets and hamsters. The use of young, immunocompetent, and healthy 
rabbits however may not reflect virus shedding and disease in other rabbit breeds or rabbits at different ages. Thus, 
surveillance studies - including serological testing - may be needed to assess the presence of SARS-CoV-2 in farmed 
rabbits (Mykytyn preprint on bioRxiv : https://doi.org/10.1101/2020.08.27.263988). To examine the susceptibility of 
cattle for SARS-CoV-2 and to characterize the course of infection under experimental conditions, six 4-5 months old, 
male Holstein-Friesian dairy calves were intranasally inoculated with 1×105 tissue culture infectious dose 50% (TCID50) 
of SARS-CoV-2 strain “2019_nCoV Muc-IMB-1” (GISAID ID_EPI_ISL_406862, designation “hCoV-
19/Germany/BavPat1/2020”) at 1ml per nostril ; 24 hours after inoculation three contact cattle, were introduced. 
Ulrich (preprint on https://doi.org/10.1101/2020.08.25.254474) demonstrated that under selected experimental 
conditions cattle show low susceptibility to SARS-CoV-2, since two out of six animals appeared to be infected as 
demonstrated by SARS-CoV-2-genome detection in nasal swabs and specific seroconversion. The sample was small 
and - despite for controlling for bovine CoV cross-seroreactivity - results should be taken with caution. 
SARS-CoV-2 emergence risk maps 
A modelling study by Walsh (One Health 2020, see below) provided a first systematic, data-driven, quantitative 
geography investigation of high-impact spillover wildlife-livestock/poultry-human interfaces taking into account 
human health system performance and global connectivity via the network of air travel. It showed that many of the 
world’s most connected cities are adjacent to or within areas (50km radius) where wildlife share space with humans 
and their domesticated animals. Indeed, more than 40% of these cities were within or adjacent to landscapes of 
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extensive animal-human interface, while approximately 14%-20% were located in landscapes of both extensive 
interface and poor health system performance. The output is an alert-level map (yellow, orange, and red zones 
classified according to increased risk) which can be used as a tool to develop targeted surveillance systems and 
improving health infrastructure in vulnerable areas that may present conduits for future pandemics (Figure 12). As 
sensitive and SARS-Cov-2 specific tests (e.g. new ELISA) develop, and experimental evidence of transmission from 
infected animal hosts to naïve conspecifics and the nature and amount of viral shedding build up, new data should 
ultimately help refine the above-mentioned model and design more specific, data informed, SARS-CoV-2 emergence 
risk maps at fine scale human-animal interfaces.   
Figure 12 Alert-level red zones depicting interfaces between mammalian richness, human population density, and livestock/ poultry 
densities based on the intersection of the top quartile of each feature’s distribution, extending the intersection of these interfaces with the 
top quartile of infant mortality (from Walsh One Health 2020). 
 
Cities of high network centrality (75th percentile) based on global air travel and within 50 km of red interfaces are overlaid. The proportion of 
highly connected transportation hubs (75th percentile of airport network centrality) within 50 km of each interface is presented with the 
airplane icon. Cities mapped twice have two high centrality airports. 
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Human to human transmission 
Early observations  
In the 99 patients cohort reported by Chen (Lancet 2020, see below), 49 (49%) patients had a history of exposure to 
the Huanan seafood market, where wild animals were served at a restaurant. Among them, there were 47 patients 
with long-term exposure history, most of whom were salesmen or market managers, and two patients with short-
term exposure history, who were shoppers. None of the patients were medical staff. These early data suggested that 
a point-source zoonotic (animal-to-human) route was likely the main mode of transmission of the disease (Nishiura J 
Clin Med 2020, see below). However, the reporting of a family cluster including a family member, who did not travel 
to Wuhan, but became infected with the virus after several days of contact with four of the family members, soon 
provided strong evidence of human-to-human transmission (Chan Lancet 2020, see below). In this cluster none of the 
family members had contacts with Wuhan markets or animals, although two had visited a Wuhan hospital. In line with 
this observation, the genetic epidemiology data suggest that from the beginning of December, 2019, when the first 
cases were retrospectively traced in Wuhan, the spread of infection has been almost entirely driven by human-to-
human transmission, not the result of continued spillover (Heymann Lancet 2020, see below). 
Transmission mode 
In March 2020, Han (Infl Other Resp Inf 2020, see below) summarized available information on the different 
transmission modes of SARS-CoV-2. A more recent review has been provided by Kutti-Sridharan (Int J Prev Med 2020, 
see below). It appears that SARS-CoV-2 has the potential to be spread by all modes of transmission: direct contact (i.e., 
person-to-person) and indirect contact (e.g., via contaminated objects and aerosol) (Fennelly Lancet Resp Med 2020, 
see below; Santarpia Sci Rep 2020, see below; and for instance, Cai Em Inf Dis 2020, see below). As of today, it is not 
yet clear which mode occurs most frequently. 
Respiratory secretions and saliva 
Virus shedding has been demonstrated in multiple studies that analysed respiratory secretions by RT-PCR testing (see 
for instance Zou NEJM 2020 below; more detailed data on virus shedding are presented in section Virus shedding & 
virus load above). 
The duration of shedding was initially measured by RT-PCR and found highly variable (see Kinetic studies). A study by 
Zhou (Clin Inf Dis, see below), for instance, reported virus detection in throat samples for a median duration of 31.0 
(IQR: 24.0-40.0) days from illness onset, ranging between 18 and  48 days. A review by Fontana (Inf Contr Hosp Epi 
2020, see below)  found an overall pooled median duration of RNA shedding from respiratory sources of 18.4 days 
(95% CI: 15.5 days - 21.3 days; I2=98.87%, p<0.01) among 28 studies. Viable virus was isolated by culture from -6 days 
to 20 days relative to symptom onset. Importantly, limited correlation was found between SARS-CoV-2 detection by 
RT-PCR and presence of culturable virus. 
Respiratory droplet emissions are typically dichotomized into “large” and “small” droplets. Large droplets settle faster 
than they evaporate, contaminating the immediate vicinity of the infected individual. In contrast, small droplets 
evaporate faster than they settle (Bourouiba JAMA 2020, see below). In this model, as small droplets transition from 
the warm and moist conditions of the respiratory system to the colder and drier outside environment, they evaporate 
and form residual particulates made of the dried material from the original droplets. These residual particulates are 
referred to as aerosols. Such classification systems employ various arbitrary droplet diameter cutoffs, from 5 to 10 μm, 
to categorize host-to-host transmission as droplets or aerosol routes. 
However, more recent work has demonstrated that exhalations, sneezes, and coughs not only consist of mucosalivary 
droplets following short-range semi-ballistic emission trajectories but are primarily made of a multiphase turbulent 
gas cloud that entrains ambient air and traps and carries within it clusters of droplets with a continuum of droplet 
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sizes. The locally moist and warm atmosphere within the turbulent gas cloud allows the contained droplets to evade 
evaporation for much longer than occurs with isolated droplets. Under these conditions, the lifetime of a droplet could 
be considerably extended by a factor of up to 1000, from a fraction of a second to minutes. Given various combinations 
of an individual patient’s physiology and environmental conditions, such as humidity and temperature, the gas cloud 
and its payload of pathogen-bearing droplets of all sizes can travel 23 to 27 feet (7-8 m) (Figure 13). Although no 
studies have directly evaluated the biophysics of droplets and gas cloud formation for patients infected with SARS-
CoV-2, several properties of the exhaled gas cloud and respiratory transmission may apply to this pathogen.  
Stadnytskyi (PNAS 2020, see below) reported data suggesting a substantial probability that normal speaking causes 
airborne virus transmission in confined environments. Highly sensitive laser light scattering observations revealed 
indeed that loud speech can emit thousands of oral fluid droplets per second. In a closed, stagnant air environment, 
they disappear from the window of view with time constants in the range of 8 to 14 min, which corresponds to droplet 
nuclei of ca. 4 μm diameter, or 12- to 21-μm droplets prior to dehydration. 
Figure 13 Multiphase Turbulent Gas Cloud From a Human Sneeze (from Bourouiba JAMA 2020) 
 
In July 2020, a commentary signed by 239 scientists appealed to the medical community and to the relevant national 
and international bodies to recognize the potential for airborne spread of COVID-19 (Morawska Clin Infect Dis 2020, 
see below). The authors indicated that there is significant potential for inhalation exposure to viruses in microscopic 
respiratory droplets (microdroplets) at short to medium distances (up to several meters, or room scale), and advocated 
for the use of preventive measures to mitigate this route of airborne transmission. A viewpoint published at the same 
time by Klompas (JAMA 2020, see below), also provided a strong rationale to support the importance of this route of 
transmission.  
More recently, a short letter by Prather (Science 2020, see below) pointed to the need to harmonize discussions about 
modes of virus transmission across disciplines to ensure the most effective control strategies and provide clear and 
consistent guidance to the public. The authors confirmed the need to distinguish between aerosols and droplets using 
a size threshold of 100 µm, instead of the historical 5 µm, as this size more effectively separates their aerodynamic 
behaviour, ability to be inhaled, and efficacy of interventions. Viruses in droplets (larger than 100 µm) typically fall to 
the ground in seconds within 2 m of the source. Because of their limited travel range, physical distancing reduces 
exposure to these droplets. Viruses in aerosols (smaller than 100 µm) can remain suspended in the air for many 
seconds to hours and be inhaled. They are highly concentrated near an infected person, so they can infect people most 
easily in close proximity. But aerosols containing infectious virus can also travel more than 2 m and accumulate in 
poorly ventilated indoor air, leading to superspreading events.  
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Some recent reports indicate that individuals with COVID-19, many of whom have no symptoms, release thousands of 
virus-laden aerosols and far fewer droplets when breathing and talking. These data led Prather to consider that one is 
far more likely to inhale aerosols than be sprayed by a droplet. In addition to existing mandates of mask-wearing, 
social distancing, and hygiene efforts, the authors urged public health officials to add clear guidance about the 
importance of moving activities outdoors, improving indoor air using ventilation and filtration, and improving 
protection for high-risk workers 
Conjunctiva 
Two samples of tear and conjunctival secretions obtained from a COVID-19 patient with conjunctivitis yielded positive 
RT-PCR results (Xia J Med Vir 2020, see below). A manuscript by Sun (on medRxiv: 
https://www.medrxiv.org/content/10.1101/2020.02.26.20027938v1) reported a similar observation, with SARS-COV-
2 RNA detected in ocular discharges in one patient with conjunctivitis. Although conjunctivis is a rare symptom of 
COVID-19 (observed in 2.8% of patients in this study), the authors suggested a potential route of nosocomial infection 
through the eyes after occupational exposure. Furthermore, Colavita (Ann Intern Med. 2020, see below) 
demonstrated that ocular fluids from SARS-CoV-2-infected patients may contain infectious virus. The first RNA-
positive ocular sample of a 65-year-old woman, who had travelled from Wuhan to Italy, was inoculated in Vero E6 
cells, and cytopathic effect was observed 5 days postinoculum. Viral replication was confirmed by real-time RT-PCR on 
RNA purified from spent cell growth medium. 
Peng (J Med Vir 2020, see below) suggested that the detection of SARS-CoV-2 RNA in tears and conjunctival secretions 
of very few COVID-19 patients complicated with conjunctivitis is a coincident event, rather than a causal event of SARS-
CoV-2 infection of the conjunctiva. Similarly, Seah (Ophtalmology 2020, see below) evaluated virus shedding in tears 
in 17 COVID-19 patients. All tear samples showed negative results, even when nasopharyngeal swab samples 
continued to show positive results. Furthermore, patients with symptoms of upper respiratory tract infections did not 
demonstrate any viral shedding in tears, suggesting that the hypothesis of the lacrimal duct as a viral conduit may not 
be true. Most importantly, only 1 patient showed ocular symptoms during the disease course, and no evidence of 
SARS-CoV-2 could be found in the tear samples. This suggests that transmission through tears regardless of the phase 
of infection likely is low. 
Faecal excretion 
The observation that 14 out of 138 patients (10 percent) in a Wuhan hospital (Wang JAMA 2020, see below) initially 
presented with diarrhoea and nausea one or two days prior to development of fever and dyspnoea supported the 
hypothesis of faecal transmission of the virus. A similar observation had already been made with the first U.S. patient 
diagnosed with COVID-19, who also experienced loose bowel movements for two days and subsequent viral RNA 
detection in stool. Zhang (Emerg Micr Inf 2020, see below) reported presence of virus RNA in anal swabs and blood, 
with more anal swab positives than oral swab positives in a later stage of infection. Xiao (Gastroent 2020, see below) 
found 53.42% of patients testing positive in stool. 23.29% of the patients remained positive in faeces even after the 
viral RNA decreased to undetectable level in respiratory tract.  
Wu (Lancet Gastroenterol Hepatol 2020, see below) presented real-time RT-PCR results of respiratory and faecal 
samples from COVID-19 patients. Faecal samples from 33 (45%) of 74 patients were negative for SARS CoV-2 RNA, 
while their respiratory swabs remained positive for a mean of 15·4 days (SD 6.7) from first symptom onset. Of the 41 
(55%) of 74 patients with faecal samples that were positive for SARS-CoV-2 RNA, respiratory samples remained positive 
for SARS-CoV-2 RNA for a mean of 16·7 days (SD 6.7) and faecal samples remained positive for a mean of 27·9 days 
(10.7) after first symptom onset. The full disease course of the 41 patients with faecal samples that were positive for 
SARS-CoV-2 RNA is shown in Figure 14. Notably, patient 1 had positive faecal samples for 33 days continuously after 
the respiratory samples became negative, and patient 4 tested positive for SARS-CoV-2 RNA in their faecal sample up 
to 47 days after first symptom onset. 
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Figure 14 Timeline of results from throat swabs and faecal samples through the course of disease for patients with SARS-CoV-2 RNA positive 
faecal samples (from Wu Lancet Gastroenterol Hepatol. 2020) 
 
Similarly, from a cohort of 42 patients, Chen, Chen et al. (J Med Vir 2020, see below) identified 18 (64.29%) patients 
who remained positive for viral RNA in faeces after pharyngeal swabs turned negative. Viral shedding in faeces 
continued for 7 (6-10) days after pharyngeal swabs became negative, regardless of COVID-19 severity. 
In a meta-analysis of 60 studies, comprising 4243 COVID-19 patients, the pooled prevalence of all gastrointestinal 
symptoms was 17.6% (95% CI, 12.3%-24.5%); 11.8% of patients with non-severe COVID-19 had gastrointestinal 
symptoms (95% CI, 4.1%-29.1%) and 17.1% of patients with severe COVID-19 had gastrointestinal symptoms (95% CI, 
6.9%-36.7%) (Cheung Gastroenterol 2020, see below). The pooled prevalence of stool samples that were positive for 
virus RNA was 48.1% (95% CI, 38.3%-57.9%); of these samples, 70.3% of those collected after loss of virus from 
respiratory specimens tested positive for the virus (95% CI, 49.6%-85.1%). 
Vertical transmission 
Preliminary studies soon suggested the absence of vertical transmission of SARS-CoV-2 (see for instance Chen Lancet 
2020, see below). Subsequent reports largely supported this contention, even though the possibility that vertical 
transmission might occur in some cases could not be completely ruled out (see Pregnancy and newborns above). A 
very recent review of available data by Bwire (J Med Vir 2020, see below) concluded that  the current evidence reveals 
a low possibility of vertical transmission of COVID-19. 
Blood products 
SARS-CoV-2 shedding in plasma or serum is common, which leads to a theoretical risk of transmission of coronaviruses 
through transfusion of blood products. Chang (Transfus Med Rev 2020, see below) noted that because more and more 
asymptomatic infections are being found among COVID-19 cases, considerations of blood safety and coronaviruses 
have arisen especially in endemic areas. 
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Semen 
A study by Song (Biol Reprod 2020, see below) analysed semen samples collected from 12 patients in their recovery 
phase, as well as in testicular samples from one patient who died of COVID-19 during the acute phase. All samples 
were negative by RT-PCR, suggesting that SASR-CoV-2 does not infect the testis and the male reproductive tract. 
Ruling out vector-borne transmission 
The possibility of vector borne transmission of SARS-CoV-2 has been debated since the beginning of the COVID-19 
pandemic. Huang (Sci Rep 2020, see below) tested experimentally the capacity of SARS-CoV-2 to infect and be 
transmitted by three widely distributed species of mosquito (Aedes aegypti, Ae. albopictus and Culex quinquefasciatus). 
They carried out intrathoracic inoculation of mosquitoes with SARS-CoV-2 WA1/2020 strain. Based upon the lack of 
detectable infectious virus in any of the 277 samples collected at all time points beyond 24 h post-inoculation, they 
concluded that SARS-CoV-2 is unable to replicate in mosquitoes and therefore cannot be transmitted to people in that 
way. Only 3 species were tested and one cannot arbitrarily rule out susceptibility of all human-biting mosquitoes in 
localities where infected people are found. However, the results of Huang and colleagues strongly suggest that 
mosquitoes in general are not susceptible to infection by this virus, which should end speculation about biological 
transmission of SARS-CoV-2 by mosquitoes being epidemiologically significant. Mechanical transmission (soiled mouth 
parts) by interrupted mosquito feeding would require very high viremias in infected individuals (probably 106-7 or more 
and for which there is no evidence) followed almost immediately by feeding on a susceptible person (Promed archive 
number : 20200721.7595820). Xia (Virol Sinica 2020, see below) performed experimental infection of wild mosquitoes 
(Aedes cells C6/36 and Aag2 in vitro) collected in Wuhan. They also showed that SARS-CoV-2 does not replicate in the 
field collected Culex and Anopheles mosquitoes, supporting the lack of evidence for mosquito-borne transmission of 
SARS-CoV-2. The susceptibility of biting insects to SARS-CoV-2 has been further examined after experimental feeding 
on SARS-CoV-2 infected blood meal (Balaraman, manuscript on bioRxiv : https://doi.org/10.1101/2020.09.29.317289). 
Species tested included Culicoides sonorensis biting midges, Culex tarsalis and Culex quinquefasciatus mosquitoes, all 
known biological vectors for numerous RNA viruses. Arthropods were allowed to feed on SARS-CoV-2 spiked blood 
and at various time points post-infection analysed for the presence of viral RNA and infectious virus. Additionally, cell 
lines derived from C. sonorensis (W8a), Ae. aegypti (C6/36), Cx. quinquefasciatus (HSU), and Cx. tarsalis (CxTrR2) were 
tested for SARS-CoV-2 susceptibility. Their results indicated that none of the biting insects, nor the insect cell lines 
support SARS-CoV-2 replication and, similar to previous studies, concluded that biting insect do not pose a risk for 
transmission of SARS-CoV-2 to humans or animals following an infected blood meal. 
Social drivers of transmission 
While the basic reproductive number only captures the average dynamics of transmission, a crucial question for 
control is whether specific situations and settings might be driving the epidemic (Liu Lancet 2020, see below). The 
secondary attack rate, defined as the probability that an infection occurs among susceptible people within a specific 
group (i.e., household or close contacts), can provide an indication of how social interactions relate to transmission 
risk.  Drawing on data from nine recent reports of secondary transmission associated with a specific event such as a 
meal or holiday visit, Liu estimated that 48 secondary infections occurred among 137 attendees. Assuming that all 
these secondary infections were generated by a single primary case, which is probable given the short-term nature of 
the exposure events, would imply a secondary attack rate among close contacts of 35% (95% CI 27-44). More data are 
needed to reliably estimate the true within-household and between-household transmission for SARS-CoV-2; recent 
reports might be biased towards larger transmission events. However, if it transpires that most at-risk contacts have 
a close relationship with cases, and superspreading events tend to occur at large gatherings of these close contacts 
measures to reduce infection risk during such gatherings and subsequent tracing of close contacts of cases might have 
a disproportionate effect on reducing overall transmission. 
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Public transportation 
A retrospective analysis of early data found a significant association between domestic travel by train and the number 
of COVID-19 cases in China, whereas the associations of the other two means of transportation (car, flight) failed to 
reach statistical significance (Zhao Travel Med Inf Dis 2020, see below). However, a subsequent analysis by Chen (Chin 
Med J 2020, see below), based on cases up to Jan 30 and population migration data extracted from Baidu Qianxi, found 
a correlation coefficient between the provincial number of cases and emigration from Wuhan up to 0.943.  
Zheng (Trav Med Inf Dis 2020, see below) studied the spatial transmission of COVID-19 via public and private 
transportation in China, and found a significant and positive association between the frequency of flights, trains, and 
buses from Wuhan and the daily as well as the cumulative numbers of COVID-19 cases in other cities with progressively 
increased correlations for trains and buses. 
A study by Lau (J Microbiol Immunol Infect 2020, see below) indicated that the number of flight routes as well as total 
passenger volume are highly relevant risk factors for the spread of current COVID-19. 
Qifang Bi on medRxiv (https://www.medrxiv.org/content/10.1101/2020.03.03.20028423v1) studied 391 cases and 
1286 close contacts identified by the Shenzhen CDC. In this dataset, cases were found older than the general 
population (mean age 45) and balanced between males (187) and females (204). Household contacts and those 
travelling with a case where at higher risk of infection (ORs 6 and 7) than other close contacts.  
A rapid review by Zhen (S Afr Med J 2020, see below) also suggested an increased risk of viral transmission with public 
transportation use, which may be reduced with improved ventilation. 
Mass gatherings 
Ebrahim (Trav Med Inf Dis 2020, see below) highlighted the fact that mass gatherings, both those clearly defined and 
those spontaneously occurring, are key determinants of epidemiologic expansion of disease outbreaks. The authors 
noted that COVID-19 had already provided examples of both clearly planned event cancellations such as the Umrah 
suspension in Saudi Arabia, and situations where outbreaks and events were continued. 
Schools 
To what extent schools and kindergartens impact SARS-CoV-2 transmission remains a topic of debate. Studies to 
determine the contribution of children as sources of infection are complicated by the fact that non-pharmaceutical 
interventions including school- and kindergarten closures were in place before observational trials could begin. A 
household study in China and observations in a limited number of contact investigations in Germany suggest that 
children are infected by SARS-CoV-2 at a rate that may not be different from that of adults. However, the extent to 
which children can act as sources of infection remains unclear (Jones, manuscript on medRxiv: 
https://www.medrxiv.org/content/10.1101/2020.06.08.20125484v1). 
Estimates of key epidemiological parameters 
Serial interval 
The serial interval of COVID-19 is defined as the time duration between a primary case (infector) developing symptoms 
and secondary case (infectee) developing symptoms (Du Em Inf Dis 2020, see below). Obtaining robust estimates for 
the distribution of COVID-19 serial intervals is a critical input for determining the reproduction number which can 
indicate the extent of interventions required to control an epidemic. The serial intervals reported by Du had a mean 
of 3.96 days (95% confidence interval: 3.53-4.39), a standard deviation of 4.75 days (95% confidence interval: 4.46-
5.07), and 12.6% of reports indicating pre-symptomatic transmission. 
Subsequently, from the analysis of a total of 28 infector-infectee pairs, Nishiura (Int J Inf Dis 2020, see below) 
estimated the median serial interval at 4.0 days (95% credible interval [CrI]: 3.1, 4.9). Limiting our data to only the 
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most certain pairs, the median serial interval was estimated at 4.6 days (95% CrI: 3.5, 5.9). Considering that the serial 
interval of COVID-19 is close to or shorter than its median incubation period, the data suggest that a substantial 
proportion of secondary transmission may occur prior to illness onset. 
Zhao (Infect Control Hosp Epidemiol. 2020, see below) evaluated 48 transmission events including 21 in Hong Kong 
and 27 in Shenzhen. The authors found find that the serial interval had been decreasing by 0.4 (95%CI: 0.1−0.7) per 
day, or 6.2% (95%CI: 0.4−11.6%) in percentage, from January 10 to February 2 in Hong Kong and Shenzhen. The 
Pearson correlation coefficient between the serial interval and calendar date was estimated at −0.37 with p-value < 
0.01. The serial interval of male primary cases was 3.5 days (95%CI: 1.2−5.7) shorter than that of a female primary 
case, or 49.7% (95%CI: 15.3−70.1%) less in percentage. 
The systematic review of COVID-19 epidemiology by Park (J Clin Med 2020, see below), which included 41 studies, 
estimated the serial interval to be 4-8 days.  
Reproductive number 
Different estimates of the basic reproductive number (R0) were reported from a number of studies since the start of 
the epidemic (see Table 7).  
A preliminary R0 estimate of 1.4-2.5 was presented at the “meeting of the International Health Regulations (2005) 
Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)”  (https://www.who.int/news-
room/detail/23-01-2020-statement-on-the-meeting-of-the-international-health-regulations-(2005)-emergency-
committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)) 
Liu (J Trav Med 2020, see below) had previously presented an overview of published R0 estimates for the disease, and 
found the average R0 to be 3.28 and median 2.79. 
Zhao (J Trav Med 2020, see below) subsequently demonstrated that using an overestimated serial interval leads to 
overestimation of R0, and found an R0 at 2.0 when using a more recent estimate of the serial interval at 4.6 days. 
Table 7 Published estimates of R0 (adapted from Liu J Trav Med 2020) 
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early outbreak trajectories 
Stochastic simulations of early outbreak 
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4 J Med Vir 2020 
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Wu10     2·68  
2·47-
2·86 
Liu11     3.28  

















    
The systematic review of COVID-19 epidemiology by Park (J Clin Med 2020, see below), which included 21 estimates 
for the basic reproduction number ranging from 1.9 to 6.5, noted that 13/21 estimates were found between 2.0 and 
3.0.  
The effective reproduction number (R, the expected number of secondary cases generated by an infectious case once 
the epidemic is underway) is now assessed by a growing number of studies, and the impact of public health 
interventions thereby illustrated (see Modelling the impact of public health measures below). 
Liu (on medRxiv: https://www.biorxiv.org/content/10.1101/2020.01.25.919787v2) reported a continuous decline in 
the R values especially after January 16 nationwide and in Wuhan. Such temporal effect was also observed by Kucharski 
(Lancet Inf Dis 2020, see below), who estimated that the median daily reproduction number (Rt) in Wuhan declined 
from 2.35 (95% CI 1.15–4.77) 1 week before travel restrictions were introduced on Jan 23, 2020, to 1.05 (0.41–2.39) 1 
week after. Interestingly, Kucharski’s model also found that in locations with similar transmission potential to Wuhan 
in early January, once there are at least four independently introduced cases, there is a more than 50% chance the 
infection will establish within that population. 
                                                          
5 Em Inf Dis 2020 
6 NEJM 2020 
7 Int J Infect Dis 2020 
8 Eurosurv 2020 
9 J Evid Based Med 2020 
10 Lancet 2020 
11 J Travel Med 2020 
12 https://www.medrxiv.org/content/10.1101/2020.02.17.20023747v2 
13 Emerg Infect Dis 2020 
14 Biosaf Health. 2020 
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In another example, Salje (Science 2020, see below) estimated that in France, the lockdown reduced the reproductive 
number of the disease from 2.90 to 0.67. By 11 May 2020, when interventions were scheduled to be eased, the authors 
projected 2.8 million (range: 1.8-4.7) people, or 4.4% (range: 2.8-7.2) of the population, would have been infected. 
Attack rate of the disease 
Information is still lacking as to the incidence of the disease in various populations. However, some publications have 
assessed the disease prevalence in specific cohorts of subjects. 
A study by Wang (Trav Med Inf Dis 2020, see below) estimated the prevalence of COVID-19 in 2004 participants under 
home quarantine in Shenzhen. Of people who provided clear travel history, 129 people have travelled to Wuhan city 
and 1,046 people have travelled to other cities in Hubei province within 14 days before the home quarantine. Few 
(less than 1%) participants reported contact history with confirmed or suspected cases during their trip and most 
arrived in Shenzhen more than a week before the study. Three cases were found in the cohort, corresponding to 1.5‰ 
prevalence (95% CI: 0.31‰-4.37‰). 
Contact tracing of 2,370 individuals from the first 30 COVID-19 cases in Korea indicated that the risk of symptomatic 
cases from transmission to contacts was low at 0.55% (95% CI 0.31–0.96) (COVID-19 National Emergency Response 
Center Osong Public Health Res Perspect 2020, see below). However, the findings also suggested that the transmission 
of COVID-19 was significant among household contacts:  there were 119 household contacts, of which 9 individuals 
developed COVID-19 resulting in a secondary attack rate of 7.56% (95% CI 3.7–14.26), which is in line with other 
reports. In the earlier reports, familial clusters of COVID-19 had been reported and household transmission was 
thought to be a major driver in the spread of the outbreak in the community. Of the first 262 COVID-19 cases in Beijing, 
China, 133 (50.8%) were family cluster cases. In the US, active symptom monitoring was performed for 445 close 
contacts of the 12 cases with travel-related COVID-19, resulting in symptomatic cases with a secondary attack rate of 
0.45% (95% CI, 0.12–1.6) among all contacts, and 10.5% (95% CI, 2.9–31.4) among household members. 
Li (Clin Inf Dis 2020, see below) enrolled 105 index patients and 392 household contacts to determine the features of 
household transmission of COVID-19. Secondary transmission of SARS-CoV-2 developed in 64 of 392 household 
contacts (16.3%). The secondary attack rate to children was 4% comparing with 17.1% to adults. The secondary attack 
rate to the contacts within the households with index patients quarantined by themselves since onset of symptoms 
was 0% comparing with 16.9% to the contacts without index patients quarantined. The secondary attack rate to 
contacts who were spouses of index cases was 27.8% comparing with 17.3% to other adult members in the households. 
Lytras (J Travel Med 2020, see below) reported screening data from passengers on repatriation flights to Greece from 
the UK, Spain and Turkey. Despite almost all passengers being asymptomatic, many tested positive (3.6% from UK, 
6.3% from Spain and 6.3% from Turkey). 
Dispersion factor and superspreading  
In real life, some people infect many others and others don’t spread the disease at all (Kupferschmidt Science 2020: 
https://www.sciencemag.org/news/2020/05/why-do-some-covid-19-patients-infect-many-others-whereas-most-
don-t-spread-virus-all). In fact, the latter is the norm, most people do not transmit. Frieden (Em Inf Dis 2020, see below) 
noted that there have been multiple reports of superspreading events, which are associated with both explosive 
growth early in an outbreak and sustained transmission in later stages. For instance, Walker (Euro Surv 2020, see 
below) whole-genome sequenced 55 SARS-CoV-2 isolates from Germany and found that the genetic structure of the 
outbreak in Heinsberg indicates a clonal origin, reflecting superspreading dynamics from mid-February during the 
carnival season. 
These observations reflect a major limitation of the concept of R0, the basic reproductive number, which is presented 
as a mean or median value and does not capture the heterogeneity of transmission among infected persons. For this 
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reason, in addition to R, the dispersion factor (k) describes how much a disease clusters. The lower k is, the more 
transmission comes from a small number of people. It has been estimated that SARS, in which superspreading played 
a major role, had a k of 0.16. The estimated k for MERS is about 0.25. In the flu pandemic of 1918, in contrast, the 
value was about one, indicating that clusters played less of a role. 
Estimates of k for SARS-CoV-2 vary. In January, Julien Riou and Christian Althaus at the University of Bern simulated 
the epidemic in China for different combinations of R and k and compared the outcomes with what had actually taken 
place. They concluded that k for COVID-19 is somewhat higher than for SARS and MERS. However, in a recent preprint, 
Kucharski estimated that k for COVID-19 is as low as 0.1. Debora MacKenzie (New Scientist 2020, see below) also 
referred to modelling data suggesting that only 10 per cent of cases are responsible for 80 per cent of transmission. 
Based on 135 cases in Tianjin, China, and utilizing a heterogeneous transmission model with branching process along 
with a negative binomial offspring distribution, Zhang (Int J Environ Res Public Health 2020, see below) estimated k to 
0.25 (95% CI: 0.13-0.88).  
Lemieux (manuscript on medRxiv, see below) studied two superspreading events that occurred in the USA. The first 
large cluster was recognized in the context of an international business conference held from February 26-27: more 
than 90 cases were associated with the conference and all 28, which were genotyped, formed a “monophyletic cluster”, 
containing a C2416T signature polymorphism, which apparently originated from Europe and subsequently spread in 
Boston, making up 35 % of all 744 genomes outside the conference. This 2416T/G26233T variant was subsequently 
exported from Boston to several US states, including Virginia, North Carolina, and Texas, and to other countries, 
including Australia, Sweden, and Slovakia. A second more limited superspreading event at a skilled nursing facility in 
the Boston area involved 82/97 (85%) of the residents and 36/97 (37%) of the staff as detected by RT-qPCR.  Of these 
SARS-CoV-2 cases, 75 comprised a single cluster of closely related genomes (59 identical), all containing a G3892T 
mutation. 
Most recently, a very large study by Laxminarayan (Science 2020, see below) that analysed data from the Indian states 
of Tamil Nadu and Andhra Pradesh, which have developed rigorous contact tracing and testing systems, concluded in 
5% of infected individuals accounting for 80% of cases . 
Transmission by asymptomatic or pre-symptomatic subjects 
Numerous reports provide data indicating that asymptomatic (or pre-symptomatic) subjects can transmit COVID-19 
with high efficiency (Chang Lancet Resp Med 2020, see below). The possibility of transmission by asymptomatic 
individuals is a critical question, as it directly impacts public health responses to the epidemic. 
The following evidence was obtained both from epidemiological observations and laboratory testing of asymptomatic 
subjects during the first weeks of the epidemic:  
 A boy aged 10 years who was infected with COVID-19 had no symptoms but had visible changes in lung imaging 
and blood markers of disease.  
 Another patient undergoing surgery in a hospital in Wuhan infected 14 health-care workers (HCWs) even 
before fever onset.  
 A patient who travelled from Shanghai to attend a meeting in Germany was subclinical until on the flight back 
to China. However, two of this patient's close contacts and another two patients attending the meeting 
without close contact were found to be infected with COVID-19.  
 Yu (J Inf Dis 2020, see below) reported on a familial cluster of four patients in Shanghai, of which one was an 
88 year-old man with moving difficulties who was only exposed to his asymptomatic family members who 
developed symptoms later 
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 Hoehl (NEJM 2020, see below) reported that in the effort to evacuate 126 people from Wuhan to Frankfurt, a 
symptom-based screening process was ineffective in detecting SARS-CoV-2 infection in 2 persons who later 
were found to have evidence of SARS-CoV-2 in a throat swab. 
 Zhou (NEJM 2020, see below) analysed the viral load in one asymptomatic patient and found it similar to that 
in symptomatic patients, which suggests the transmission potential of asymptomatic or minimally 
symptomatic patients. 
 Bai (JAMA 2020, see below) described a case of transmission from a presumed asymptomatic carrier with one 
positive PCR, but normal chest CT findings. 
 Luo (Chin Med J 2020, see below) identified a confirmed case of asymptomatic SARS-CoV-2 infection in a 50-
year old woman. Despite largely normal laboratory and chest CT findings, her persistent positivity of the virus 
nucleic acid in her throat swabs and anal swabs for at least 17 days suggested that she was very likely a healthy 
carrier. 
 Tang (Emerg Infect Dis 2020, see below) reported on an asymptomatic child who was positive for SARS-CoV-2 
by RT PCR in a stool specimen 17 days after the last virus exposure. The child was virus positive in stool 
specimens for at least an additional 9 days. 
 Kam (Clin Inf Dis 2020, see below) described a 6-month-old infant with COVID-19, who had persistently 
positive nasopharyngeal swabs to day 16 of admission, but no clinical signs or symptoms apart from a single 
transient temperature of 38.5°C. 
 Pan (Lancet Inf Dis, see below) described two individuals who were under active surveillance because of a 
history of exposure to infected patients and showed positive results on RT-PCR a day before disease onset. 
 Tong (Emerg Infect Dis. 2020, see below) described 2 infections resulting from contact with a potentially pre-
symptomatic traveller from the city of Wuhan. 
 Huang (J Inf 2020, see below) monitored a cluster of close-contacts of a 22-year-old male with laboratory-
confirmed COVID-19 in Anhui Province. 
 Day (BMJ 2020, see below) also reported the story of an Italian village, where identifying and isolating 
asymptomatic people helped eliminate the virus.  
A more recent review by Han (Int J Inf Dis 2020, see below) provided the evidence that asymptomatic infections can 
result in person-to-person transmission, and suggested that the virus can be transmitted by asymptomatic patients 
for at least two consecutive generations, indicating its strong infectivity. A set of studies aimed at quantifying the role 
of transmission by asymptomatic vs. symptomatic subjects. Du (Em Inf Dis 2020, see below) analyzed 468 infector-
infectee pairs with confirmed COVID-19 cases reported in China between January 21, 2020, and February 8, 2020. 
Interestingly, 12.1% of reports indicated pre-symptomatic transmission.  
He (Nat Med 2020, see below) reported temporal patterns of viral shedding in 94 patients with laboratory-confirmed 
COVID-19 and modelled COVID-19 infectiousness profiles from a separate sample of 77 infector-infectee transmission 
pairs. The highest viral load was observed in throat swabs at the time of symptom onset, and the authors inferred that 
infectiousness peaked on or before symptom onset. The authors estimated that 44% (95% confidence interval, 25-
69%) of secondary cases were infected during the index cases' presymptomatic stage. 
Buitrago-Garcia (manuscript on medRxiv, see https://www.medrxiv.org/content/10.1101/2020.04.25.20079103v3) 
addressed the topic with a living systematic review and meta-analysis focused on three questions: 1. amongst people 
who become infected with SARS-CoV-2, what proportion does not experience symptoms at all during their infection? 
2. Amongst people with SARS-CoV-2 infection who are asymptomatic when diagnosed, what proportion will develop 
symptoms later? 3. What proportion of SARS-CoV-2 transmission is accounted for by people who are either 
asymptomatic throughout infection, or pre-symptomatic? A total of 94 studies was included. The overall estimate of 
the proportion of people who become infected with SARS-CoV-2 and remain asymptomatic throughout infection was 
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20% (95% CI 17-25) with a prediction interval of 3-67% in 79 studies that addressed this question. There was some 
evidence that biases in the selection of participants influence the estimate. In seven studies of defined populations 
screened for SARS-CoV-2 and then followed, 31% (95% CI 26-37%, prediction interval 24-38%) remained asymptomatic. 
The proportion of people that is pre-symptomatic could not be summarised, owing to heterogeneity. The secondary 
attack rate was slightly lower in contacts of people with asymptomatic infection than those with symptomatic infection 
(relative risk 0.35, 95% CI 0.10-1.27). Modelling studies fit to data found a higher proportion of all SARS-CoV-2 
infections resulting from transmission from pre-symptomatic individuals than from asymptomatic individuals.  
Transmission by recovered patients 
Lan (JAMA 2020, see below) reported data suggesting that at least a proportion of recovered patients still may be virus 
carriers. In this study four patients with COVID-19 who met criteria for hospital discharge or discontinuation of 
quarantine in China (absence of clinical symptoms and radiological abnormalities and 2 negative RT-PCR test results) 
had positive RT-PCR test results 5 to 13 days later, while they were continuing the quarantine protocol at home for 5 
days. All patients had 3 repeat RT-PCR tests performed over the next 4 to 5 days and all were positive. An additional 
RT-PCR test was performed using a kit from a different manufacturer and the results were also positive for all patients. 
The patients continued to be asymptomatic by clinician examination and chest CT findings showed no change from 
previous images. They did not report contact with any person with respiratory symptoms. No family member was 
infected. 
Ling (Chin Med J 2020, see below) analysed, in 66 convalescent patients, the clearance time and factors influencing 
viral RNA detection in different samples from patients with COVID-19. A majority of patients had a longer duration 
until stool specimens were negative for viral RNA than for throat swabs, with a median delay of 2.0 (1.0-4.0) days. Only 
6.9% urine samples were positive for viral nucleic acid; viral RNA was still present in three patients’ urine specimens 
after throat swabs were negative. Using a multiple linear regression model (F = 2.669, P = 0.044, and adjusted R2 = 
0.122), the analysis showed that the CD4+ T lymphocyte count may help predict the duration of viral RNA detection in 
patients’ stools (t = −2.699, P = 0.010). The duration of viral RNA detection from oropharyngeal swabs and faecal 
samples in the glucocorticoid treatment group was longer than that in the non-glucocorticoid treatment group (15 
days vs. 8.0 days, respectively; t = 2.550, P = 0.013) and the duration of viral RNA detection in faecal samples in the 
glucocorticoid treatment group was longer than that in the non-glucocorticoid treatment group (20 days vs. 11 days, 
respectively; t = 4.631, P < 0.001). 
Chen (Int J Inf Dis 2020, see below) reported a confirmed case of COVID-19 whose oropharyngeal swab test of SARS-
CoV-2 RNA turned positive during convalescence. 
Xing (Eurosurv 2020, see below) also reported detection of RNA in two asymptomatic cases out of 62 recovered 
patients (3.23%). Mao (Int J Inf Dis 2020, see below) similarly reported two cases of positive RT-PCR in asymptomatic 
(recovered) patients. Among the recurrence cases described by Jiang (J Inf 2020, see below), one case had significant 
post-discharge clinical symptoms and discomfort for nine days, one case had a mild cough, and 4 cases were 
asymptomatic with positive RT-PCR nucleic acid test. 
Yuan (Clin Inf Dis 2020, see below) provided additional evidence of virus shedding from recovered patients. The study 
population included 172 discharged COVID-19 patients from Jan 23th 2020 to Feb 21th 2020, of which 25 patients 
(total 14.5%) subsequently developed a positive RT-PCR result. These 25 patients (median age of 28 years) had an 
average of 7.32±3.86 days from their last negative RT-PCR result to turning positive again. 
A study by Tang (Infect Control Hosp  Epidemiol. 2020, see below) showed that among all 209 discharged COVID-19 
patients in Shenzhen between January 23 and February 21, 2020, 9 (4.3%) patients showed RT-PCR positive in throat 
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swabs, 13 (6.2%) patients showed RT-PCR positive in anal swabs, and 22 (10.5%) positive in either type. The time 
between discharge and positive RT-PCR tests was 4.7 days on average. 
Of note, A case report by Qu (Trav Med Inf Dis 2020, see below) pointed to the importance of the specimen choice. 
Both a throat swab and sputum were collected before the patient was discharged. SARS-COV-2 nucleic acid was still 
detectable in sputum while the throat swab was negative. 
Human to animal transmission and risk of reverse spillover  
As SARS-CoV-2 infections are now widely distributed in the human population, there is a possibility for some animals 
to become infected through close contact with infected humans. Evidence of “reverse zoonotic” transmission, 
sometime referred to as “spillback,” from people to wildlife and domestic animals is widespread (Messenger PLoS ONE 
2014, see below); however, systematic surveys to determine the proportion of emerging infectious diseases that spill 
back into novel wildlife hosts are lacking (Olival 2020 PLoS Pathogen 2020, see below). Infection of animals with SARS-
CoV-2 may have implications for animal health and welfare, and for wildlife conservation. Conservationists and health 
officials are, therefore, confronted with the challenge of informing the public about the potential health risks 
associated with bats and other potential animal hosts of SARS-CoV-2 without eroding already limited support for their 
conservation. This complex problem requires an integrated, transdisciplinary research agenda to support the design 
of evidence-based guidance and action plans on how to minimize zoonotic health risks while supporting bats and their 
associated ecosystem services (Rocha Anim Conserv 2020, see below). Wildlife health capacity is as much about 
protecting wild animal populations and biodiversity as it is about protecting people and as such there is a need for a 
global wildlife health authority (https://www.iucn.org/crossroads-blog/202009/it-time-a-global-wildlife-health-
authority). 
Understanding the risk of exposure of humans or animals to SARS-CoV-2 from animals and their products is essential 
for containing virus spread, prioritizing research, design informed conservation policies, protecting food systems, and 
informing national One Health investigations and mitigation measures. The FAO has issued a “Qualitative Exposure 
Assessment” tool which provides a comprehensive review of available scientific evidence and assessment of exposure 
risk from different wild or domestic animal species. Results can inform country-level risk assessment and provide the 
evidence base for targeted SARS-CoV-2 investigations in animals and mitigation options (El Masry 2020, see below).  
Moreover, the impact of the reduced human mobility on wildlife during the lockdown enforced in many countries in 
response to the pandemic may enable a detailed, mechanistic understanding of human–wildlife interactions that could 
inspire realistic, evidence-based proposals for improving human–wildlife coexistence (Rutz 2020, see below). An 
internationally recognized standard for managing wildlife trade on the basis of known disease risks should be 
established. A decentralized network could improve feedback between those who screen samples and those who 
curate data to bolster the safety of wildlife and humans, a fundamentally “One Health” approach. This would increase 
localized knowledge of emerging infectious diseases risks, provide earlier warnings and faster global responses to 
spillovers, and inform wildlife trade policy. This model is more robust to shifting political landscapes and funding and 
does not ignore the role of advanced regional research laboratories, which also provide vital targeted pathogen 
screening (Watsa Science 2020, see below). Their analysis and Dobson’s (Science 2020, see below) suggest that the 
associated costs of preventive efforts (preventing deforestation, regulating wildlife trade and zoonotic disease 
surveillance) would be substantially less than the economic and mortality costs of responding to these pathogens once 
they have emerged. The gross estimated costs of the actions total $22 to $31 billion per year. Reduced deforestation 
has the ancillary benefit of around $4 billion per year in social benefits from reduced greenhouse gas emissions, so net 
prevention costs range from $18 to $27 billion per year. In comparison, COVID-19 has shown us the immense potential 
cost of a pandemic. The world may lose at least $5 trillion in GDP in 2020, and the willingness to pay for the lives lost 
constitutes many additional trillions (Dobson Science 2020 ; supplementary material, see below). These costs exclude 
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the rising tally of morbidity, deaths from other causes due to disrupted medical systems, and the loss to society of 
foregone activities due to social distancing. 
On 2nd June 2020, the International Union for Conservation of Nature (IUCN) issued a comprehensive “Questions and 
answers on COVID-19 and nature conservation” addressing the impact of the pandemic on the conservation of 
threatened species (e.g. non-human primates, bats), and indigenous communities and recommending conservation 
measures to minimise the risk of zoonotic diseases being transmitted to humans (https://www.iucn.org/covid-19-
resources/questions-and-answers-covid-19-and-nature-conservation). The Office for Epizootics (OIE) has produced a 
complete special edition bulletin on COVID-19 which is regularly updated 
(https://www.oie.int/fileadmin/Home/eng/Our_scientific_expertise/docs/pdf/COV-19/A_Q%26A_COVID-19.pdf). 
OIE also published a document to guide testing of human diagnostic specimens in veterinary laboratories 
(https://www.oie.int/fileadmin/Home/eng/Our_scientific_expertise/docs/pdf/COV-
19/A_Guidance_for_animal_health_laboratories_1April2020.pdf) to support the evaluation of human-animal 
contacts. The European Commission issued a comprehensive Q&A document tackling COVID-19 in farmed and 
domestic animals including policies related to the responsibilities of the veterinary authorities in this public health 
crisis (https://ec.europa.eu/food/sites/food/files/animals/docs/ah_covid-19_qandas_en.pdf?wtclear=laco).  
Surrogate virus neutralization test (sVNT), which is species and isotype independent, has an advantage over VNT in 
that it does not use live virus and can therefore be conducted in a biosafety level 2 (BSL2) laboratory. It has been 
presented as an option to test for the presence of antibodies to SARS-CoV-2 in all animal species. The OIE’s 
organisation response to the pandemic has also been communicated in a special bulletin (https://oiebulletin.com/wp-
content/uploads/2020/05/OIE-News-May2020-Special-Edition-COVID-19-main-news-article_withoutstatement.pdf), 
which outlines the development of special ad-hoc advisory groups for animal health laboratories and animal health 
surveillance. According to OIE's Terrestrial Animal Health Code, the infection of animals with SARS-CoV-2 meets the 
criteria of an emerging disease ("animal" is defined as "a mammal, reptile, bird, or bee"). Therefore, any case of 
infection of animals with SARS-CoV-2 should be reported to the OIE in accordance with the OIE Terrestrial Animal 
Health Code and include information about the species, diagnostic tests, and relevant epidemiological information. 
On April 1st, the US Fish and Wildlife Service sent out a directive advising scientists to suspend all bat studies and take 
appropriate sanitary precautions and safety measures (PPEs, disinfection of equipment) when working with wildlife in 
general, concerned that researchers could spread the disease to bats and other wild animals 
(https://www.usgs.gov/media/files/nwhc-operations-during-covid-19-pandemic-and-info-about-coronaviruses). This 
is supported by the global distribution and host range of β-CoV evolutionary lineages which suggests that over 40 
species of temperate-zone North American bats could be immunologically naïve and susceptible to infection by SARS-
CoV-2 (Olival PLoS Pathogen 2020, see below). On 21st August 2020, Guidelines for Working with Free-Ranging Wild 
Mammals in the Era of the COVID-19 Pandemic were released by OIE and the IUCN Wildlife health Specialist Group 
(http://www.iucn-whsg.org/COVID-19GuidelinesForWildlifeResearchers). These recommendations are based on first 
principles of biosecurity and hygiene, current knowledge of human-to-animal SARS-CoV-2 transmission and the 
precautionary principle (minimize contact with animals, assess your own health condition, and protect yourself). It 
also provides useful references to taxa specific guidelines (felid and small carnivores, apes, bats). A real time on-line 
resource for people working at the human - NHP interface has also been launched in the view to create a community 
of practice, connecting relevant facts, experts and resources from several professional communities (human health, 
captive, sanctuary, and in situ conservation 'facilities' and sites) to assist with response and management of the SARS-
CoV-2 epidemic (https://umnadvet.instructure.com/courses/324). A comprehensive paper (Zhang Transbound Emerg 
Dis 2020, see below) reviewed the current understanding about animal coronaviruses and SARS-CoV-2 for their 
emergence, transmission, zoonotic potential, alteration of tissue/host tropism, evolution, status of vaccines, and 
surveillance. The paper also provides guidance for control of COVID-19 and preventative strategies for possible future 
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outbreaks of zoonotic coronavirus via cross-species transmission. The risk of introduction of SARS-CoV-2 in Antarctica 
wildlife is discussed in a preprint (Barbosa, manuscript  on Preprints: 
https://www.preprints.org/manuscript/202008.0478/v1) and list a series of guidelines for visitors. This follows the 
story of a SARS-CoV-2 positive tourist who visited several sites along the Antarctic Peninsula, which raised concerns 
regarding the potential human introduction of the virus on this continent through research activities or tourism. Cold 
conditions can potentially facilitate fomite transmission, especially via scientific equipment used by several people or 
in contact with both humans and other animals. Based on score for the binding affinity of their ACE2 receptor (Damas, 
Proc Natl Acad Sci USA 2020, see below), transmission of SARS-CoV-2 to Antarctic birds seems unlikely while cetaceans 
appear to have the highest risk of SARS-CoV-2 infection amongst Antarctic wildlife. The potential role of bats as hosts 
of SARS-CoV and SARS-CoV-2 has been challenged by Yan (manuscript on Biorxiv : 
https://doi.org/10.1101/2020.09.08.284737). The authors analysed genetic and functional ACE2 orthologs from 46 
bat and argued that many bat species are not potential hosts of SARS-CoV and SARS-CoV2. Their results are partly 
consistent with Damas (Proc Natl Acad Sci USA 2020, see below) who confirmed the role of critical residues of bat 
ACE2 in supporting SARS-CoV-2 entry in 19 bats species. However, disparities between in silico analyses and functional 
experiments confirm the complexity of ACE2 functionality and the importance of complementary methodologies as 
our understanding of ACE2 sequences and structures is yet incomplete. 
Fenton (Facets 2020, see below) summarized the essential ecosystem services provided by bats, and how people’s 
perceptions may be an additional threat to bats worldwide following the emergence of SARS-CoV-2. As such, reverse 
spillover events - the risk of SARS-COV-2 being introduced into endemic wildlife from humans - raises an additional 
concern and another serious public health threat. Preventing human-to-wildlife SARS-CoV-2 transmission is important 
for protecting these (sometimes endangered) animals from disease, but also to avoid establishment of novel SARS-
CoV-2 reservoirs in wild animals. The risk of repeated re-infection of humans from such a wildlife reservoir could 
severely hamper SARS-CoV-2 control efforts (Gryseels, manuscript  on Preprints: 
https://www.preprints.org/manuscript/202005.0141/v1). While containing the human outbreak is a priority, 
estimating the transmission potential and introduction of SARS-COV-2 in domestic and wild animals similarly requires 
immediate action, especially when considering viral discharge in the environment and survival times. 
The use of network- and trait-based statistical models to predict suitable wildlife hosts for SARS-CoV-2 (e.g. pangolins, 
civets, bats) is presented as a cost-efficient strategy to optimize reservoir research and prioritize taxa sampling (Becker, 
manuscript on bioRxiv: https://doi.org/10.1101/2020.05.22.111344). Several reviews on the risk of the potential 
modes and risk of human-to-domestic animals and wildlife transmission of SARS-CoV-2 have been published recently 
(Mahdy, manuscript  on Preprints:  https://www.preprints.org/manuscript/202004.0192/v1; McNamara Vector Borne 
Zoonotic Dis 2020, see below; Gryseels,  manuscript  on Preprints: 
https://www.preprints.org/manuscript/202005.0141/v1).  
As of 3rd July 2020, the animal species for which information on natural or experimental infection with SARS-CoV-2, 
and for which infection can lead to transmission between animals, included cats (domestic), tigers and lions, ferrets, 
minks, Egyptian fruit bats (Rousettus aegyptiacus), Golden Syrian hamsters, Macaques (Macaca fascicularis and 
Macaca mulatta) (https://www.oie.int/fileadmin/Home/eng/Our_scientific_expertise/docs/pdf/COV-
19/A_Factsheet_SARS-CoV-2.pdf). Two preprints addressing the risk of reverse zoonosis in North America (Griffin, 
manuscript on bioRxiv, see: https://doi.org/10.1101/2020.07.25.221291 and Fagre, manuscript on bioRxiv, see:  
https://doi.org/10.1101/2020.08.07.241810) subsequently added relevant information to the topic. The former 
demonstrated that adult deer mice (Peromyscus maniculatus) are susceptible to SARS-CoV-2 infection following 
intranasal exposure to a human isolate, resulting in viral replication in the upper and lower respiratory tract with little 
or no signs of disease. The later infected experimentally deer mice with SARS-CoV-2 and found detectable viral RNA 
for up to 21 days in oral swabs and 14 days in lungs while no conspicuous signs of disease were observed and no deer 
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mice succumbed to infection. Contact transmission occurred from infected to naive deer mice showing for the first 
time sustained natural transmission in an endemic rodent outside Asia, and determining the potential role as 
secondary reservoir host in a North American rodent, which could lead to periodic outbreaks of COVID-19. Schlottau 
(The Lancet Microbe 2020, see https://europepmc.org/article/pmc/pmc7340389) experimentally investigated the 
susceptibility of potential animal hosts and the risk of anthropozoonotic spill-over infections by intranasally inoculating 
fruit bats (Rousettus aegyptiacus), ferrets (Mustela putorius), pigs (Sus scrofa domesticus), and chickens (Gallus gallus 
domesticus) with SARS-CoV-2. Pigs and chickens were not found susceptible to SARS-CoV-2. All swabs, organ samples, 
and contact animals were negative for viral RNA, and none of the pigs or chickens seroconverted. Fruit bats had a 
transient infection, with virus detectable by RT-qPCR, immunohistochemistry, and in situ hybridisation in the nasal 
cavity, associated with rhinitis. Viral RNA was also identified in the trachea, lung, and lung-associated lymphatic tissue. 
One of three contact bats became infected. More efficient virus replication but no clinical signs were observed in 
ferrets, with transmission to all three direct contact animals. Mild rhinitis was associated with viral antigen detection 
in the respiratory and olfactory epithelium. Both species developed SARS-CoV-2-reactive antibodies reaching 
neutralising titres of up to 1/1024 after 21 days. 
A subsequent experimental study somewhat contradicted these previous reports which suggested that pigs are not 
susceptible to SARS-CoV-2 infection. Using a ten-fold higher viral dose for inoculation, Pickering (manuscript on 
bioRxiv : https://doi.org/10.1101/2020.09.10.288548) found that following oronasal inoculation, SARS-CoV-2 
persisted in swine for at least 13 days. Viral RNA was detected in group oral fluids and nasal wash from at least two 
animals while live virus was isolated from a pig. Further, antibodies could be detected in two animals at 11 and 13 
days post-infection. The authors therefore defined domestic swine as a species susceptible to SARS-CoV-2 infection, 
albeit at low level. 
Naturally acquired infections in animals 
Current evidence indicates that some animal species can become infected with SARS-CoV-2 under natural conditions. 
These events appear to be rare and sporadic and are predominantly epidemiologically linked to confirmed human 
cases of COVID-19. However, there is limited testing and surveillance data available at this time. With over 150 reports 
of animal infection by SARS-CoV-2 with economical, conservation, veterinary and public health impact,  Mobasheri is 
calling for One Health and comparative medicine (Front Vet Sci 2020, see below).  
The US CDC has now issued clear criteria to guide evaluation and laboratory testing for SARS-CoV-2 in animals 
(https://www.cdc.gov/coronavirus/2019-ncov/animals/animal-testing.html). 
Table 8 Criteria to Guide Evaluation and Laboratory Testing for SARS-CoV-2 in Animals (from 
https://www.cdc.gov/coronavirus/2019-ncov/animals/animal-testing.html) 
Criteria Epidemiological Risk  Clinical Features 
A 
Animal with history of exposure to a person 
or animal suspected or confirmed to be 
infected with SARS-CoV-2. 
AND 
Animal has clinical signs suspicious of 
SARS-CoV-2 infection. 
B 
Animal with exposure to a known high-risk 
environment (i.e., where human cases or 
animal cases have occurred), such as a 
residence, facility, or vessel (e.g. nursing 
home, prison, cruise ship). 
C 
Threatened, endangered or otherwise 
imperiled/rare animal in a rehabilitation or 
zoological facility with possible exposure to 
SARS-CoV-2 through an infected person or 
animal. 
AND 
Animal is asymptomatic; OR Animal 
has clinical signs suspicious of SARS-
CoV-2 infection. 
Delivered by Ingenta
IP: 157.193.240.2 On: Fri, 04 Jun 2021 12:29:12
Copyright Leuven University Press
 
Authors: Martine Denis, Valerie Vandeweerd, Rein Verbeke, Anne Laudisoit, Tristan Reid, Emma Hobbs, Laure Wynants, Diane 
Van der Vliet  
COVIPENDIUM version: 20 OCT 2020  Transdisciplinary Insights - Living Paper | 102 
D 
Animals in a mass care or group setting 
(e.g., farm, animal feeding operation, animal 
shelter, boarding facility, zoo, or other 
animal holding) including companion 
animals, livestock, and other species, where 
their exposure history to people with 
COVID-19 is unknown. 
AND 
A cluster of animals show clinical signs 
suspicious of SARS-CoV-2 infection. 
 
Although the clinical spectrum of illness for this virus remains largely undefined in animals, clinical signs more likely to 
be compatible with SARS-CoV-2 infection in mammalian animals may include a combination of the following: fever, 
coughing, difficulty breathing or shortness of breath, lethargy, sneezing, nasal discharge, ocular discharge, vomiting 
and diarrhoea. The exposure is defined as i) being within approximately 2 meters of a person with suspected or 
confirmed COVID-19 starting from 2 days before the person’s illness onset (or, for asymptomatic human patients, 2 
days before positive specimen collection) until the time the person is isolated, and ii) having direct contact with 
infectious secretions from a person with suspected or confirmed COVID-19 starting from 2 days before the person’s 
illness onset (or, for asymptomatic human patients, 2 days before positive specimen collection) until the time the 
person is isolated. Direct contact could include an animal being coughed, sneezed, or spit on by an infected person or 
sharing food or consuming something that was recently contaminated with an infected person’s mucous or saliva. 
There have been multiple notifications to OIE of non-human animals testing positive to SARS-CoV-2 by PCR, and both 
individual animal cases and farm outbreaks have been reported in the scientific media. The species and location of 
reported cases are shown in Table 9 below.  
Table 9 Numbers of animals, by species and country, that have tested positive for SARS-CoV-2  
Animal species affected 
ASIA AMERICAS AFRICA EUROPE 
TOTALS 
HK JA USA** SA BE NL DK FR ES DE UK RU 
DOMESTIC             37 
Dogs 3 12 4+1^   1^† 1†      20 (+2^) 
Cats 4  6  1*   2* 1* 1* 1 1 17 
ZOO             9 
Tigers   5          5 
Lions   3          3 
Puma    1         1 
FARMED             163 
Mink   9   64# 89#   1       163# 
Legend : HK, Hong Kong; JA, Japan ; USA, United states of America; SA, South Africa; BE, Belgium ; NL, the Netherlands; DK, 
Denmark; FR, France; ES, Spain ; DE, Germany ; UK, United Kingdom and RU, Russia 
† Not reported to the OIE 
* Unofficially reported to the OIE 
** The U.S. Department of Agriculture (USDA) maintains a list of all animals with confirmed infections with SARS-CoV-2 in the 
United States (https://www.aphis.usda.gov/aphis/ourfocus/animalhealth/sa_one_health/sars-cov-2-animals-us) 
^ Antibody positive only  
# Number of affected farms. Number of animals not reported.  
Infection of any animal with SARS-CoV-2 should be notified to the OIE as an emerging disease in accordance with 
Chapter 1.1 of the OIE Terrestrial Animal Health Code.  
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An animal should be classified as a suspected case of SARS-CoV-2 infection if: 
o The animal has clinical signs suggestive of SARS-CoV-2 infection, including but not limited to; nasal discharge, 
respiratory distress, coughing, vomiting or gastrointestinal disease. As in humans, mild or asymptomatic 
infections are likely to occur and should be considered in epidemiological investigations; and  
o All other likely differential diagnostic aetiologies have been effectively ruled out by a veterinarian; and 
o The animal has an epidemiological link with a confirmed human COVID-19 patient, SARS-CoV-2 infected animal 
or suggestive case history indicating potential exposure.  
An animal should be classified as a confirmed case of SARS-CoV-2 infection if: 
o SARS-CoV-2 has been isolated from a sample15 taken directly from an animal; or 
o Viral nucleic acid has been identified in a sample taken directly from an animal, giving cause for suspicion of 
previous association or contact with SARS-CoV-2, by: 
a) Targeting at least two specific genomic regions at a level indicating presence of infectious virus; or 
b) Targeting a single genomic region followed by sequencing of a secondary target. 
At least 20 domestic dogs and 17 domestic cats have tested positive to SARS-CoV-2 by RT-PCR and/or antibody-capture 
ELISA, following close contact with confirmed (or suspected) COVID-19 human patients (OIE WAHID, 
https://www.oie.int/wahis_2/public/wahid.php/Diseaseinformation/WI; Zhang manuscript on bioRxiv: 
https://doi.org/10.1101/2020.04.01.021196). Seroconversion has been detected in some cases. So far, no cases of cat- 
or dog-to-human transmission have been reported.  
In a recent study on the potential epidemiological role of domestic cats and dogs, a higher seroprevalence of SARS-
CoV-2 antibodies (microsphere immunoassays (MIA) targeting anti-SARS-CoV-2 IgGs and a retrovirus-based 
pseudoparticle assay targeting SARS-CoV-2 neutralizing antibodies), ranging from 21% to 53% was detected (Fritz, 
manuscript on bioRxiv : https://www.biorxiv.org/content/10.1101/2020.09.22.307751v1). The seropositivity among 
pets from COVID-19 positive households (10/47) was significantly greater compared to households with unknown 
status (1/38). Though these results do not prove that all positive animals were infected with SARS-CoV-2, the much 
greater seroprevalence in animals from COVID-19 positive households provide strong evidence that pets have been 
infected with SARS-CoV-2.  
This study along with multiple punctual reports issued between January and October 2020 strongly suggest that 
globally – due to the unsystematic testing of domestic and wild animals – there is a dramatic underestimation of the 
prevalence and incidence of SARS-CoV-2 in animals, and that the epidemiological role of animal in SARS-CoV-2 
transmission is far from being understood. The amount of effort dedicated to control and test human in priority – 
while obviously justified – have however overlooked the broader epidemiological complexity of SARS-CoV-2 
transmission which should be tackled using a One Health approach. These crucial gaps - 8 months after the official 
recognition of the COVID-19 pandemic by WHO - therefore limit our abilities to control the emergence and re-
emergence of SARS-CoV-2 in both human and animal populations worldwide. There is an urgent need to re-assess the 
panzootic status of SARS-CoV-2. 
Details of the detected cases in dogs and cats include: 
 Dog (Pomeranian, Hong Kong) 
(ProMED-mail, Archive Number: 20200326.7146438, https://promedmail.org/promed-
post/?id=20200326.7146438; OIE WAHID, 
https://www.oie.int/wahis_2/public/wahid.php/Reviewreport/Review?reportid=33762). A 17-year-old 
Pomeranian was placed in quarantine in Hong Kong on the 26th February 2020, after its 60-year-old owner was 
                                                          
15 Samples for virus isolation and viral nucleic acid are preferably nasal swab, oropharyngeal swab, nasal washing, tracheal swab 
and/or a rectal sample may be taken, or a faecal sample may be used in situations where direct sampling is not possible due to 
risks to the animal or testing staff; or from internal organs collected post-mortem.  
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diagnosed with COVID-19 the previous day. Prior to entry to the quarantine facility, the animal was examined 
by a veterinarian and found to be clinically well. Nasal, oral, rectal swabs and a fresh faecal sample were 
collected and tested for SARS-CoV-2. The nasal and oral swab samples collected at this initial examination 
tested positive to SARS-CoV-2 by real time RT-PCR, and viral gene sequencing was performed. The viral 
sequence was highly similar to SARS-CoV-2 sequences detected in humans in close contact with the dog, 
indicating that human-to-animal transmission was the most likely cause of infection.  
The animal tested positive to SARS-CoV-2 by PCR over a period of 12 days, and was subsequently shown to 
have developed a neutralising antibody response by PRNT. No clinical signs of coronavirus had been detected 
throughout the period of testing. The dog is assumed to have been infected through close contact with its 
infected owner. The animal was released from quarantine following successive negative PCR tests, however it 
died 2 days later. It has been widely reported that the death was suspected to be due to an unrelated geriatric 
disease, however the definitive cause of death was unable to be determined as the owner declined an autopsy 
on the dog.  




On the 19th March, a second dog belonging to a COVID-19 patient tested positive in Hong Kong. A 2-year-old 
German Shepherd and a 4-year-old mixed breed dog from the same household had been placed under 
quarantine on 18 March 2020 after their owner was hospitalized due to COVID-19 infection. Neither dog 
showed any clinical signs of infection (Almendros Vet Rec 2020, see below). 
Nasal, oral and rectal swab samples were collected from both animals on admission to the facility (18th March), 
and again on 19th and 20th March. Samples from the German Shepherd tested positive by real time RT-PCR at 
all 3 timepoints, and seroconversion was confirmed by PRNT. Virus isolation was also successful. The mixed 
breed dog was negative on all testing. Subsequent swab samples collected over the following 10 days were 
negative. Based on the epidemiological history it is suspected that this is a case of human-to-animal 
transmission, however there is no publicly available sequencing results to support this. 
 Cat (Belgium) 




The Belgian Chief Veterinary Officer reported on 18th March that a cat had tested positive to SARS-CoV-2. The 
cat’s owner was confirmed to have COVID-19 and started home confinement immediately upon their return 
from Italy. One week after the owner’s return, the cat started showing clinical signs of respiratory and digestive 
disease, including anorexia, diarrhoea, vomiting, coughing and superficial breathing. 
Samples of the cat’s faeces and vomit were confirmed positive for SARS-CoV-2 viral RNA by PCR and 
sequencing. High viral loads have been reported and are suggestive of a productive infection occurring in the 
cat, but contamination of samples from the environment/owner cannot be ruled out because the samples 
were taken from the environment (and not directly from the animal) by the owner, who is not a technical 
expert. On 19th March, the FASFC requested an urgent opinion to the independent Scientific Committee 
established at the FASFC. According to this Committee, the elements reported do not allow confirmation of a 
productive viral infection in the cat, but it is suspected based on the PCR Ct values compatible with a high 
number of viral genome copies and clinical signs compatible with a coronavirus infection. The cat began to 
improve clinically nine days after the onset of clinical signs. No serological studies have been reported to date. 
 Cat (Domestic Short Hair, Hong Kong)  
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(ProMED-mail Archive Number: 20200403.7179945, https://promedmail.org/promed-
post/?id=20200403.7179945; OIE WAHID, 
https://www.oie.int/wahis_2/public/wahid.php/Reviewreport/Review?page_refer=MapFullEventReport&re
portid=34221). On 31st March, The Hong Kong Government reported that a pet cat of a COVID-19 patient had 
tested positive for SARS-CoV-2. As was the case with previous detections in dogs in Hong Kong, the cat tested 
positive following veterinary examination and sampling on arrival at a quarantine facility. No clinical signs were 
observed. Nasal, oral and rectal swabs all tested positive for SARS-CoV-2 by real time RT-PCR. Repeat oral and 
nasal swab samples were also positive by PCR. Virus neutralising antibody was subsequently detected. Virus 
isolation attempts were unsuccessful. Successive negative swab samples were obtained during the quarantine 
period and the animal was eventually returned to its owner.  
 Cats (New York, USA)  
(ProMED-mail, Archive Number 20200422.7256272 https://promedmail.org/promed-post/?id=7256272; CDC 
media release https://www.cdc.gov/media/releases/2020/s0422-covid-19-cats-NYC.html; OIE WAHID 
statement, https://www.oie.int/wahis_2/public/wahid.php/Reviewreport/Review?reportid=34086).  
On April 22, the CDC released a statement that two domestic cats in New York had tested positive to SARS-
CoV-2. On April 23, the NVDL confirmed virus neutralising antibodies were detected in follow-up samples from 
both affected domestic cats. The two cats lived in separate parts of New York and the cases are not considered 
to be epidemiological linked. Both cats were displaying mild signs of respiratory disease, including sneezing 
and ocular discharge. Only one of the cats was owned by a confirmed COVID-19 patient, who tested positive 
prior to the cat developing disease. A second cat in this household has tested negative. It is unclear how the 
other animal became infected – the CDC press release states ‘the virus may have been transmitted to this cat 
by mildly ill or asymptomatic household members or through contact with an infected person outside its 
home’. News reports suggest that a member of the household experienced a short respiratory illness 
approximately 1 week prior to the cat developing signs of disease, however it appears that the person was not 
tested for COVID-19.  The cat is also reported to spend time outdoors and the possibility of exposure from the 
nearby area remains viable.  
 Cats (France)  
(ProMED-mail Archive Number: 20200501.7289409, https://promedmail.org/promed-post/?id=7289409; 
https://www.vet-alfort.fr/images/Communication/CP/2020-05-01_-_CP_Chat_SRAS-cov2.pdf). On 30th April, 
the Deputy Head of the Animal Health Laboratory ANSES in France communicated to ProMED a preliminary 
report of a study investigating SARS-CoV-2 infections in cats owned by people suspected to have had COVID-
19. Rectal and nasopharyngeal swabs were taken from each cat and tested by qRT-PCR, with any positives to 
be confirmed by the OIE Collaborating Centre at the Pasteur Institute in Paris. One cat, which had reportedly 
showed mild respiratory and digestive signs, tested positive for SARS-CoV-2 on its rectal swab, while its 
nasopharyngeal swab tested negative. A description of this case was provided by Sailleau (Transbound Em Dis 
2020, see below).  
A second French cat, from the city of Bordeaux, was reported by the National Veterinary School of Toulouse 
(France) to have positive for SARS-COV-2  on  the 12th of May (ProMED-mail Archive Number: 
20200513.7332909, https://promedmail.org/promed-post/?id=7332909).  The cat lived in a household with 
people suspected of having contracted COVID-19 and developed a persistent cough that was non-responsive 
to antibiotic and anti-inflammatory treatment.  A nasopharyngeal swab was positive on PCR, whilst rectal 
swabs were negative.  
 Cat (Germany)  
SARS-CoV-2 infection has been reported in a cat in Germany following the death of its owner from COVID-19 
(ProMED-mail Archive Number: 20200513.7332909, https://promedmail.org/promed-post/?id=7332909). 
The cat lived with its owner in a retirement home in which there is an ongoing COVID-19 outbreak. Two other 
cats living in the facility have tested negative. No clinical signs were observed in the infected cat. All 3 cats 
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have been transferred to a quarantine facility and despite being housed together, the non-infected cats have 
continued to return negative PCR results on follow-up sampling. The investigation is ongoing.  
 Cat (Spain)  
On 11th May 2020, the Spanish Ministry of Agriculture, Fisheries and Food confirmed the first SARS-CoV-2 
infection in a cat in the country but advised caution regarding the interpretation of the infection. The cat was 
taken to a veterinary facility on 22nd April 2020 as it was in respiratory distress (dyspnea and tachypnea), and 
upon examination was shown to have a mild anaemia and severe thrombocytopenia. At the radiographic level, 
a broncho-interstitial pattern with increased opacity of the lung was noted. The cat was euthanized due to its 
degrading condition and the body was sent for autopsy, which determined that the cat’s death was caused by 
an underlying hypertrophic cardiomyopathy of probable genetic origin, not consistent with SARS-COV-2 viral 
infection. Nasal swabs, and one mesenteric lymph node were SARS-COV-2 positive by RTqPCR (3 markers 
tested). The cat belonged to a household with several family members previously diagnosed with COVID-19 in 
late April. However, the detection of SARS-CoV-2 RNA in several samples from the animal is suggested to be 
incidental, potentially associated with being in an environment contaminated by the virus, but in any case, not 
responsible for the clinical symptoms he was suffering from 
(https://www.oie.int/fileadmin/Home/eng/Our_scientific_expertise/docs/pdf/COV-19/Nota_Gato%20SARS-
CoC-2_spain.pdf).  
 Dog (Netherlands)  
In her letter dated 15th May 2020, Dutch agriculture minister Carola Schouten reported that an eight-year-old 
American bulldog, owned by a COVID-19 patient, was euthanised on 30th April due to severe and deteriorating 
respiratory disease. Testing of samples did not detect SARS-CoV-2, but did identify antibodies to SARS-CoV-2 
in the dog’s blood. It was not reported whether the dog’s death was attributed to SARS-CoV-2 or to another 
cause. The minister has since implemented requirements for veterinarians to report of suspected COVID-19 
in animals, and laboratories to report positive test results, to the Netherlands Food and Consumer Product 
Safety Authority (NVWA). 
(https://www.rijksoverheid.nl/documenten/kamerstukken/2020/05/08/kamerbrief-stand-van-zaken-
corona-en-dieren).  
• Cat (Russia) 
On 26th May 2020, the OIE WAHID received a report of the first confirmed SARS-CoV-2 animal case in Russia, 
after throat and nasal swabs taken from a five-year-old cat tested positive by rRT-PCR on 22nd May 
(https://www.oie.int/wahis_2/public/wahid.php/Reviewreport/Review?page_refer=MapFullEventReport&re
portid=34443). The PCR amplification products were detected by electrophoresis and subsequently 
underwent sequencing, which showed 100% correlation with the 232 bp N gene fragment OFR1ab of the SARS-
CoV-2 virus. The cat is reportedly under quarantine, presumably at home in Moscow Oblast, but no details of 
the clinical condition of the cat or its owner have been provided. 
• Dog (New York, USA) 
The USDA APHIS have confirmed that 2 dogs have tested positive to SARS-CoV-2 in Richmond County, New 
York State (https://www.aphis.usda.gov/aphis/newsroom/stakeholder-info/sa_by_date/sa-2020/sa-06/sars-
cov-2-dog). One dog, a German Shepherd, initially tested positive by PCR at a private laboratory after 
presenting to a veterinarian with respiratory illness. This result was later confirmed by the National Veterinary 
Services Laboratories (NVSL). Serological testing by VNT confirmed the presence of antibodies. This is the first 
reported case of a dog with clinical disease consistent with COVID-19 testing positive to SARS-CoV-2 by PCR.   
A second dog in the household also tested serologically positive, indicating prior exposure, however no clinical 
signs were observed. One of the animals’ owners was a confirmed COVID-19 patient.   
• Cat (Minnesota, USA) 
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On 3rd June the OIE WAHIS reported a confirmed case of SARS-CoV-2 in a domestic pet in Minnesota, USA, 
from a household with known COVID-19 cases 
(https://www.oie.int/wahis_2/public/wahid.php/Reviewreport/Review?page_refer=MapFullEventReport&re
portid=34548). The cat was showing clinical signs including depression, fever and harsh lung sounds, and 
tested positive for both SARS-CoV-2 and Mycoplasma felis – another potential respiratory pathogen – on initial 
testing. SARS-CoV-2 was confirmed by rRT-PCR and sequencing on 27th and 28th May 2020, respectively. A 
dog residing in the household appears to be healthy, but it was not reported whether the dog was also tested 
for SARS-CoV-2. The cat is reportedly being quarantined at home for 14 days, and both the cat and the owners 
are reported to be recovering well. 
 Cat (Illinois, USA)  
A domestic cat from a known COVID-19 household in Illinois, USA, was reported to positive for SARS-CoV-2 on 
10th June after developing respiratory illness. Clinical signs included fever, oral lesions and ulcerations on the 
tongue. Initial feline respiratory panel testing was negative to FIV and FeLV, and positive to feline coronavirus, 




 Dog (Denmark)  
On 20th June 2020, veterinary and Food Administration Minister in Denmark, COVID-19 infection was found 
in a family dog belonging to the 1st infected mink farm in Denmark. The nature of the testing is not known. 
The dog is being kept inside and avoid close contact with other animals and people outside the household by 
its owner as per recommendations of the authorities (https://mfvm.dk/nyheder/nyhed/nyhed/regeringen-
igangsaetter-testprogram-efter-nyt-covid-19-fund-i-danske-mink/). 
 Dog (Texas, USA) 
A Tarrant County dog was confirmed to be infected with SARS-CoV-2, the on 7 Jul 2020 by the U.S. Department 
of Agriculture (USDA) National Veterinary Services Laboratories (NVSL). The private veterinarian chose to test 
the dog for SARS-CoV-2 as a precautionary measure after its owners were confirmed to have COVID-19. The 
veterinarian reports the 2-year-old dog is healthy at this time (Promed Archive Number: 20200708.7554832). 
 Cat (Hong Kong)  
On 24th July 2020, a cat which did not exhibit any relevant clinical signs and kept in the same household as a 
confirmed COVID-19 patient of Hong-Kong has been tested positive for SARS-CoV-2. The cat was placed under 
quarantine on 21 Jul 2020 after confirmation of a human case from the same household. Following veterinary 
examination, nasal, oral and rectal swab samples were taken; the oral sample was tested positive for SARS-
CoV-2 by real time RT-PCR. As of 11th August, faecal sample was tested positive by real time RT-PCR. And the 
cat subsequently confirmed to be seropositive by a surrogate virus neutralisation test. A Siberian Husky dog 
kept in the same household of a close contact of a confirmed COVID-19 patient tested positive for SARS-CoV-
2 by real time RT- PCR. None of the animals exhibited any specific clinical signs. Risk management measures 




 Cat (United Kingdom)  
On 27th July 2020, the Department for Environment, Food and Rural Affairs of the UK reported to OIE that a 
domestic cat from a COVID positive household in South England tested positive for SARS-CoV-2 by PCR. The 
cat was showing respiratory signs indicative of Feline Herpes Virus (FHV) and a swab was taken for 
confirmation in May and a SARS-CoV-2 test was undertaken as part of a surveillance project in a private 
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laboratory.  The cat was co-infected with FHV and SARS-CoV-2. In July 2020, a new oral swab was negative, 
and the blood sample was positive to the virus neutralisation test. A second cat in the household was tested 
negative by PCR and virus neutralisation. The positive cat completely recovered (PCR negative and seropositive) 
(Promed Archive Number: 20200727.7617582 and reported to OIE: 
https://www.oie.int/wahis_2/public/wahid.php/Reviewreport/Review?page_refer=MapFullEventReport&re
portid=35182.) 
 Cat (Louisiana, USA)  
The Louisiana Department of Agriculture and Forestry (LDAF) received its 1st reported case of a SARS-CoV-2-
positive dog in Louisiana. No details were given about clinical symptoms or household owner COVID status 
(Promed archive number : 20200805.7648734). 
 Dogs (Japan)  
On 7th August, the Japan Ministry of Agriculture, Forestry and Fisheries (MAFF) reported SARS-CoV-2 infection 
in two dogs belonging to COVID-19 confirmed patients 
(https://www.oie.int/fileadmin/Home/MM/Japan_08.2020.pdf). The two dogs were brought to a private 
company in Japan that has been running a voluntary service to take care of companion animals owned by 
COVID-19 patients while the owners are in hospital or isolation. Newly arrived animals are kept in isolation 
until tested negative for SARS-CoV-2 by rRT-PCR. In late July, the throat swabs of 2 asymptomatic dogs were 
subjected to rRT-PCR which confirmed the dogs were positive for SARS-CoV-2. Positive samples were 
subsequently submitted to the National Institute for Infectious Diseases (NIID) and confirmed to be positive 
by rRT-PCR, RT-PCR and sequencing. Overall, since 26th July 2020, the Japan Ministry of Agriculture, Forestry 




 Cat (Texas, USA)  
On 8th August, 2020, Texas A&M researchers from the College of Veterinary Medicine & Biomedical Sciences 
(CVMBS) have identified 2 cats in Brazos County that tested positive for COVID-19. The team is working to 
understand how pets living in "high-risk" households may be impacted by COVID-19 by sampling pets, dogs 
and cats, whose owners have tested positive. The team has sampled several dozen households across the 
county so far (about the project, visit http://tx.ag/BCSCovidResearch; Promed archive number : 
20200808.7658191). 
 Dog (North Carolina, USA)  
A North Carolina dog supposedly died from COVID-19 complications the week of 3rd August 2020 said state 
health officials however there is little information about the dog and if there were underlying factors in the 
death of this animal (ProMed archive number : 20200813.7672505). The dog's owner took it to a veterinary 
hospital, reporting breathing problems, and told staff it had earlier tested positive for SARS-CoV-2 and 
recovered. A test for the dog came back positive at the vet's office. 
The majority of the confirmed domestic animal cases are strongly linked to a confirmed existing human infection, and 
there is no evidence of animal to animal transmission in companion animal settings. This suggests human to animal 
transmission is the primary mode of spread in domestic settings. Viral load, route of infection, national and 
international context and age of pets may influence transmission probability (Shi , manuscript on bioRxiv: 
https://www.biorxiv.org/content/10.1101/2020.03.30.015347v1). 
There is currently no evidence that cats or dogs play a significant role in human exposure; however, reverse zoonosis 
is possible if infected owners expose their domestic pets during acute infection (Bosco-Lauth, manuscript on Biorxiv: 
https://doi.org/10.1101/2020.05.28.120998). Detection of SARS-CoV-2 infections in domestic animals has raised some 
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concern that there may be an increase in the number of people leaving their pets (Gönültaş 2020, see below). 
Computer simulations have been performed to estimate how this may affect outbreak related outcomes. 
Abandonment of animals may result in significant differences in the risk of transmission (Gönültaş 2020, see below; 
Gao 2020, see below). 
As of August 15, it is debated that dogs have died of COVID19 without post-mortem examination with ancillary 
diagnostics, and a clear history of the health status of the dead animals (ProMed archive Number: 20200815.7681907). 
The factual information gained from a post-mortem examination can then benefit the veterinary community and pet 
owners. It thus seems premature and inappropriate to make claims that dogs (NC dog and NY German shepherd) are 
dying of COVID-19 as coronavirus infection and coronavirus disease should not be considered synonymous and 
differential diagnosis should be systematically carried out (e.g. for canine coronavirus infection (CCV)). Only then can 
such statements like "...dog died from coronavirus [COVID-19] complications..." actually be verified.  Until this happens, 
these statements continue to create confusion and panic in the population. An animal specific RT-PCR test has been 
developed by IDEXX Reference Laboratories to detect SARS-CoV-2 based on the published genetic sequences of the 
virus from the human outbreak. The test targets the same nucleocapsid gene as the CDC assay but has been adapted 
with a unique alignment for use in animals. As such it is designed to avoid cross-reactivity with other veterinary-specific 
coronaviruses (Promed archive number: 20200818.7689234). 
The CDC are recommending that people treat pets as they would other human family members and to not let them 
interact with people or animals outside the household. It also recommended that if someone in the family develops 
symptoms, they also be isolated from pets (https://www.cdc.gov/coronavirus/2019-ncov/daily-life-coping/pets.html). 
A possible role of cats in the epidemiology of COVID-19 is yet to be further studied.  Akhmetzhanov (manuscript on 
MedRvix: https://www.medrxiv.oreg/content/10.1101/2020.05.21.20109041v1) reviewed 17 case reports on 
confirmed SARS-CoV-2 infections in animals as of 15 May 2020 and estimated the basic reproduction number R0 under 
a scenario of cat-to-cat transmission at 1.09 (95% confidence interval: 1.05, 1.13). This value is much lower than the 
R0 reported for humans and close to one, suggesting that the sustained transmission between cats is unlikely to occur. 
Bosco-Lauth (manuscript on bioRxiv : https://doi.org/10.1101/2020.05.28.120998) found that cats are highly 
susceptible to subclinical infection, with oral and nasal viral shedding that is not accompanied by clinical signs, and are 
capable of direct contact transmission to other cats. Dogs do not shed virus following infection. Cats and dogs 
developed a robust neutralizing antibody response indicative of established protective immunity against SARS-CoV-2 
following repeated exposure. Despite early reports of possible mink-to-human transmission in the Netherlands, there 
is currently no peer reviewed evidence that animals contribute to the transmission of SARS-CoV-2 within human 
populations.  
Zoo animals 
Five tigers and three lions at the Wildlife Conservation Society’s (WCS) Bronx Zoo in New York have tested positive for 
SARS-CoV-2. (ProMED-mail, Archive Number: 20200406.7191352., https://promedmail.org/promed-
post/?id=20200406.7191352; ProMED-mail, Archive Number: 20200406.7191480., https://promedmail.org/promed-
post/?id=20200406.7191480; OIE WAHID, 
https://www.oie.int/wahis_2/public/wahid.php/Reviewreport/Review?page_refer=MapFullEventReport&reportid=3
4054; Wildlife Conservation Society, https://newsroom.wcs.org/News-
Releases/articleType/ArticleView/articleId/14084/Update-Bronx-Zoo-Tigers-and-Lions-Recovering-from-COVID-
19.aspx). 
All five tigers and three lions were housed in two enclosures at the zoo, which had been closed to the public since mid-
March. Initially, the OIE WAHID received a report on 6th April that COVID-19 was confirmed in one of the Malayan 
tigers (Panthera tigris jacksoni) that developed mild clinical signs of respiratory disease (dry cough and some wheezing) 
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on the 27th March.  Duplicate nasal and oropharyngeal swabs and tracheal wash samples were collected and confirmed 
to be positive for SARS-CoV-2 by RT-PCR and sequencing on 4th April.  
By 3rd April, three additional tigers (one additional Malayan tiger and two Amur tigers) and all three African lions were 
also showing the same clinical respiratory signs as the index case, with anorexia also reported in one or more animals 
(no further details provided). No dyspnoea, or ocular or nasal discharge were observed in any of the cats. 
These tigers and lions were not initially tested due to logistical challenges, but were assumed to also be infected 
with SARS-CoV-2. All animals in the two affected enclosures were isolated, and symptomatic animals were 
administered antibiotics and/or supportive care as needed. They reportedly showed daily improvement of clinical 
signs and appeared to be recovering well.  A subsequent notification to the OIE on 17th April reported confirmation of 
SARS-CoV-2 infection in one of the lions, and reportedly also in all five other suspected animals, via a faecal test. An 
8th case in an in-contact tiger with no clinical signs was also detected. No further details were provided regarding the 
test performed. All the large cats were reported to be recovering well.   
Transmission is presumed to have occurred from a pre- or asymptomatic animal keeper infected with SARS-CoV-2, but 
no confirmed staff infections have been reported to date. It is also not confirmed whether all the animals were 
infected at the same time by the presumed infected keeper, or whether the first tiger to show clinical signs 
subsequently transmitted the virus to the other animals.  As of October 20 2020, the source of SARS-CoV-2 infection 
in the lions remains unknown. Epidemiological data and genetic similarities between keeper and tiger viruses indicate 
human to animal transmission (McAloose, 2020 mBio : see below). An in-depth review of this case series provided a 
detailed description of the the clinical presentation, diagnostic evaluation, and management of tigers and lions 
infected with SARS-CoV-2 (Bartlett, manuscript on bioRxiv : 
https://www.biorxiv.org/content/10.1101/2020.08.14.250928v1). A second case study of this series presented the 
first known natural transmission of SARS-CoV-2 from humans to animals in the USA, the results of radiography and 
ultrasonography, viral shedding and samples positivity (oropharyngeal, nasal swabs, tracheal wash fluid, faecal) and 
provided the first report of SARS-CoV-2 in non-domestic felids. 
On August 12, OIE received the notification of the Department of Agriculture, Forestry and Fisheries, Animal 
Production and Health, Pretoria, in South Africa that a zoo puma (Felis concolor) in Johannesburg’s zoo (Gauteng) had 
tested positive for SARS-CoV-2. Disease symptoms appeared on 17th July with quarantine of the infected animal ; 
testing of the 2nd puma that was in direct contact with the case will be repeated in the following weeks (ProMed 
archive number : 20200813.7672007). On 31st July, the PCR test carried out by the University of Pretoria - Virology 
Laboratory (Private Laboratory) confirmed that the animal was positive for SARS-COV-2. The transmission is presumed 
to have occurred after contact with an infected handler as in the New York scenario 
(https://www.oie.int/wahis_2/public/wahid.php/Reviewreport/Review?page_refer=MapFullEventReport&reportid=
35399). 
None of the other big cat species, including snow leopard, cheetah, clouded leopard, Amur leopard or serval, nor other 
animals at the zoo have shown any signs of respiratory disease.  
Sanctuaries and protected areas 
Non-human primates 
On 13th March 2020, the International Primate Society together with the UICN Primates SG strongly recommended 
that great ape visitations by humans are reduced to the minimum needed to ensure the safety and health monitoring 
for the non-human primates. For those essential staff, great ape visitation rules need to be strictly enforced at all sites 
(maintenance of a 10 meters distance from great apes at all times; moreover, no clinically ill person or who has been 
in contact with anybody ill in the preceding 14 days is allowed to visit great apes). While there has been no report of 
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SARS-CoV-2 infection in wildlife sanctuaries so far, it is safest to assume that great apes are susceptible to SARS-CoV-
2 infection (Melin, manuscript on bioRxiv: https://www.biorxiv.org/content/10.1101/2020.04.09.034967v2). Patrono 
(Em Micr Inf 2020, see below) reported a mild respiratory outbreak of βCoV 1 (HCov-OC43) in habituated Tai forest 
chimpanzees in Cote d’Ivoire. Viral RNA was found in faeces of chimpanzees. The virus was probably introduced by 
asymptomatic visitors whose throat swabs tested positive for the virus. 
Wild cats 
On 4th April 2020, a wild tiger of the Pench Tiger Reserve area in Madhya Pradesh and Maharashtra, India, died after 
exhibiting altered behaviours and high fever. This area is considered one of the critical tiger habitats remaining in 
central India, hosting a population of around 44 tigers. Based on the confirmation of SARS-CoV-2 infections in captive 
tigers in the USA, all forest department officials of Pench Tiger Reserve were immediately quarantined in the forest 
and the reserve was closed to visitors. Veterinary authorities subsequently reported that an impacted intestine had 




On April 26th, the Ministry of Agriculture of The Netherlands confirmed that two mink farms reported cases of COVID-
19 among their animals (https://www.oie.int/fileadmin/Home/eng/Our_scientific_expertise/docs/pdf/COV-
19/OIE_SARS_CoV%202_infection_of_mink_in_the_Netherlands_26April2020.pdf). Minks showed various symptoms 
including respiratory problems, pneumonia, gastrointestinal problems and increased mortality (OIE statement, 28th 
April, https://www.oie.int/fileadmin/Home/eng/Our_scientific_expertise/docs/pdf/COV-
19/6th_call_OIE_AHG_COVID19_and_animals.pdf). An investigation by Utrecht University 
(UU), GD Animal Health, Erasmus MC and Wageningen Bioveterinary 
Research (WBVR) has been launched to determine the source of the infections, to better understand the epidemiology 
and allow for a better risk assessment. Authorities assumed that employees with COVID-19 symptoms infected the 
minks. Some employees at each of the farms had reportedly shown signs consistent with COVID-19 infection, however 
no details of testing in humans were provided at the time. It was later reported that at least one employee on each of 
the two farms had tested positive for SARS-CoV-2 (Oreshkova, manuscript on bioRxiv: 
https://www.biorxiv.org/content/biorxiv/early/2020/05/18/2020.05.18.101493.full.pdf).  
As of 8th May, three additional mink farms tested positive for the virus; in these farms, contamination from humans 
to animals is presumed to be the cause. The government immediately established a 400m buffer zone around the 
affected farms, closed the nearest public roads, banned transport of animals and manure from the infected farms and 
requested other mink farm employees and veterinarians to notify any clinical signs resembling of COVID-19 in mink. 
Follow-up testing showed that virus was found in the air samples outside the immediate vicinity of minks on dust 
particles within the house. It is still unknown whether people can become infected with COVID-19 through these dust 
particles, but personal protective equipment has been recommended for all employees at infected mink farms 
(Statement of Dutch Minister of Agriculture, Nature and Food Quality (LNV), 8th May 2020; 
https://www.rijksoverheid.nl/ministeries/ministerie-van-landbouw-natuur-en-
voedselkwaliteit/nieuws/2020/05/08/eerste-resultaten-onderzoek-naar-covid-19-op-nertsenbedrijven-binnen). 
Virus was not detected in dust or air samples taken from outside the buildings, meaning the risk to public health was 
negligible; consequently, the 400-metre closure zones around infected farms were cancelled by the Dutch Agriculture 
Minister as of 15th May (Statement of Dutch Minister of Agriculture, Nature and Food Quality (LNV), 15th May 2020, 
https://www.tweedekamer.nl/kamerstukken/brieven_regering/detail?id=2020Z08824&did=2020D18884). 
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Serological investigations of cats living on the mink farms identified antibodies against SARS-CoV-2 in 7/24 cats tested 
on the first farm, and virus was isolated from one of the seven positives, although in insufficient quantities to allow 
genetic sequencing. While it is not yet possible to determine how or when the cats became infected, or what their role 
may have been in transmission, the possibility of mink-to-cat transmission is being considered (Joint Statement of 
Dutch Ministers of Health, Welfare and Sport (VWS) and Agriculture, Nature and Food Quality (LNV), 25th May 2020; 
https://www.rijksoverheid.nl/regering/bewindspersonen/carola-
schouten/documenten/kamerstukken/2020/05/25/kamerbrief-ontwikkelingen-covid-19-op-nertsenbedrijven). 
Whether SARS-COV-2 can be transmitted from mink-to-mink is still debated but a preprint paper discusses minks as a 
potential SARS-CoV-2 reservoir due to similar infectivity patterns to bats (Guo, manuscript on bioRxiv: 
https://www.biorxiv.org/content/10.1101/2020.01.21.914044v2.full). Further concerns have been raised linked to 
potential transmission from cage to cage, the breeding seasonality of minks (March-May), increased mink density (5 
mink kits/female) as high densities of a species that has proven to be permissive to SARS-CoV-2 replication is a likely 
scenario that might increase mink-to-mink and mink-to-human transmission risk (ProMED-mail, Archive Number: 
20200511.7323845, https://promedmail.org/promed-post/?id=20200511.7323845). 
In an update on 19th May, Minister Schouten declared infection of mink with SARS-CoV-2 on mink farms to be an 
infectious animal disease according to the Animal Health and Welfare Act, after genetic sequencing of viral samples 
from employees and animals on the farms indicated a “plausible” case of mink-to-human infection (Statement of 
Dutch Minister of Agriculture, Nature and Food Quality (LNV), 19th May 2020; 
https://www.rijksoverheid.nl/documenten/brieven/2020/05/19/stand-van-zaken-onderzoek-covid-19-naar-
nertsenbedrijven). The employee, who has since recovered, had worked with the mink before the farm was known to 
be infected, and prior to the implementation of employee personal protective equipment. At least one more potential 
occurrence of mink-to-human transmission was also reported on a second infected farm on 25th May, after genetic 
sequencing of viral samples from three infected humans revealed high homology of the viral strains with those in the 
farm’s infected mink, and the absence of similar SARS-CoV-2 strains in other people in the region or in the environment 
(Joint Statement of Dutch Ministers of Health, Welfare and Sport (VWS) and Agriculture, Nature and Food Quality 
(LNV), 25th May 2020; https://www.rijksoverheid.nl/regering/bewindspersonen/carola-
schouten/documenten/kamerstukken/2020/05/25/kamerbrief-ontwikkelingen-covid-19-op-nertsenbedrijven) 
Given the rapidly evolving situation, and the fact that sub-clinically infected mink could see infected farms remaining 
“under the radar”, mandatory weekly submission of all naturally dead mink for PCR testing (“early warning”) and one-
off serological screening of all mink farms in the country was implemented from 20th May. Visitors to infected farms 
have been banned, and owners are advised to prevent cats from entering or leaving company premises due to their 
susceptibility to infection with SARS-CoV-2 and potential role in viral transmission on farm premises. The role of cats 
in the spread of SARS-CoV-2 within and between mink farms in the Netherlands is currently under investigation. It will 
be of particular interest to note if such spread could involve the faecal route (Promed archive number: 
20200617.7480013). By 15th June, the weekly carcass testing of naturally dead mink had detected SARS-CoV-2 
infection in an additional ten farms, bringing the country’s total number of infected mink farms to 15. In a letter to 
parliament dated 3rd June it was announced that in the interest of public health, all mink on the infected farms are to 
be culled within the following week (Joint Statement of Dutch Ministers of Health, Welfare and Sport (VWS) and 
Agriculture, Nature and Food Quality (LNV), 3rd June 2020; https://www.rijksoverheid.nl/onderwerpen/coronavirus-
covid-19/documenten/kamerstukken/2020/06/03/kamerbrief-over-aanvullende-maatregelen-voor-
nertsenbedrijven). The presence of peak numbers of mink kits on the farms at present and their decreasing maternal 
antibody protection over time will increase the number of susceptible animals on-farm by five to six times. This would 
pose the risk of uncontrolled viral transmission between mink and the potential for viral mutation and reassortment, 
as well as the establishment of a viral reservoir that could continue to re-infect humans. Infected farms will be required 
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to be cleaned and disinfected following the cull, and must remain empty for a period of time. Owners will be 
compensated for the loss of their animals. The uninfected mink farms are still required to continue the ‘early warning’ 
and screening activities described earlier. On 30th July, a total of 27 mink farms in the Netherlands have been declared 
infected and all 26 previously infected farms, in which SARS-CoV-2 was established, have been culled (Promed archive 
Number: 20200727.7617582 and 20200801.7635820). As of 17th August, SARS-CoV-2 had been found on 33 mink farms, 
and ±1.5 million mink had been culled because of SARS-CoV-2, representing some 30% of the animals kept on the 
country's 128 mink farms (Promed archive number: 20200817.7687830). By September 25 2020, the number of 
infected mink farms reached 57 in the Netherlands, and it went up to 64 by October 12 (Promed archive number: 
20201013.7858915). Despite the tightening of control measures, the infection of distant farms raises further concerns 
on the pathways and mechanism of continued circulation and spread of the virus (Promed archive numbers : 
20200909.7761598, 20200914.7777661, 20200918.7794239, 20200925.7813579). In the framework of these 
investigations, 1000 blood samples from 500 dogs, 500 cats and rabbits (number unknown) were examined. Antibodies 
against SARS-CoV-2 have been detected in 2 of the 500 cats (0.4%), one of the 500 dogs (0.2%), but not in rabbits. The 
prevalence within this tested population was thus found low, indicating that infections in cats and dogs are occasional, 
probably due to human spread. 
In 2015, mink farming was banned in the Netherlands, but the ban was said to become fully effective in 2024 
(https://www.eurogroupforanimals.org/news/dutch-court-confirms-ban-mink-farming-netherlands) even though 
pressure is mounting on the government to order a preventative cull across the entire sector now especially since 
mink are known to have passed the virus on to at least 2 farm workers (Promed archive number: 20200817.7687830). 
The world's largest fur production is located in China, and minks have been mentioned in China among the animal 
species addressed as potential intermediate hosts of COVID-19 (Guo, manuscript on bioRxiv: 
https://www.biorxiv.org/content/10.1101/2020.01.21.914044v4). Following these developments, the Chinese 
agriculture ministry is considering rebranding minks (and other wildlife such as raccoon dogs, silver foxes and blue 
foxes) – that were also sold at Wuhan market - as domestic livestock, rather than wild animals, lobbying welfare and 
sanitary standards will be improved while protecting the fur farming business (ProMED-mail, Archive Number: 
20200511.7323845, https://promedmail.org/promed-post/?id=20200512.7328587).  As a consequence of the SARS-
CoV-2 widespread infection in mink farms in the Netherlands, more than 100 mink farms will be ordered to close 
earlier than 2024. According to the Dutch Federation of Pelt Farmers, the Netherlands exports around 90 million euros 
[USD 101 million] worth of fur a year for use in China and globally. The country had roughly 900 000 mink at 130 farms 
(Promed archive number : 20200830.7730463). 
A first in-depth investigation of outbreaks on 16 mink farms and humans living or working on these farms, using whole-
genome sequencing (sequences available on GISAID: www.gisaid.org/) examined how SARS-CoV-2 was initially 
introduced from humans and evolved, most likely reflecting widespread circulation among mink in the beginning of 
the infection period several weeks prior to detection. The report also documented the first reverse spillover 
transmission events – that is animal-to-human transmissions - of SARS-CoV-2 from mink to people (Oude Munnink, 
manuscript on bioRxiv : https://doi.org/10.1101/2020.09.01.277152). In total, 18 sequences from mink farm 
employees or close contacts were generated from seven different farms. In most cases, these human sequences were 
near-identical to the mink sequences from the same farm. For two farms, the human sequences clustered deeply 
within the sequences derived from mink, with 7 nucleotides and 4 nucleotides difference with the closest related mink 
sequence. Moreover, sequences of employees sampled at a mink farm clustered with animals from another farm 
which can be explained by the exchange of personnel between these two farms. As of September 2, 2020, despite 
enhanced biosecurity, early warning surveillance, and immediate culling of infected farms, there was ongoing 
transmission between mink farms with 3 big transmission clusters with unknown modes of transmission. This 
exhaustive paper relating the One Health investigation outbreak team efforts to understand the epidemiology of SARS-
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CoV-2 in mink farms was based upon data collected up to 26 Jun 2020 from 16 mink farms; as of September 2 2020, 
28 additional farms have been found infected. 
On June 17th, the Danish Veterinary and Food Authority issued a press release to advise that SARS-CoV-2 had been 
confirmed on a mink farm in the North Jutland region (press release of the Danish Veterinary and Food authority, 
https://www.foedevarestyrelsen.dk/Nyheder/Aktuelt/Sider/Pressemeddelelser%202020/Covid-19-i-nordjysk-
minkbes%C3%A6tning.aspx); a dog from this household was tested positive for COVID-19 and isolated indoors with its 
owners (Promed Archive Numer : https://promedmail.org/promed-post/?id=7506728). Samples from 34 mink were 
tested after a person who was associated with the farm was diagnosed with COVID-19. Entry and egress restrictions 
were placed on the mink farm while testing was being completed, and normal hygiene protocols for visitors to mink 
farms (including washing hands and changing clothes before and after animal handling) are still in force. The Danish 
government decreed that the infected farm will be depopulated in the interest of public health, and strategies for 
testing other mink farms in the country are reportedly being drawn up. As of July 5th, mink holdings infected with SARS-
CoV-2 are no longer culled in Denmark. That is the decision of the Agriculture Ministry in Copenhagen. Based on a new 
strategy, a series of preventive measures are being pursued, such as the obligation to use protective equipment on 
farms and the promulgation of hygiene guidelines. A council's order will come into effect in the course of this month 
[July 2020] (Promed Archive Number: 20200708.7553067). The Danish Veterinary and Food Administration is currently 
testing all Danish mink farms for COVID-19 which led to detection on 14 Aug 2020, of a 4th infected farm (Promed 
archive number: 20200817.7687830). Since September 16, the DVFA no longer issues press releases on individual 
findings of COVID-19 on Danish mink farms. Instead, herds with confirmed infections are identified on the DVFA's 
website in a continuously updated map and table. In total, as of 18th and 25th September, 20 and 25 mink holdings 
respectively have been found COVID-19 infected out of the country's total of 1136 holdings (Promed archive number: 
20200918.7794239, Promed archive number: 20200925.7813579). Since September 11, the Danish Veterinary and 
Food Administration (DVFA) has monitored Denmark's 1136 mink farms for the presence of the COVID-19 and 
identified 6 positive mink farms. With a monitoring strategy and the stricter restrictions for infected mink farms, the 
DVFA and the Danish health authorities assess that it is justifiable to let infected herds live because they consider that 
the risk of spreading infection to humans is minimal (Promed archive number: 20200914.7777661). However, this 
policy has apparently changed (https://www.oie.int/fileadmin/Home/MM/Update_4_Letter_to_OIE_on_Sars-CoV-
2_in_mink_farms_in_Denmark.pdf). As of October 4th 2020, an increase in infected mink farms was noted, with 41 
confirmed and 20 suspected farms. By October 14 2020, the number had risen to 89 (Promed archive number: 
20201004.7835635 and 20201014.7861560). The Danish Ministry of Environment and Food stated that as many as 
one million mink will have to be culled (Promed archive number: 20201004.7835635).  Interestingly, 1500 Danish fur 
farmers produce approx. 19 million mink skins; Denmark is a global hub for the mink fur trade, sells the 19 million 
Danish mink skins and around 7 million mink skins from other countries annually; China being its largest market.  
On July 17th 2020, Spanish health authorities ordered the culling of all 93 000 mink at a farm in eastern Spain to prevent 
human contagion after discovering that most of the animals had been infected with the coronavirus where the owner 
had previously tested positive (May 20202). The farm is located in the village of La Puebla de Valverde in the region of 
Aragon, 200 km (125 miles) east of Madrid. Authorities initially ordered that the animals should be isolated. But a few 
weeks later, after several rounds of testing, they decided to cull the mink, which are farmed for their fur. As many as 
80% of a sample of the animals tested positive. 
On August 17th, the USA Department of Agriculture (USDA) reported the two first cases of mink fur farms in Utah to 
have tested positive for SARS-CoV-2. A state agriculture laboratory in Utah performed necropsies on several minks 
after "unusually large numbers of mink died at the farms," the USDA said. A Washington State University lab found 
that samples of 5 animals were positive for the virus, and the USDA's veterinary lab confirmed the results. The two 
farms have been quarantined, and there are no immediate plans for culling (Promed archive number: 
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20200818.7692815). The USDA-APHIS, United States Department of Agriculture, Washington, United States of 
America reported a third infected mink farm to the OIE on August 27, 2020. 
(https://www.oie.int/wahis_2/public/wahid.php/Reviewreport/Review?reportid=35525). Following increased 
mortality rates (from 10.26% to 41.99%), domestic American Mink (Neovison vison) from three commercial premises 
were confirmed positive for SARS-CoV-2 at the National Veterinary Services Laboratories based upon molecular testing 
(PCR and sequencing). Clinical signs included respiratory signs and sudden death. State Officials in Utah have 
quarantined the premises and are working closely with federal One Health partners to complete disposal and monitor 
the situation. 
By October 19 2020, thousands of minks at Utah fur farms in the USA had died because of SARS-CoV-2 infection in the 
preceding 10 days, forcing 9 sites in 3 counties to quarantine. The exact number of infected farms was not known. 
(Promed archive number : 20201009.7847704). Between 7000 and 8000 minks have died since the disease swept 
through the ranches producing the animals. No animals in Utah have been euthanized because of the disease : 
according to the Utah chief veterinarian, such measure did not appear to be necessary. Fur from the dead infected 
animals will be processed to remove any traces of the virus and then used for coats and other garments, according to 
Fur Commission USA, a mink farming trade group. The US produces more than 3 million mink pelts each year. It is 
interesting to compare how the USA, as compared to the Netherlands, Spain, and Denmark, are tackling this issue. As 
of October 20 2020, only the USA seem to consider the culling of infected mink unnecessary. 
Human populations at risk 
Early publications provided preliminary analyses of the main risk factors of COVID-19. For instance, a retrospective, 
single-centre study, including all confirmed cases of COVID-19 in Wuhan Jinyintan Hospital from Jan 1 to Jan 20, 2020 
described 99 patients with PCR-confirmed COVID-19 pneumonia (Chen Lancet 2020, see below). Forty-nine (49%) had 
a history of exposure to the Huanan seafood market. The average age of the patients was 55.5 years (SD 13.1), 
including 67 men and 32 women. Fifty (51%) patients had chronic diseases. In this study, the disease was found more 
likely to affect older males with comorbidities.  
Guan (Eur Respir J 2020, see below) analysed the data from 1590 laboratory-confirmed hospitalised patients 575 
hospitals in 31 province/autonomous regions/provincial municipalities across mainland China between December 11th 
2019 and January 31st 2020. The mean age of patients was 48.9 years. 686 patients (42.7%) were females. Severe cases 
accounted for 16.0% of the study population. 131 (8.2%) patients reached to the composite endpoints. 399 (25.1%) 
reported having at least one comorbidity. The most prevalent comorbidity was hypertension (16.9%), followed by 
diabetes (8.2%). 130 (8.2%) patients reported having two or more comorbidities. After adjusting for age and smoking 
status, COPD [hazards ratio (HR) 2.681, 95% confidence interval (95%CI) 1.424-5.048], diabetes (HR 1.59, 95%CI 1.03-
2.45), hypertension (HR 1.58, 95%CI 1.07-2.32) and malignancy (HR 3.50, 95%CI 1.60-7.64) were risk factors of reaching 
to the composite endpoints. The HR was 1.79 (95%CI 1.16-2.77) among patients with at least one comorbidity and 
2.59 (95%CI 1.61-4.17) among patients with two or more comorbidities. 
Similarly, a meta-analysis by Wang (Aging 2020, see below) analysed six studies from China, including 324 severe cases 
and 1234 non-severe cases, which provided data in terms of hypertension, diabetes, and COPD. Hypertension, 
diabetes, COPD, cardiovascular disease, and cerebrovascular disease were found to be major risk factors for patients 
with COVID-19. The meta-analysis revealed no correlation between increased risk of COVID-19 and liver disease, 
malignancy, or renal disease. 
Epidemiological data were also reported from other countries. For instance, a report of the Korean Society of 
Infectious Diseases; Korean Society of Pediatric Infectious Diseases; Korean Society of Epidemiology; Korean Society 
for Antimicrobial Therapy; Korean Society for Healthcare-associated Infection Control and Prevention; and Korea 
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Centers for Disease Control and Prevention (J Korean Med Sci 2020, see below) described the key epidemiological 
features of the disease in Korea.  
Jordan (BMJ 2020, see below) provided a quick overview of previously reported observations that older age, 
cardiovascular disease, diabetes, chronic respiratory disease, hypertension, and cancer were all associated with an 
increased risk of death. A meta-analysis of eight studies including 46 248 patients with laboratory confirmed covid-19 
indicated that those with the most severe disease were more likely to have hypertension (odds ratio 2.36 (95% 
confidence interval 1.46 to 3.83)), respiratory disease (2.46 (1.76 to 3.44)), and cardiovascular disease (3.42 (1.88 to 
6.22)). In other studies, obesity and smoking were associated with increased risks. However, the authors noted that 
the relative importance of different underlying health conditions remains unclear, owing to inadequate adjustment 
for important confounding factors such as age, sex, and smoking status; insufficient follow-up; and likely under-
reporting of pre-existing conditions. In China, health records are often incomplete or inaccurate and chronic conditions 
are underdiagnosed. 
Risk factors  
A retrospective study involving COVID-19 cases reported through February 11, 2020, and corresponding to 72 314 
patient records including 44 672 (61.8%) confirmed cases, was reported by the Novel Coronavirus Pneumonia 
Emergency Response Epidemiology Team (Zhonghua Liu Xing Bing Xue Za Zhi 2020, see below; and Wu JAMA 2020, 
see below). Among confirmed cases, most were aged 30-79 years (86.6%), diagnosed in Hubei (74.7%). The male-to-
female ratio was 0.99:1 in Wuhan, 1.04:1 in Hubei, and 1.06:1 in China overall.  
Yang (manuscript on medRxiv: https://www.medrxiv.org/content/10.1101/2020.02.28.20028068v1), who analysed 
55 consecutive cases in Beijing, also showed that compared with patients without pneumonia, those with pneumonia 
were 15 years older and had a higher rate of hypertension. 
The characteristics of patients may also at least in part reflect the movement and the social activities of individuals in 
different societies (Korean Society of Infectious Diseases J Korean Med Sci 2020, see below). In the Korean situation, 
for instance, a predominance of females and subjects in their 20s among COVID-19 cases may be due to the fact that 
the outbreak related to a religious group. 
Age  
Early studies identified age as a major risk factor for COVID-19. Table 5 presented above, showed the risk of infection 
according to age as detected in the analysis of 72 314 patient records in China. Multiple reports described the same 
risks factors leading to severe disease and death as those identified as disease risk factors. Wang (J Med Virol 2020, 
see below) reported the details of the first 17 deaths up to 24:00 pm 22 Jan 2020. The deaths included 13 males and 
4 females. The median age of the deaths was 75 (range 48-89) years. The median days from first symptom to death 
were 14.0 (range 6-41) days, and tended to be shorter among people 70 years of age and above (11.5 [range 6-19] 
days) than those with ages below 70 years (20 [range 10-41] days, P=0.033). 
Dudley (Clin Inf Dis 2020, see below), based on available data as of Feb 11 and March 11 respectively, compared the 
incidence of the disease and related deaths in China and South Korea according to age (Figure 15). Unexpectedly, a 
bimodal distribution of disease cases was observed in Korea, with highest morbidity in the 20-29 years cohort.  
Of note, available studies usually considered chronological age as a risk factor. As highlighted by Lauc (Aging 2020, see 
below), a number of biomarkers aimed at objective estimation of biological age have been developed in the past 
several years, the most prominent ones being the epigenetic clock and the glycan clock. The repertoire of glycans 
changes with age, especially in the age ranges that are most susceptible to SARS-CoV-2. Furthermore, both SARS-CoV-
2 and its target ACE2 are known to be highly glycosylated, a pattern that likely changes with age. Recent study analysed 
site-specific N-linked glycosylation of MERS and SARS S glycoproteins, indicating that each of these glycosylation sites 
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can be occupied by up to ten different glycans (called glycoforms), which greatly extends epitope diversity. The authors 
therefore recommended modern profiling technologies to be used to identify molecular risk factors of COVID-19. 
Figure 15 Incidence of disease and related death per age group in China and South Korea (from Dudley Clin Inf Dis 2020) 
 
In the cohort of 78 patients reported by Liu (Chin Med J 2020, see below), the patients in the progression group were 
also older than those in the disease improvement/stabilization group (66 [51, 70] vs. 37 [32, 41] years, U = 4.932, P = 
0.001). Chen (BMJ 2020, see below) analysed the profile of 113 patients who died and 161 who recovered with a 
diagnosis of COVID-19 up to February 28.  The median age of deceased patients (68 years) was significantly older than 
recovered patients (51 years). Similarly, Shi (Crit Care 2020, see below) found age, occupation, hypertension (p<0.001 
for the comparisons between mild and severe cases), gender and cardiovascular disease (p<0.003) as risk factors. 
Zhang (manuscript on medRxiv: https://www.medrxiv.org/content/10.1101/2020.02.26.20028191v1) presented the 
clinical characteristics of 82 death cases of laboratory-confirmed as SARS-CoV-2 infection in Wuhan. Most of these 
death cases were male (65.9%). More than half of dead patients were older than 60 years (80.5%) and the median age 
was 72.5 years. The bulk of death cases had comorbidity (76.8%), including hypertension (56.1%), heart disease 
(20.7%), diabetes (18.3%), cerebrovascular disease (12.2%), and cancer (7.3%). 
The retrospective study involving 44 672 confirmed COVID-19 cases reported by the Novel Coronavirus Pneumonia 
Emergency Response Epidemiology Team in China (Zhonghua Liu Xing Bing Xue Za Zhi 2020, see below; and Wu Jama 
2020, see below)  described a proportion of 13.8% severe cases and 4.7% critical cases in their database. The study 
concluded that the ≥80 years age group had the highest case fatality rate of all age groups at 14.8%. Case fatality rate 
for males was 2.8% and for females was 1.7%. While patients who reported no comorbid conditions had a case fatality 
rate of 0.9%, patients with comorbid conditions had much higher rates - 10.5% for those with cardiovascular disease, 
7.3% for diabetes, 6.3% for chronic respiratory disease, 6.0% for hypertension, and 5.6% for cancer. 
In line with the observations made in China, Porcheddu (J Infect Dev Ctries 2020, see below) observed that fatalities 
in Italy mostly occurred in the elderly with known comorbidities. 
Gender 
Evidence of sex differences in COVID-19 severity emerged in China, where hospital admissions and mortality were 
higher among males than females. In South Korea, where community testing was widespread, females represented 
~60% of those testing positive for SARS-CoV-2, suggesting that females acquire infection, despite having a lower case 
fatality rate (CFR). In the United States, where testing was prioritized for people with symptomatic disease, the 
diagnosis rates were similar in males and females, but males had 1.5 times higher mortality. A male bias in COVID-19 
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mortality has been reported in 37 of the 38 countries that have provided sex-disaggregated data. A report by Scully 
(Nat Rev Imm 2020, see below)  showed that the average male CFR across 38 countries is 1.7 times higher than the 
average female CFR (P < 0.0001) (male CFR 7.3 (95% CI 5.4–9.2); female CFR 4.4 (95% CI 3.4–5.5)). 
Occupational risks 
As noted by Koh (Occup Med 2020, see below), a significant proportion of cases related to occupational exposure. The 
first documented occupational groups at risk were persons working in seafood and wet animal wholesale markets in 
Wuhan. At the start of the outbreak, workers and visitors to the market comprised 55% of the 47 cases with onset 
before 1 January 2020, when the wholesale market was closed.  
Health care workers (HCWs) were next recognized as another high-risk group to acquire this infection. In a case series 
of 138 patients treated in a Wuhan hospital, 40 patients (29% of cases) were HCWs. Among the affected HCWs, 31 
(77.5%) worked on general wards, 7 (17.5%) in the emergency department, and 2 (5%) in the intensive care unit (ICU). 
In Singapore, among the first 25 locally transmitted cases, 17 cases (68%) were probably related to occupational 
exposure. They included staff in the tourism, retail and hospitality industry, transport and security workers, and 
construction workers. A number of reports also highlighted the risks associated with the virus in saliva, especially for 
dentists and healthcare professionals that perform aerosol-generating procedures (e.g. Peng Int J Oral Science 2020, 
see below; Sabino-Silva Clin Oral Investig 2020, see below). 
A situation to monitor is that of vegetable packing facilities, slaughterhouses, meat plants and seafood production 
facilities - including onboard fish processing factories - globally. Outbreaks in meat-processing plants have been 
common features of the pandemic, with research by the London School of Hygiene and Tropical Medicine showing 
that after ships, workers' dormitories, and jails (Promed archive number : Archive Number: 20200618.7482347) - food-
processing factories have been responsible for the biggest localised outbreaks (ProMed Archive Number : 
20200621.7492011). After Germany’s red flags on the issue (https://www.dw.com/en/germanys-meat-industry-
under-fire-after-covid-19-outbreaks/a-53502751), on May 20, 25.4% (570/2244) of workers in a poultry facility in 
North Carolina, U.S.A. tested positive for COVID-19 ; the majority of whom were asymptomatic (ProMed Archive 
Number: 20200523.7370321). Since April 2020, at least 15 300 reported COVID-19-positive cases have been connected 
to meatpacking facilities in at least 192 plants in 32 U.S. states (Dyal 2020, see below). On May 25 2020, a pork 
processing facility in the Netherlands reported 22.3% (147/657) prevalence of COVID-19 among workers (79 
originating from Germany where outbreak had occurred earlier) which prompted the authorities to close the facility, 
quarantine the infected workers and conduct an extensive track and trace program (ProMed Archive Number:  
20200527.7381561). On May 26, a poultry and pork meat processing facility in Brazil reported a prevalence of 6.6% 
COVID-19 positive workers; the same measures are taken to prevent further spread (ProMed Archive Number:  
20200527.7381561). On June 6, Seattle-based American Seafoods confirmed that 92/126 crew onboard a fish 
production ship had tested positive for COVID-19 (Source: Alaska Public Media on ProMed Archive Number: 
20200606.7434798). There has been no mention of testing the animal products. A pork processing plant in Belgium 
reported 67 COVID-19 infections on August 7 2020 (ProMed Archive number: 20200809.7659384) and a frozen meat 
packing plant in Argentina reported 18/50 workers infected on August 2 2020 (Promed archive number: 
20200901.7737977), joining the string of outbreaks at abattoirs and meat processing facilities around the world). As 
SARS-COV-2 survival times on surfaces is still poorly described (see Virus in the environment below), there is a need 
for research and cautionary control measures in these facilities. The July 2020 outbreak in a seafood plant in Northern 
China with a suspected index case contaminated with imported frozen products from South America raised further 
concern about virus survival and transcontinental circulation in packaged food (ProMed archive number: 
20200724.7606897) and concerns that contaminated food shipments could lead to new outbreaks (ProMed archive 
Number: 20200814.7676661). On August 12, it was reported that SARS-CoV-2 was found on the outer packaging of 
frozen seafood bought by 3 companies in Yantai, a port city in eastern Shandong province (ProMed archive number: 
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20200812.7669363). A hierarchy of safety measures and the use of face shields for work stations of 1 meter or less 
seem to be the way forward in facilities where working on a chain does not allow increasing social distance (ProMed 
Archive Number: 20200602.7417630). However, a risk factor in such premises might be the environment - besides 
close contacts - with colder temperatures and absence of natural light, hence UV, that may favour live virus survival 
(ProMed Archive Number: 20200621.7492011). The latter conditions could also allow for virus survival in extreme cold 
natural environment such as the Antarctica and North pole (Barbosa, manuscript on Preprints: 
https://www.preprints.org/manuscript/202008.0478/v1). Low-temperature environment (and storage conditions in 
refrigerators, cold rooms, or transport carriers for storage of fish before selling) are increasingly pointed at since the 
beginning of the COVID-19 pandemic as potentially extending virus survival times. New experimental evidence 
suggests that SARS-CoV-2 may be viable on frozen salmon for one week at 4°C (Dai, manuscript on bioRxiv : 
https://doi.org/10.1101/2020.09.06.284695). Such report highlights the need for all employers to carry out a COVID-
19 risk assessment prior to reopening or enhancing the operations, with the objective to reduce workplace risk to the 
lowest reasonably practicable level by implementing preventative measures (e.g., 
https://www.gov.uk/guidance/working-safely-during-coronavirus-covid-19/factories-plants-and-
warehouses#factories-1-1). The Codex Alimentarius Commission has adopted several practical guidelines on how to 
apply and implement best practices to ensure food hygiene (Codex General Principles of Food Hygiene, CXC 1- 1969), 
handle meats (Codex Code of Hygienic Practice for Meat, CXC 58 – 2005), and control viruses in foods (Guidelines for 
the Application of General Principles of Food Hygiene to the Control of Viruses in Food (CAC/GL 79-2012) and others 
can be consulted on the Codex website (OIE, 2020: https://www.oie.int/en/scientific-expertise/specific-information-
and-recommendations/questions-and-answers-on-2019novel-coronavirus/). Specifically, coronaviruses are 
thermolabile, which means that they are susceptible to normal cooking temperatures (70°C). Therefore, as a general 
rule, the consumption of raw or undercooked animal products should be avoided. Raw meat, raw milk or raw animal 
organs should be handled with care to avoid cross-contamination with uncooked foods. The WHO also issued a 
document entitled “COVID-19 and Food Safety: Guidance for competent authorities responsible for national food 
safety control systems” which aims to address how to ensure the effectiveness of a reduced food safety inspection 
programme in mitigation of risk, and temporary measures that can be introduced to contain widespread food safety 
risks (WHO, 2020: https://www.who.int/publications/i/item/covid-19-and-food-safety-guidance-for-competent-
authorities-responsible-for-national-food-safety-control-systems). 
Genetics 
Delanghe (Clin Chim Acta 2020, see below)  postulated that the variability in deletion/insertion D/I ACE1 enzyme 
genotype distribution might partly explain the variable prevalence of the COVID-19 infection amongst continental 
European countries. ACE1 is indeed characterized by a genetic (D/I) polymorphism in intron 16, which is associated 
with alterations in circulating and tissue concentrations of ACE. This D/I polymorphism shows important geographical 
variation. The authors found that the log transformed prevalence of COVID-19 infections is inversely correlated with 
the D allele frequency: log (prevalence; number of cases/106 inhabitants) = 6.358–0.079 (D-allele frequency, %), r2 = 
0.378; p = 0.001, which led to the conclusion that the ACE D/I genotype may affect the clinical course of the infection. 
The first robust genetic susceptibility loci for the development of respiratory failure in COVID-19 were reported by 
Ellinghaus (manuscript on medRxiv, see https://www.medrxiv.org/content/10.1101/2020.05.31.20114991v1). The 
study involved 1,980 patients with COVID-19 respiratory failure (8,582,968 single-nucleotide polymorphisms), in a 
genome-wide association analysis. Cross-replicating associations with rs11385942 at chromosome 3p21.31 and 
rs657152 at 9q34, which were genome-wide significant. Among six genes at 3p21.31, SLC6A20 encodes a known 
interaction partner with ACE2. The association signal at 9q34 was located at the ABO blood group locus and a blood-
group-specific analysis showed higher risk for A-positive individuals (OR=1.45, 95% CI, 1.20 to 1.75, P=1.48x10-4) and 
a protective effect for blood group O (OR=0.65, 95% CI, 0.53 to 0.79, P=1.06x10-5). Katz (manuscript on medRxiv, see 
https://www.medrxiv.org/content/10.1101/2020.06.09.20125690v1) further utilized proteomic profiling and genetic 
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information from three cohorts including black and white participants to identify proteins influenced by these loci. 
The authors observed that variants in the ABO locus are associated with levels of CD209/DC-SIGN, a known binding 
protein for SARS-CoV and other viruses, as well as multiple inflammatory and thrombotic proteins, while the 3p21.31 
locus is associated with levels of CXCL16, a known inflammatory chemokine. 
Recently, a review by Anastassopoulou (Hum Genomics 2020, see below) provided an overview of  human genetic 
factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity (summarized in Table 10).  
Table 10. Summary of reported associations between human genes and COVID-19 
 
Smoking 
Cai (manuscript on medRxiv: https://www.medrxiv.org/content/10.1101/2020.02.05.20020107v3) observed 
significantly higher ACE2 gene expression in former smoker's lung compared to non-smoker's lung. Also, the authors 
found higher ACE2 gene expression in Asian current smokers compared to non-smokers, but not in Caucasian current 
smokers, which may indicate an existence of gene-smoking interaction. In addition, they found that ACE2 gene is 
expressed in specific cell types related to smoking history and location. In bronchial epithelium, ACE2 is actively 
expressed in goblet cells of current smokers and club cells of non-smokers. In alveoli, ACE2 is actively expressed in 
remodelled AT2 cells of former smokers. Leung (Eur Respir J 2020, see below) demonstrated increased ACE2 
expression in the small airway epithelia of current (but not former) smokers and those with COPD. These results are 
consistent with previous observations in small animals wherein smoke exposure has been shown to upregulate both 
the expression and activity of ACE2 in the airways. While the up-regulation of ACE2 may be useful in protecting the 
host against acute lung injury, chronically, this may predispose individuals to increased risk of coronavirus infections. 
Based on a review of published data as of 17 March 2020, Vardavas (Tobacco Induced Diseases 2020, see below) 
concluded that smoking is most likely associated with the negative progression and adverse outcomes of COVID-19. 
Indeed, the authors identified five studies reporting data on the smoking status of patients infected with COVID-19. 
Notably, in the largest study that assessed severity (Guan NEJM 2020, see below), there were higher percentages of 
current and former smokers among patients that needed ICU support, mechanical ventilation or who had died, and a 
higher percentage of smokers among the severe cases. From these published data Vardavas calculated that the 
smokers were 1.4 times more likely (RR=1.4, 95% CI: 0.98–2.00) to have severe symptoms of COVID-19 and 
approximately 2.4 times more likely to be admitted to an ICU, need mechanical ventilation or die compared to non-
smokers (RR=2.4, 95% CI: 1.43–4.04).  
However, another review published in parallel by Lippi (Eur J Int Med 2020, see below) reached different conclusions 
from the analysis of almost the same studies. The authors reported that in only one study (the study by Liu Chin Med 
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J 2020, see below), active smoking was found to be a significant predictor of COVID-19 severity, whilst in the other 
four studies the association was not statistically significant. 
Cai (Lancet Resp Med 2020, see below) also considered that the relatively small proportion of current smokers in 
reported studies compared with the proportion of male smokers in China (50·5%) are unlikely to be associated with 
increased incidence or severity of COVID-19. 
Moreover, a study by Shi (Crit Care 2020, see below) based on 487 patients, not included in any of these 2 reviews, 
did not identify smoking as a risk factor.  
A meta-analysis by Guo (J Med Virol 2020, see below) was based on data from 8 trials, including a more recent study 
in 125 patients. The pooled OR of the fixed effect model was 2.16 (95% CI: 1.45-3.22). The study from Guan contributed 
to most of the cases in the meta-analysis (1 085 out of 1 851 cases). The sensitivity analysis excluding this study (that 
appeared as a major source of heterogeneity) revealed a pooled OR of 1.89 (95% CI: 1.10-3.24).  
Alqahtani (PLoS One 2020, see below) published a systematic review and meta-analysis on the potential severity and 
mortality risks caused by COVID-19 in patients with chronic obstructive pulmonary disease (COPD) and in smokers. A 
total of 15 studies, which included a total of 2473 confirmed COVID-19 patients were included in the meta-analysis. 
The crude case fatality rate of COVID-19 was 7.4%. The pooled prevalence rates of COPD patients and smokers in 
COVID-19 cases were 2% (95% CI, 1%-3%) and 9% (95% CI, 4%-14%) respectively. COPD patients were at a higher risk 
of more severe disease (risk of severity = 63%, (22/35) compared to patients without COPD 33.4% (409/1224) 
[calculated RR, 1.88 (95% CI, 1.4-2.4)]. This was associated with higher mortality (60%). The results showed that 22% 
(31/139) of current smokers and 46% (13/28) of ex-smokers had severe complications. The calculated RR showed that 
current smokers were 1.45 times more likely [95% CI: 1.03-2.04] to have severe complications compared to former 
and never smokers. Current smokers also had a higher mortality rate of 38.5%. 
In June 2020, a meta-analysis of retrospective observational case series by Farsalinos (Ther Adv Chronic Dis 2020, see 
below) found an unexpectedly low prevalence of current smoking among hospitalized patients with COVID-19. 
Hospitalized current smokers had higher odds compared with non-current smokers but lower odds compared with 
former smokers for an adverse outcome. Smoking cannot be considered a protective measure for COVID-19. However, 
the hypothesis that nicotine may have a protective effect in COVID-19 that is partially masked by smoking-related 
toxicity and by the abrupt cessation of nicotine intake when smokers are hospitalized should be explored in laboratory 
studies and clinical trials using pharmaceutical nicotine products. 
Obesity 
An editorial by Ryan (Obesity 2020, see below) noted that persons with obesity around the world are already at high 
risk for severe complications of COVID-19, by virtue of the increased risk of the chronic diseases that obesity drives. 
The authors also consider likely that obesity shall be an independent risk factor for COVID-19. 
A number of studies identified higher BMI as a risk factor for severe disease. For instance, at the beginning of the 
epidemic, Peng (Zhonghua Xin Xue Guan Bing Za Zhi 2020, see below) conducted a retrospective analysis on 112 
COVID-19 patients with cardiovascular disease in Wuhan, from January 20, 2020 to February 15, 2020. Patients were 
divided into critical group (ICU, n=16) and general group (n=96) according to the severity of the disease. The BMI of 
the critical group was significantly higher than that of the general group (25.5 (23.0, 27.5) kg/m(2) vs. 22.0 (20.0, 24.0) 
kg/m(2), P=0.003). Patients were further divided into non-survivor group (n=17) and survivor group (n=95). Among the 
non-survivors, there were 88.24% (15/17) patients with BMI> 25 kg/m(2), which was significantly higher than that of 
survivors (18.95% (18/95), P<0.001). 
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The analysis of the clinical characteristics, treatment and prognosis of 280 patients from four Chinese hospitals (from 
January 20 to February 19, 2020) by Wu (J Intern Med 2020, see below) also found that the severe group had a 
significantly higher BMI  values than the group of patients with mild disease (25.8  ±  1.8  vs.  23.6 ± 3.2, P = 0.005). 
However, a multifactor analysis revealed that other factors (comorbidity, time from illness onset to antiviral treatment, 
and age >=65) were independent risk factors for COVID-19 progression.  
In the USA, among 6916 Kaiser Permanente Southern California members diagnosed with COVID-19 from 13 February 
to 2 May 2020, there was a J-shaped association between BMI and risk for death, even after adjustment for obesity-
related comorbidities (Tartof Ann Int Med 2020, see below). Compared with patients with a BMI of 18.5 to 24 kg/m2, 
those with BMIs of 40 to 44 kg/m2 and greater than 45 kg/m2 had relative risks of 2.68 (95% CI, 1.43 to 5.04) and 4.18 
(CI, 2.12 to 8.26), respectively. This risk was most striking among those aged 60 years or younger and men. Of note, in 
this cohort, increased risk for death associated with Black or Latino race/ethnicity or other sociodemographic 
characteristics was not detected. 
In Mexico, Giannouchos (Eur Respir J 2020, see below) used a publicly available nation-level dataset released on May 
31, 2020 by the Mexican Ministry of Health and examined the associations between patient characteristics and 
hospitalisation and adverse outcome. COVID-19 patients were found disproportionately older, males and with 
increased prevalence of one or more comorbidities, particularly diabetes, obesity, and hypertension. Age, male gender, 
diabetes, obesity and having one or more comorbidities were independently associated with laboratory-confirmed 
COVID-19. Male gender, older age, having one or more comorbidities, and chronic renal disease, diabetes, obesity, 
COPD, immunosuppression and hypertension were associated with hospitalisation and adverse outcome. 
In England, Hamer (PNAS 2020, see below) used data from a community-dwelling sample in England (n = 334,329; 56.4 
±8.1 y; 54.5% women) with prospective linkage to national registry on hospitalization for COVID-19. Around 0.2% (n = 
640) of the sample were hospitalized for COVID-19. There was an upward linear trend in the likelihood of COVID-19 
hospitalization with increasing BMI, that was evident in the overweight (odds ratio, 1.39; 95% CI 1.13 to 1.71; crude 
incidence 19.1 per 10,000) and obese stage I (1.70;1.34 to 2.16; 23.3 per 10,000) and stage II (3.38; 2.60 to 4.40; 42.7 
per 10,000) compared to normal weight (12.5 per 10,000). This gradient was little affected after adjustment for a wide 
range of covariates; however, controlling for biomarkers, particularly high-density lipoprotein cholesterol and glycated 
hemoglobin, led to a greater degree of attenuation. A similar pattern of association emerged for waist-hip ratio. The 
authors suggested that mechanisms of impaired glucose and lipid metabolism may be involved. 
More recently, a systematic review by Chang (Obes Rev 2020, see below) examined the effects of BMI and obesity 
(BMI ≥ 30 kg/m2 ) on COVID-19. Sixteen articles were included in the meta-analysis, and a random effects model was 
used. BMI was found to be higher in patients with severe disease than in those with mild or moderate disease (MD 
1.6, 95% CI, 0.8-2.4; p = .0002) in China; however, the heterogeneity was high (I2 = 75%). Elevated BMI was associated 
with invasive mechanical ventilation use (MD 4.1, 95% CI, 2.1-6.1; p < .0001) in Western countries, and this result was 
consistent across studies (I2 = 0%). Additionally, there were increased odds ratios of invasive mechanical ventilation 
use (OR 2.0, 95% CI, 1.4-2.9; p < .0001) and hospitalization (OR 1.4, 95% CI, 1.3-1.60; p < .00001) in patients with 
obesity. There was no substantial heterogeneity (I2 = 0%). 
Diabetes 
A meta-analysis of studies reporting the prevalence of diabetes among people infected with SARS-CoV-2 and its impact 
on disease severity or progression was reported by Fadini (J Endocrinol Invest 2020, see below). 12 studies reporting 
data from 2108 Chinese patients with confirmed SARS-Cov-2 infection yielded an estimate of the prevalence of 
diabetes of 10.3%. For comparison, the nationwide prevalence of diabetes in China in 2013 was 10.9% overall and 
12.3% among people aged 40–59. The authors concluded that diabetes may not increase the risk of SARS-CoV-2 
infection, but can worsen the outcome of COVID-19. 
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Cardiovascular diseases 
Results of a pooled analysis of the scientific literature (available as of March 26) by Lippi (Pol Arch Intern Med 2020, 
see below) would suggest that hypertension may be associated with an up to 2.5-fold higher risk of severe and fatal 
COVID-19, especially among older individuals. A brief meta-analysis by Zuin (J Inf 2020, see below) also demonstrated 
that patients with COVID-19 infection and hypertension have a significant high mortality risk.  
Ruan (Intensive Care Med 2020, see below) conducted a retrospective multicenter study of 68 death cases and 82 
discharged cases with laboratory-confirmed infection. The authors found a significant difference in age between the 
death group and the discharge group (p < 0.001) but no difference in the sex ratio (p = 0.43). A total of 63% (43/68) of 
patients in the death group and 41% (34/82) in the discharge group had underlying diseases (p = 0.0069). Patients with 
cardiovascular diseases had a significantly increased risk of death when infected with SARS-CoV-2 (p < 0.001). A total 
of 16% (11/68) of the patients in the death group had secondary infections vs. 1% (1/82) of the patients in the discharge 
group (p = 0.0018). 
Aggarwal (Curr Probl Cardiol 2020, see below) conducted another meta-analysis of 18 recent studies that reported the 
association of cardio-vascular disease with worse prognosis and increased mortality in COVID-19 patients. Pre-existing 
cardiovascular disease was associated with a significantly increased risk of a severe form of COVID-19 (OR = 3.14; 95% 
CI 2.32-4.24; I2 = 0%; Q = 8.68, P= 0.73) and overall risk of COVID-19 all-cause mortality (OR = 11.08; 95% CI: 2.59-
47.32; I2 = 55%; P = 0.11). 
A meta-analysis by Krittanawong (Prog Cardiovasc Dis 2020, see below) concluded that patients with pre-existing 
cardiovascular disease risk, such as diabetes mellitus and hypertension risk, as well as patients with established 
cardiovascular disease, are associated with a higher risk of developing severe COVID-19 disease.  
Treatment with ACE inhibitors and angiotensin II type-I receptor blockers? 
Wu (JAMA Int Med 2020, see below) found that diabetes and hypertension to be more frequent in those who 
developed ARDS than those who did not. Fang (Lancet Resp Med 2020, see below) noted that the most frequent 
comorbidities reported in studies of patients with COVID-19 are often treated with angiotensin-converting enzyme 
(ACE) inhibitors and angiotensin II type-I receptor blockers (ARBs) (even though treatment was not assessed in these 
published studies), which increase ACE2 expression. The authors therefore hypothesized that such treatment would 
increase the risk of developing severe and fatal COVID-19 in patients with cardiac diseases, hypertension, or diabetes. 
Diaz (J Travel Med 2020, see below) developed a similar hypothesis. However, Patel (JAMA 2020, see below) listed 
some arguments pointing to a very different view of the topic. For instance, there is limited evidence showing ACE2 
expression increases in serum or lung after treatment with these drugs. Moreover, the significance of ACE2 expression 
on COVID-19 pathogenesis and mortality is not specifically known. And there are preclinical data suggesting that 
increasing ACE2 expression can attenuate SARS-CoV-2-induced lung injury. Cheng, Wang et al. (J Med Vir 2020, see 
below) and Vaduganathan (NEJM 2020, see below) provided similar arguments, and even suggested the possibility to 
treat ARDS with recombinant human ACE2 or ARBs. Meng (Em Micr Inf 2020, see below) evaluated the ability of renin-
angiotensin inhibitors to protect against COVID-19 in a small cohort of 42 patients with hypertension. The authors 
concluded in a protective effect of ACE inhibitors and ARBs on the severity of the disease. A study by Feng (Am J Respir 
Crit Care Med 2020, see below), which included 476 patients, found a significant difference in ACE inhibitors/ARBs 
usage among patients with different disease severity. Compared with severe and critical groups, there were more 
patients taking ACE inhibitor/ARB in the moderate disease group. This observation may seem to confirm the data by 
Meng. However only few patients in this study used ACE inhibitor/ARB treatment (33/476), suggesting that more data 
are still required to draw firm conclusions on this topic.  
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Chronic kidney disease 
Another meta-analysis by Henry (Int Urol Nephrol 2020, see below) included four studies, corresponding to 1389 
COVID-19 patients, among which 273 (19.7%) were classified as having severe disease. No study individually found 
chronic kidney disease as significant clinical predictor of severe COVID-19. However, when data of individual studies 
were pooled, a significant association of chronic kidney disease with severe COVID-19 was observed, with no relevant 
heterogeneity [OR 3.03 (95% CI 1.09–8.47), I2 = 0.0%, Cochran’s Q, p = 0.84]. 
Cancer  
Liang (Lancet Oncol 2020, see below) described a retrospective analysis of cancer patients among 1590 COVID-19 
cases. Eighteen (1%; 95% CI 0·61–1·65) of 1590 COVID-19 cases had a history of cancer, which seems to be higher than 
the incidence of cancer in the overall Chinese population (285·83 [0·29%] per 100 000 people, according to 2015 cancer 
epidemiology statistics). Lung cancer was the most frequent type (5/18 patients).  
Similarly, Sidaway (Nature Rev Clin Oncol 2020, see below) provided a short overview of the evidence available to 
document the link between cancer and COVID-19. While data remained limited, patients with cancer seem to be both 
more likely to be diagnosed with COVID-19 and have more severe symptoms. 
From the analysis of a small cohort of 28 cancer patients, Zhang (Ann Oncol 2020, see below) reported a case-fatality 
rate of COVID-19 reaching 28.6%. 
Liang (Lancet Oncol 2020, see below) reported that patients with cancer have a higher risk of severe events (a 
composite endpoint defined as the percentage of patients being admitted to the intensive care unit requiring invasive 
ventilation, or death) compared with patients without cancer (seven [39%] of 18 patients vs 124 [8%] of 1572 patients; 
Fisher's exact p=0·0003).  
Other sources of risk 
Following a cross-sectional study conducted in 3947 participants in Vietnam, Nguyen (J Clin Med 2020, see below) 
reported that people with COVID-19 had a higher depression likelihood (OR, 2.88; p < 0.001) and lower Health Related 
Quality of Life-score (B, -7.92; p < 0.001). 
Wise (BMJ 2020, see below) reported a large UK study on ethnic background and risk of dying from COVID-19. Contrary 
to speculation, the higher risk of death in Asian and black ethnic backgrounds was only partly explained by comorbidity, 
deprivation, or other risk factors. The study found that black people had more than double the risk of dying from 
COVID-19 compared with those with ethnicity recorded as white (age-sex adjusted hazard ratio 2.17, 95% CI 1.84-
2.57). After adjusting for deprivation and clinical risk factors the hazard ratio was still 1.71 (95% CI 1.44-2.02). For Asian 
people the age-sex adjusted hazard ratio was 1.95 (95% CI 1.73-2.18) which was reduced to 1.62 after full adjustment 
for other risk factors (95% CI 1.43-1.82). 
Dyer (BMJ 2020, see below) discussed the excess COVID-19 deaths among African-Americans, an observation related 
at least in part to a higher burden of underlying medical conditions such as diabetes, hypertension, obesity, and asthma 
among African-Americans. The author noted that the true scale of the disparity is unknown because few states and 
counties include racial data in their reporting. Another factor likely to be at play is the fact that many black people in 
the US work in essential jobs or in jobs that require in-person human interaction or cannot be done from home. Many 
also live in southern states, where Republican governors delayed lockdowns or played down the threat from the virus. 
Khalatbari-Soltani (J Epidemiol Community Health. 2020, see below) observed that from 29 studies that reported the 
characteristics of patients with COVID-19 and their potential risk factors, only one study reported the occupational 
position of patients with mild or severe disease. This brief overview highlighted that important socioeconomic 
characteristics are being overlooked when data are collected. A systematic recording of socioeconomic characteristics 
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of patients with COVID-19 would be beneficial to identify most vulnerable groups, to identify how socioeconomic 
position relates to COVID-19 and to develop equitable public health prevention measures, guidelines and interventions. 
Zhao (manuscript on medRxiv: https://www.medrxiv.org/content/10.1101/2020.03.11.20031096v2) compared the 
ABO blood group distribution in 2,173 patients with COVID-19 confirmed by SARS-CoV-2 test from three hospitals in  
China with that in normal people from the corresponding regions. The results showed that blood group A was 
associated with a higher risk for acquiring COVID-19 compared with non-A blood groups (OR 1.12, 95% CI 1.02-1.43), 
whereas blood group O was associated with a lower risk for the infection compared with non-O blood groups (OR 0.67, 
95% CI 0.60-0.75). This early study should encourage further investigation of the relationship between the ABO blood 
group and COVID-19 susceptibility. Interestingly, as noted by Dai (Eur J Prev Cardiol 2020, see below), the A allele of 
the ABO blood group has been associated with an increased risk of developing cardiovascular diseases. 
Clinical prediction models 
Clinical prediction models combine patient characteristics, biomarkers and other predictors to estimate individual risks 
related to COVID-19. As the vast majority of countries have limited testing and ICU capacity, case identification and 
prognosis tools could play a crucial role in containment and mitigation strategies, as well as efficient triage. Various 
international studies have already described attempts at generating clinical prediction models for COVID-19. As listed 
in the living reviewing by Wynants (BMJ 2020, see below), 7 models are proposed for identifying people at risk in the 
general population; 33 diagnostic models for detecting COVID-19, 75 diagnostic models based on medical imaging 
(including deep learning on CT or Rx), 10 to diagnose disease severity), and 107 prognostic models for prediction 
mortality risk, intensive care unit admission, ventilation, intubation, or length of hospital stay. The most frequently 
reported predictors of diagnosis and prognosis of covid-19 are vital signs (incl. body temp, respiratory rate, oxygen 
saturation), age, comorbidities, and image (CT, Rx) features, in addition to flu-like symptoms for diagnosis and sex, C-
reactive protein, and lymphocyte counts for prognosis. Reported index estimates (which provide an estimate of the 
ability of the model to discriminate) ranged from 0.71 to 0.99 in prediction models for the general population, from 
0.65 to 0.99 in diagnostic models, from 0.80 to 0.99 for diagnostic severity models, for 0.70 to >0.99 for imaging models, 
and from 0.54 to 0.99 in prognostic models. All studies were rated at high or unclear risk of bias, mostly because of 
mainly because of model overfitting, inappropriate model evaluation (e.g. calibration ignored), and use of 
inappropriate data sources. Therefore, their performance estimates are probably optimistic and not representative 
for the target population. Reporting quality varied substantially between studies. Similarly, Hooli (Clin Inf Dis 2020, see 
below) questioned the reproducibility of four COVID-19 case prediction models presented in another study. 
Distribution 
Case count dashboards  
A disease situation dashboard is available on the WHO website, which presents the number of confirmed cases globally, 
per region and per country over time (https://covid19.who.int/). A snapshot of the number of cases reported (total 
and weekly) per region as of October 20 2020 12:00 CET is provided in Figure 16. 
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Figure 16 Snapshot of the WHO COVID-19 dashboard as of October 20 2020 12:00 CET (confirmed disease cases reported weekly and total 
per region) 
 
The Johns Hopkins University developed its own dashboard to visualize and track the reported cases of COVID-19 on 
a daily timescale (Dong Lancet Infect Dis 2020, see below). The dataset can be found at 
https://coronavirus.jhu.edu/map.html. It is collected from various sources, including WHO, U.S. CDC, ECDC China CDC 
(CCDC), NHC and DXY. DXY is a Chinese website that aggregates NHC and local CCDC situation reports in near real-time, 
and has provided more current regional case estimates than the national level reporting organizations at the beginning 
of the epidemic.  
HealthMap has made an interactive map for SARS-CoV-2 available at https://www.healthmap.org/covid-19/. It offers 
near-real-time geolocated updates from various sources to better understand the progression of the pandemic.  
Another interesting resource is the worldwide timeline of cases provided by Worldometers 
(https://www.worldometers.info/coronavirus/worldwide-graphs/). This website provides an animated presentation 
of the evolution of the total number of cases per country from January 14 2020 (cases timeline). A snapshot of the 
world map as of October 20 2020 is provided by Figure 17. 
Figure 17 Snapshot of the worldometers world map as of October 20 2020 
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Data quality issues 
Koh (Ann Acad Med Singapore 2020, see below) highlighted the multiple issues affecting the accuracy of COVID-19 
case counts. A serious issue highlighted by Lau (J Microbiol Immunol Infect 2020, see below) relates to inconsistencies 
in reporting COVID-19 cases. The authors presented preliminary data indicating that countries with lower Health 
Access Quality-index may either underreport COVID-19 cases or are unable to adequately detect them. Another 
problem relates to variability in the case definitions used for reporting (see Case definition above). A change in the 
case definition in China in February, for instance, led to a spike in the reported figures 
(https://www.sciencemediacentre.org/expert-reaction-to-the-latest-change-in-case-definitions-in-china-for-covid-
19/).  
Interestingly, Boëlle (EuroSurv 2020, see below) indicated that several French regions where COVID-19 has been 
reported showed a renewed increase in ILI cases in the general practice-based Sentinelles network. The number of 
excess cases by region from 24 February to 8 March 2020 was computed and a correlation found with the number of 
reported COVID-19 cases, which suggested larger circulation of SARS-CoV-2 in the French population than apparent 
from confirmed cases. 
Of note, WHO issued guidance to member states on the implementation of global surveillance of COVID-19 (lasted 
version dated August 7 2020, see https://www.who.int/publications/i/item/who-2019-nCoV-surveillanceguidance-
2020.7). The objectives of this global surveillance are to monitor trends of the disease where human to human and/or 
zoonotic transmission occurs; rapidly detect new cases in countries where the virus is not circulating; provide 
epidemiological information to conduct risk assessment at the national, regional and global level; and provide 
epidemiological information to guide response measures. 
Desjardins (Appl Geogr 2020, see below) utilized a prospective space-time scan statistic to detect emerging clusters of 
COVID-19 in the United States at the county level. This prospective approach can be useful for state and local health 
departments to monitor the outbreaks in a timely fashion. The system adds updated COVID-19 counts and reruns the 
statistic to identify new emerging clusters; while also tracking the previously detected clusters to determine if they 
are growing or shrinking in magnitude. Doing so can help determine if current mitigation and isolation techniques are 
effective at curbing the spread of COVID-19. 
Seroepidemiology 
For later phases of pandemic control, when the key questions involve when, where, and how to lift confinement 
measures and relax social distancing constraints, serological testing to measure antibody responses to the virus 
becomes paramount to refine understanding of transmission intensity and population susceptibility (Bryant Sci Imm 
2020, see below). At the population level, representative cross-sectional serosurveys can provide aggregate 
“snapshots” of infection history and immunity of a population. Clapham (Em Inf Dis 2020, see below) presented the 
various seroepidemiologic study designs that may help determine SARS-COV-2 transmission and immunity. 
Up to now, despite the progression of the epidemic, published data point to a very limited level of immunity in the 
populations tested. In Geneva, Switzerland, for example, a study by Stringhini (Lancet 2020, see below) enrolled 2766 
participants from 1339 households between April 6 and May 9, 2020. In the first week, a seroprevalence of 4·8% (95% 
CI 2·4-8·0, n=341) was found. The estimate increased to 8·5% (5·9-11·4, n=469) in the second week, to 10·9% (7·9-14·4, 
n=577) in the third week, 6·6% (4·3-9·4, n=604) in the fourth week, and 10·8% (8·2-13·9, n=775) in the fifth week. 
Individuals aged 5-9 years (relative risk [RR] 0·32 [95% CI 0·11-0·63]) and those older than 65 years (RR 0·50 [0·28-
0·78]) had a significantly lower risk of being seropositive than those aged 20-49 years. 
In Spain, in a population sampled from April 27 to May 11 2020, Pollan found a seroprevalence of 5·0% (95% CI 4·7–
5·4) by the point-of-care test and 4·6% (4·3–5·0) by immunoassay, with a specificity–sensitivity range of 3·7% (3·3–4·0; 
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both tests positive) to 6·2% (5·8–6·6; either test positive), with no differences by sex (Lancet 2020, see below). Lower 
seroprevalence was observed in children younger than 10 years (<3.1% by the point-of-care test). There was 
substantial geographical variability, with higher prevalence around Madrid (>10%) and lower in coastal areas (<3%). 
Seroprevalence among 195 participants with positive PCR more than 14 days before the study visit ranged from 87·6% 
(81·1–92·1; both tests positive) to 91·8% (86·3–95·3; either test positive). In 7273 individuals with anosmia or at least 
three symptoms, seroprevalence ranged from 15·3% (13·8–16·8) to 19·3% (17·7–21·0). Around a third of seropositive 
participants were asymptomatic, ranging from 21·9% (19·1–24·9) to 35·8% (33·1–38·5). 
Havers (JAMA Int Med 2020, see below) reported the outcome of a study that analysed serum samples from 16 025 
persons in the U.S. (55.2% of whom were women; 7.5% were 18 years or younger and 36.2% were 65 years or older). 
Most specimens from each site had no evidence of antibodies to SARS-CoV-2. Adjusted estimates of the proportion of 
persons seroreactive to the SARS-CoV-2 S protein ranged from 1.0% in the San Francisco Bay area (collected April 23-
27) to 6.9% of persons in New York City (collected March 23-April 1). The estimated number of infections ranged from 
6 to 24 times the number of reported cases; for 7 sites (Connecticut, Florida, Louisiana, Missouri, New York City metro 
area, Utah, and western Washington State), an estimated greater than 10 times more SARS-CoV-2 infections occurred 
than the number of reported cases. 
Similar low seroprevalence data were reported by other studies conducted in the U.S. In a random sample of Indiana 
residents aged ≥12 years, the estimated prevalence of current or previous SARS-CoV-2 infection in late April 2020 
reached 2.79% (Menachemi MMWR 2020, see below). And in two counties in metropolitan Atlanta during April 28–
May 3, a community seroprevalence survey,  using a two-stage cluster sampling design and serologic testing, estimated 
that 2.5% of the population had antibodies to SARS-CoV-2 (Biggs MMWR 2020, see below). 
Some studies also specifically focused on health care personnel. For instance, in the U.S., Stubblefield (Clin Inf Dis 2020, 
see below) found that among 249 healthcare personnel who worked in hospital units with COVID-19 patients for one 
month, 19 (7.6%) tested positive for SARS-CoV-2 antibodies. In China, Chen reported 17.14% (18/105) of health care 
workers being seropositive (J Inf 2020, see below). 
Virus migration pathways 
Using phylodynamic analyses, Yang (Em Micr Inf Dis 2020, see below) identified four genetic clusters, found to be 
responsible for the major outbreaks that subsequently occurred in various countries. Data showed that derivative 
strains of the original virus have been transmitted worldwide and contributed to the early outbreak of COVID-19. As 
illustrated in Figure 18, SS1 strains were transmitted mainly in Asia and the US but were less prevalent in other parts 
of the world. SS2 and SS3 strains were transmitted mainly in Asian countries other than China, as well as Europe from 
mid-January to mid-February 2020. SS4 strains were transmitted mainly in Europe at the beginning of the pandemic 
and were then transmitted to all over the world. The data are consistent with those obtained earlier by Forster (PNAS 
2020, see below), who analysed 160 complete genomes of SARS-CoV-2 and identified three central variants, namely 
Type A, B and C. Type A was the ancestral virus. Type B strains carried the C8782T and T28144G mutations, which was 
equivalent to SS1. Type C, which carried the G26144T change, was equivalent to SS2. Forster found that Type A and C 
were mainly transmitted in Europe and America, whereas Type B was the most common type in East Asia. 
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Figure 18. Transmission of SARS-CoV-2 in different parts of the world (from Yang Em Micr Inf Dis 2020) 
 
Factors impacting the distribution of the epidemic 
In different countries, the COVID-19 epidemic takes variable shapes and forms in how it affects communities. Until 
now, the insights gained on COVID-19 have been largely dominated by the COVID-19 epidemics and the lockdowns in 
China, Europe and the USA. However, as noted in July 2020 by Van Damme (BMJ Glob Health 2020, see below), the 
variety of global trajectories is little described, analysed or understood. 
A study by Yao (Eur Resp J 2020, see below), for instance, aimed to determine the association of meteorological factors 
with transmission of COVID-19. Associations of meteorological factors (including temperature, relative humidity and 
UV radiation) with the spread ability of COVID-19 in various Chinese cities (from early Jan to early March) were 
analysed. The study did not support the hypothesis that high temperature and UV radiation can reduce the 
transmission of COVID-19.  However, a study by Liu (Sci Total Environ 2020, see below) concluded that meteorological 
factors play an independent role in the COVID-19 transmission after controlling population migration. Local weather 
condition with low temperature, mild diurnal temperature range and low humidity likely favour the transmission. 
Martelletti (SN Compr Clin Med 2020, see below) showed how the Italian Northern Regions, which have been the most 
affected by COVID-19, are also those with a high amount of atmospheric particulate matter (PM10 and PM2.5) going 
above the standard limit of 50 μg/m3 per day in the month of February 2020. This relationship was also illustrated by 
comparing the nitrogen dioxide emissions and the COVID-19 case fatality in Northern Italy in January 2020. However, 
epidemiological studies in multiple geographic regions affected by the Covid-19 pandemic remain to be conducted to 
confirm the association with air pollution. 
Arias-Reyes (Respir Physiol Neurobiol. 2020, see below) suggested a lower incidence of COVID-19 in people living at 
high altitude (above 3000m from sea level).  
Across the continents and specifically in Africa, all index cases were travel related and multiple introductions events 
recorded. In order to disentangle populational mediated intrinsic factors potentially limiting COVID-19 spread locally, 
it is also crucial to identify if there are distinguishing mutations in the SARS-CoV-2 genomes. Phylogenetic analysis and 
amino acid sequence alignments of the S and replicase (NSP12) proteins showed a similarity between the African SARS-
CoV-2 genomes and genomes in countries including China, Brazil, France, the United Kingdom, Italy, France and the 
Delivered by Ingenta
IP: 157.193.240.2 On: Fri, 04 Jun 2021 12:29:12
Copyright Leuven University Press
 
Authors: Martine Denis, Valerie Vandeweerd, Rein Verbeke, Anne Laudisoit, Tristan Reid, Emma Hobbs, Laure Wynants, Diane 
Van der Vliet  
COVIPENDIUM version: 20 OCT 2020  Transdisciplinary Insights - Living Paper | 130 
USA. A majority of African S proteins have a D614G substitution as shown in the alignment of the amino acid which 
was also identified to be predominant in Asian and European SARS-CoV-2 sequences (Longjohn, manuscript on bioRxiv : 
https://doi.org/10.1101/2020.09.08.287201). However, in silico studies using structural bioinformatics to assess the 
effect of D614G mutation on SARS-CoV-2 virulence and epidemiology suggest that this mutation may be neutral to 
protein function (Isabel, Sci Rep 2020, see below). A pan-African study (52 countries) attempted to estimate the impact 
and possible trajectory of COVID-19 under different intervention scenarios (Frost, manuscript on medRxiv : 
https://doi.org/10.1101/2020.09.04.20188102). While their model provided estimates suggesting that the burden of 
severe disease caused by SARS-CoV-2 is likely to be high for the African continent, especially in populations with high 
prevalence of TB, HIV, and malnutrition, these projections did not take into account the populational socio-
demographical characteristics which may limit natural spread. For example a regional study used a simple 
deterministic SIR model to understand the spread and percolation of SARS-CoV-in 16 West African countries (Honfo, 
manuscript on medRxiv : https://doi.org/10.1101/2020.09.04.20188532). The study revealed an overall relatively low 
proportion of susceptible individuals (1.2% across West Africa) but also highlighted local discrepancies (e.g. Guinea-
Bissau and Cape Verde) that cannot be explained by interventions (lockdown) and other non-therapeutic measures 
alone. Mbow (Science 2020, see below) discussed the possible factors that may contribute to lower prevalence and 
mortality rates caused by COVID-19 in Africa. Differences between Africa and the most affected countries in reliable 
reporting and death registration, lockdown stringency, demography (age-pyramid), sociocultural aspects, 
environmental exposures (hygiene hypothesis, microbiota), genetics, and the immune system (trained immunity and 
virtual memory T cells) could help to explain the continent experience of COVID-19. As such, Africa should be part of 
the roadmap for COVID-19 research. Although there are no available data on the immune responses in African COVID-
19 patients, studies show clear differences in the activation, proinflammatory, and memory profiles of the immune 
cells not only in Africans versus Europeans but also among Africans with high and low exposure to microorganisms 
and parasites (Mbow Immunology 2014, see below). 
A MMWR report identified geographic differences in numbers of COVID-19 cases and deaths, cumulative incidence, 
and changes in incidence across U.S. jurisdictions (CDC COVID-19 Response Team MMWR Morb Mortal Wkly Rep 2020 
April, see below). These were interpreted as likely reflecting a combination of jurisdiction-specific epidemiologic and 
population-level factors, including 1) the timing of COVID-19 introductions; 2) population density; 3) age distribution 
and prevalence of underlying medical conditions among COVID-19 patients; 4) the timing and extent of community 
mitigation measures; 5) diagnostic testing capacity; and 6) public health reporting practices. The authors concluded 
that monitoring jurisdiction-level numbers of COVID-19 cases, deaths, and changes in incidence is critical for 
understanding community risk and making decisions about community mitigation, including social distancing, and 
strategic health care resource allocation. 
In terms of research activities, various modelling studies analyse available information and make attempts at 
forecasting future spread of the disease (see Modelling key characteristics of the epidemic below).  
Virus in the environment 
Kampf (J Hosp Infect 2020, see below) reviewed the literature on the persistence of human and veterinary 
coronaviruses on inanimate surfaces as well as inactivation strategies with biocidal agents used for chemical 
disinfection, e.g. in healthcare facilities. This analysis revealed that human coronaviruses such as SARS and MERS CoVs 
or endemic human CoVs can persist on inanimate surfaces like metal, glass or plastic for up to 9 days, but can be 
efficiently inactivated by surface disinfection procedures with 62-71% ethanol, 0.5% hydrogen peroxide or 0.1% 
sodium hypochlorite within 1 minute. Other biocidal agents such as 0.05-0.2% benzalkonium chloride or 0.02% 
chlorhexidine digluconate were found less effective. 
Similarly, Yeo (Lancet Gastroenterol Hepatol 2020, see below) indicated that observations made with SARS and MERS 
CoVs support a relatively good viability of these viruses on surfaces depending on temperature and humidity. SARS-
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CoV RNA was found in the sewage water of two hospitals in Beijing treating patients with SARS. When SARS-CoV was 
seeded into sewage water obtained from the hospitals in a separate experiment, the virus was found to remain 
infectious for 14 days at 4°C, but for only 2 days at 20°C.  
Environmental sampling  
A report by Ong (JAMA 2020, see below) described the detection of virus RNA in the environment of 3 COVID-19 cases 
in isolation in Singapore. Samples from the environment of one of the patients yielded positive results by RT-PCR, with 
13 (87%) of 15 room sites (including air outlet fans) and 3 (60%) of 5 toilet sites (toilet bowl, sink, and door handle) 
positive. The patient had upper respiratory tract involvement with no pneumonia and had 2 positive stool samples for 
SARS-CoV-2 on RT-PCR. Of note, only one personal protective equipment (PPE) swab, from the surface of a shoe front, 
was positive. All other PPE swabs were negative. All air samples were negative. In a subsequent study, the same 
authors (Ong Infect Control Hosp Epidemiol 2020, see below) conducted a one-day PPE sampling study on 30 HCWs 
(doctors, nurses, and cleaners) caring for 15 confirmed SARS-CoV-2 infected patients with varying characteristics (i.e. 
day of illness, presence/absence of symptoms, RT-PCR Ct value). None was requiring ventilatory support and no 
aerosol generating procedures were carried out prior to or during sampling. Median time spent in the patient’s room 
was 6 minutes for activities ranging from casual contact (e.g. administering medications, cleaning) to closer contact 
(e.g. physical examination, collection of respiratory samples). All samples (swabs from the entire front of goggles, front 
surface of N95 respirator, and front surface of shoes) were negative. 
Environmental surveillance was also performed by Cheng (Inf Contr Hosp Epidem 2020, see below) in a patient with 
viral load of 3.3x106 copies/ml (pooled nasopharyngeal/ throat swab) and 5.9x106 copies/ml (saliva) respectively. 
SARS-CoV-2 was revealed in 1 (7.7%) of 13 environmental samples, but not in 8 air samples collected at a distance of 
10 cm from patient’s chin with or without wearing a surgical mask. 
Another important study was conducted by Guo in a hospital in Wuhan (Em Inf Dis 2020, see below) and showed that 
SARS-CoV-2 was widely distributed in the air and on object surfaces, implying a potentially high infection risk for 
medical staff and other close contacts. The environmental contamination was greater in the ICU than in the general 
COVID-19 ward. Moreover, SARS-CoV-2 aerosol distribution characteristics indicated that the transmission distance of 
SARS-CoV-2 might be 4 m. As of March 30, no staff members at this hospital had been infected with SARS-CoV-2, 
indicating that appropriate precautions could effectively prevent infection. In addition, these findings suggested that 
home isolation of persons with suspected COVID-19 might not be a good control strategy.  
Liu (Nature 2020, see below) measured viral RNA in aerosols in different areas of two Wuhan hospitals during the 
COVID-19 outbreak in February and March 2020. The concentration of SARS-CoV-2 RNA in aerosols detected in 
isolation wards and ventilated patient rooms was very low, but it was elevated in the patients' toilet areas. Airborne 
SARS-CoV-2 RNA in the majority of public areas was undetectable except in two areas prone to crowding. The authors 
suggested that SARS-CoV-2 may have the potential to be transmitted via aerosols. 
During the initial isolation of 13 individuals with COVID-19 at the University of Nebraska Medical Center in the U.S.A., 
Santarpia (Sci Rep 2020, see below) collected air and surface samples to examine viral shedding from isolated 
individuals. The authors detected viral contamination among all samples. 
Failure to isolate viable (infectious) virus in aerosols has been commonly reported, and there has been controversy in 
the first months of the epidemic whether SARS-CoV-2 can be transmitted through aerosols. According to Lednicky (Int 
J Infect Dis 2020, see below), this conundrum occurs because common air samplers can inactivate virions through their 
harsh collection processes. The authors then sought to resolve the question whether viable SARS-CoV-2 can occur in 
aerosols using VIVAS air samplers that operate on a gentle water-vapor condensation principle. Air samples were 
collected in the hospital room of two COVID-19 patients, one ready for discharge, the other newly admitted. Viable 
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SARS-CoV-2 was isolated from air samples collected 2 to 4.8 m away from the patients. The genome sequence of the 
SARS-CoV-2 strain isolated from the material collected by the air samplers was identical to that isolated from the newly 
admitted patient. Estimates of viable viral concentrations ranged from 6 to 74 TCID50 units/L of air. The data therefore 
indicated that patients with respiratory manifestations of COVID-19 produce aerosols in the absence of aerosol-
generating procedures that contain viable SARS-CoV-2, and that these aerosols may serve as a source of transmission 
of the virus. 
In a study by Wang (Int J Inf Dis 2020, see below), sewage samples were positive from inlets of the sewage disinfection 
pool, but negative from the outlet of the last sewage disinfection pool. Moreover, no viable virus was detected by 
culture. The monitoring data in this study suggested that strict disinfection and hand hygiene measures could decrease 
the hospital-associated COVID-19 infection risk of the staffs in isolation wards. 
La Rosa (Water Res 2020, see below) reviewed available information on other coronaviruses in water environments. 
12 publications were included. The data suggested that: i) CoV seems to have a low stability in the environment and 
is very sensitive to oxidants, like chlorine; ii) CoV appears to be inactivated significantly faster in water than non-
enveloped human enteric viruses with known waterborne transmission; iii) temperature is an important factor 
influencing viral survival (the titer of infectious virus declines more rapidly at 23°C-25 °C than at 4 °C); iv) there is no 
current evidence that human coronaviruses are present in surface or ground waters or are transmitted through 
contaminated drinking-water. Ahmed (Sci Total Envir 2020, see below) reported the first confirmed detection of SARS-
CoV-2 in untreated wastewater in Australia. SARS-CoV-2 RNA was concentrated from wastewater in a catchment in 
Australia and viral RNA copies were enumerated using RT-qPCR, resulting in two positive detections within a six-day 
period from the same wastewater treatment plant. 
Experimental conditions  
van Doremalen (NEJM 2020, see below) found that SARS-CoV-2 remained viable in aerosols (generated with the use 
of a three-jet Collison nebulizer and fed into a Goldberg drum to create an aerosolized environment) for at least 180 
minutes, with a reduction in infectious titer 3 hours post-aerosolization from 103.5 to 102.7 CID50/L (mean across three 
replicates). This reduction in viable virus titer was relatively similar to the reduction observed in aerosols containing 
SARS-CoV-1. A subsequent report by Fear (Em Inf Dis 2020, see below) agreed with these conclusions.  In this study, 
the authors analysed the virus dynamic aerosol efficiency using 3 different nebulizers to generate viral aerosols. The 
aerosol size distributions produced by the generators used, in mass median aerodynamic diameter, were 1–3 μm and 
had a geometric heterodispersity of ≈1.2–1.4. The data suggested retained infectivity and virion integrity for up to 16 
hours. Of note, a fraction of naturally generated aerosols falls within the size distribution used in the experimental 
studies (<5 μm), which leads us to conclude that SARS-CoV-2-infected persons may produce viral bioaerosols that 
remain infectious for long periods after production through human shedding and airborne transport. 
The virus was found most stable on plastic and stainless steel (van Doremalen NEJM 2020, see below). Viable virus 
could be detected up to 72 hours post application, though by then the virus titer was greatly reduced (polypropylene 
from 103.7 to 100.6 TCID50/mL after 72 hours, stainless steel from 103.7 to 100.6 TCID50/mL after 48 hours). 
Since the beginning of the pandemics, few authors have attempted to test a wider array of environmental and 
climatological conditions (temperature, humidity, surface texture) conducive to SARS-CoV-2 survival. This was even 
more required as summer-winter transition and colder temperatures coincided with school and factories re-opening 
and an easing of restrictive isolation measures in the Northern hemisphere. Kwon (manuscript on bioRxiv : 
https://doi.org/10.1101/2020.08.30.274241) tested SARS-CoV-2 stability on 12 material surfaces including nitrile 
glove, Tyvek, N95 mask, cloth, Styrofoam, cardboard, concrete, rubber, glass, polypropylene, stainless steel and 
galvanized steel under 3 conditions based on Midwestern U.S. weather. SARS-CoV-2 remained viable and infectious 
on surfaces for 1 to 4 days at indoor conditions (21°C/60% relative humidity, RH), 1 to 3 days during summer conditions 
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(25°C/70% RH) and over 7 days during spring/fall conditions (13°C/66% RH). They provide experimental evidence that 
the virus is significantly more stable on all surfaces under the outdoor spring/fall condition and suggests that virus 
stability on surfaces is highly dependent on temperature and RH. They conclude that prolonged virus survival on 
surfaces in spring/fall and winter might support SARS-CoV-2 transmission through contaminated fomites and 
potentially contribute to new outbreaks and/or seasonal occurrence in the post-pandemic era, a scenario described 
for influenza virus and other human coronaviruses (Kissler Science 2020, see below). 
Patient management  
In China, a rapid advice guideline suitable for the first frontline doctors and nurses, managers of hospitals and 
healthcare sections, as well as community residents or public health persons has been provided by Jin in February 
2020 (Mil Med Res 2020, see below). This guideline covered disease screening and population prevention, diagnosis, 
treatment and control (including traditional Chinese Medicine), nosocomial infection prevention and control, and 
disease nursing of the 2019-nCoV.  
WHO issued a document intended for clinicians taking care of patients with COVID-19, including those with mild, 
moderate, severe, and critical disease (interim guidance last updated on May 27, see 
https://www.who.int/publications/i/item/clinical-management-of-covid-19).  Developed by a multidisciplinary panel 
of health care providers with experience in the clinical management of patients with COVID-19 and other viral 
infections, including SARS and MERS, as well as sepsis and acute respiratory distress syndrome (ARDS), this guidance 
should serve as a foundation for optimized clinical care to ensure the best possible chance for survival. The guidance 
stresses the importance of using investigational therapeutic interventions as part of randomized controlled trials. 
In addition to this document, a huge number of publications describe both the disease course and clinical management 
of patients in China as well as in other countries. A few examples are provided in the following sections for illustrative 
purposes. 
Triage and patient flow 
A publication by Zhang (Lancet Resp Med 2020, see below) indicates that one effective strategy for disease control in 
Wuhan was the establishment of fever clinics for triaging patients. The clinical strategies that were used in these adult 
fever clinics for COVID-19 management is illustrated by the flowchart presented in Figure 19. 
Many aspects of this algorithm would not be feasible in developing countries setting, as chest CT, differential blood 
counts, and CRP testing are not available. Ayebare (Lancet Resp Med 2020, see below) proposed a modified COVID-
19 screening algorithm for use in resource-limited settings that do not have established local transmission.  
Hu (Acad Emerg Med 2020, see below) provided a first exploration on 2 rapid scoring systems for critical ill patients 
with COVID-19, the Modified Early Warning Score (MEWS) and Rapid Emergency Medicine Score (REMS). The authors 
concluded that the REMS could provide emergency clinicians with an effective adjunct risk stratification tool for critical 
ill patients with COVID-19, especially for the patients aged<65 years. The effectiveness of REMS for screening these 
patients is attributed to its high negative predictive value. 
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Figure 19 Flow chart for treatment of COVID-19 in fever clinics in Wuhan China (CRP=C-reactive protein. CAP=Community-acquired 
pneumonia. SARS-CoV-2=severe acute respiratory syndrome corona virus 2) 
 
Treatment practices 
Numerous reports provided by various authors at the start of the epidemic in China described patient management 
for severe cases of COVID-19. 
For instance, Wang, Chen et al. (Biosci Tr 2020, see below) reported on the diagnosis and treatment of four patients 
with mild or severe COVID-19 pneumonia. All patients received antiviral treatment, including lopinavir/ritonavir 
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(Kaletra®, lopinavir 400 mg/ritonavir 100 mg, q12h, po), arbidol (0.2 g, tid, po), and Shufeng Jiedu Capsule (2.08 g, tid, 
po). The duration of antiviral treatment was 6-15 days. In addition, all patients were all given antibiotic treatment and 
started on supplemental oxygen, delivered by nasal cannula after admission to hospital. 
Liu (Crit Care 2020, see below) reported that patient management in Shenzhen was largely supportive, including 
intubation, early prone positioning, neuromuscular blockade, and extracorporeal membrane oxygenation (ECMO) 
according to the recommendations updated by China’s National Health Committee. Low-dose systematic 
corticosteroids, lopinavir/ritonavir, and atomization inhalation of interferon were encouraged. 
Murthy (JAMA 2020, see below) noted that evidence-based treatment guidelines for ARDS should be followed, 
including conservative fluid strategies for patients without shock following initial resuscitation, empirical early 
antibiotics for suspected bacterial co-infection until a specific diagnosis is made, lung-protective ventilation, prone 
positioning, and consideration of extracorporeal membrane oxygenation for refractory hypoxemia. 
Wang (Lancet 2020, see below) reported on the classification of COVID-19 patients in 3 types for effective triage in a 
hospital in Wuhan. Patients with pneumonia were classified as type A. Basic treatments were provided, such as 
antivirals, antibiotics, oxygen therapy, and glucocorticoids. Type B patients had disease accompanied by serious 
comorbidities. Their pneumonia was managed and specific treatment plans were developed, including 
antihypertensives, hypoglycaemic therapy, and continuous renal replacement therapy. Critically ill patients were 
classified as type C. Attention was paid to organ function in these patients and necessary protective measures, 
including mechanical ventilation, glucocorticoids, antivirals, symptomatic treatments, and anti-shock therapy. 
Based on the experience with 631 confirmed cases of COVID-19 (with a portion of critically ill patients whose ages 
ranged from 9 months to 96 years old), Sun (Ann Intensive Care 2020, see below) reported a cure rate of confirmed 
cases of 96.67%in Jiangsu Province, far exceeding that of national Chinese data. The authors noted that essential 
strategies to improve outcomes consist of early detection of high-risk and critically ill patients. In Jiangsu Province, 
critical care was shifted forward. All COVID-19 patients were screened twice every day and respiratory rate (RR), heart 
rate (HR), SpO2 (room air) were monitored regularly. Once SpO2 < 93%, RR > 30/min, HR > 120/min or any signs of 
organ failure were observed, patients would be transferred to ICU. Intervention to prevent the progression of disease 
were then three-fold: (1) For patients with ARDS or pulmonary extensive effusion in CT scan, high-flow nasal cannula 
oxygen therapy or non-invasive mechanical ventilation was used to maintain positive end expiratory pressure to 
prevent alveolar collapse even if some of these patients did not have refractory hypoxemia. (2) Restrictive fluid 
resuscitation under the premise of adequate tissue perfusion was performed to relieve pulmonary oedema. (3) Awake 
prone position was attempted in patients which showed significant effects in improving oxygenation and pulmonary 
heterogeneity. 
Duca (Emerg Med Pract. 2020, see below) presented the Brescia-COVID Respiratory Severity Scale (BCRSS)/Algorithm, 
a step-wise approach to managing patients with confirmed/presumed COVID-19 pneumonia. The tool was described 
as in use in Italy for assessment, trending, and treatment recommendations. 
A review paper by Nicola (Int J Surg 2020, see below) also provided an interesting update on COVID-19 patient 
management. In addition, more than twenty nursing experts in China developed a consensus on holistic nursing care 
of patients with severe COVID-19, which included nursing assessment, nursing priorities, nursing goals, and 13 key 
points of nursing such as nursing of oxygen therapy and respiratory nursing (Int J Nurs Sci 2020, see below). 
Respiratory support 
To reduce respiratory symptoms and improve prognosis, respiratory support is the most important means of life 
support, and non-invasive respiratory support systems, including various conventional oxygen therapies, non-invasive 
positive pressure ventilation (NPPV), and high-flow nasal cannula (HFNC), are most commonly used (Xia Chin Med J 
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2020, see below). However, their efficacy and safety remain unclear, and whether they increase the risk of aerosol 
dispersion and disease transmission is particularly controversial (see Safety of procedures below, and Ñamendys-Silva 
Lancet Respir Med 2020, see below).  The retrospective epidemiological study of 99 COVID-19 pneumonia patients in 
China revealed that NPPV is the most commonly used mechanical ventilation method for acute respiratory failure, 
with reported rates of using non-invasive and invasive mechanical ventilation of 13% and 4%, respectively. For strictly 
selected early-stage patients with mild-to-moderate (partial pressure of arterial oxygen [PaO2]/fraction of inspired 
oxygen [FiO2] > 200 mmHg) hypoxic respiratory failure and especially for units with limited numbers of invasive 
ventilators, it has been recommended that NPPV be attempted for short periods of time (1-2 hours) and to intubate 
immediately if no improvement is observed. 
Of note, MacLaren (JAMA 2020, see below) commented on the WHO interim guidelines making general 
recommendations for treatment of ARDS in the context of the COVID-19 epidemic, including that consideration be 
given to referring patients with refractory hypoxemia to expert centres capable of providing ECMO. ECMO being a 
resource-intensive, highly specialized, and expensive form of life support with the potential for significant 
complications, he recommended limiting support with ECMO to the most critically ill patients in regions with the 
extensive resources required to provide this therapy. In less well-resourced countries, his hypothesis is that many 
more lives will be saved by ensuring oxygen and pulse oximetry are widely available. Li (Chin Med J 2020, see below) 
reported experience compared with that in patients receiving only conventional respiratory care, the fatality of those 
who had received ECMO was significantly lower (100% vs. 65%). However, a review by Henry (J Crit Care 2020, see 
below) raised questions about real utility of ECMO in COVID-19 patients and concluded that further research is 
urgently needed. A more recent systematic review by Haiduc (J Card Surg 2020, see below) also concluded that the 
recuperative effects of ECMO remain inconclusive. 
Treatment of coagulopathy 
The use of heparin in COVID-19 has been recommended by some expert consensus due to the risk of disseminated 
intravascular coagulation and venous thromboembolism. However, the efficacy of such treatment remains to be 
validated. A study in 449 patients with severe COVID-19, 99 of them receiving heparin  for  7  days  or  longer suggested 
that anticoagulant therapy mainly with low-molecular weight heparin appears to be associated with better prognosis 
in severe COVID-19 patients meeting sepsis-induced coagulopathy criteria or with markedly elevated D-dimer (Tang J 
Thromb Haemost 2020, see below). The 28-day mortality of heparin users was lower than that in non-users when 
considering patients with sepsis-induced coagulopathy score ≥4 (40.0% vs 64.2%, P=0.029), or D-dimer > 6-fold the 
upper limit of normal range (32.8% vs 52.4%, P=0.017). 
Treatment options in pregnancy 
Recent studies have identified remdesivir and chloroquine as candidate drugs for the treatment of COVID-19 (see 
Antiviral drugs below). Remdesivir appears to be safe in human pregnancies (Mulangu NEJM 2019, see below) 
Although chloroquine and its metabolites cross the placenta, it may be safely used in all trimesters of pregnancy with 
no increased risk of adverse perinatal outcomes. Of note, chloroquine is a drug with a large volume of distribution and 
pharmacokinetic studies have shown significantly lower plasma drug concentrations in pregnancy (Karunajeewa 
Antimicr Ag Chemother 2010, see below). Nevertheless, hydroxychloroquine has been reported as a common 
treatment options used in pregnant women (Diriba Eur J Med Res 2020, see below). Lopinavir-ritonavir has also been 
evaluated in management of COVID-19. It was not studied in context of pregnancy complicated with respiratory 
infection, however in HIV-positive pregnancies, no increased risk of foetal anomalies, preterm birth or low birth weight 
infants was observed (Tookey BMC Infect Dis 2016, see below). Conversely, ribavirin and baricitinib are teratogenic 
(Winthrop Nat Rev Rheumatol 2017, see below; Kochhar Toxicol Appl Pharmacol 1980, see below). Use of ribavirin 
has led to miscarriages, craniofacial and limb defects in animal studies and should be avoided, especially in early 
pregnancy. 
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In general, use of corticosteroids is not recommended as it may delay the virus clearance from the body. A common 
practice in obstetrics is to give corticosteroids for foetal lung maturity to those at risk of delivering prematurely. 
Travers (BMJ 2017, see below) demonstrated that the lowest gestations receive the largest benefit from 
corticosteroids. Indeed, the number of mothers needed to treat with corticosteroids to prevent one neonatal death is 
six at 23 to 24 weeks but can increase to 798 women at 34 weeks. During this pandemic, balancing out the possible 
risks and benefits of corticosteroid use appeared important.  McIntosh (Am J Perinatal 2020, see below) examined the 
maternal risks and foetal benefits and recommended that no women COVID-19 positive or person under investigation 
(PUI) receive corticosteroids beyond 32 weeks. Use of drugs in pregnant women needs to be on the basis of solid 
evidence. Clinical trials are needed to prove the effectiveness of drugs and the effects on the foetus. WHO advised 
caution and careful risk-benefit analysis before using investigational therapeutic agents in pregnant women outside 
clinical trials and WHO did not recommend the use of corticosteroids for COVID-19. 
Ethical issues 
An ethically sound framework has been outlined in the Hastings Center’s 3-tiered approach to a pandemic; namely, 
the duty to plan, the duty to safeguard, and the duty to guide. Furthermore, in the U.S.A. the landmarks proposed by 
the American College of Surgeons of transparency, advocacy, and commitment to support all those affected directly 
or indirectly clarify a way forward. Multiple ethical challenges have been raised by the COVID-19 pandemic. A few 
reports have made proposals to address them. For instance, Kramer (J Am Coll Surg 2020, see below) provided a few 
recommendations based on the concepts highlighted above to questions such as “Do providers have the right to refuse 
to treat a COVID-19 positive patient, or do they have a professional duty to treat the patient, no matter how high the 
personal risk?” . The question of  “ How do we allocate scarce resources such as ICU beds, ventilators, and certain 
medications?” has also been addressed by Manelli (J Med Ethics 2020, see below), who insisted on the relevance of a 
medical ethics perspective that does not place the burden of care and choice solely on physicians. 
Diagnostics  
Interim guidance to laboratories and stakeholders involved in laboratory testing of patients who meet the definition 
of suspected case of pneumonia associated with SARS-CoV-2 has been provided by WHO on March 19 2020 
(https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-
20200117). Until validated diagnostic tests become available, the goals of diagnostic testing was to detect 
conventional causes of pneumonia early, to support disease control activities, and to work with reference laboratories 
that can perform pan-coronavirus detection and directed sequencing. 
WHO took a three-pronged approach to enhance diagnostic capacity for COVID-19: 
 Forming a network of specialized referral laboratories with demonstrated expertise in the molecular 
detection of coronaviruses. These international labs could support national labs to confirm COVID-19 cases 
and troubleshoot their molecular assays; 
 Strengthening national capacity for detection of COVID-19 so that diagnostic testing can be performed 
rapidly without the need for overseas shipping. One way this has been achieved was through working with 
existing global networks for detection of respiratory pathogens such as, notably, the National Influenza 
Centers that support the Global Influenza Surveillance and Response System; 
 Ensuring test availability. This has involved a) screening of SARS-CoV-2 PCR protocols from academic 
laboratories for validation data (e.g. limits of detection, specificity), b) looking for sequence alignment of 
established commercial coronavirus assays (e.g. SARS) to see if any were likely to be able to detect 2019- 
nCoV with high sensitivity, and c) working with commercial and non-commercial agencies with capacity to 
manufacture and distribute newly-developed SARS-CoV-2 PCR assays. 
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Specimen type 
Lower respiratory specimens were soon considered likely to have a higher diagnostic value than upper respiratory 
tract specimens for detecting SARS-CoV-2 infection. However, Yang (on medRxiv: 
https://www.medrxiv.org/content/10.1101/2020.02.11.20021493v1) noted that no data on the difference of viral 
shedding between the upper and lower respiratory tract specimens was available. He reported that while viral RNAs 
could be detected in all the lower respiratory tract of severe cases, the situation was different for mild cases. Sputum 
specimen were recommended as most accurate for laboratory diagnosis of COVID-19, followed by nasal swabs.  
A study by Zou (NEJM 2020, see below) analysed the viral load in nasal and throat swabs obtained from 17 
symptomatic patients in relation to day of onset of any symptoms. Higher viral loads were detected soon after 
symptom onset, with higher viral loads detected in the nose than in the throat. This analysis suggests that the viral 
nucleic acid shedding pattern of patients infected with SARS-CoV-2 resembles that of patients with influenza and 
appears different from that seen in patients infected with SARS-CoV. While describing 2 cases, Han (Lancet Inf Dis 
2020, see below) suggested that sputum induction might be more helpful than throat swabs for the detection of SARS-
CoV-2 RNA in convalescent patients. Recently, Mohammadi (EBioMed 2020, see below) performed a systematic 
review and meta-analysis of studies comparing respiratory sampling strategies for the detection of SARS-CoV-2 RNA. 
The inclusion criteria were studies that assessed at least two respiratory sampling sites (oropharyngeal swab, 
nasopharyngeal swab, and sputum) in participants with COVID-19. The authors identified 11 studies that met the 
inclusion criteria, with SARS-CoV-2 testing results from a total of 3442 respiratory tract specimens. Compared to 
nasopharyngeal swab sampling, sputum testing resulted in significantly higher rates of SARS-CoV-2 RNA detection 
while oropharyngeal swab testing had lower rates of viral RNA detection. Earlier sampling after symptom onset was 
associated with improved detection rates, but the differences in SARS-CoV-2 RNA detection by sampling method was 
consistent regardless of the duration of symptoms. 
Zhang (J Med Virol 2020, see below) presented PCR testing results on stool and oropharyngeal swabs specimens from 
14 patients. 
A larger study analysed a total of 1070 specimens of different types that were collected from 205 patients with COVID-
19 (Wang JAMA 2020, see below). Bronchoalveolar lavage fluid specimens showed the highest positive rates (14 of 15; 
93%), followed by sputum (72 of 104; 72%), nasal swabs (5 of 8; 63%), fibrobronchoscope brush biopsy (6 of 13; 46%), 
pharyngeal swabs (126 of 398; 32%), faeces (44 of 153; 29%), and blood (3 of 307; 1%). None of the 72 urine specimens 
tested positive. 
Alternative samples 
A manuscript by Srivatsan (on bioRxiv: https://www.biorxiv.org/content/10.1101/2020.04.22.056283v1) suggested 
the possibility to use a dry swab without transport medium for RT-PCR testing. 
Khoubnasabjafari (Bioanalysis 2020, see below) suggested exhaled breath condensate (EBC) as a sample for RT-PCR. 
EBC is a condensed form of small droplets of lung lining fluid which is normally exhaled and contains a variety of 
components from small ions to proteins and organelles, even viruses, fungi and bacteria. Technical tips for improving 
the quality and quantity of extracting nucleic acid from EBC samples have been reported. The same procedure with 
some modifications could be used to detect the genome of SARS-CoV-2 by RT-PCR. EBC samples could be easily 
collected using a simple cold trap, commercially available EBC sampling device (such as EcoScreen® or RTube®) or even 
using a tube passing water-ice mixture. The mechanism of sample collection by these devices is cooling down the 
temperature of the collection chamber from 0 to -25°C. Collection of EBC is simple, well tolerated by sample donors 
and no adverse effects have been reported so far, therefore it could be employed for sampling on a large scale to 
screen COVID-19 suspected patients.  
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The potential breath-borne volatile organic compound (VOC) biomarkers for COVID-19 are other potential candidates 
to develop rapid diagnostic test. In particular, the monitoring of ethyl butanoate, butyraldehyde and isopropanol could 
lend considerable support in rapidly screening COVID-19; and alerting the presence of COVID-19 patient in particular 
environments (Chen,  manuscript on medRxiv : https://doi.org/10.1101/2020.06.21.20136523). Breath test are 
currently being developed by US-based Canary Health Technologies and clinical trials under discussion in the UK, the 
USA and South Africa (Promed Archive Number: 20200621.7492311 : https://promedmail.org/promed-
post/?id=7492311). The exhaled breath is sampled directly utilizing Airostotle’s breath sensor system and a response 
is given in under 5 minutes.  Airostotle has an array of differentially selective sensors that show interactions with VOCs 
in the exhaled breath of users.  This sensor data creates a breath signature, a digital pattern of sensor response changes 
for the individual sensors that reflects the unique profile of the breath VOC mixture, that can be furthered classified 
using Artificial Intelligence.  These breath patterns can be stored in an online database (a “breath-cloud”) and coupled 
to clinical data.  Comparison of the digitized breath patterns of a suspected subject to the breath-cloud allows for a 
rapid decision on the presence or absence of a pathogen (https://www.canaryhealthtech.com/news/preparing-for-
pandemics-using-canary-health-technologies-cloud-based-rapid-breath-analysis-platform). 
Self-collection 
Molecular testing (PCR) using specimens collected from nasopharyngeal and/or oropharyngeal swabs is the standard 
screening approach for COVID-19. The method requires costly laboratory equipment and healthcare professionals that 
limit its use for large-scale screening of mild or asymptomatic patients. Self-collection kits for use in the home could 
remedy this and have consequently received great attention. In April, 2020, a self-collection kit from LapCorp was the 
first such kit to be approved by the FDA (Liao Adv Biosyst 2020, see below). In the following month, May 2020, another 
kit developed by Everlywell received FDA approval, and more kits are evidently on their way to the market. Various 
authors reported data supporting the feasibility of this approach. Wehrhahn (J Clin Virol 2020, see below), for instance, 
successfully evaluated the self-collection of nasal and throat swabs in a cohort of 236 patients.  
Testing methods 
Udugama (ASC nano 2020, see below) presented an overview on the techniques used at the start of the epidemic, as 
well as on emerging diagnostic methods in March 2020. More recently, a review by Ravi (Biosens Bioelectron 2020, 
see below) focused on molecular and serological assays with FDA Emergency Use Authorization. A list of assays 
commercially available for diagnosis of COVID-19 is updated by FIND (https://www.finddx.org/covid-19/pipeline/). 
Assays that are still in development stage are also presented. As indicated by Premraj (Diagnostics Basel 2020, see 
below), there are now serious debates globally and regionally on the sensitivity and specificity of these tests and about 
the overall accuracy and reliability of the tests for decision making on COVID-19 control strategies. 
Molecular methods  
In April 2020, a review by Shen (J Pharm Anal 2020, see below) summarized available detection methods for SARS-
CoV-2 nucleic acid. The paper is short, but provides very clear explanations about the different methods that have 
been developed. A list of currently available molecular assays can be found at FIND (https://www.finddx.org/covid-
19/pipeline/?section=molecular-assays#diag_tab). 
RT-PCR 
Initially developed RT-PCR assays 
In acute respiratory infection, RT-PCR is routinely used to detect causative viruses from respiratory secretions. Early 
reports presented various assays for COVID-19 diagnosis. A real-time reverse-transcription PCR (rtRT-PCR) was used 
to identify SARS-CoV-2 through preliminary and validation detection of its E gene, RNA-dependent RNA polymerase 
(RdRp) gene, and N gene (Yu Micr Inf 2020, see below). Chu (Clin Chem 2020, see below) reported the development 
of two 1-step quantitative rtRT-PCR assays detecting the ORF1b and N regions of the viral genome. The primer and 
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probe sets were designed to react with SARS-CoV-2 and its closely related viruses, such as SARS coronavirus. These 
assays were evaluated using a panel of positive and negative controls and shown to have a dynamic range of at least 
seven orders of magnitude (2x10−4-2000 TCID50/reaction).  
Fluorescence-based quantitative PCR kit were rapidly distributed by the Chinese CDC for laboratory confirmation of 
disease in China. And a whole array of commercial tests became available. Wang  (on medRxiv: 
https://www.medrxiv.org/content/10.1101/2020.02.12.20022327v2) reported for instance the use of a detection kit 
(Bioperfectus, Taizhou, China) to detect the ORF1ab gene and the N gene using real-time RT-PCR. Positive results on 
both the ORF1ab gene and the N gene are required for laboratory confirmation of the disease. 
In Europe, the envelope (E)-gene screening test as published by Corman (Euro Surv 2020, see below) has been widely 
implemented. 
Sharfstein (JAMA 2020, see below) and Babiker (Am J Clin Pathol 2020, see below)  provided a detailed explanation of 
the issues faced in the USA at the beginning of the epidemic, which delayed COVID-19 PCR testing in the country. Lu 
(Em Inf Dis 2020, see below) described the design and validation of the US CDC rRT-PCR panel and presented 
comprehensive data on its performance with multiple specimen types and clinical specimens. The panel consisted of 
3 RT-PCR assays targeting the N gene. The US FDA issued an Emergency Use Authorization on Feb 4 2020 to enable 
emergency use of this panel. 
Improving PCR assays 
Chan (J Clin Microb 2020, see below) developed a novel real-time RT-PCR assay targeting the RNA-dependent RNA 
polymerase (RdRp)/helicase (Hel) (COVID-19-RdRp/Hel assay). The assay has a low limit of detection (1.8 TCID50/ml 
with genomic RNA and 11.2 RNA copies/reaction with in vitro RNA transcripts). It was compared to the RdRp-P2 assay 
currently used in European laboratories. Among 273 specimens from 15 patients with laboratory-confirmed COVID-
19 in Hong Kong, 77 (28.2%) were positive by both the COVID-19-RdRp/Hel and RdRp-P2 assays. The COVID-19-
RdRp/Hel assay was positive for an additional 42 RdRd-P2-negative specimens [119/273 (43.6%) vs 77/273 (28.2%), 
P<0.001], including 29/120 (24.2%) respiratory tract specimens and 13/153 (8.5%) non-respiratory tract specimens. 
The mean viral load of these specimens was 3.21×104 RNA copies/ml (range, 2.21×102 to 4.71×105 RNA copies/ml). 
The COVID-19-RdRp/Hel assay did not cross-react with other human-pathogenic coronaviruses and respiratory 
pathogens in cell culture and clinical specimens, whereas the RdRp-P2 assay cross-reacted with SARS-CoV in cell 
culture. 
Won (ExpNeurobiol 2020, see below) presented a low cost, rapid alternative RT PCR protocol for COVID-19 diagnosis, 
composed of specimen self-collection by the patient via pharyngeal swab, Trizol-based RNA purification, and SYBR 
Green-based RT PCR. 
Automated platforms 
Pfefferle (Euro Surveill 2020, see below) evaluated the performance of a molecular assay for detection of SARS-CoV-2 
on a high-throughput platform, the cobas 6800, using the 'open channel' for integration of a laboratory-developed 
assay. The authors observed good analytical performance in clinical specimens. The fully automated workflow enabled 
high-throughput testing with minimal hands-on time, while offering fast and reliable results. 
Cepheid announced that it has received Emergency Use Authorization (EUA) from the U.S. FDA for Xpert® Xpress SARS-
CoV-2, a rapid molecular diagnostic test for qualitative detection of SARS-CoV-2 
(http://cepheid.mediaroom.com/2020-03-21-Cepheid-Receives-Emergency-Use-Authorization-from-FDA-for-Rapid-
SARS-CoV-2-Test). The test has been designed to operate on any of Cepheid's automated GeneXpert® Systems, with a 
detection time of approximately 45 minutes.  
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Validation data & assay limitations 
Xie (Int J Inf Dis 2020, see below) compared nucleic acid amplification testing performed with 3 different fluorescent 
RT-PCR kits on different samples, including oropharyngeal swab, blood, urine and stool. Nine out of the 19 patients 
tested were found positive for SARS-CoV-2 using oropharyngeal swab samples, and the virus nucleic acid was also 
detected in eight of these nine patients using stool samples. None of positive results was identified in the blood and 
urine samples. Similar data were obtained with the 3 kits. 
Of note, a lack of assay sensitivity was reported by Xie (Radiol 2020, see below), who described five patients with 
SARS-CoV-2 infection who had initial negative RT-PCR results in mouth swabs but typical imaging findings, including 
ground-glass opacity (5 patients) and/or mixed ground-glass opacity and mixed consolidation (2 patients). All patients 
were eventually confirmed with SARS-CoV-2 infection by repeated swab tests. Similar cases were reported by various 
authors: 
 Huang (Radiol 2020, see below).  
 Winichakoon (J Clin Microb 2020, see below) reported a case of COVID-19 pneumonia diagnosed from 
bronchoalveolar lavage fluid in Thailand, who initially had negative tests from nasopharyngeal/oropharyngeal 
swabs.  
 A publication by Wang, Kang et al. (J Med Vir 2020, see below) further illustrates the sensitivity limitation of 
current RT-PCR based diagnosis, previously reported by others. Although the paper does not provide details, 
the authors described a COVID-19 case not confirmed by SARS-CoV-2 RT-qPCR testing at the first three 
evaluations within three weeks, before bronchoalveolar lavage fluid was acquired and results from both RT-
qPCR and next-generation sequencing (NGS) testing became positive for SARS-CoV-2. 
 Ruan (Chin Med J 2020, see below) presented a case with negative RT PCR result until day 11 of disease onset. 
Interestingly, a study by Li, Yao et al. (J Med Vir 2020, see below) evaluated the sensitivity of RT-PCR testing on 
sequential samples. The study illustrated well on one hand the importance of retest for improving detection of positive 
cases, and on the other hand the instability of results over time in a same patient. 
Wang (Clin Chem 2020, see below) showed that the limit of detection (LOD) of the six commercial kits approved in 
China differ substantially, with the poorest LODs likely leading to false-negative results when RT–PCR is used to detect 
SARS-CoV-2 infection. 
Rhoads (J Clin Microbiol 2020, see below) compared the Abbott ID Now, Diasorin Simplexa, and CDC FDA EUA methods 
for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs. The 95% CIs for the positive percent agreement 
was overlapping for the ID Now and Simplexa assays when using the modified CDC method as the reference standard. 
The sample size of this study was not large enough to conclude one of these assays had clearly superior or inferior 
performance for the detection of SARS-CoV-2 from upper respiratory specimens in liquid transport media. 
Another report by Moran (J Clin Microbiol 2020, see below) compared results from specimens tested with Cepheid 
Xpert Xpress SARS-CoV-2 and Roche cobas SARS-CoV-2 assays. Of these 103 specimens, 42 tested positive and 60 
tested negative with both systems for agreement of 99%. 
A possible technical limitation of current RT-PCR was raised by Fan, Zhang et al. (Chin Med J 2020, see below). The 
authors evaluated the potential impact of SARS-CoV-2 genome evolution on RT-PCR performance by analysing 
published primer sets and their match with 77 publicly available whole genome sequences. They found five RT-qPCR 
primer sets (targeting Orf1ab or N) that may potentially cause false negative results.  Targeting the more conserved 
nsp12 (RdRp) gene was thus recommended. 
Tahamtan (Expert Rev Mol Diagn. 2020, see below) provided an overview of the performance issues with RT-PCR. 
Conclusions were that in case of negative RT-PCR result with clinical features suspicion for COVID-19, especially when 
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only upper respiratory tract samples were tested, multiple sample types in different time points, including from the 
lower respiratory tract if possible, should be tested. Combination of real time RT-PCR and clinical features especially 
CT image could facilitate disease management. Proper sampling procedures, good laboratory practice standard, and 
using high quality extraction and real-time RT-PCR kit could improve the approach and reduce inaccurate results. 
RT-LAMP 
Other molecular-based detection techniques include reverse transcription loop-mediated isothermal amplification 
(RT-LAMP), which feasibility for detection of SARS-CoV-2 has been established by various groups. Isothermal 
amplification, unlike PCR, enables amplification at a constant temperature using two or three sets of primers and a 
polymerase with high strand displacement activity, avoiding the need for thermal cycling (Ravi Biosens Bioelectron 
2020, see below). To achieve comparable specificity, four different primers are used to amplify six distinct regions on 
the target gene. As a result, isothermal amplification can achieve higher amounts of nucleic acid copies in a shorter 
amount of time compared to standard PCR. 
Lamb (manuscript on medRxiv: https://www.medrxiv.org/content/10.1101/2020.02.19.20025155v1) demonstrated 
the feasibility of rapid screening diagnosis completed in under 30 minutes, using Reverse Transcription Loop-Mediated 
Isothermal Amplification (RT-LAMP) . No validation data have been presented yet. Only simulated patient samples 
were used, which were created by spiking serum, urine, saliva, oropharyngeal swabs, and nasopharyngeal swabs with 
a portion of the COVID-19 nucleic sequence. 
Yu (Clin Chem 2020, see below) developed an isothermal LAMP based method for COVID-19, amplifying a fragment of 
the ORF1ab gene. The assay detected synthesized RNA equivalent to 10 copies of virus. Reaction time varied from 15-
40 minutes, depending on the loading of virus in the collected samples. 42/43 patient samples initially diagnosed with 
RTqPCR showed consistent signal after 40 min incubation with the new assay (97.6% sensitivity). 
Another LAMP method was described by Baek (Em Micr Inf 2020, see below). 
Among the commercially available assays, the ID NOW COVID-19 Test relies on isothermal nucleic acid amplification, 
targeting a unique region of the RNA-dependent RNA polymerase (RdRP) gene of SARS-CoV-2 (Ravi Biosens Bioelectron 
2020, see below). ID NOW COVID-19 Test provides results in 13 minutes or less from throat, nasal or nasopharyngeal 
swab samples, with reported analytical sensitivity of 125 copies/mL. The ID NOW COVID-19 Test is performed on the 
ID NOW Instrument, which gives a simple method for mixing sample with test reagents and transferring to the test 
base through a cartridge. 
Another test is Cue Health's Cue COVID-19 Test, a rapid, portable assay that delivers results to a mobile phone in less 
than 25 minutes. Similar to ID NOW, Cue's test also uses isothermal amplification on nasal swabs, but it detects the 
SARS-CoV-2 N gene. Additionally, Cue's disposable POC test cartridge forms a connected diagnostic platform with a 
mobile phone that enables a patient to have convenient access to their health information. 
CRISPR-based methods  
Several CRISPR-based diagnostic methods have also been described: 
 Hou (manuscript on medRxiv: https://www.medrxiv.org/content/10.1101/2020.02.22.20025460v1) reported 
the development of an isothermal, CRISPR-based diagnostic. The assay demonstrated a near single-copy 
sensitivity. It was evaluated on 61 specimens with suspected infection (52 positives) and showed great clinical 
sensitivity with a shorter turn-around time (40 min) than RT-PCR.  
 Proof-of-principle of another CRISPR-based detection method was also described by Curti (manuscript on 
bioRxiv: https://www.biorxiv.org/content/10.1101/2020.02.29.971127v1).  
 Broughton (Nat Biotech 2020, see below) reported development of a rapid (<40 min), easy-to-implement and 
accurate CRISPR-Cas12-based lateral flow assay for detection of SARS-CoV-2 from respiratory swab RNA 
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extracts. The method was validated using clinical samples from patients in the United States, including 36 
patients with COVID-19 infection and 42 patients with other viral respiratory infections. The CRISPR-based 
DETECTR assay provided a 95% positive predictive agreement and 100% negative predictive agreement 
compared to the US CDC SARS-CoV-2 real-time RT-PCR assay. 
 Javalkote (Methods 2020, see below) presented a compilation of state-of-the-art detection techniques for 
COVID-19 using CRISPR technology, stating that this approach has tremendous potential to transform 
diagnostics and epidemiology. 
Other molecular methods 
Guan (Chin Med J 2020, see below) reported a case with inconsistent fluorescence quantitative-PCR results, for which 
high-throughput sequencing was used to make a further diagnosis of SARS-CoV-2 infection. Although high-throughput 
sequencing appears too costly and labour-intensive for routine diagnosis, the authors believe that it can be used for 
further diagnosis of COVID-19 patients with unclear PCR results under the condition of strict operation and quality 
control. 
Serological methods  
A review paper by Infantino (Isr Med Assoc J 2020, see below) provided an overview on serological diagnostic assays. 
Bryant (Sci Imm 2020, see below) provided important considerations with regards to use cases of serological assays 
and implications in terms of assay validation. The review by Pecora (Clin Lab Med 2020, see below) is the most recent 





Various ELISA protocols for detection of antibodies to SARS-CoV-2 emerged rapidly, in the first few weeks of the 
epidemic. For instance, a SARS-CoV-2 IgM and IgG ELISA has been reported by Zhang (Em Micr Inf 2020, see below). 
The assay is based on recombinant N. A preliminary evaluation was conducted in 16 patients (incl. 3 patients with 
severe disease). As shown by Figure 20, an increase of specific antibodies was seen in part of the patients as early as 
by day 5.  
Figure 20 Serological detection of SARS-CoV-2. Dashed line indicates cut-off, which was determined based on data from healthy controls 
(from Zhang Em Micr Inf 2020). 
 
Xiang (manuscript on medRxiv https://www.medrxiv.org/content/10.1101/2020.02.27.20028787v1) reported the 
evaluation of 2 serological assays: an IgG and IgM ELISA and a colloidal gold-immunochromatographic assay kit for 
detection of COVID-19. Using 63 samples for the ELISA and 91 plasma samples for the colloidal gold-
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immunochromatographic assay, they found a sensitivity of the combined ELISA IgM and ELISA IgG of 55/63 (87.3%), 
and that of the colloidal gold-immunochromatographic IgM and IgG assay of 75/91 (82.4%). Both methods displayed 
a specificity of 100%. 
Liu (J Clin Micr 2020, see below) reported the evaluation of N and S protein-based IgM and IgG ELISAs in 214 confirmed 
COVID-19 patients (Table 11).  
Table 11 IgM and IgG detection in the 214 serum samples from patients with COVID-19 (from Liu J Clin Micr 2020) 
 
The sensitivity of the S-based ELISA for IgM detection was found significantly higher than that of the N-based ELISA. 
An increase in the sensitivity of IgM and IgG detection was observed with an increasing number of days post-disease 
onset. The positive rate of N-based and S-based IgM and IgG ELISAs was less than 60% during the early stage of the 
illness (day 0-10), and increased after 10 days. 
A study by Zhao (Clin Inf Dis 2020, see below) investigated the dynamics of total Ab, IgM and IgG antibody against 
SARS-CoV-2 in serial blood samples collected from 173 confirmed COVID-19 patients. Testing was performed ELISA 
kits supplied by Beijing Wantai Biological Pharmacy Enterprise. Antibodies were found in <40% of patients within 1-
week since onset, and rapidly increased to 100.0% (Ab), 94.3% (IgM) and 79.8% (IgG) by day-15 after onset. In contrast, 
RNA detectability decreased from 66.7% (58/87) in samples collected before day-7 to 45.5% (25/55) between day 15 
and 39. Combining RNA and antibody detections significantly improved the sensitivity of pathogenic diagnosis for 
COVID-19. 
Okba (Em Inf Dis 2020, see below) presented validation data for in house S and N based ELISAs as well as for a β version 
of the Euroimmun commercial S1 IgG or IgA ELISAs. In the 3 in-house ELISAs tested, the RBD and N protein ELISAs were 
more sensitive than S1 ELISA in detecting antibodies in mildly infected patients and showed stronger correlations with 
PRNT50 titers. Therefore, the authors indicated that detecting antibodies against 2 different antigens might be needed 
to avoid false-negative results in surveillance studies. 
Wang (J Clin Microb 2020, see below) reported that middle-high level of rheumatoid factor-IgM in sera could lead to 
false-positive reactivity in SARS-CoV-2 IgM GICA (colloidal gold immunochromatography assay) and ELISA assays. The 
authors suggested that urea dissociation tests would be helpful in reducing such false-positive SARS-CoV-2 IgM results. 
Hicks (manuscript on medRxiv : https://doi.org/10.1101/2020.06.22.20137695) evaluated the serologic reactivity of 
pre-pandemic archival blood serum samples (pre2019) and samples collected in April 2020 in the US (New York and 
New Jersey) from a community highly affected by SARS-CoV-2. Utilizing twelve previously reported ELISAs, the authors 
tested IgG, IgM and IgA reactivity against S proteins from SARS-CoV-2, MERS-CoV, SARS-CoV, HCoV-OC43, and HCoV-
HKU1. They detected the potential cross-reactivity of antibodies against SARS-CoV-2 towards the four other 
coronaviruses, with the strongest cross-recognition between SARS-CoV-2 and SARS /MERS-CoV antibodies. They 
advised that the interpretation of current serological results should take into account archival patient sera (pre2019), 
including sera from known SARS-CoV and MERS convalescent patients, to properly analyse the resulting data and 
adjust any estimates of seropositivity as needed. 
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Of note, Stadlbauer (Curr Protoc Microbiol 2020, see below) described a detailed protocol for expression of antigens 
derived from the S protein of SARS-CoV-2 that can serve as a substrate for immunological assays, as well as the protocol 
of a two-stage ELISA. 
Chemiluminescence (CLIA) 
Jin (Int J Infect Dis 2020, see below) investigated the diagnostic value of serological test and evolution of test results 
over time in 43 COVID-19 patients. SARS-CoV-2 IgM and IgG chemiluminescence immunoassay (CLIA) kits from 
Shenzhen YHLO Biotech Co., Ltd (China) were used, with two antigens of SARS-CoV-2 coated on the magnetic beads 
of these CLIA assays (N and S proteins). Compared to molecular test, the sensitivity of serum IgM and IgG antibodies 
to diagnose COVID-19 was 48.1% and 88.9%, and the specificity was 100% and 90.9%. However, IgG positive rate 
increased till 100% over time. 
Padoan (Clin Chem Lab Med 2020, see below) and Lippi (Clin Chem Lab Med 2020, see below) reported on the 
validation of MAGLUMI 2000 Plus CLIA assay for the measurement of specific IgM and IgG in sera. Results of MAGLUMI 
IgM and IgG were well aligned with those of Euroimmun Anti-SARS-CoV-2 IgA and IgG, especially concerning the IgG 
and the cumulative immunoglobulin profile. 
Pseudotype neutralization assay 
Nie (Emerg Microbes Infect 2020, see below) reported on a pseudovirus neutralization assay for SARS-CoV-2 and its 
validation. The assay is based on a VSV pseudovirus system. The key parameters for this assay were optimized, 
including cell types, cell numbers, virus inoculum. With this test, SARS-CoV-2 convalescent patient sera showed high 
neutralizing potency. The assay showed relatively low coefficient of variations with 15.9% and 16.2% for the intra- and 
inter-assay analyses respectively. 
Rapid test for antibody detection  
Li, Yi et al. (J Med Vir 2020, see below) reported the development of a rapid and simple point-of-care lateral flow SARS-
CoV-2 immunoassay which can detect IgM and IgG antibodies simultaneously in human blood within 15 minutes. The 
clinical detection sensitivity and specificity of this test were measured using blood samples collected from 397 PCR-
confirmed COVID-19 patients and 128 negative patients at 8 different clinical sites. The overall testing sensitivity 
reached 88.66% and specificity 90.63%. The assay was evaluated on fingerstick blood samples, as well as serum and 
plasma from venous blood. 
In March 2020, Cassaniti (J Med Vir 2020, see below) reported a study aimed at validating the VivaDiagTM COVID-19 
IgM/IgG Rapid Test lateral flow immunoassay (LFIA) for the rapid diagnosis of COVID-19, in real-life conditions. The 
performance of VivaDiagTM COVID-19 test was assessed in 50 patients at their first access at emergency room 
department with fever and respiratory syndrome in comparison with results of nasal swab molecular screening. 
Sensitivity of the VivaDiagTM COVID-19 IgM/IgG Rapid Test was only 18.4%, specificity was 91.7%, while NPV was 26.2% 
and PPV was 87.5% in patients enrolled from emergency room department. The assay could thus not be recommended 
for triage of suspect patients. 
Pan (J Inf 2020, see below) compared an immunochromatographic strip assay targeting viral IgM or IgG antibody 
(Zhuhai Livzon Diagnositic Inc.) to RT-PCR. The sensitivity of ICG assay with IgM and IgG combinatorial detection in 
nucleic acid confirmed cases were 11.1%, 92.9% and 96.8% at the early (1-7 days after onset), intermediate (8-14 days 
after onset), and late stage (more than 15 days), respectively. The ICG detection capacity in nucleic acid-negative 
suspected cases was 43.6%. 
Performance of serological testing 
Early in the pandemic, lack of regulatory restrictions on serologic testing led to a wave of more than 40 antibody tests 
to detect immunoglobulin (Ig) G and/or IgM binding to SARS-CoV-2 S and N. Many of these tests were poorly 
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characterized, which caused concern about the quality of serologic data (Pecora Clin Lab Med 2020, see below). The 
US FDA then moved to tighten regulation of new commercial serologic tests; more than 30 were subsequently 
withdrawn from distribution. These events highlighted the importance of rigorous testing evaluation and scope of use. 
A Cochrane review assessed the performance of serological assays (Deeks Cochrane Database Syst Rev 2020, see 
below). The authors concluded that the sensitivity of antibody tests is too low in the first week since symptom onset 
to have a primary role for the diagnosis of COVID-19, but that these assays may still have a role complementing other 
testing in individuals presenting later, when RT-PCR tests are negative, or are not done. Antibody tests are likely to 
have a useful role for detecting previous SARS-CoV-2 infection if used 15 or more days after the onset of symptoms. 
However, the duration of antibody rises is currently unknown, and very little data was found beyond 35 days post-
symptom onset, leading to uncertainty about the utility of these tests for seroprevalence surveys. Concerns about high 
risk of bias and applicability made it likely that the accuracy of tests when used in clinical care will be lower than 
reported in published studies. Sensitivity has mainly been evaluated in hospitalised patients, so it is unclear whether 
the tests are able to detect lower antibody levels likely seen with milder and asymptomatic COVID-19. The design, 
execution and reporting of studies of the accuracy of COVID-19 tests was found to require considerable improvement.  
Rapid test for antigen detection 
Numerous commercial assays are now available for SARS-CoV-2 antigen detection (https://www.finddx.org/covid-
19/pipeline/?avance=Commercialized&type=all&test_target=Antigen&status=all&section=show-all&action=default). 
The performance of rapid tests for antigen detection was analysed by Dinnes (Cochrane Database Syst Rev 2020, see 
below). This review identified early-stage evaluations of point-of-care tests for detecting SARS-CoV-2 infection, largely 
based on remnant laboratory samples. The findings currently have limited applicability, as it is uncertain whether tests 
will perform in the same way in clinical practice, and according to symptoms of COVID-19, duration of symptoms, or 
in asymptomatic people. The sensitivity of rapid antigen tests varied considerably across studies (from 0% to 94%): 
the average sensitivity was 56.2% (95% CI 29.5 to 79.8%) and average specificity was 99.5% (95% CI 98.1% to 99.9%; 
based on 8 evaluations in 5 studies on 943 samples). Data for individual antigen tests were limited with no more than 
two studies for any test. The authors concluded that rapid tests have the potential to be used to inform triage of RT-
PCR use, allowing earlier detection of those testing positive, but the evidence currently is not strong enough to 
determine how useful they are in clinical practice. Prospective and comparative evaluations of rapid tests for COVID-
19 infection in clinically relevant settings are urgently needed. 
Chest CT for COVID-19 detection 
Chest CT soon emerged as an alternative approach to COVID-19 diagnosis. Fang (Radiol 2020, see below) reported, for 
instance, that in a series of 81 patients, the sensitivity of chest CT was found greater than that of RT-PCR (98% vs 71%, 
respectively, p<.001). In that early study, subjects with initial negative RT-PCR became positive upon retest 1 to 7 days 
later. These results provided first evidence of a possible role for chest CT for screening patients with clinical and 
epidemiologic features compatible with COVID-19 particularly when RT-PCR testing is negative. 
Ai (Radiol 2020, see below) reported a large study further supporting the diagnostic value of chest CT. Of 1014 patients 
included in the study, 59% had positive RT-PCR results, and 88% had positive chest CT scans. The sensitivity of chest 
CT in suggesting COVID-19 was 97% based on positive RT-PCR results. In patients with negative RT-PCR results, 75% 
(308/413) had positive chest CT findings; among them, 48% were considered as highly likely cases, 33% as probable 
cases. The mean interval time between the initial negative to positive RT-PCR results was 5.1 ± 1.5 days. Moreover, 
60% to 93% of cases had initial positive CT consistent with COVID-19 prior (or parallel) to the initial positive RT-PCR 
results. Interestingly, 42% (24/57) cases showed improvement in follow-up chest CT scans before the RT-PCR results 
turning negative.  
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A meta-analysis by Kim (Radiology 2020, see below), based on 68 publications, assessed the diagnostic performance 
of chest CT and RT-PCR. The pooled sensitivity was 94% (95% CI: 91%, 96%; I2=95%) for chest CT and 89% (95% CI: 
81%, 94%; I2=90%) for RT-PCR. The pooled specificity was 37% (95% CI: 26%, 50%; I2=83%) for chest CT. For chest CT 
scans, the positive predictive value (PPV) ranged from 1.5% to 30.7%, and the negative predictive value (NPV) ranged 
from 95.4% to 99.8%. For RT-PCR, the PPV ranged from 47.3% to 96.4%, while the NPV ranged from 96.8% to 99.9%. 
The sensitivity of CT was affected by the distribution of disease severity, the proportion of patients with comorbidities, 
and the proportion of asymptomatic patients (all p < 0.05). Interestingly, the sensitivity of RT-PCR was negatively 
associated with the proportion of elderly patients (p = 0.01). 
Several researchers developed artificial intelligence systems to interpret CT images. These are discussed in the Clinical 
prediction models section above. 
Combination of chest CT and RT-PCR 
A publication in Lancet (Shi Lancet Inf Dis 2020, see below), which presented clinical imaging data from a cohort of 81 
patients, stated that combining imaging assessments with clinical and laboratory findings could help identify SARS-
CoV-2 infections early. A similar conclusion was reached by Ren (manuscript on medRxiv: 
https://www.medrxiv.org/content/10.1101/2020.02.25.20027755v2) based on 87 confirmed COVID-19 cases and 481 
exclusion cases. Combination of RT-PCR and CT had higher sensitivity (91.9%) than RT-PCR alone (78.2%) or CT alone 
(66.7%) or combination of two RT-PCR tests (86.2%). 
Virus isolation 
The first SARS-CoV-2 was successfully isolated by inoculating human airway epithelial cells with bronchoalveolar-
lavage fluid samples from a patient with pneumonia (Zhu NEJM 2020, see below). Since human airway epithelial cells 
(because of their resemblance to pseudostratified mucociliary epithelium) require 4-6 weeks to differentiate in vivo, 
isolation of SARS-CoV-2 using Vero cells or Caco-II cells is more convenient. Kim (Osong Public Health Res Perspect 
2020, see below) showed virus replication in Vero cells, with cytopathic effects observed. The author indicated that 
further studies are needed to select more sensitive cell lines suitable for virus isolation from low viral load samples. 
Harcourt (Em Inf Dis 2020, see below) presented data showing that the virus replicates to high titer in Vero-CCL81 cells 
and Vero E6 cells in the absence of trypsin. 
Matsuyama (PNAS 2020, see below) showed that a TMPRSS2-expressing Vero E6 cell line is highly susceptible to SARS-
CoV-2 infection, making it useful for isolating and propagating the virus. 
Alternative diagnostic methods 
Various alternative approaches to COVID-19 diagnosis have been reported. For instance, a manuscript by Wang (on 
arXiv: https://arxiv.org/abs/2002.05534) described the development of a technology for detection of abnormal 
respiratory patterns for large-scale screening of COVID-19 patients in an unobstructive manner. 
Seo (ACS Nano 2020, see below) reported a field-effect transistor (FET)-based biosensing device for detecting SARS-
CoV-2 in clinical samples. This type of device has several advantages, including the ability to make highly sensitive and 
instantaneous measurements using small amounts of analytes. The sensor was produced by coating graphene sheets 
of FET with a specific antibody against SARS-CoV-2 spike protein. The performance of the sensor was determined using 
antigen protein, cultured virus, and nasopharyngeal swab specimens from COVID-19 patients. The FET device could 
detect SARS-CoV-2 S protein at concentrations of 1 fg/ml in PBS and 100 fg/ml clinical transport medium. In addition, 
the FET sensor successfully detected SARS-CoV-2 in culture medium (limit of detection [LOD]: 1.6 x 101 pfu/ml) and 
clinical samples (LOD: 2.42 x 102 copies/ml). The device exhibited no measurable cross-reactivity with MERS-CoV 
antigen. Even though more validation data are needed, these results appear very promising.  
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The sweat produced by SARS-CoV-2 PCR-positive individuals may have a different odour for trained detection dogs 
than the sweat produced by non-PCR-positive persons. A proof-of-concept study by Grandjean (manuscript on bioRxiv : 
https://doi.org/10.1101/2020.06.03.132134) tested this hypothesis on a total of 198 armpit sweat samples obtained 
from different hospitals (3 sites). For each dog, the acquisition of the specific odour of SARS-CoV-2 sweat samples 
required from one to four hours, with a number of positive samples sniffing ranging from 4 to 10. They kept 8 dogs of 
the initial group (explosive detection dogs and colon cancer detection dogs), who performed a total of 368 trials. The 
success of the dogs in finding positive sample in a line containing several negative samples or mocks (2 to 6) were 100% 
for 4 dogs, and respectively 83%, 84% and 94% for the others. They conclude that there is a very high evidence that 
the armpit sweat odour of SARS-CoV-2 positive individuals is different, and that dogs can detect a person infected by 
SARS-CoV-2. 
Similarly, Vesga (manuscript on bioRxiv: https://doi.org/10.1101/2020.06.17.158105) trained six dogs to identify the 
scent-mark of SARS-CoV-2 using respiratory secretions obtained from COVID-19 patients confirmed by RT-PCR. The 
initial training phases took 28 days for in vitro recognition and 21 days for in vitro diagnosis of SARS-CoV-2, during 
which time the dogs scent-interrogated 3,200 and 6,000 samples, respectively. As a group, the six dogs achieved 
overall diagnostic accuracy of 99.6%, diagnostic sensitivity of 95.5% (95% CI 90.4–97.9%), specificity of 99.6% (95% CI 
99.5–99.8%), and positive and negative predictive values of 85.7% (95% CI 79.2–90.5%) and 99.9% (95% CI 99.8–
100.0%) with a mean testing population prevalence of 2.2%. The next phase, in which the dogs will be exposed to 
humans for diagnosis of COVID-19, is reportedly ongoing. 
Jendrny trained eight detection dogs were for 1 week to detect saliva or tracheobronchial secretions of SARS-CoV-2 
infected patients in a randomised, double-blinded and controlled study (BMC Inf Dis 2020, see below). The dogs were 
able to discriminate between samples of infected (positive) and non-infected (negative) individuals with average 
diagnostic sensitivity of 82.63% (95% confidence interval [CI]: 82.02–83.24%) and specificity of 96.35% (95% CI: 96.31–
96.39%). During the presentation of 1012 randomised samples, the dogs achieved an overall average detection rate 
of 94% (±3.4%) with 157 correct indications of positive, 792 correct rejections of negative, 33 incorrect indications of 
negative or incorrect rejections of 30 positive sample presentations. 
Prevention and control strategies 
Human disease surveillance guidelines 
WHO issued guidance on implementation of global surveillance of COVID-19 by Member States 
(https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-
ncov), last updated on August 7 2020). The objectives of this global surveillance were to monitor trends of the disease 
where human to human transmission occurs; rapidly detect new cases in countries where the virus is not circulating; 
provide epidemiological information to conduct risk assessments at the national, regional and global level; and provide 
epidemiological information to guide preparedness and response measures. 
Recommendations for laboratory testing 
Any persons meeting the criteria for testing should be tested for COVID-19 infection. Depending on the intensity of 
transmission, the number of cases and laboratory testing and surge capacity, it may be necessary to prioritize who 
gets tested. A WHO guidance (dated March 21st)  is available to help define such priorities 
(https://apps.who.int/iris/bitstream/handle/10665/331509/WHO-COVID-19-lab_testing-2020.1-eng.pdf). The 
document focusses solely on molecular testing. 
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Recommendations for reporting surveillance data to WHO 
WHO requested that national authorities report probable and confirmed cases of novel coronavirus infection within 
24 hours of identification, by providing the minimum data set outlined in the “Interim case reporting form for 2019 
Novel Coronavirus of confirmed and probable 
cases”( https://www.icao.int/safety/CAPSCA/PublishingImages/Pages/Coronavirus/WHO%2020200121-2019-ncov-
reporting-form.pdf). For countries with extensive importation or human-to-human transmission, daily aggregated 
data were requested, with reporting of the number of new confirmed and probable cases and deaths by first 
administrative level (e.g. region, province, state, municipalities) if possible. Of note, in a press conference on Feb 4, 
WHO mentioned they only received complete information about 38% of the cases reported outside of China 
(https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-technical-briefing-on-
2019-novel-coronavirus). 
Surveillance in animal populations 
Approaches to testing of Companion Animals of COVID-19 patients 
Reports from Hong Kong soon suggested that authorities routinely quarantined and tested companion animals owned 
by COVID-19 patients (ProMed-mail, Archive Number: 20200403.7179945, https://promedmail.org/promed-
post/?id=20200403.7179945). In March 2020, the US CDC reported that they are applying an ad hoc approach to the 
testing of pets belonging to human COVID-19 patients in the USA. This is being done on a case by case basis according 
to a risk assessment (OIE, https://www.oie.int/fileadmin/Home/eng/Our_scientific_expertise/docs/pdf/COV-
19/3rd_call_OIE_informal_advisory_group_on_COVID19_and_animals.pdf). The minutes of the 4th meeting of the 
OIE Advisory Group on COVID-19 stated that ‘FAO have informed the OIE that some laboratories in Italy are preparing 
to test pets. No routine testing of pets has been reported in other European countries, although in Germany any animal 
that shows respiratory disease symptoms and has had contact with a COVID-19 positive human is eligible for testing’. 
(OIE, https://www.oie.int/fileadmin/Home/eng/Our_scientific_expertise/docs/pdf/COV-
19/4th_call_OIE_informal_advisory_group_on_COVID19_and_animals.pdf). 
In April 2020, IDEXX Laboratories have reported testing more than 5000 specimens from dogs, cats and horses with 
respiratory disease in more than 17 countries (in North America, Europe and Asia) with their SARS-CoV-2 (COVID-19) 
RealPCR Test since 14th February (IDEXX, https://www.idexx.com/en/about-idexx/news/idexx-makes-pet-test-covid-
19-virus-available-veterinarians/; IDEXX, https://www.idexx.com/en/veterinary/reference-laboratories/coronavirus-
diagnostic-update/). Over 3500 of these samples had been sourced from the USA (all 50 states) and South Korea. Areas 
with high community transmission at the time of sample collection (such as Seattle) were represented. 55% of 
specimens were canine, 41% were feline and 4% were equine; 77% were respiratory samples (mostly deep pharyngeal 
and conjunctival), 23% were faecal samples. Specimens were also tested in parallel with 3 assays from the CDC. No 
samples tested positive. Detailed metadata regarding sample type and location is not available. In the report, IDEXX 
stated ‘Our monitoring of canine and feline specimens submitted for diagnostic respiratory RealPCR panels is ongoing 
and has now expanded to Canada, all US states, and countries within the EU, including areas with high rates of COVID-
19 in the human population’.  
Surveillance studies in animal populations  
Temmam (One Health 2020, see below) reported a study in which they tested 21 domestic animals (9 cats and 12 dogs) 
belonging to members of a veterinary student community in which 11/18 students had clinical signs consistent with 
COVID-19 (including fever, cough, anosmia etc) and 2 tested positive to SARS-CoV-2 by RT-PCR. Whilst 3 cats displayed 
clinical signs consistent with coronavirus disease (respiratory or digestive signs), no pet tested positive for SARS-CoV-
2 by RT-PCR on nasal and rectal swabs and no animals demonstrated an antibody response when screened with an 
immunoprecipitation assay.  
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Mallapaty (Nature 2020, see below) discussed data from a manuscript on a preprint server showing that cats can be 
infected by SARS-CoV-2 in experimental conditions, and develop antibodies against the virus in the absence of disease 
symptoms. Virus transmission was observed in 1/3 cats exposed to infected animals. Dogs were not found to excrete 
infectious virus, and investigations in pigs, chickens and ducks identified no viral RNA in inoculated animals. Overall, 
none of these species is thought to play a part in the epidemiology of COVID-19.  Halfmann (New Eng J Med, 2020, see 
below) experimentally evaluated the nasal shedding of SARS-CoV-2 from inoculated cats and the subsequent 
transmission to cats with no previous infection with the virus. Despite the low sample size (n=3), SARS-COV-2 was 
detected in nasal swab specimens of all healthy cohoused cats 3 to 6 days post-exposure to the infected cat. Cats 
showed no symptoms, including abnormal body temperature, substantial weight loss or conjunctivitis. All the animals 
had IgG antibody titers between 1:5120 and 1:20480 on day 24 after the initial inoculation. The authors emphasized 
the fact that cats may be silent intermediate host of SARS-CoV-2. This is supported by the results of Gaudreault 
(manuscript on bioRxiv : https://doi.org/10.1101/2020.08.04.235002) who found that asymptomatic cats can be 
productively infected and readily transmit SARS-CoV-2 (USA-WA1/2020 strain) to other susceptible cats. The ease of 
transmission between domestic cats indicates a significant public health necessity to investigate the potential chain of 
human-cat-human transmission.  Moreover, SARS-CoV-2 RNA was detected in nasal swabs of the principal infected 
cats at 1 through 10 days post challenge (DPC), with maximal quantities observed from 1 through 5 DPC. The nasal 
swabs of contact animals became RNA positive for SARS-CoV-2 starting at day 2 post contact (i.e. 3 DPC) and remained 
positive up to 9 days post contact/10 DPC, with a maximum on day 6 post contact/7 DPC that is nearly as high as the 
copy number detected in the principal infected animals at 1 through 5 DPC. These findings warrant COVID-19 screening 
of felines for surveillance/epidemiological purposes and for implementing of mitigation strategies; they also point 
towards nasal swabs/washes and rectal swabs as appropriate diagnostic samples. High viral RNA levels were detected 
throughout nearly all tissues tested for all cats at 4 and 7 DPC, with reduced levels or clearing by 21 DPC in some 
tissues: residual RNA was detected mainly in the upper respiratory tract, the lymphoid tissues and the CNS. Since no 
virus was detected in blood, it remains to be studied how the virus reaches and infects non-respiratory tissues. The 
detection of high levels of viral RNA from swab samples and in various organs and tissues, along with mild to moderate 
histologic changes in trachea and bronchi associated with viral RNA and viral antigen, and the development of SARS-
CoV-2-specific antibodies demonstrates that cats were productively infected, without developing any obvious clinical 
signs. As such, cats may thus serve as potential models for asymptomatic COVID-19 infections in humans. 
China reported to the OIE on 5th February 2020 that veterinary departments ‘had carried out 2019-nCoV testing 
towards samples of pigs, poultry and dogs and other domestic animals collected since 2019 (mainly in late 2019). So 
far, results of such testing are all negative.’ ProMED mail and OIE meeting minutes indicate that prior to 9th February, 
the China Animal Health Epidemiology Center (CAHEC) tested over 4800 archived animal samples (including samples 
from poultry, cat, dogs and pigs) that had been collected in 2019 in numerous locations around China. There is no 
indication that these samples included animals known or suspected to be exposed to COVID-19 infected people. SARS-
CoV-2 was not detected in any samples. Further reports indicated that ‘animals from fur farms (including mink, foxes, 
raccoon dogs) had been tested for SARS-CoV-2 by RT-PCR’ and found negative. (ProMED-mail, Archive Number: 




Zhang (manuscript on bioRxiv:  http://biorxiv.org/content/early/2020/04/03/2020.04.01.021196.abstract) reported 
results of a serosurveillance study performed on a cohort of feline serum samples in the Wuhan region prior to and 
during the outbreak. 15 of 102 (14.7%) cat sera collected after the outbreak were positive for antibody to the RBD of 
SARS-CoV-2 by indirect ELISA. Among the positive samples, 11 had SARS-CoV-2 neutralizing antibodies with a titer 
ranging from 1/20 to 1/1080. No serological cross-reactivity was detected between the SARS-CoV-2 and type I or II 
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feline infectious peritonitis virus (FIPV). The data demonstrated that SARS-CoV-2 has infected cat population in Wuhan 
during the outbreak.  Of note, there was very limited information provided in the paper regarding the sampling 
strategy applied to the surveillance. Some of the animals were reported to be pets of COVID-19 patients, whilst others 
are stray cats and those from pet hospitals. All animals in the study were reported to have had nasopharyngeal and 
rectal swabs collected at the time of sampling, and all swabs tested negative on a SARS-CoV-2 specific qRT-PCR using 
a commercial kit which targeted ORF1ab and N genes.  
Deng (Transbound Emerg Dis 2020, see below) performed a serological survey of on 1914 serum samples from 35 
animal species in (including pigs, cows, sheep, horses, chickens, ducks, geese, experimental mice, rats, guinea pigs, 
rabbits, monkeys, dogs, cats, wild camels, foxes, minx, alpacas, ferrets, bamboo rats, peacocks, eagles, tigers, 
rhinoceroses, pangolins, leopard cats, jackals, giant pandas, masked civets, porcupines, bears, yellow-throated 
martens, weasels, red pandas and wild boar) using a double-antigen sandwich ELISA, with no positive results. 
Importantly, positive ELISA results were not reported among 15 pet and 99 street dogs from Wuhan. Otherwise, there 
was very limited information presented regarding the animal populations from which the samples were derived.   
An indirect multi-species ELISA based on the RBD of SARS-CoV-2 was made available to support animal studies. The 
assay was validated using 59 sera of infected or vaccinated animals including ferrets, raccoon dogs, hamsters, rabbits, 
chickens, cattle and a cat, and a total of 220 antibody-negative sera of the same animal species. Overall, a diagnostic 
specificity of 100.0% and sensitivity of 98.31% was achieved. This test (based on two markers SARS-CoV-2 S1 and the 
RBD-SD1 domain) enabled high-throughput antibody detection in a broad range of animal species, which may be used 
for outbreak investigations, to assess the seroprevalence in susceptible species or to screen for reservoir or 
intermediate hosts (Wernike, on bioRxiv : https://doi.org/10.1101/2020.08.26.266825). 
Overview of public health responses  
Public health response in China 
As of 26 January 2020, in China, 30 provinces initiated a level-1 public health response to control COVID-19. As 
described by Deng (J ClinMed 2020, see below), level-1 response means that during the occurrence of a particularly 
serious public health emergency, the provincial headquarters shall organize and coordinate the emergency response 
work within its administrative area according to the decision deployment and unified command of the State Council. 
Fever observation rooms were to be set up at stations, airports, ports, and so on to detect the body temperature of 
passengers entering and leaving the area and implement observation/registration for the suspicious patients. The 
government under its jurisdiction, in accordance with the law, is to take compulsory measures to restrict all kinds of 
the congregation, and ensure the supply of living resources. They also ensure the sufficient supply of masks, 
disinfectants, and other protective articles on the market, and standardize the market order. The strengthening of 
public health surveillance, hygiene knowledge publicity, and monitoring of public places and key groups is required. 
Comprehensive medical institutions and some specialized hospitals are to be prepared to accept COVID-19 patients to 
ensure that severe and critical cases can be differentiated, diagnosed, and effectively treated in time. The health 
administration departments, public health departments, and medical institutions at all (province, city, county, district, 
township, and street) levels, and social organizations function in epidemic prevention and control and provide 
guidance for patients and close contact families for disease prevention. 
Chen, Yang et al. (Lancet 2020, see below) also underlined the importance of the social distancing measures that were 
applied during the Chinese Lunar New Year holiday in China. People in China are indeed estimated to make close to 3 
billion trips over the 40-day travel period, or Chunyun, of the Lunar New Year holiday. As part of these social distancing 
policies, the Chinese Government encouraged people to stay at home; discouraged mass gatherings; cancelled or 
postponed large public events; and closed schools, universities, government offices, libraries, museums, and factories. 
Only limited segments of urban public transport systems remained operational and all cross-province bus routes were 
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taken out of service. As a result of these policies and public information and education campaigns, Chinese citizens 
started to take measures to protect themselves against COVID-19, such as staying at home as far as possible, limiting 
social contacts, and wearing protective masks when they needed to move in public. The Chinese Government even 
extended the Lunar New Year holiday, so that the duration of the holiday would be sufficiently long to fully cover the 
suspected incubation period of COVID-19. 
China took draconian measures to contain the outbreak, including the quarantine of at least 30 million residents of 
Wuhan and neighbouring cities (Kickbusch British Med J 2020, see below). Countrywide interventions include delaying 
resumption of school after the spring festival holiday, encouraging citizens to work from home and stay at home, using 
personal protective equipment such as face masks, and cancelling all mass gatherings. Vehicular traffic in Wuhan was 
banned. Authorities closed public transit and cancelled outbound transportation (air, train, and long-haul buses). China 
also imposed a ban on overseas travel with tour groups and suspended sale of flight and hotel packages. Authorities 
cancelled Lunar New Year gatherings in Beijing as well as intraprovince bus service into the nation’s capital. China's 
Finance Ministry announced ¥1 billion (U.S. $145 million) to fund the response as well as the rapid construction of 2 
hospitals in Wuhan to treat those affected (Phelan JAMA 2020, see below). 
Most districts of Hangzhou announced in a statement that every community would be kept under closed management, 
and only one family member was allowed to leave his house and buy daily living supplies outdoors every two days 
(Diao Infect Control Hosp Epidemiol 2020, see below). Furthermore, "non-contact delivery", a new delivery method, 
was adopted by many express delivery companies, which could reduce contagion risk. Fourth, in order to reduce the 
concentration of personnel to avoid the risk of cross-infection, online working and network teaching were encouraged 
for workers and students, respectively, which were supported by mobile technology companies. Fifth, to meet the 
need of resumption of production and curb the transmission of the virus as far as possible, Hangzhou arranged 
chartered transportation to help numbers of migrants return to workplaces. Lastly, in cooperation with Alipay, 
Hangzhou adopted the health QR code system on February 11, 2020, which were designated by green, yellow or red. 
People who wanted to get into Hangzhou needed to submit their travel history and health information online in 
advance. Residents with a green code indicated they had a low current risk of being infected, while residents with 
yellow or red codes were quarantined for seven or fourteen days and required to report their health condition every 
day to exclude infection before the codes turned green. 
The strong public health response in China could not prevent the spread of COVID-19 to other countries, causing a 
worldwide public health crisis. Shangguan (Int J Environ Res Public Health 2020, see below) analysed the various 
reasons why China could not contain the outbreak. The authors suggested that the country should adopt a 
Singaporean-style public health crisis information management system to ensure information disclosure and 
information symmetry and should use it to monitor public health crises in real time. They added that the central 
government should adopt the territorial administration model of a public health crisis and increase investment in 
public health in China. 
Public health response in other countries 
The first COVID-19 case outside China is said to have  been reported on January 13 2020: a patient in Thailand was 
said to have visited the Huanan Seafood Wholesale Market (Bruinen de Bruin Saf Sci 2020, see below). Due to the 
absence of a cure or a vaccine, controlling the infection to prevent the spread of COVID-19 was correctly seen as the 
only intervention that could be used. Risk mitigation measures were soon implemented on other areas and countries 
such as Hong Kong, Taiwan, South Korea and Mongolia. One of them consisted of contact tracing and recommending 
a set of precautions. In the United States, on January 20, state and local health departments, in collaboration with 
teams deployed from CDC, began identifying and monitoring all persons considered to have had close contact with 
patients with confirmed COVID-19 (Burke MMWR Morb Mortal Wkly Rep 2020, see below). The aims of these efforts 
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were to ensure rapid evaluation and care of patients, limit further transmission, and better understand risk factors for 
transmission. 
Tanne, Hayasaki et al. (BMJ 2020, see below) provided a rapid overview of how selected countries (USA, Canada, 
Australia, India, Japan, South Korea, Italy, Spain, France, Germany, Iran) were tackling the epidemic in March 2020). 
Hong Kong declared its highest-tier emergency, curtailed public events, and barred travellers from Hubei Province. 
Travelers from mainland China had to complete health declarations. Hong Kong has also rapidly closed schools and 
universities. Governments have not banned travel from China, with 2 exceptions: North Korea prohibited entry of all 
Chinese travellers and Kyrgyzstan closed its border with China. Multiple countries (e.g., Australia, Thailand, South 
Korea, Japan, India, Italy, Singapore, Malaysia, and Nigeria) implemented temperature screening, symptom screening, 
and/or questionnaires for arriving passengers from China. The U.S. Centers for Disease Control and Prevention 
launched enhanced, non-invasive screening of travellers from Wuhan at 20 major airports, while the U.S. State 
Department issued its highest-level travel advisory for Hubei Province: level 4, “do not travel.”  
Legido-Quigley (Lancet 2020, see below) analysed the response in Hong Kong, Singapore and Japan. The three 
locations introduced appropriate containment measures and governance structures; took steps to support health-care 
delivery and financing; and developed and implemented plans and management structures. However, their response 
was found vulnerable to shortcomings in the coordination of services; access to adequate medical supplies and 
equipment; adequacy of risk communication; and public trust in government. Three important lessons emerged. The 
first is that integration of services in the health system and across other sectors amplifies the ability to absorb and 
adapt to shock. The second is that the spread of fake news and misinformation constitutes a major unresolved 
challenge. Finally, the trust of patients, health-care professionals, and society as a whole in government is of 
paramount importance for meeting health crises. 
The response of Singapore to contain the epidemic was also described in a publication by Lee (J Trav Med 2020, see 
below). 
From January 30, the Italian Government implemented extraordinary measures to restrict viral spread, including 
interruptions of air traffic from China, organised repatriation flights and quarantines for Italian travellers in China, and 
strict controls at international airports’ arrival terminals (Spina Lancet 2020, see below). Local medical authorities 
adopted specific WHO recommendations to identify and isolate suspected cases of COVID-19. Such recommendations 
were addressed to patients presenting with respiratory symptoms and who had travelled to an endemic area in the 
previous 14 days or who had worked in the health-care sector, having been in close contact with patients with severe 
respiratory disease with unknown aetiology. Suspected cases were transferred to preselected hospital facilities where 
the SARS-CoV-2 test was available and infectious disease units were ready for isolation of confirmed cases. Since the 
first case of SARS-CoV-2 local transmission was confirmed, the Emergency Medical System in the Lombardy region 
(reached by dialling 112, the European emergency number) represented the first response to handling suspected 
symptomatic patients, to adopting containment measures, and to addressing population concerns. The Emergency 
Medical System of the metropolitan area of Milan instituted a COVID-19 Response Team of dedicated and highly 
qualified personnel, with the ultimate goal of tackling the viral outbreak without burdening ordinary activity. More 
details on the consequences of the COVID-19 outbreak on critical care capacity were provided by Grasselli (JAMA 2020, 
see below). 
Johnson (Euro Surv 2020, see below) characterised three sequential scenarios for the spread of SARS-CoV-2 in the 
EU/EEA, with the third scenario divided in two sub-scenarios based on impact on the healthcare system. The scenarios 
were: (1) short, sporadic chains of transmission, (2) localised sustained transmission, (3a) widespread sustained 
transmission with increasing pressure on the healthcare system and (3b) widespread sustained transmission with 
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overburdened healthcare system. These scenarios were presented together with suggested control measures to limit 
the impact of the epidemic. At different points in time, it was expected that different countries may find themselves 
in different scenarios.  
Bruinen de Bruin (Saf Sci 2020, see below) collated and clustered (using harmonised terminology) the risk mitigation 
measures taken around the globe in the combat to contain, and since March 11 2020, to limit the spread of the SARS-
CoV-2 virus. Figure 21 describes the timeline of events up to end of March 2020.  
Figure 21 Time line of events and application of COVID-19 risk mitigation measures (from Bruinen de Bruin Saf Sci. 2020) 
 
A WHO report dated August 20 2020 provided information on pandemic preparedness and response in Malaysia 
(https://www.who.int/publications/m/item/malaysia-strong-preparedness-and-leadership-for-a-successful-covid-
19-response). Another report issued on September 30 2020 described how the strong health system in Thailand fights 
the pandemic (https://www.who.int/publications/m/item/thailand-how-a-strong-health-system-fights-a-pandemic).  
Of note, a convenient platform has been created for access to detailed information on how different countries respond 
to the pandemic (see: https://www.covid19healthsystem.org/mainpage.aspx). 
Infection control in health care settings 
As reported by Wang (J Hosp Inf 2020, see below), by 24th February, the National Health Commission of the People’s 
Republic of China reported in a press conference of WHO-China Joint Mission on COVID-19 that 3 387 healthcare 
workers had been confirmed with COVID-19, with 22 (0.6%) deaths. More than 90% of infected HCWs were from Hubei 
province. The director of National Hospital Infection Management and Quality Control Centre summarized some 
reasons for such high number of infected HCWs during emergency outbreak. These included inadequate personal 
protection of HCWs at the beginning of the epidemic; long-time exposure to large-scale of infected patients, which 
directly increased the risk of infection for HCWs; pressure of treatment, work intensity, and lacking of rest, which 
indirectly increased the probability of infection for HCWs; shortage of PPE ; and  inadequate training to infection 
prevention and control for front-line HCWs (except infectious disease physicians). 
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Guidance on infection prevention and control strategies for use when COVID-19 is suspected has been issued by WHO 
as early as in March 2020 (https://www.who.int/publications-detail/infection-prevention-and-control-during-health-
care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125). This guidance was intended for HCWs, 
healthcare managers and IPC teams at the facility level but it was also relevant for the national and district/provincial 
level. More detailed practical recommendations could also be found at : https://www.who.int/teams/risk-
communication/health-sector. 
Additional recommendations are available at country level, as done for instance in Canada (Wax Can J Anaesth 2020, 
see below). 
Personal protection of health-care workers 
Very early in the epidemic, available epidemiological data showed that not only can subclinical patients transmit the 
virus effectively but patients can also shed high amounts of the virus and infect others even after recovery from the 
acute illness. Chang (Lancet Resp Med 2020, see below) concluded that these findings warrant aggressive measures 
(such as N95 masks, goggles, and protective gowns) to ensure the safety of HCWs during the COVID-19 outbreak 
especially in the initial stages where limited information about the transmission and infective potency of the virus is 
available. Wang (J Hosp Inf 2020, see below) presented data supporting the efficacy of N95 respirators, disinfection 
and hand washing to reduce risk of COVID-19 transmission among medical staff at Zhongnan Hospital of Wuhan 
University. 
A systematic review and meta-analysis of randomized trials by Bartoszko (Influenza Other Respir Viruses 2020, see 
below) compared medical masks to N95 respirators in preventing laboratory confirmed viral infection and respiratory 
illness including coronavirus. Compared to N95 respirators; the use of medical masks did not increase laboratory 
confirmed viral (including coronaviruses) respiratory infection (OR 1.06; 95% CI 0.90-1.25; I2 =0%; low certainty in the 
evidence) or clinical respiratory illness (OR 1.49; 95%CI 0.98-2.28; I2 =78%; very low certainty in the evidence). Only 
one trial evaluated coronaviruses separately and found no difference between the two groups (p=0.49). 
Of note, a limitation to the effectiveness of face masks was first raised when a medical expert, who visited Wuhan to 
investigate the COVID-19 outbreak, after returning to Beijing, initially exhibited conjunctivitis of the lower left eyelid 
before the appearance of catarrhal symptoms and fever. The individual tested positive for COVID-19, suggesting the 
virus tropism to non-respiratory mucosal surfaces (Chang Lancet Resp Med 2020, see below). 
Yan (Dermatol Ther 2020, see below) presented a consensus of Chinese experts on protective measures and advice 
on hand-cleaning- and medical-glove-related hand protection, mask- and goggles-related face protection, UV-related 
protection, eye protection, nasal and oral mucosa protection, outer ear and hair protection. The authors noted that 
insufficient and excessive protection will have adverse effects on the skin and mucous membrane barrier and that 
using moisturizing products is highly recommended to achieve better protection. 
Zhao (J Cardiothorac Vasc Anesth 2020, see below) described more specifically the level 3 personal protective 
measures for healthcare workers to be used for emergency procedures in patients with confirmed or suspected SARS-
CoV-2 infection in China. They included hand disinfection, wearing a cap, a medical protective mask, goggles/face 
screens/eye protective surgical masks, isolation gowns/protective suits, shoe-covers and gloves. 
A review by Cook (Anaesthesia 2020, see below) indicated that personal protective equipment is an important 
component, but only one part, of a system protecting staff and other patients from COVID-19 cross-infection. 
Appropriate use significantly reduces risk of viral transmission. Personal protective equipment should logically be 
matched to the potential mode of viral transmission occurring during patient care - contact, droplet, or airborne. 
Recommendations from international organisations are broadly consistent, but equipment use is not. Only airborne 
precautions include a fitted high-filtration mask, and this should be reserved for aerosol-generating procedures. 
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Uncertainty remains around certain details of personal protective equipment including use of hoods, mask type and 
the potential for re-use of equipment. 
Due to the risk of hand-skin damage, it has also been recommended that HCWs are instructed about rational hand-
hygiene measures respectful of the skin along with proper use of protective gloves and moisturizers (Cavanagh J Am 
Acad Dermatol 2020, see below). 
Availability of medical supplies 
A comment by Wang (Biosci Trends 2020, see below) addressed the importance of medical supplies availability. As the 
pandemic developed in China, a serious dearth of emergency medical supplies emerged, and especially an extreme 
shortage of personal protective equipment such as masks and medical protective clothing. This is considered as one 
of the major factors affecting the progress of epidemic prevention and control. 
Facilities 
As of February 19th, the Chinese government converted 13 large-scale public places in Wuhan into makeshift hospitals 
for patients with COVID-19 with mild symptoms. Chen (J Hosp Inf 2020, see below) noted that insufficient ventilation 
in these makeshift hospitals may increase infection risk of opportunistic airborne transmission.  
Patient flow and triage 
In February 2020, an innovative approach was developed in the United Kingdom to stop unnecessary ambulance use 
and hospital visits, whereby people with suspected COVID-19 are being tested in their homes (Mahase BMJ 2020, see 
below). The community testing scheme started at the end of January at North West London NHS Trust and has now 
been implemented in other trusts. More than 130 patients have been reported to be tested in two weeks. Mahase 
(BMJ 2020, see below) subsequently indicated that in Wales, 90% of suspected cases are managed at home. Members 
of the public who call NHS or 111 and are assessed as a possible case, are evaluated for their suitability for home 
testing on the basis of their self-reported health status and their ability to self-isolate at home. Public Health Wales’s 
microbiology team then coordinates with the relevant health board community testing teams to arrange home testing 
within 12-36 hours. 
Safety of procedures 
Wong (Can J Anaesth 2020, see below) described the outbreak response measures of the anaesthetic department of 
2 hospitals in Singapore. These included engineering controls such as identification and preparation of an isolation 
operating room, administrative measures such as modification of workflow and processes, introduction of personal 
protective equipment for staff, and formulation of clinical guidelines for anaesthetic management. 
Aerosol-generating procedures, such as non-invasive ventilation (NIV), high-flow nasal cannula (HFNC), bag-mask 
ventilation, and intubation are of particularly high risk when dealing with COVID-19 patients. Cheung (Lancet Respir 
Med 2020, see below) described the approach developed by a local intensive care unit in a Hong Kong hospital to 
managing the risks to health-care staff, while maintaining optimal and high-quality care. They did not recommend 
using NIV or HFNC until the patient is cleared of COVID-19. Airway devices providing 6 L/min or more of oxygen were 
considered high-flow and they discouraged their use if an airborne infection isolation room is unavailable. They 
recommended that endotracheal intubation is done by an expert specialised in the procedure, and early intubation 
considered in a patient with deteriorating respiratory condition. They recommended avoiding bag mask ventilation for 
as long as possible; and optimising preoxygenation with non-aerosol-generating means. Methods included the bed-
up-head-elevated position, airway manoeuvres, use of a positive end expiratory pressure valve, and airway adjuncts. 
Zuo (Chin Med Sci J. 2020, see below) noted that endotracheal intubation may put the anaesthesiologists at high risk 
of nosocomial infection. In fact, SARS-CoV-2 infection of anaesthesiologists after endotracheal intubation for 
confirmed COVID-19 patients have been reported in hospitals in Wuhan. The expert panel of airway management in 
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Chinese Society of Anaesthesiology drafted a recommendation to guide the performance of endotracheal intubation 
by frontline anaesthesiologists and critical care physicians.  
Zhang (Anesthesiology 2020, see below) also reported that the  Wuhan Union Hospital’s Department of 
Anaesthesiology drafted the “Perioperative Care Provider’s Considerations in Managing Patients with COVID-19” and 
carried out 45 surgical procedures on such patients. An upgraded surgical safety checklist for patients with suspected 
or confirmed COVID-19 was drawn up and implemented, along with infection-control guidelines for the care of such 
patients. Task forces dedicated to procedure standardization, infection control, and staff scheduling within 
anaesthesia were quickly assembled in most hospitals across the country. Monitoring was implemented to ensure that 
anaesthesia providers wore and removed personal protective equipment before working in the perioperative 
environment. Drills were held to ensure the optimal management of emergencies, with mandatory multidisciplinary 
participation across anaesthesia, surgery, critical care, paediatrics, and obstetrics and gynaecology. 
Of note, another report noted that during pandemics the number of intensive care unit beds for mechanical ventilation 
through tracheal intubation could rapidly become insufficient. Therefore, non-invasive ventilation could be required 
outside the intensive care unit. To increase safety during NIV, use of a helmet has been suggested by Cabrini (Lancet 
2020, see below). 
In order to limit the risk of nosocomial transmission, Chen, Tian et al. (Lancet Inf Dis 2020, see below) reported the 
use of an innovative infection-control system in a Guangdong hospital, called the "observing system", whereby 
cameras cover the negative pressure isolation  ward and infection control observers monitor medical staff and provide 
assistance in real time via computer monitors. The main responsibilities of these infection control observers are to 
maintain the normal operation of the negative pressure isolation wards, supervise the implementation of disinfection, 
ensure a sufficient supply of protective materials, arrange specimens for inspection, and relieve anxiety of the medical 
personnel while treating patients. 
A role for telehealth and telemedicine 
The COVID-19 pandemic has had unprecedented global effects, yet the rapid emergence of telehealth across the globe 
has allowed healthcare professionals to connect virtually with patients and families while following safe social 
distancing guidelines (reviewed by Cohen Curr Opin Cardiol 2020, see below). For instance, Zhai (manuscript on 
MedRXiv : https://www.medrxiv.org/content/10.1101/2020.02.20.20025957v1) described the Emergency 
Telemedicine Consultation System (ETCS), a telemedicine-enabled outbreak alert and response network, established 
by the National Telemedicine Center of China in Zhengzhou. ETCS was built upon a doctor-to-doctor (D2D) approach, 
in which health services can be accessed remotely through terminals across hospitals. The system architecture of ETCS 
comprises three major architectural layers: (1) telemedicine service platform layer, (2) telemedicine cloud layer, and 
(3) telemedicine service application layer. The ETCS has demonstrated substantial benefits in terms of the 
effectiveness of consultations and remote patient monitoring, multidisciplinary care, and prevention education and 
training. 
Hollander (NEJM 2020, see below) presented the benefits that can be expected from telemedicine. Direct-to-
consumer (or on-demand) telemedicine allows patients to be efficiently screened. It is both patient-centered and 
conducive to self-quarantine, and it protects patients, clinicians, and the community from exposure. It can allow 
physicians and patients to communicate 24/7, using smartphones or webcam-enabled computers. Health care 
providers can easily obtain detailed travel and exposure histories. Automated screening algorithms can be built into 
the intake process, and local epidemiologic information can be used to standardize screening and practice patterns 
across providers. Interestingly, more than 50 U.S. health systems already have such programs, and systems lacking 
such programs can outsource similar services. However, the authors also identified the numerous challenges to be 
faced (incl. reimbursement) before such approach can be used in the management of COVID-19 in the U.S. 
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Greenhalgh (BMJ 2020, see below) reported that video could be useful for people with heightened anxiety (for whom 
a video consultation may be more reassuring than a phone call), those with mild symptoms suggestive of coronavirus 
(for which visual cues may be useful), and those with more severe symptoms (when a video consultation may reduce 
the need to visit a potentially contagious patient). Well patients seeking general advice could be directed to a website 
or recorded phone message. Moreover, there may be a trade-off between staying at home and coming to clinic for a 
full examination—for example, in frail older patients or immunosuppressed patients. 
A study by Khairat (JMIR Public Health Surveill 2020, see below) assessed the potential of a system call Virtual Care. 
The study included 733 total virtual visits, including 257 (35%) with COVID-19-like symptoms. Of the COVID-19 like 
visits, the number of females was 178 (70%). People in the 30-39 years of age (26%) and 40-49 years (25%) were 50% 
of the total patients. Virtual Care was shown to provide efficient triaging. The authors concluded that Virtual Care is 
capable to reduce emergency room visits, conserve healthcare resources, and avoid the spread of COVID-19 by 
treating patient remotely. 
It is well recognized that telehealth visits will not supplant all patient-physician interactions, but is a very acceptable 
first step in the majority of cases and can often steer the patient to subsequently undergo more selective and 
streamlined care. 
Screening approaches 
It has been reported that Thailand had 58 international flights connecting with Wuhan (Sriwijitalai Int J Prev Med 2020, 
see below). At the start of the epidemic, active screening at the airport (by body temperature scanning and clinical 
history taking) has been done to identify possible infected cases. In the first month, active screening identified 12 cases 
with positive result. However, the final diagnosis by molecular diagnostic tests could identify only one case with SARS-
CoV-2 infection, which was the first case report of infection outside China. The other 11 cases were infected with 
influenza virus. 
As reported by Ge (manuscript on medRxiv: https://www.medrxiv.org/content/10.1101/2020.02.20.20025973v1), 
symptom-based mass screening and testing intervention (MSTI) can identify a large fraction of infected individuals 
during an infectious disease outbreak. China is currently using this strategy for the COVID-19 outbreak. The authors 
noted that this might lead to increased transmission if not properly implemented. The outcome of a modelling study 
suggested that the approach can be useful if the probability of transmission at testing sites is less than the probability 
that a symptomatic person is infected with SARS-CoV-2. This type of data is important to generate, as it may support 
recommendations such as for instance the use of dedicated testing sites separate from the usual healthcare facilities. 
Gostic (Elife 2020, see below) estimated the impact of different screening programs given current knowledge of key 
COVID-19 life history and epidemiological parameters. Even under best-case assumptions, the authors predicted that 
screening will miss more than half of infected people. Most cases missed by screening are fundamentally undetectable, 
because they have not yet developed symptoms and are unaware that they were exposed.  
Rao (Infect Control Hosp Epidemiol 2020, see below) proposed to use machine learning algorithms to help improve 
possible COVID-19 case identifications using a mobile phone-based web survey capturing with the most common 
manifestations of disease, along with basic travel history. 
For safe and efficient screening for COVID-19, drive-through screening centres have been designed and implemented 
in South Korea. Kwon (J Korean Med Sci 2020, see below) presented the overall concept, advantages, and limitations 
of these screening centres. The steps of the drive-through centres include registration, examination, specimen 
collection, and instructions (Figure 22). The entire service takes about 10 minutes for one testee without leaving his 
or her car. Increased testing capacity over 100 tests per day and prevention of cross-infection between testees in the 
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waiting space were reported as major advantages, while protection of staff from the outdoor atmosphere was said to 
be challenging. 
Choi (Clin Exp Emerg Med 2020, see below) compared the advantages and disadvantages of Drive-Through and Walk-
Through methods of testing. Similar drive-through testing centers have been reported in Israel for instance (Kim 
Disaster Med Public Health Prep 2020, see below). 
Figure 22 Illustration of drive-through COVID-19 screening centre provided for the public in South Korea (from Kwon J Korean Med Sci 2020) 
 
Contact tracing 
When several unknown epidemiological and clinical characteristics of the disease remain and an effective medical 
intervention is lacking (as in the case of COVID-19), contact management becomes one of the core strategies to 
minimize additional transmission. A WHO interim guideline of May 2020 provides guidance on how to establish contact 
tracing capacity for the control of COVID-19 (https://www.who.int/publications/i/item/contact-tracing-in-the-
context-of-covid-19). Another WHO document also offers operational guidance to Member States for the rapid 
investigation of suspected COVID-19 cases (https://www.who.int/publications-detail/considerations-in-the-
investigation-of-cases-and-clusters-of-covid-19). This guidance may be implemented in different countries with 
varying resources and epidemiological patterns and it is expected to be adapted accordingly. 
A contact is defined as a person who has experienced any one of the following exposures during the 2 days before and 
the 14 days after the onset of symptoms of a probable or confirmed case: 
1. face-to-face contact with a probable or confirmed case within 1 metre and for at least 15 minutes 
2. direct physical contact with a probable or confirmed case 
3. direct care for a patient with probable or confirmed COVID-19 disease without using recommended personal 
protective equipment 
OR 
4. other situations as indicated by local risk assessments.  
Among the first 10 patients with travel-related confirmed COVID-19 reported in the United States, a total of 445 
persons (range = 1-201 persons per case) who had close contact with one of the 10 patients on or after the date of the 
patient’s symptom onset were identified (Burke MMWR Morb Mortal Wkly Rep 2020, see below). 222 (50%) were 
health care personnel. Active symptom monitoring of the 445 close contacts, consisting of daily telephone, text, or in-
person inquiries about fever or other symptoms for 14 days following the last known exposure to a person with 
confirmed COVID-19, was conducted by local health jurisdictions. 
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Contact tracing is typically triggered by a confirmed index case identified via symptom-based surveillance (Endo, 
manuscript on medRxiv, see https://www.medrxiv.org/content/10.1101/2020.08.01.20166595v1). Traditional 
investigative methods, depending on the patient or proxy interview, has the limitation of omissions and errors 
associated with recalling previous activities (COVID-19 National Emergency Response Center Osong Public Health Res 
Perspect 2020, see below). In South Korea for instance, the methods used to overcome recall and confirmation biases 
that can occur while determining the location of the contact include checking medical facilities records, phone-based 
global positioning system (GPS), card transaction records, and closed-circuit television (CCTV).   
Pan (Irish J Med Sci 2020, see below) also reported that several personal-oriented and mobile phone-based 
information technologies were developed and widely used in China. For instance, the application “Diagnosed Cases in 
Community” enables people to check the distribution of COVID-19 cases in local communities on the map. The map 
covers more than 130 cities in China and shows case number and location.  
Kamel Boulos (Int J Health Geogr 2020, see below) described a range of online/mobile geographic information systems 
(GIS) and applications for tracking the coronavirus epidemic and associated events as they unfold around the world. 
Some of these dashboards and applications are receiving data updates in near-real-time (at the time of writing). 
However, as noted by Buckee (Science 2020, see below), the protection of personal privacy must be paramount. 
Consent-based data sharing models and data protection laws provide for the legal grounds to use personal data during 
emergencies. However, the use of individual data is not advocated by all experts.  
Contacts of this index case are thus identified via interviews by public health officials (manual contact tracing) or by 
tracking proximity records on digital devices (digital contact tracing), and then asked to quarantine in order to prevent 
further transmissions (Endo, manuscript on medRxiv, see 
https://www.medrxiv.org/content/10.1101/2020.08.01.20166595v1).  
Figure 23. Schematic illustration of forward and backward contact tracing (from Endo 2020) 
 
Contact tracing often targets ‘downstream’ individuals, who may have been infected by the index case (‘forward 
tracing’); i.e. those who have been in contact with the index case after the index case likely became infectious (often 
assumed as 2 days before illness onset for COVID-19). However, ‘backward tracing’ can also be used to identify the 
upstream primary case who infected the index case (or a setting or event at which the index case was infected) by 
retracing history of contact to the likely point of exposure, i.e. up to 14 days prior to symptom onset (Figure 23). If this 
primary case is identified, a larger fraction of the transmission chain can be detected by forward tracing each of the 
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contacts of this primary case. This approach is particularly valuable when there is high individual-level variation in the 
number of secondary transmissions. By using a simple branching process model, Endo explored the potential of 
combining backward contact tracing with more conventional forward contact tracing for control of COVID-19. 
Immunity passports 
A widely discussed idea in the media has been the issuance of “immune passports,” the proposed use of serology to 
infer immunity and thus enable a person to work on the front lines or return to daily work routines when containment 
measures are in place (Bryant Sci Imm 2020, see below). Such an application must be predicated on an established 
surrogate of protection, a given antibody end point associated with clinical protection from infection, and a test with 
sufficient specificity to ensure people are not unintentionally put in harm’s way. On April 24, WHO indicated that there 
was no evidence that people who have recovered from COVID-19 and have antibodies are protected from a second 
infection (https://www.who.int/publications/i/item/10665-331866). A most recent review on this topic is provided by 
Brown (Lancet Infect Dis 2020, see below).  
Face masks 
Liu (Influenza Other Respir Vir 2020, see below) reported an interesting anecdote suggesting the efficacy of face masks 
to present transmission of SARS-CoV-2. The authors observed a typical case of cluster outbreak caused by public 
transportation exposure during the outbreak of COVID-19. One patient from Chongqing, China, didn’t wear a face 
mask in the first vehicle, while he wore a face mask in the second vehicle he took. This male patient with COVID-19 
found himself coughing. Unaware of the fact that he might have been infected with COVID-19 and in a hurry, he didn’t 
manage to get a face mask before he took the coach bus from the city back to his county. Many passengers didn’t 
wear face masks on the same coach bus. The duration of this bus was 2 hours and 10 minutes; there were 39 other 
passengers on the same coach bus. According to epidemiological survey, 5 other passengers on the same coach bus 
were infected. Upon arrival in the county, this male patient bought a face mask and took a minibus to his final 
destination wearing the mask. The duration of minibus was 50 minutes, there were 14 other passengers on the same 
minibus. The Centre for Disease Control and Prevention conducted an epidemiological investigation and close contact 
tracing management. The passengers on the minibus that were screened and treated as suspected cases. A 14-day 
medical observation period was conducted. During the observation period, passengers were taken temperature twice 
a day. All the passengers did not have fever, cough or other abnormal symptoms, two quantitative RT-PCR test results 
were negative. No passengers were infected in the same minibus. 
In the first weeks of the pandemic, the sudden surge of demand on facemasks in East Asia (together with reduced 
productivity in China and other factors) contributed to a global shortage that in turn disrupted supplies to health care 
providers worldwide. This unprecedented global shortage of medical facemasks was accompanied by contrasting 
views on the utility of medical facemasks among the public but also governments and public health experts.  
Efficacy of face masks 
An overview by Chan published on March 31st indicated that for infected individuals, facemasks are likely to be superior 
to active practices such as covering up the nose or mouth when sneezing or coughing (Int J Epidemiol 2020, see below). 
However, a small study in 4 patients by Bae (Ann Intern Med 2020, see below) concluded that both surgical and cotton 
masks seem to be ineffective in preventing the dissemination of SARS-CoV-2 from the coughs of patients with COVID-
19 to the environment and external mask surface. 
A meta-analysis by Chu (Lancet 2020, see below) assessed the use of face masks and eye protection to prevent 
transmission of viruses in a more systematic way. The study found that face mask use could result in a large reduction 
in risk of infection (n=2647; aOR 0·15, 95% CI 0·07 to 0·34, RD −14·3%, −15·9 to −10·7; low certainty), with stronger 
associations with N95 or similar respirators compared with disposable surgical masks or similar (e.g., reusable 12–16-
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layer cotton masks; pinteraction=0·090; posterior probability >95%, low certainty). Eye protection also was associated 
with less infection (n=3713; aOR 0·22, 95% CI 0·12 to 0·39, RD −10·6%, 95% CI −12·5 to −7·7; low certainty). 
Mandates for mask use in public during the recent COVID-19 pandemic, worsened by global shortage of commercial 
supplies, have led to widespread use of homemade masks and mask alternatives. It is assumed that wearing such 
masks reduces the likelihood for an infected person to spread the disease, but many of these mask designs have not 
been tested in practice. Fischer (Sci Advances 2020, see below) presented a simple optical measurement method to 
evaluate the efficacy of masks to reduce the transmission of respiratory droplets during regular speech. In proof-of-
principle studies, the authors compared a variety of commonly available mask types and observed that some mask 
types approach the performance of standard surgical masks, while some mask alternatives, such as neck fleece or 
bandanas, offer very little protection. A review by Jain (Cureus 2020, see below) indicated that household fabrics such 
as cotton T-shirts and towels have some filtration efficacy and therefore potential for droplet retention and protection 
against virus-containing particles. However, the percentage of penetration in cloth masks was found higher than 
surgical masks or N95 respirators. The authors concluded that cloth masks have limited inward protection in 
healthcare settings where viral exposure is high, but may be beneficial for outward protection in low-risk settings and 
use by the general public where no other alternatives to medical masks are available. 
Solving shortage and environmental issues 
As noted by Das (Sci Total Envir 2020, see below), billions of facemasks are produced from petrochemicals derived raw 
materials, which are non-degradable upon disposal after their single use, thus causing environmental pollution and 
damage. The sustainable way forward is to utilise raw materials that are side-stream products of local industries to 
develop facemasks having equal or better efficiency than the conventional ones.  
Swennen (Int J Oral Maxillofac Surg 2020, see below) presented a proof of concept and prototype demonstrating a 
reusable custom-made three-dimensionally (3D) printed face mask based on materials and techniques (3D imaging 
and 3D printing) with global availability. The individualized 3D protective face mask consists of two 3D-printed reusable 
polyamide composite components (a face mask and a filter membrane support) and two disposable components (a 
head fixation band and a filter membrane). 
Das indicated that wheat gluten biopolymer, a by-product or co-product of cereal industries, can be electrospun into 
nanofibre membranes and subsequently carbonised at over 700 °C to form a network structure, which can 
simultaneously act as the filter media and reinforcement for gluten-based masks (Sci Total Envir 2020, see below). In 
parallel, the same gluten material can be processed into cohesive thin films using plasticiser and hot press. Additionally, 
lanosol, a naturally-occurring substance, imparts microbe resistance in gluten plastics. Thus, thin films of flexible gluten 
with very low amounts of lanosol can be bonded together with the carbonised mat and shaped by thermoforming to 
create the facemasks. The carbon mat acting as the filter can be attached to the masks through adapters that can also 
be made from injection moulded gluten. 
Among other proposed strategies for mitigating the massive demand for N95 FFRs is their reuse after a process of 
decontamination that allows the inactivation of any potentially infectious material on their surfaces. A review by 
Rodriguez-Martinez (Am J Infect Control 2020, see below) summarized available evidence on the different inactivation 
methods available. In July 2020, a review by Steinberg (Can J Anaesth 2020, see below) found that moist mask heating 
(65-80°C at 50-85% relative humidity for 20-30 min) and vaporous hydrogen peroxide treatment were supported by 
the literature to provide consistent viral decontamination without compromising mask seal and filtration efficiency. 
Other investigated decontamination methods lacked comprehensive scientific evidence for all three of these key 
criteria. 
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Efficacy of non-pharmaceutical interventions 
A manuscript by Tian (Science 2020, see below) provided a preliminary evaluation of the efficacy of control measures 
implemented in China. The Wuhan city travel ban is considered to have slowed the dispersal of infection to other cities 
by an estimated 2.91 days (95% CI, 2.54-3.29) on average. Among the other urban centres across mainland China, 
cities that implemented control measures pre-emptively, before the first case was reported, had 37% fewer cases in 
the week following the first reported case (13.0, 95%CI 7.1-18.8) compared with cities starting control after the first 
case (20.6, 95%CI 14.5-26.8). Among individual control measures investigated, the most effective were suspending 
intra-city public transport, and closing entertainment venues and banning public gatherings. 
Chu (Lancet 2020, see below) conducted a systematic review and meta-analysis to investigate the optimum distance 
for avoiding person-to-person virus transmission. The authors identified 172 observational studies across 16 countries 
and six continents, with no randomised controlled trials and 44 relevant comparative studies in health-care and non-
health-care settings (n=25 697 patients). Transmission of viruses was lower with physical distancing of 1 m or more, 
compared with a distance of less than 1 m (n=10 736, pooled adjusted odds ratio [aOR] 0·18, 95% CI 0·09 to 0·38; risk 
difference [RD] −10·2%, 95% CI −11·5 to −7·5; moderate certainty); protection was increased as distance was 
lengthened (change in relative risk [RR] 2·02 per m; pinteraction=0·041; moderate certainty). 
A Cochrane rapid review assessed the effects of quarantine (alone or in combination with other measures) of 
individuals who had contact with confirmed cases of COVID-19, who travelled from countries with a declared outbreak, 
or who live in regions with high transmission of the disease (Nussbaumer-Streit Cochrane Database Syst Rev 2020, see 
below). Evidence for COVID-19 was found limited to modelling studies that make parameter assumptions based on 
the current, fragmented knowledge of the disease (see Modelling the impact of public health measures below). 
Nevertheless, findings consistently indicated that quarantine is important in reducing incidence and mortality during 
the COVID-19 pandemic. 
Bo (Int J Inf Dis 2020, see below) evaluated the effectiveness of four types of non-pharmaceutical interventions in 
containing the time-varying effective reproduction number (Rt) of COVID-19. The study included 1 908 197 confirmed 
COVID-19 cases from 190 countries between 23 January and 13 April 2020. Interventions were categorized into four 
types: mandatory face mask in public, isolation or quarantine, social distancing and traffic restriction. The 
implementations of mandatory mask, quarantine, distancing and traffic were associated with changes (95%confidence 
interval, CI) of -15.14% (-21.79% to -7.93%), -11.40% (-13.66% to -9.07%), -42.94% (-44.24% to -41.60%) and -9.26% (-
11.46% to -7.01%) in the Rt of COVID-19 compared with those without the implementation of the corresponding 
measures. Distancing and the simultaneous implementation of two or more types of non-pharmaceutical 
interventions seemed to be associated with a greater decrease in the Rt of COVID-19. Overall, this study indicated that 
non-pharmaceutical interventions can significantly contain the COVID-19 pandemic. The authors concluded that 
distancing and the simultaneous implementation of two or more non-pharmaceutical interventions should be the 
strategic priorities for containing COVID-19. 
Acceptability of public health measures 
As outlined by Bero (Am J Public Health 2020, see below), public health measures such as isolation, quarantine, and 
social distancing have fundamentally changed the way we live.  
In Japan, Machida (Int J Infect Dis 2020, see below) evaluated the level of adoption of personal protective measures 
by citizens. The prevalence of the five personal protective measures (hand hygiene, social distancing measures, 
avoiding touching the eyes, nose and mouth, respiratory etiquette, and self-isolation) ranged from 59.8% to 83.8%, 
with the lowest being avoiding touching the eyes, nose, and mouth. In total, 34.7% implemented all personal 
protective measures. The median daily hand hygiene events were 5 per day (25th percentile, 75th percentile: 3,8). The 
authors concluded in an insufficient implementation of the protective measure. 
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A survey of 72,417 adults in 27 countries (Australia, Brazil, Canada, Denmark, Finland, France, Germany, Hong Kong, 
Italy, Japan, Malaysia, South Korea, Mexico, Netherlands, Norway, Philippines, Saudi Arabia, Singapore, South Korea, 
Spain, Sweden, Taiwan, Thailand, United Arab Emirates, UK, USA and Vietnam) asked respondents if they would isolate 
themselves for 7 days if they felt unwell and had certain symptoms of COVID-19 or if they would do so if urged to by 
a healthcare or public health professional (Daoust PLoS One 2020, see below). It also asked how often they had taken 
infection-prevention measures such as handwashing, avoiding public transportation, and cleaning often-touched 
surfaces. Elderly people’s response was found substantially similar to their fellow citizens in their 50’s and 60’s. This 
research provided the first thorough description of the most vulnerable population’s attitudes and compliance in a 
comparative perspective. It suggested that governments’ strategies toward elderly people are far from successful. 
Barriers to implementation of interventions 
While non-pharmaceutical interventions including physical distancing, isolation, and mask use may flatten the peak in 
communities (see Efficacy of non-pharmaceutical interventions above, these strategies rely on community 
understanding and motivation to engage to ensure appropriate compliance and impact. Seale (BMC Inf Dis 2020, see 
below) reviewed the key determinants impacting on engagement. The results revealed that there are a range of 
demographic, social and psychological factors underpinning engagement with quarantine, school closures, and 
personal protective behaviours. Aside from the factors impacting on acceptance and compliance, there are several 
key community concerns about their use that need to be addressed including the potential for economic consequences. 
The authors indicated that understanding the barriers helps identify what strategies need to be adopted to motivate 
individuals and improve community compliance.  
Communication 
Risk communication, as defined by the World Health Organization, is “the exchange of real-time information, advice 
and opinions between experts and people facing threats to their health, economic or social well-being.” One of the 
most important and effective interventions in a public health response to any event is to proactively communicate 
what is known, what is unknown, and what is being done to get more information, with the objectives of saving lives 
and minimizing adverse consequences (https://www.who.int/risk-communication/background/en/). It is increasingly 
recognized that society, communities, and patients view risk from a social constructionist approach whereby risk is 
seen to be interrelated with sociocultural context (Smith Soc Sci Med 2006, see below). This is especially the case 
during pandemics that have high rates of infection, significant morbidity, lack of therapeutic measures, and rapid 
increases in cases, all of which - so-called dread factors - apply to the COVID-19 pandemic (Abrams J Allergy Clin 
Immunol Pract 2020, see below). These factors can be drivers of serious, and often unmeasurable, consequences 
resulting from heightened risk perception. The scale of the crisis and governments’ responses have been matched by 
a colossal flow of information about COVID-19 in terms of 24/7 news coverage, televised press conferences provided 
by both political leaders and health authorities, prime time speeches to the people by kings, presidents, prime 
ministers and religious leaders, as well as news analyses, debates and social media posts (Finset Patient Educ Counsel 
2020, see below). Understanding the audiences (class, age, risk, communication style) and tailoring the message to 
reach the public is thus key to avoid hoarding behaviour (e.g. stockpiling masks, PPEs, curative drugs, toilet paper), 
anger and outrage (e.g. demonstration against masks wearing regulations, lockdown enforcement), mistrust (e.g. 
multiple experts and shifting inconsistent messages), panic or paranoia and fear (e.g. hospital avoidance, 
stigmatisation of nationals of some countries, denunciation of people perceived as sick or not complying with the 
COVID-19 measures). The alteration of the number of people allowed to meet over the course of the crisis - the social 
bubble - is an example of poor risk-benefit communication by the Belgian authorities. On several occasions, the bubble 
expanded or contracted and the mere principle of who can be part of your bubble of 15, 10 or 5 people was poorly 
understood by citizens, as evidenced by interviews in trusted television and radio channels. The same confusion and 
misunderstanding were observed in relation to face mask use messages. Shifting from an initial message that masks 
were not needed to an obligation of wearing masks lead to mistrust and reduced confidence in political and health 
Delivered by Ingenta
IP: 157.193.240.2 On: Fri, 04 Jun 2021 12:29:12
Copyright Leuven University Press
 
Authors: Martine Denis, Valerie Vandeweerd, Rein Verbeke, Anne Laudisoit, Tristan Reid, Emma Hobbs, Laure Wynants, Diane 
Van der Vliet  
COVIPENDIUM version: 20 OCT 2020  Transdisciplinary Insights - Living Paper | 165 
experts alike. This forced the government to resort to strict manu militari law enforcement under the new “paradigm” 
- masks are now saving lives. The misbehaviour and non-compliance to the new rules and the strong response (i.e. 
fines and imprisonment sentence threat) triggered outrage and even more mistrust in official channels. Such 
inconsistent message, shifting on a short time scale from one measure to its complete contrary by the same political 
and health experts have affected individuals at different degrees with potentially serious psychological long-term 
effect. Mental health is as important to protect as physical health during a health crisis, especially if the cause is 
invisible, unknown, novel, deadly and reported in a sensationalistic manner. Hope can heal fear as exemplified by the 
shortage of hydroxychloroquine as far as the small rural clinic in Eastern African countries - that had then not yet been 
hit by the virus – only a few days after the statement about its curative properties on COVID-19 was released. 
Systems approaches  
Bradley (EClinicalMedicine 2020, see below) highlighted the importance of a systems approach to help policymakers 
understand and influence the spread of infection and its multifaceted consequences across the community. The author 
outlined a causal loop diagram to illustrate some important interacting components in a society that is responding to 
the threat of COVID-19 (Figure 24). 
Figure 24 An example causal loop diagram illustrating some of the interacting components in a society responding to the threat of COVID-19 




An impressive number of modelling studies related to COVID-19 has been reported since the beginning of the epidemic. 
In March 2020, Roy Anderson (Lancet 2020, see below) provided an interesting discussing on the various unknowns 
that remained with regard to the epidemiology of the disease and the expected impact of various public health 
strategies. The aim of modelling studies was indeed not only to characterize the epidemiology of the disease in various 
countries, but also to predict the impact of the public health measures that could be implemented. Numerous 
publications (with date of issue up to April 1st) can be found at https://github.com/midas-network/COVID-
19/wiki/Documents#estimate. The examples presented in the 2 sections below are classified according to the 
objectives of the study. 
Delivered by Ingenta
IP: 157.193.240.2 On: Fri, 04 Jun 2021 12:29:12
Copyright Leuven University Press
 
Authors: Martine Denis, Valerie Vandeweerd, Rein Verbeke, Anne Laudisoit, Tristan Reid, Emma Hobbs, Laure Wynants, Diane 
Van der Vliet  
COVIPENDIUM version: 20 OCT 2020  Transdisciplinary Insights - Living Paper | 166 
Of note, Roda (Inf Dis Modelling 2020, see below) demonstrated that non-identifiability in model calibrations using 
the confirmed-case data is the main reason for the wide variations observed across prediction models for the COVID-
19 epidemics in Wuhan and other parts of China. The authors suggested that predictions using more complex models 
may not be more reliable compared to using a simpler model. 
Jewell (JAMA 2020, see below) addressed the topic of epidemic modelling and accuracy of projections. It indicated for 
instance, that for large countries, such as the USA, modelling is more problematic because of heterogeneous 
subepidemics in local areas. Individual characteristics, such as age and comorbidities, influence the risk of serious 
disease from COVID-19, but population distributions of these factors vary widely in the USA. 
Modelling key characteristics of the epidemic 
 Pan (on medRxiv https://www.medrxiv.org/content/10.1101/2020.02.19.20025387v3) described 2 
mathematical models simulating the epidemic in Wuhan and other parts of China, taking into account the 
mobility of people. The data suggest that the peak of new asymptomatic cases per day in Wuhan occurred on 
February 6, and the peak of new symptomatic infections on February 3. The model predicts that COVID-19 
cases will gradually wane by the end of April 2020, both in Wuhan and the other parts of China. 
 Based on the 199 first confirmed cases on the Diamond Princess cruise ship, Nishiura (J Clin Med 2020, see 
below) employed a back-calculation method to estimate the incidence of infection. Without the movement 
restriction policy imposed from 5 February, it was predicted that the cumulative incidence with and without 
close contact would have been as large as 1373 (95% CI: 570, 2176) and 766 (95% CI: 587, 946) cases, 
respectively, out of a total of 3711 persons (2666 passengers and 1045 crew members). With the application 
of a Bayesian model to data from the same outbreak, the R0 was estimated as high as 5.71 (95% credible 
interval: 4.08-7.55) (Chao-Chih, manuscript on medRxiv: https://doi.org/10.1101/2020.06.21.20136465). The 
simulated trajectory showed the entire epidemic period without containment measurements was 
approximately 47 days and reached the peak one month after the index case. 
 Thompson (J Clin Med 2020, see below) estimated the probability that an imported case is followed by 
sustained human-to-human transmission to 0.41 (credible interval [0.27, 0.55]). 
 Tuite (Lancet Inf Dis 2020, see below) suggested that the numerous COVID-19 case exportations from Italy 
early March indicated an epidemic that was larger than official case counts suggested. The authors estimated 
non-identification of cases to reach 72% (61–79%) of cases, corresponding to a true outbreak size of 3971 
cases (95% CI 2907–5297) vs. a reported case count of 1128 on Feb 29, 2020. 
 De Salazar (Em Inf Dis 2020, see below) used air travel volume estimates from Wuhan, China, to international 
destinations and a generalized linear regression model to identify locations that could have undetected 
imported cases. The data led to a recommendation of rapid strengthening of surveillance and control efforts 
in locations like Indonesia. By contrast, India and Singapore were found to have more cases reported than 
expected from the model. 
 Li (Science 2020, see below) used observations of reported infections within China, in conjunction with 
mobility data, a networked dynamic metapopulation model and Bayesian inference, to infer critical 
epidemiological characteristics associated with SARS-CoV2, including the fraction of undocumented infections 
and their contagiousness. The authors estimated 86% of all infections were undocumented (95% CI: 82%–90%) 
prior to 23 January 2020 travel restrictions. Per person, the transmission rate of undocumented infections was 
55% of documented infections (46%–62%), yet, due to their greater numbers, undocumented infections were 
the infection source for 79% of documented cases. These findings help explain the rapid geographic spread of 
SARS-CoV-2 and indicate containment of this virus is particularly challenging. 
 Rocklöv (J Travel Med 2020, see below) noted that empirical observations suggesting population density can 
have large impacts on R0 through the contact rates. On the Diamond Princess cruise ship, both the population 
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density and R0 was estimated approximately four times greater than that in Wuhan. Therefore, the authors 
recommend avoiding situations with higher population densities to limit the spread of COVID-19. 
 Kissler (Science 2020, see below) used estimates of βCoVs OC43 and HKU1 to inform a model of SARS-CoV-2 
transmission. The authors projected that recurrent wintertime outbreaks of SARS-CoV-2 will probably occur 
after the initial, most severe pandemic wave. They suggested that, to avoid exceeding critical care capacities, 
prolonged or intermittent social distancing may be necessary into 2022. Moreover, they predicted that even 
in the event of apparent elimination, a resurgence in contagion could be possible as late as 2024. 
 Debora MacKenzie (New Scientist 2020, see below) referred to modelling data suggesting that only 10 per 
cent of cases are responsible for 80 per cent of transmission. 
 Kim (Epidemiol Health 2020, see below) modelled the COVID-19 outbreak in the Republic of Korea by applying 
a mathematical model of transmission that factors in behavioural changes. The model demonstrated that the 
relatively high per-capita rate of transmission and the low rate of changes in behaviour have caused a large-
scale transmission of COVID-19 in the Daegu/Gyeongbuk area in the Republic of Korea. 
 Age disparities in observed cases could be explained by children having lower susceptibility to infection, lower 
propensity to show clinical symptoms or both. Davies (Nat Med 2020, see below) evaluated these possibilities 
by fitting an age-structured mathematical model to epidemic data from China, Italy, Japan, Singapore, Canada 
and South Korea. The authors estimated that susceptibility to infection in individuals under 20 years of age is 
approximately half that of adults aged over 20 years, and that clinical symptoms manifest in 21% (95% credible 
interval: 12-31%) of infections in 10- to 19-year-olds, rising to 69% (57-82%) of infections in people aged over 
70 years.  
Modelling the impact of public health measures 
 Gostic estimated the effectiveness of symptom and risk screening to prevent the spread of COVID-19 (Elife. 
2020, see below) 
 Anzai assessed the impact of reduced travel on exportation dynamics of COVID-19 (J Clin Med 2020, see 
below) 
 Hellewell (Lancet Glob Health 2020, see below) used a mathematical model to assess if isolation and contact 
tracing are able to control onwards transmission from imported cases of COVID-19. The authors found that 
the probability of controlling an outbreak decreased with the number of initial cases, when R0 was 2·5 or 3·5 
and with more transmission before symptom onset. Across different initial numbers of cases, the majority of 
scenarios with an R0 of 1·5 were controllable with less than 50% of contacts successfully traced. To control 
the majority of outbreaks, for R0 of 2·5 more than 70% of contacts had to be traced, and for an R0 of 3·5 more 
than 90% of contacts had to be traced. The delay between symptom onset and isolation had the largest role 
in determining whether an outbreak was controllable when R0 was 1·5. For R0 values of 2·5 or 3·5, if there 
were 40 initial cases, contact tracing and isolation were only potentially feasible when less than 1% of 
transmission occurred before symptom onset. 
 Chinazzi (Science 2020, see below) used a global metapopulation disease transmission model to project the 
impact of travel limitations on the national and international spread of the epidemic. The model was calibrated 
based on internationally reported cases, and shows that at the start of the travel ban from Wuhan on 23 
January 2020, most Chinese cities had already received many infected travellers. The travel quarantine of 
Wuhan delayed the overall epidemic progression by only 3 to 5 days in Mainland China, but had a more marked 
effect at the international scale, where case importations were reduced by nearly 80% until mid-February. 
Modelling results also suggested that sustained 90% travel restrictions to and from Mainland China only 
modestly affected the epidemic trajectory unless combined with a 50% or higher reduction of transmission in 
the community.  
Delivered by Ingenta
IP: 157.193.240.2 On: Fri, 04 Jun 2021 12:29:12
Copyright Leuven University Press
 
Authors: Martine Denis, Valerie Vandeweerd, Rein Verbeke, Anne Laudisoit, Tristan Reid, Emma Hobbs, Laure Wynants, Diane 
Van der Vliet  
COVIPENDIUM version: 20 OCT 2020  Transdisciplinary Insights - Living Paper | 168 
 Wells (PNAS 2020, see below) estimated the impact of these control measures and investigated the role of 
the airport travel network on the global spread of the COVID-19 outbreak. Our results show that the daily risk 
of exporting at least a single SARS CoV-2 case from mainland China via international travel exceeded 95% on 
January 13, 2020. The authors found that 779 cases (95% CI: 632 to 967) would have been exported by 
February 15, 2020 without any border or travel restrictions and that the travel lockdowns enforced by the 
Chinese government averted 70.5% (95% CI: 68.8 to 72.0%) of these cases. In addition, during the first three 
and a half weeks of implementation, the travel restrictions decreased the daily rate of exportation by 81.3% 
(95% CI: 80.5 to 82.1%), on average.  
 Lau (J Trav Med 2020, see below) evaluated whether rigorous lockdown measures as implemented by China 
have the potential to slow down the virus’ spread. The authors reported a significant decrease in the growth 
rate of the epidemic. Moreover, a corresponding increase in the doubling time of COVID-19 cases within China 
was observed, from 2 days (95% Confidence Interval, CI): 1.9-2.6), to 4 days (95% CI: 3.5-4.3) after lockdown. 
However, the authors also noted that the number of cases outside lockdown areas have increased, and new 
epicenters are developing across the globe. 
 Pan (JAMA 2020, see below) divided the epidemic in China into four periods based on key events and 
interventions, compared epidemiological characteristics across periods and demographic groups, and 
developed a susceptible-exposed-infectious-recovered model to evaluate the impact of interventions. The 
authors found that the effective reproductive number dropped from 3.86 (95% credible interval 3.74 to 3.97) 
before interventions to 0.32 (0.28 to 0.37) post interventions. The interventions were estimated to prevent 
94.5% (93.7 to 95.2%) infections till February 18. They noted that at least 59% of infected cases were 
unascertained in Wuhan, potentially including asymptomatic and mild-symptomatic cases. 
 Liu (Biology 2020, see below) developed another mathematical model for the disease, which predictions 
emphasize the importance of major public health interventions such as isolation, quarantine, and public 
closings, to greatly reduce the final size of this epidemic, and make the turning point much earlier than without 
these measures. 
 Karako (Biosci Trends 2020, see below) presented a stochastic transmission model by extending the 
Susceptible-Infected-Removed (SIR) epidemiological model with an additional modelling of the individual 
action on whether to stay away from the crowded areas. The authors concluded that the infection spread in 
Japan would be gradually contained by reducing the time spent in the crowded zone to less than 4 hours. 
 Kraemer (Science 2020, see below) used real-time mobility data from Wuhan and detailed case data including 
travel history to elucidate the role of case importation on transmission in cities across China and ascertain the 
impact of control measures. The authors showed that travel restrictions are particularly useful in the early 
stage of an outbreak when it is confined to a certain area that acts as a major source. However, travel 
restrictions may be less effective once the outbreak is more widespread. 
 Rong (Math Biosci Eng 2020, see below) investigated the effect of delay in diagnosis on disease transmission 
with a new formulated dynamic model, and showed that improving the proportion of timely diagnosis and 
shortening the waiting time for diagnosis cannot eliminate COVID-19, but can effectively decrease the basic 
reproduction number and significantly reduce the transmission risk. 
 Ferretti (Science 2020, see below) determined requirements for case isolation and contact-tracing to stop the 
epidemic. The authors concluded that viral spread is too fast to be contained by manual contact tracing, but 
could be controlled if this process was faster, more efficient and happened at scale. A contact-tracing App 
which builds a memory of proximity contacts and immediately notifies contacts of positive cases can achieve 
epidemic control if used by enough people. The model concluded that such mobile phone App could reduce 
transmission enough to achieve R < 1 and sustained epidemic suppression, stopping the virus from spreading 
further. A web interface has been made available online to explore the uncertainty in the modelling 
assumptions (https://bdi-pathogens.shinyapps.io/covid-19-transmission-routes/). 
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 Sjödin (Euro Surveill 2020, see below) investigated the extent of physical distancing needed to effectively 
control the outbreak in a lockdown situation in a small size town setting typical of Italy. The authors showed 
that very high adherence to community quarantine (total stay-home policy) and a small household size is 
necessary for curbing the outbreak in a locked-down town. The larger the household size and amount of time 
in the public, the longer the lockdown period needed. 
 A study by Siedner (PLoS Med 2020, see below) suggested that social distancing measures were associated 
with a statistically significant decrease in the COVID-19 case growth rate in the US. Statewide social distancing 
measures were also associated with a decrease in the COVID-19-attributed mortality growth rate beginning 7 
days after implementation, although this decrease was no longer statistically significant by 10 days. 
 The model developed by Park (Envir Res Econ 2020, see below), assuming an R0 value of 2.0 and vaccine 
effectiveness of 0.5, found that herd immunity would require at least 62% of the susceptible population 
vaccinated in South Korea. 
 Considering that in the absence of vaccination, or when vaccine efficacy is poor, social distancing may help to 
curb the spread of diseases, Choi developed a game-theoretic epidemiological model that considers both 
vaccination and social distancing (J Theor Biol 2020, see below). 
 Block (Nat Hum Behav 2020, see below) demonstrated the impact of social network-based distancing 
strategies. 
Therapeutic interventions and research  
Identifying treatment options as soon as possible is critical for the response to the COVID-19 outbreak (Lu Biosci Trends 
2020, see below). Various approaches, including evaluation of existing broad-spectrum antiviral drugs using standard 
assays, screening of a chemical library containing many existing compounds or databases, and the redevelopment of 
new specific drugs based on the genome and biophysical understanding of individual coronaviruses, can be used to 
identify potential therapies. Numerous candidates were proposed from the beginning of the epidemic, some of which 
were very soon administered to patients. In addition to antivirals, research and development on host-directed 
therapies was also recommended (Zumla Lancet 2020, see below). 
A list of candidate therapeutics was published by WHO in February 2020 
(https://www.who.int/publications/m/item/overview-of-the-types-classes-of-candidate-therapeutics). At the same 
time, the Chinese Academy of Sciences suggested a list of 30 different compounds, with 12 HIV medicines, including 
saquinavir, indinavir, lopinavir, ritonavir and carfilzomib, two respiratory syncytial virus drugs, a schizophrenia 
medication and an immunosuppressant. Candidates also included certain Traditional Chinese Medicines.  
Subsequent publications on this topic presented additional lists of potential compounds. For instance, a manuscript 
by Yan (https://www.preprints.org/manuscript/202002.0254/v1) indicated that in addition to synthetic compounds 
(including FDA-approved drugs), Chinese Patent Drugs (CPD) can also be a source of therapies against COVID-19. He 
compiled major components from 38 CPDs that are commonly used in the respiratory diseases and docked them 
against two drug targets, ACE2 receptor and viral main protease. Ten antiviral components, including hesperidin, 
saikosaponin, rutin, baicalin, glycyrrhizin, mulberroside A, puerarin, orientin, amygdalin, and ilexgenin A, were 
predicted as able to directly bind to both host cell target ACE2 receptor and viral target main protease, indicating their 
potential for treatment.  
In silico work is still ongoing to identify potential drug candidates. Using network proximity analyses of drug targets 
and known human CoV-host interactions in the human protein-protein interactome, Zhou (Cell Discov 2020, see below) 
computationally identified 135 putative repurposable drugs for the potential prevention and treatment of human CoV 
infections. In addition, 16 potential repurposable drugs (including melatonin, mercaptopurine, and sirolimus) were 
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further validated by enrichment analyses of drug-gene signatures and CoV-induced transcriptomics data in human cell 
lines. Finally, the authors presented three potential drug combinations (including sirolimus plus dactinomycin, 
mercaptopurine plus melatonin, and toremifene plus emodin) captured by the Complementary Exposure pattern: the 
targets of the drugs both hit the human CoV-host subnetwork, but target separate neighbourhoods in the human 
protein-protein interactome network. 
As live SARS-CoV-2 handling requires high-level biosafety facilities, Fan (Chin Med J 2020, see below) suggested the 
use of a pangolin coronavirus model to facilitate in vitro studies of potential drug candidates against COVID-19. The 
drug candidates were screened for their ability to inhibit cytopathic effect upon GX_P2V/pangolin/2017/ Guangxi 
strain infection of Vero E6 cells. The approach identified cepharanthine, selamectin and mefloquine hydrochloride as 
potential drugs. 
In another example, Gordon (Nature 2020, see below) presented a SARS-CoV-2 protein interaction map providing 
another approach to the identification of targets for drug repurposing. The authors cloned, tagged and expressed 26 
of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins that physically associated with each 
of the SARS-CoV-2 proteins using affinity-purification mass spectrometry, identifying 332 high-confidence protein-
protein interactions between SARS-CoV-2 and human proteins. Among these, 66 druggable human proteins or host 
factors targeted by 69 compounds were identified (of which, 29 drugs are approved by the US FDA, 12 are in clinical 
trials and 28 are preclinical compounds). Two sets of pharmacological agents that displayed antiviral activity were 
found: inhibitors of mRNA translation and predicted regulators of the sigma-1 and sigma-2 receptors.  
As early as in February 2020, a publication in Nature (Maxmen 2020, see below) reported the launch of more than 80 
clinical trials to test candidate coronavirus treatments. However, as illustrated by the Global Coronavirus COVID-19 
Clinical Trial Tracker (https://www.covid-trials.org/), this number quickly increased to close to 2000. A list and 
classification of COVID-19 experimental treatments has been made available by WHO on April 28 
(https://www.who.int/publications/m/item/covid-19-candidate-treatments). A more recent overview of the 
advancement of candidate therapeutics, with classification by mode of action, can be found at 
https://www.racap.com/media/Covid-19/COVID-
19_TX_10232020_F.pdf?v=0JDeeRgx6286WufrJxh_Cm1PquJVqf2KdCM4-vk2f38. 
Management of early symptoms 
The French minister, Oliver Veran, tweeted on March 14th that people with suspected COVID-19 should avoid anti-
inflammatory drugs. “Taking anti-inflammatory drugs (ibuprofen, cortisone . . .) could be an aggravating factor for the 
infection. If you have a fever, take paracetamol,” he said. His comments seem to have stemmed in part from remarks 
attributed to an infectious diseases doctor in south west France (Day BMJ 2020, see below). She was reported to have 
cited four cases of young patients with covid-19 and no underlying health problems who went on to develop serious 
symptoms after using non-steroidal anti-inflammatory drugs (NSAIDs) in the early stage of their symptoms. Some 
experts in the UK backed this sentiment that for treating symptoms such as fever and sore throat, it seems sensible to 
stick to paracetamol as first choice. In parallel, the EMA stated that there is currently no scientific evidence establishing 
a link between ibuprofen and worsening of COVID‑19 (https://www.ema.europa.eu/en/news/ema-gives-advice-use-
non-steroidal-anti-inflammatories-covid-19). An overview by Sodhi (Chest 2020, see below) confirmed that the current 
epidemiological evidence is not strong enough to infer a causal link of a harmful effect of ibuprofen in patients with 
COVID-19. A review by Smart (Inflammopharmacology 2020, see below) indicated that double-blind, placebo-
controlled study results are still required regarding the use of ibuprofen in COVID-19 patients. The authors noted that 
limited studies have suggested: (i) no direct interactions between ibuprofen and SARS-CoV-2 and (ii) there is no 
evidence to suggest ibuprofen affects the regulation of ACE2 in human studies. Furthermore, in vitro studies suggest 
ibuprofen may facilitate cleavage of ACE2 from the membrane, preventing membrane-dependent viral entry into the 
cell, the clinical significance of which is uncertain. Additionally, in vitro evidence suggests that inhibition of the 
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transcription factor nuclear factor-κB (NF-kB) by ibuprofen may have a role in reducing excess inflammation or 
cytokine release in COVID-19 patients. Finally, there is no evidence that ibuprofen will aggravate or increase the chance 
of infection of COVID-19. A prospective cohort study recently reported by Abu Esba (manuscript on Research Square: 
https://www.researchsquare.com/article/rs-85148/v1) concluded that ibuprofen and other NSAID acute or chronic 
use were not associated with worse COVID-19 disease outcomes. 
Antiviral drugs  
Various antiviral drug candidates have been rapidly assessed in COVID-19 patients. However, as of today, the outcome 
of only a limited number of randomized controlled trials is available, and the search for a safe and efficacious treatment 
of COVID-19 is still ongoing. 
Inhibitors of virus entry 
Chloroquine, hydroxychloroquine and analogues 
Chloroquine and its structural analogues such as hydroxychloroquine, amodiaquine, pamaquine, plasmoquine, 
primaquine, mefloquine or ferroquine, have been used for decades as the primary and most successful drugs against 
malaria (Al-Bari Pharmacol Res Perspect 2017, see below). These drugs are also found to be effective against a wide 
variety of viral infections. Chloroquine is known to block virus infection by increasing endosomal pH required for 
virus/cell fusion, as well as interfering with the glycosylation of cellular receptors of SARS-CoV (Wang Cell Res 2020, 
see below). Besides its antiviral activity, chloroquine has an immune-modulating activity, which may synergistically 
enhance its antiviral effect in vivo. Chloroquine is widely distributed in the whole body, including lung, after oral 
administration. Devaux (Int J Antimicr Ag 2020, see below) recently provided an overview of the possible mechanisms 
of chloroquine interference with SARS-CoV-2 replication. 
Of note, several clinical studies of chloroquine and its analogues have been conducted for treatment of dengue, 
hepatitis C virus, chikungunya and HIV-1 infections. Disappointingly, the outcome of one of these clinical trials showed 
no benefit of chloroquine treatment of dengue virus infection (Tricou PLoS Negl Trop Dis 2010, see below). More 
recently, Garbern (Open For Inf Dis 2019, see below) found a non-statistically significantly decreased risk of mortality 
in Ebola patients exposed to artesunate-amodiaquine during mass drug administrations as compared with Ebola 
patients not exposed to artesunate-amodiaquine. 
A comprehensive review by Morrisette (Inf Dis Ther 2020, see below), published on August 1st 2020, described the 
current understanding of hydroxychloroquine and its use against SARS-CoV-2 infection, and discussed remaining 
knowledge gaps. 
Preclinical data 
Chloroquine was found to potently inhibit infection of Vero E6 cells by a SARS-CoV-2 clinical isolate (EC50 = 1.13 μM; 
CC50 > 100 μM, SI > 88.50). The drug was shown to function at both entry, and at post-entry stages of the SARS-CoV-
2 infection in Vero E6 cells. The EC90 value of chloroquine against SARS-CoV-2 was 6.90 μM, which can be clinically 
achievable as demonstrated in the plasma of rheumatoid arthritis patients who received 500 mg administration.  
Yao (Clin Inf Dis 2020, see below) found hydroxychloroquine (EC50=0.72 μM) to be more potent than chloroquine 
(EC50=5.47 μM) in vitro. Based on physiologically-based pharmacokinetic models results, a loading dose of 400 mg 
twice daily of hydroxychloroquine sulfate given orally, followed by a maintenance dose of 200 mg given twice daily for 
4 days would be recommended for SARS-CoV-2 infection, as it reached three times the potency of chloroquine 
phosphate when given 500 mg twice daily 5 days in advance. Similar results were reported by Liu (Cell Discov 2020, 
see below). At all conditions tested (MOI of 0.01, 0.02, 0.2, and 0.8), the EC50 for chloroquine (2.71, 3.81, 7.14, and 
7.36 μM) was lower than that of hydroxychloroquine (4.51, 4.06, 17.31, and 12.96 μM). The differences in EC50 values 
were statistically significant at an MOI of 0.01 (P < 0.05) and MOI of 0.2 (P < 0.001). 
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On May 6 2020, Maisonnasse (manuscript on Research Square: https://www.researchsquare.com/article/rs-27223/v1) 
reported the antiviral activity of hydroxychloroquine both in vitro and in SARS-CoV-2-infected macaques. 
Hydroxychloroquine showed antiviral activity in African green monkey kidney (Vero E6) cells, but not in a model of 
reconstituted human airway epithelium. In macaques, the authors tested different treatment strategies in comparison 
to placebo, before and after peak viral load, alone or in combination with azithromycin. Neither hydroxychloroquine 
nor hydroxychloroquine + azithromycin showed a significant effect on the viral load levels in any of the tested 
compartments. When the drug was used as a pre-exposure prophylaxis, hydroxychloroquine did not confer protection 
against acquisition of infection. 
Clinical data 
Cortegiani (J Crt Care 2020, see below) identified 23 clinical trials in China evaluating the efficacy and safety of 
chloroquine or hydroxychloroquine in the treatment of COVID-19 associated pneumonia. The trials varied in study 
design, severity of the disease in the target population and in dosing and duration of the treatment (as illustrated in 
March 2020 by Li Nature, see below). The first results, from more than 100 patients, were released by the China 
National Centre for Biotechnology Development and said to indicate that chloroquine phosphate is superior to control 
treatment in inhibiting the exacerbation of pneumonia, improving lung imaging findings, promoting a virus-negative 
conversion, and shortening the disease course, according to a news briefing (Gao BioSci Trends 2020, see below). 
Severe adverse reactions to chloroquine phosphate were not noted in the aforementioned patients. 
In order to guide and regulate the use of chloroquine in patients with COVID-19, the “multicenter collaboration group 
of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for 
chloroquine in the treatment of novel coronavirus pneumonia” recommended chloroquine phosphate tablet, 500mg 
twice per day for 10 days for patients diagnosed as mild, moderate and severe cases of novel coronavirus pneumonia 
and without contraindications to chloroquine (Zhonghua Jie He He Hu Xi Za Zhi 2020, see below). 
The Dutch CDC suggested to treat severe infections requiring admission to the hospital and oxygen therapy or 
admitted to the ICU, with chloroquine (Cortegiani J Crt Care 2020, see below). However, the document also stated 
that treating patients only with optimal supportive care is still a reasonable option, due to lack of supportive evidence. 
The suggested regimen in adults consists of 600mg of chloroquine base followed by 300mg after 12 h on day 1, then 
300mg × 2/die per os on days 2–5.  
Huang (J Mol Cell Biol 2020, see below) reported the outcome of a small randomized trial that compared a group of 
10 patients, including 3 severe and 7 moderate cases, treated with chloroquine 500mg orally twice-daily for 10 days 
to another group of 12 patients, including 5 severe and 7 moderate cases, treated with lopinavir/ritonavir 400/100mg 
orally twice-daily for 10 days. Compared to the lopinavir/ritonavir group, the percentages of patients who became 
SARS-CoV-2 negative in the chloroquine group were slightly higher at Day 7, Day 10, and Day 14. Patients treated with 
chloroquine were also discharged from hospital more rapidly. The data therefore point to a superior efficacy of 
chloroquine. However, larger studies remain needed before solid conclusions on this topic can be drawn. 
In addition, Gautret (International Journal of Antimicrobial Agents 2020, see below) reported the outcome of an open-
label non-randomized clinical trial that evaluated hydroxychloroquine alone or combined with azithromycin compared 
to untreated patients from another centre and cases refusing the protocol. Twenty cases received treatment in this 
study and showed a significant reduction of the viral carriage at day 6 post inclusion compared to controls, and much 
lower average carrying duration than reported of untreated patients in the literature. Azithromycin added to 
hydroxychloroquine was significantly more efficient for virus elimination. A second open-label trial of the combination 
of hydroxychloroquine and azythromycin in 80 patients was also reported by the same team (Gautret Trav Med Inf Dis 
2020, see below). 
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Geleris (NEJM 2020, see below) evaluated the association between hydroxychloroquine use and intubation or death 
at a large medical center in an observational study in New York City. Of 1376 patients included in the study, 811 
received hydroxychloroquine (600 mg twice on day 1, then 400 mg daily for a median of 5 days); 45.8% of the patients 
were treated within 24 hours after presentation to the emergency department, and 85.9% within 48 hours. 
Hydroxychloroquine-treated patients were more severely ill at baseline than those who did not receive 
hydroxychloroquine. Overall, 346 patients (25.1%) had a primary end-point event (180 were intubated, 66 died after 
intubation, and 166 died without intubation). In the main analysis, there was no significant association between 
hydroxychloroquine use and intubation or death (hazard ratio, 1.04, 95% confidence interval, 0.82 to 1.32). Results 
were similar in multiple sensitivity analyses.  
Another registry analysis of the use of hydroxychloroquine or chloroquine with or without a macrolide for treatment 
of COVID-19 was presented by Mehra (Lancet 2020, see below). The registry comprised data from patients hospitalised 
between Dec 20, 2019, and April 14, 2020, with a positive laboratory finding for SARS-CoV-2. Of a total of 96032 
patients included, 14 888 patients were in the treatment groups (1868 received chloroquine, 3783 received 
chloroquine with a macrolide, 3016 received hydroxychloroquine, and 6221 received hydroxychloroquine with a 
macrolide) and 81 144 patients were in the control group. After controlling for multiple confounding factors, when 
compared with mortality in the control group (9.3%), hydroxychloroquine (18.0%; hazard ratio 1.335, 95% CI 1.223–
1.457), hydroxychloroquine with a macrolide (23.8%; 1.447, 1.368–1.531), chloroquine (16.4%; 1.365, 1.218–1.531), 
and chloroquine with a macrolide (22.2%; 1.368, 1.273–1.469) were each independently associated with an increased 
risk of in-hospital mortality. In conclusion, the authors were unable to confirm a benefit of hydroxychloroquine or 
chloroquine, when used alone or with a macrolide, on in-hospital outcomes for COVID-19. They also noted that the 
study had several limitations and that the association of decreased survival with hydroxychloroquine or chloroquine 
treatment regimens should be interpreted cautiously. Importantly, after publication of this paper, several concerns 
were raised with respect to the veracity of the data and analyses conducted. As an independent third-party peer 
review could not be conducted, Mehra and 2 other co-authors requested that the paper be retracted (Mehra 
Ruschitzka and Patel, Lancet 2020, see below). 
Perinel (Clin Inf Dis 2020, see below) reported the outcome of a preliminary PK study to define the optimal dosing 
regimen for COVID-19 patients in ICU. Based on the authors’ simulations, a loading dose of 800 mg once daily on day 
1, followed by 200 mg twice daily for 7 days was proposed. Therapeutic drug monitoring was also recommended to 
personalize the optimal dosing regimen, as well as additional PK and PD (virological) studies. 
Garcia-Cremades (Clin Pharmacol Ther 2020, see below) further investigated the topic of hydrochloroquine dosing, 
using available data. The authors predicted that higher hydroxychloroquine daily doses (e.g. as high as 800 mg BID), 
were associated with rapid rates of viral decline and increased the percentage of PCR negative patients, but could 
result in increased risk of QTc prolongation (indicator of delayed ventricular repolarisation as measured by 
electrocardiogram). 
Borba (JAMA Netw Open 2020, see below) presented interim results from a double-masked, randomized, phase IIb 
clinical trial in adult patients hospitalized with severe disease to evaluate high vs. low dose chloroquine diphosphate. 
Data from 81 patients were analysed. The authors concluded that the higher chloroquine dosage should not be 
recommended for critically ill patients with COVID-19 because of its potential safety hazards, especially when taken 
concurrently with azithromycin and oseltamivir. However, a report based on data from the U.S. FDA's Adverse Event 
Reporting System (FAERS) concluded that (hydroxy)chloroquine use was not associated with a safety signal (Sarayani 
Res Social Adm Pharm 2020, see below). Azithromycin used alone was associated with TdP/QT prolongation events. 
On March 28th, the U.S. FDA issued an emergency use authorization (EUA) that allowed for chloroquine phosphate and 
hydroxychloroquine sulfate donated to the Strategic National Stockpile to be used to treat certain hospitalized patients 
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with COVID-19 when a clinical trial was unavailable, or participation in a clinical trial was not feasible. However, new 
information, including clinical trial data results, led to the conclusion that this drug may not be effective to treat COVID-
19 and that the drug’s potential benefits for such use do not outweigh its known and potential risks.  The authorization 
was thus revoked on June 15th 2020 (https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-
update-fda-revokes-emergency-use-authorization-chloroquine-and). On July 4th, the WHO discontinued the 
hydroxychloroquine arm in the Solidarity trial as interim results of the trial showed little or no reduction in the 
mortality of hospitalized COVID-19 patients when compared to standard of care (https://www.who.int/news-
room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-
19). 
A review by Rakedzon (Rambam Maimonides Med J 2020, see below) included 17 studies evaluating 
hydroxychloroquine treatment. A total of 13 were observational studies, and 4 were randomized controlled trials. In 
terms of effect on mortality rates, observational studies provided conflicting results. As a whole, randomized 
controlled trials, including one large British randomized controlled trial that has not yet been published, showed no 
significant effect of hydroxychloroquine on mortality rates, clinical cure, and virologic response. 
Boulware (NEJM 2020, see below) reported the outcome of a randomized, double-blind, placebo-controlled trial 
across the United States and parts of Canada testing hydroxychloroquine (used within 4 days after exposure) as post-
exposure prophylaxis. The study enrolled 821 asymptomatic participants. Overall, 87.6% of the participants (719 of 
821) reported a high-risk exposure to a confirmed COVID-19 contact. The incidence of new illness compatible with 
COVID-19 did not differ significantly between participants receiving hydroxychloroquine (49 of 414 [11.8%]) and those 
receiving placebo (58 of 407 [14.3%]); the absolute difference was −2.4 percentage points (95% confidence interval, 
−7.0 to 2.2; P=0.35). Side effects were more common with hydroxychloroquine than with placebo (40.1% vs. 16.8%), 
but no serious adverse reactions were reported. 
Hydroxychloroquine has also been considered for pre-exposure prophylaxis against COVID-19. Several randomized, 
double-blind, controlled studies to evaluate the effectiveness and safety of hydroxychloroquine for prophylaxis of 
COVID-19 have been reported as ongoing. For instance, a trial with chloroquine phosphate or hydroxychloroquine 
sulphate in 40 000 healthcare workers in the UK 
(https://clinicaltrials.gov/ct2/show/NCT04303507?term=healthy+coronavirus&recrs=abdf&type=Intr&draw=2&rank
=11), a trial in Mexico in 400 health care workers receiving hydroxychloroquine 
(https://clinicaltrials.gov/ct2/show/NCT04318015?term=healthy+coronavirus&recrs=abdf&type=Intr&draw=2&rank
=20), or in Thailand, a trial in 40 000 healthcare workers in a healthcare facility delivering direct care to patients 
(https://clinicaltrials.gov/ct2/show/NCT04303507?term=healthy+coronavirus+chloroquine&recrs=abdf&type=Intr&d
raw=2&rank=1).  
Additional data of interest 
Data reported by Ou on July 22 (manuscript on bioRxiv, see: 
https://www.biorxiv.org/content/10.1101/2020.07.22.216150v1) provided a mechanistic explanation for the 
disappointing in vivo data of hydroxychloroquine as a treatment for COVID-19. The authors showed that the SARS-
CoV-2 entry process is more dependent than that of SARS-CoV-1 on TMPRSS2 expression. Moreover, it was 
demonstrated that hydroxychloroquine efficiently blocks viral entry mediated by cathepsin L, but not by TMPRSS2, 
and that a combination of hydroxychloroquine and a clinically-tested TMPRSS2 inhibitor prevents SARS-CoV-2 
infection more potently than either drug alone.  
Umifenovir (arbidol)  
Umifenovir (arbidol), first developed by the Russian Research Chemical-Pharmaceutical Institute, could effectively 
inhibit SARS-CoV-2 infection at a concentration of 10-30 μM in vitro (Fang Front Pharmacol 2020, see below). This 
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suggests that umifenovir may have the ability to inhibit SARS-CoV-2 in vivo, making it a promising therapeutic drug for 
COVID-19. According to a communication of the China National Center for Biotechnology Development at a press 
conference, the drug has been added to the list of possible treatments of COVID-19 in the sixth edition of the treatment 
and diagnosis plan published by the Chinese National Health Commission 
(https://www.thestar.com.my/news/regional/2020/02/18/chinese-experts-confirm-antimalarial-drug-is-effective-
on-covid-19-infection). 
Deng (J Inf 2020, see below) presented the results of a small retrospective cohort study in 33 adults with laboratory-
confirmed COVID-19 without invasive ventilation.  The authors concluded that combined oral umifenovir (at a dose of 
200mg every 8 h) and lopinavir/ritonavir therapy was associated with a significant elevated negative conversion rate 
of COVID-19 RT-PCR at 7-day and 14-day, compared with lopinavir/ritonavir only. The combination therapy was also 
associated with a significantly improved the chest CT scans at the 7-day timepoint.  
A non-randomized clinical study that compared umifenovir to lopinavir/ritonavir in 50 patients concluded in the 
superiority of umifenovir. Patients in the umifenovir group had a shorter duration of positive RNA test compared to 
those in the lopinavir/ritonavir group (P<0.01) (Zhu J Inf 2020, see below). 
Lian (Clin Microbiol Infect 2020, below) reported a retrospective study in COVID-19 confirmed patients, with 45 having 
received arbidol and 36 in control group. 73.3% patients in umifenovir group were tested negative in SARS-CoV-2 
within 7 days after admission; 77.8% in control group (p=0.19). The median time from onset of symptoms to SARS-
CoV-2 turning negative were 18 days (interquartile range [IQR] 12-21) in umifenovir group and 16 days (IQR, 11-21) in 
control group (p= 0.42). Patients in arbidol group had longer hospital stay than patients in control group (13 days [IQR, 
9-17] vs 11 days [IQR, 9-14], p=0.04). No deaths or severe adverse reaction were found in any groups.  
A review by Huang (J Med Virol 2020, see below) in July 2020 identified a total of 12 studies of umifenovir with 1052 
COVID-19 patients.  Compared with control group, umifenovir was associated with higher negative rate of PCR on day 
14 (RR:1.27; 95% CI: 1.04 to 1.55). However, umifenovir was not related to nucleus acid negative conversion time (MD: 
0.09; 95% CI: −1.48 to 1.65), negative rate on day 7 (RR:1.09; 95% CI: 0.91 to 1.31), incidence of composite endpoint 
(RR:1.20; 95% CI: 0.61 to 2.37), rate of fever alleviation on day 7 (RR:1.00; 95% CI: 0.91 to 1.10), rate of cough 
alleviation on day 7 (RR:1.00; 95% CI: 0.85 to 1.18), or hospital length of stay (MD: 1.34; 95% CI: ‐2.08 to 4.76). 
Additionally, umifenovir was safe in COVID-19 patients (RR for incidence of adverse events: 1.29; 95% CI: 0.57 to 2.92). 
The results of sensitivity analysis and subgroup analysis were similar to pooled results. There was no evidence to 
support the use of umifenovir for improving patient-important outcomes in patients with COVID-19. 
Teicoplanin 
Teicoplanin, a glycopeptide antibiotic routinely used in the clinic to treat bacterial infection with low toxicity, had been 
previously reported to significantly inhibit the invasion of cells by Ebola virus, SARS-CoV and MERS-CoV, via specific 
inhibition of the activity of cathepsin L. The efficacy of teicoplanin against SARS-CoV-2 infection was recently tested: 
teicoplanin was found to potently prevent the entrance of S-HIV luc pseudoviruses into the cytoplasm, with an IC50 of 
1.66 μM. Although the inhibitory effect upon replication of wildtype viruses ex vivo and in vivo remains to be 
determined, these preliminary result support a potential antiviral activity of teicoplanin (Zhang on BioRixv: 
https://www.biorxiv.org/content/10.1101/2020.02.05.935387v1).  
Nafamostat  
Nafamostat, an anticoagulant, is a potent inhibitor of MERS-CoV, preventing membrane fusion. The drug has been 
found inhibitive against SARS-CoV-2 in vitro infection (EC50 = 22.50 μM, CC50 > 100 μM, SI > 4.44) (Wang Cell Res 
2020, see below). 
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EK1 
Peptide OC43-HR2P, derived from the HR2 domain of human CoV OC43, has been shown to exhibit broad fusion 
inhibitory activity against multiple human CoVs. EK1, the optimized form of OC43-HR2P, showed substantially 
improved pan-CoV fusion inhibitory activity and pharmaceutical properties (Xia Sci Adv 2019, see below). Crystal 
structures indicated that EK1 can form a stable six-helix bundle structure with both short α-HCoV and long β-HCoV 
HR1s, further supporting the role of HR1 region as a viable pan-CoV target site. Intranasal application of EK1 peptide 
before or after viral challenge protected human DPP4-transgenic mice from MERS-CoV infection (Jiang Em Micr Inf 
2020, see below).   
Xia (Cell Res 2020, see below) subsequently generated a series of lipopeptides derived from EK1 and found that EK1C4 
was the most potent fusion inhibitor against SARS-CoV-2 S protein-mediated membrane fusion and pseudovirus 
infection with IC50s of 1.3 and 15.8 nM, about 241- and 149-fold more potent than the original EK1 peptide, 
respectively. EK1C4 was also highly effective against membrane fusion and infection by other human CoV 
pseudoviruses. Intranasal application of EK1C4 before or after challenge with HCoV-OC43 protected mice from 
infection. 
Niclosamide 
Niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with 
nanomolar to micromolar potency such as SARS-CoV, MERS-CoV, Zika virus, hepatitis C virus and human adenovirus, 
indicating its potential activity against SARS-CoV-2 (Xu ACS Infect Dis 2020, see below). However, experimental data 
with SARS-CoV-2 have not been reported yet. 
Baricitinib 
Using an Artificial Intelligence-derived knowledge graph, queried by a suite of algorithms, Stebbing (Lancet Inf Dis 2020, 
see below) also identified a group of approved drugs that could inhibit clathrin-mediated endocytosis and thereby 
inhibit viral infection of cells. The drug targets are members of the numb-associated kinase (NAK) family, including the 
AP2-associated protein kinase 1 (AAK1) and GAK, the inhibition of which has been shown to reduce viral infection in 
vitro. Baricitinib was identified as a NAK inhibitor. Baricitinib also binds the cyclin G-associated kinase, another 
regulator of endocytosis. Further, baricitinib is a potent and selective JAK inhibitor and powerful anti-inflammatory. 
Because the plasma concentration of baricitinib on therapeutic dosing (either as 2 mg or 4 mg once daily) is sufficient 
to inhibit AAK1, Richardson (Lancet, see below) suggested it could be trialled, using an appropriate patient population 
with COVID-19 acute respiratory disease (see JAK-STAT inhibitors below for information on clinical trials of baricitinib). 
Camostat mesylate 
The in vitro data reported by Hoffmann (Cell 2020, see below) suggested that the Japanese drug camostat mesylate 
(trade name: Foipan), a TMPRSS2 inhibitor, might constitute a treatment option for COVID-19. The drug is currently 
evaluated in various randomized controlled trials (e.g. NCT04353284 or NCT04321096). 
RNA-dependent RNA polymerase inhibitors 
Nucleoside analogues commonly target viral replication, particularly the viral DNA or RNA polymerase, and have 
succeeded clinically in treating multiple viral infections (Agostini mBio 2018, see below). However, identification and 
development of antiviral nucleosides against coronaviruses have been hampered by the presence of the unique CoV 
proofreading 3’-5’exoribonuclease (ExoN). While nucleoside analogues such as BCX4430 inhibit CoVs, several 
previously tested nucleoside analogues have been incapable of potently inhibiting CoV replication, and others have 
demonstrated poor selectivity indexes. CoV resistance to the mutagens 5-fluorouracil and ribavirin in vitro is attributed 
to their removal by the proofreading ExoN, supporting the hypothesis that an effective nucleoside analogue must 
evade proofreading to successfully interfere with CoV RNA synthesis. 
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Remdesivir 
Remdesivir (GS-5734) is the monophosphoramidate prodrug of the C-adenosine nucleoside analogue GS-441524 
(Agostini mBio 2018, see below). This drug candidate had been shown to inhibit in vitro infections with SARS-CoV, 
MERS-CoV, and bat CoV strains that are capable of replicating in primary human airway epithelial cells and mediate 
entry using human CoV receptors. Remdesivir (EC50 = 0.77 μM; CC50 > 100 μM; SI > 129.87) potently blocked infection 
of Vero E6 cells by a clinical isolate of SARS-CoV-2 at low-micromolar concentration and showed high selectivity index16 
(Wang Cell Res 2020, see below). 
In vivo, remdesivir demonstrated both prophylactic and therapeutic efficacy against SARS-CoV disease in a mouse 
model. In a Ces1c-/- hDPP4 mouse model of MERS-CoV infection, both prophylactic and therapeutic use of remdesivir 
improved pulmonary function and reduced lung viral loads and severe lung pathology (Sheahan Nat Commun 2020, 
see below). Therapeutic remdesivir treatment 12h post-inoculation with MERS-CoV resulted in reduction in clinical 
signs, reduced virus replication in the lungs, and decreased presence and severity of lung lesions (de Wit PNAS 2020, 
see below). 
Remdesivir inhibits murine hepatitis virus (MHV) with similar 50% effective concentration values (EC50) as SARS-CoV 
and MERS-CoV (Agostini mBio 2018, see below), and this model was used to assess virus resistance to remdesivir. 
Passage of wild type MHV in the presence of the remdesivir parent nucleoside selected two mutations in the nsp12 
polymerase at residues conserved across all CoVs that conferred up to 5.6-fold resistance to remdesivir, as determined 
by EC50. The resistant viruses were unable to compete with wild type virus in direct coinfection passage in the absence 
of remdesivir. Introduction of the MHV resistance mutations into SARS-CoV resulted in the same in vitro resistance 
phenotype and attenuated SARS-CoV pathogenesis in a mouse model. Finally, an MHV mutant lacking ExoN 
proofreading was found significantly more sensitive to remdesivir. Combined, the results indicate that remdesivir 
interferes with the nsp12 polymerase even in the setting of intact ExoN proofreading activity and that resistance can 
be overcome with increased, nontoxic concentrations of the drug candidate.  
An overview of the various arguments supporting the use of remdesivir to treat COVID-19 has also been made available 
by Ko in March 2020 (Int J Antimicrob Ag, see below). A review of available data as well as (ongoing) clinical trials has 
also been published by Frediansyah (Clin Epid Glob Health 2020, see below). 
The first randomized, double-blind, placebo-controlled, multicenter clinical trial was reported on April 29, 2020 (Wang 
Lancet 2020, see below). The study was conducted in China with 237 patients (158 in the remdesivir group and 79 in 
the placebo control group; NCT04257656), and the primary endpoint was the time taken to achieve clinical 
improvement. The study revealed that treatment with remdesivir did not lead to a significant reduction in the time 
taken to achieve clinical improvement. In addition, mortality and viral clearance time in patients with severe COVID-
19 were not significantly different from those in the placebo group, suggesting that remdesivir had poor clinical 
benefits. Another phase 3 randomized controlled trial (NCT04252664) conducted in China was terminated prematurely. 
It has been mentioned that remdesivir (100 mg dose except for the first day of 200 mg) for ten days may raise safety 
concerns in China due to differences in ethnicity (Zhang, Huang et al. J Med Vir 2020, see below). 
Another phase 3 double-blind, randomized, placebo-controlled trial of the drug, the Adaptive COVID-19 Treatment 
Trial (ACTT, NCT04280705) enrolled patients in the U.S., Europe and Asia. A total of 1063 patients underwent 
randomization (Beigel NEJM 2020, see below). The data and safety monitoring board recommended early unblinding 
of the results on the basis of findings from an analysis that showed shortened time to recovery in the remdesivir group. 
Preliminary results from the 1059 patients (538 assigned to remdesivir and 521 to placebo) with data available after 
randomization indicated that those who received remdesivir had a median recovery time of 11 days (95% confidence 
                                                          
16 Importantly, in the same study, high concentrations of three nucleoside analogs including ribavirin, penciclovir and favipiravir 
were required to reduce viral infection 
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interval [CI], 9 to 12), as compared with 15 days (95% CI, 13 to 19) in those who received placebo (rate ratio for 
recovery, 1.32; 95% CI, 1.12 to 1.55; P<0.001). The Kaplan-Meier estimates of mortality by 14 days were 7.1% with 
remdesivir and 11.9% with placebo (hazard ratio for death, 0.70; 95% CI, 0.47 to 1.04). Serious adverse events were 
reported for 114 of the 541 patients in the remdesivir group who underwent randomization (21.1%) and 141 of the 
522 patients in the placebo group who underwent randomization (27.0%). 
In addition, Gilead announced the results of the phase 3 trial of remdesivir from the open-label, Phase 3 SIMPLE trial 
evaluating 5-day and 10-day dosing durations of the antiviral in hospitalized patients with severe manifestations of 
COVID-19. The study is being conducted at 180 trial sites around the world, including sites in the United States, China, 
France, Germany, Hong Kong, Italy, Japan, Korea, the Netherlands, Singapore, Spain, Sweden, Switzerland, Taiwan and 
the United Kingdom. The data that were disclosed demonstrated that patients receiving a 10-day treatment course of 
remdesivir achieved similar clinical improvement compared with those taking a 5-day treatment course. No new safety 
signals were identified with remdesivir across either treatment group. Clinical outcomes varied by geography. In an 
exploratory analysis, patients in the study who received remdesivir within 10 days of symptom onset had improved 
outcomes compared with those treated after more than 10 days of symptoms (https://www.gilead.com/news-and-
press/press-room/press-releases/2020/4/gilead-announces-results-from-phase-3-trial-of-investigational-antiviral-
remdesivir-in-patients-with-severe-covid-19).  
Grein (NEJM 2020, see below) analysed the data of patients hospitalized for severe COVID-19 who were treated with 
compassionate-use remdesivir in the U.S., Europe, Canada, and Japan. Clinical improvement was observed in 36 of 53 
patients (68%). Mortality reached 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among 
those not receiving invasive ventilation. 
A review of available clinical data by Brouqui (New Microbes New Infect 2020, see below), published online in June 
2020, concluded that it was far too premature to identify remdesivir as a curative or life-saving intervention against 
COVID-19. Nevertheless, the U.S. FDA authorized the emergency use of remdesivir (Veklury) for treatment of COVID-
19 on May 1st 2020 (https://www.fda.gov/media/137564/download). On August 31st, expanded emergency use 
authorisation (EUA) was granted by the US FDA for treating not only hospitalised patients suffering from severe COVID-
19, but also those who are moderately afflicted. 
While clinical trials of remdesivir are still ongoing, Doggrell (Expert Opin Investig Drugs 2020, see below) recently 
concluded that we still need to determine whether remdesivir is a game-changing remedy or a ripple in the ongoing 
search for a medicine for the treatment of COVID-19. 
Ribavirin 
In vitro data have not identified ribavirin as a lead candidate for COVID-19 treatment. However, a randomized clinical 
trial of the drug used in combination with pegylated interferon for COVID-19 has been reported in China 
(ChiCTR2000029387, Li Nat Rev Drug Discov 2020, see below). (Zhang, Huang et al. (J Med Vir 2020, see below) 
indicated in March 2020 that ribavirin was indicated for the general treatment of COVID-19 in Chinese treatment 
guidelines, and combination with interferon recommended. However, their clinical safety and efficacy against COVID-
19 were not evaluated in China. 
Favipiravir 
Randomized trials of favipiravir have been reported in China for COVID-19 therapy (ChiCTR2000029544, 
ChiCTR2000029600, Li Nat Rev Drug Discov 2020, see below). On March 17, Zhang Xinmin released in the media data 
from a Chinese trial that evaluated favipiravir 
(http://www.chinadaily.com.cn/a/202003/17/WS5e708666a31012821727fcbd.html). The Third People's Hospital of 
Shenzhen in Guangdong province conducted a clinical trial on 80 patients, with 35 receiving the drug. The results 
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showed that patients treated with favipiravir took four days before being tested negative, whereas the control group 
took 11 days. The lung conditions of 91.43 percent of the treated group improved as shown in chest imaging, compared 
with 62.22 percent of the control group. In another comparative trial on 120 patients conducted by Zhongnan Hospital 
of Wuhan University, the results were said to have shown that the treated group had a higher recovery rate at the end 
of treatment and took less time to reduce fever and relieve cough. A number of other clinical trials followed in other 
countries. Joshi (Int J Inf Dis 2020, see below) very recently reviewed available information on favipiravir and COVID-
19.  
Other RNA-dependent RNA polymerase inhibitors 
As reviewed by Al-Horani (Viruses 2020, see ), galidesivir, an adenosine nucleoside analogue, is an active site inhibitor 
of RdRp (EC50 < 50 µM). Similar to remdesivir, it is a prodrug that is metabolized by cellular kinases to the 
corresponding active form of nucleoside triphosphate. The triphosphate form binds to the active site of the viral 
enzyme and gets incorporated into the growing viral RNA chain resulting in premature chain termination. The drug is 
being tested in a phase 1 clinical trial for COVID-19 or Yellow Fever in Brazil in collaboration with the U.S. NIAID 
(NCT03891420; n = 132). 
Clevudine, a thymidine nucleoside analogue, was approved in Korea for the treatment of hepatitis B virus infection. It 
is a prodrug that requires phosphorylation to form the corresponding active nucleotide, the triphosphate. 
Mechanistically, the triphosphate active form appears to non-competitively inhibit the HBV reverse transcriptase 
protein priming and DNA synthesis. Importantly, although clevudine showed a potent antiviral response, its long-term 
use for more than a year led to the development of viral resistance and myopathy. The drug is being evaluated in a 
phase 2 as a treatment for COVID-19 in Korea (NCT04347915; n = 60). 
Emtricitabine and tenofovir disoproxil have been reported by a recent computational work as potential inhibitors of 
RdRp of SARS-CoV-2. The efficacy of emtricitabine and tenofovir disoproxil as a prophylactic combination against SARS-
CoV-2 infection is being evaluated in a large randomized, double-blind, controlled with placebo clinical trial for health 
care providers exposed to COVID-19 patients (NCT04334928). The efficacy of emtricitabine and tenofovir alafenamide 
as a prophylactic combination against SARS-CoV-2 infection is also to be evaluated in a planned large randomized, 
double-blind, controlled phase 3 trial for health care providers exposed to COVID-19 patients (NCT04405271; n = 1378). 
Alternative RNA polymerase inhibitors have been described. For instance, Lung (J Med Vir 2020, see below) screened 
chemical structures from traditional Chinese medicinal compounds proven to show anti-viral activity in SARS-CoV and 
similar chemical structures through a molecular docking study to target the RNA-dependent RNA polymerase (RdRp) 
of SARS-CoV-2, SARS-CoV and MERS-CoV. Theaflavin was identified as a SARS-CoV-2 RdRp inhibitor (Mhatre Phytomed 
2020, see below). The potential of this compound remains to be experimentally confirmed. 
Protease inhibitors 
Involved in the formation of the coronavirus replication complex, the viral main protease (3-chymotrypsin-like cysteine 
protease, 3CLpro, also called Mpro) represents an attractive target for therapy. The structure of Mpro has been 
resolved and made publicly available to facilitate global efforts to develop novel drug candidates. Chen (F1000Res 
2020, see below) prepared the three-dimensional model of the SARS-CoV-2 3CL pro using the crystal structure of the 
highly similar (96% identity) ortholog from SARS-CoV. All residues involved in the catalysis, substrate binding and 
dimerisation were found 100% conserved. Comparison of the polyprotein PP1AB sequences showed 86% identity. The 
3C-like cleavage sites on the coronaviral polyproteins appeared highly conserved. 
Lopinavir/ritonavir 
Lopinavir and ritonavir, which are used as a combination therapy for the treatment and prevention of HIV/AIDS, soon 
appeared as candidate of choice for COVID-19 therapy. Yao (J Med Vir 2020, see below) reviewed the literature on the 
efficacy of lopinavir in vitro and in vivo, especially in patients with SARS and MERS. Lin (manuscript on medRxiv: 
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https://www.biorxiv.org/content/10.1101/2020.01.31.929695v2) presented evidence supporting the mode of action 
of lopinavir, ritonavir and dapunavir through their predicted interactions with SARS-CoV-2 proteases. The authors 
suggested that the therapeutic effect of ritonavir and lopinavir on COVID-19 may be mainly due to their inhibitory 
effect on coronavirus endopeptidase C30, with ritonavir appearing to have stronger efficacy; the inhibitory effect of 
darunavir on SARS-CoV-2 and its potential therapeutic effect may be mainly due to its inhibitory effect on papain-like 
viral protease. 
Several clinical trials evaluated lopinavir and/or ritonavir (± other drug candidates) in COVID-19. Li for instance 
reported that in study NCT04252885, lopinavir/ritonavir presented little benefit over supportive care for improving 
the clinical outcome of patients hospitalized with mild/moderate COVID-19 (Med NY 2020, see below). 
Cao (NEJM 2020, see below) reported the outcome of an open-label trial involving hospitalized adult patients with 
confirmed SARS-CoV-2 infection in Wuhan. 199 patients were randomly assigned in a 1:1 ratio to receive either 
lopinavir-ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care, or standard 
care alone. Treatment with lopinavir-ritonavir was not associated with a difference from standard care in the time to 
clinical improvement (hazard ratio for clinical improvement, 1.24; 95% confidence interval [CI], 0.90 to 1.72). Mortality 
at 28 days was similar in the lopinavir-ritonavir group and the standard-care group (19.2% vs. 25.0%; difference, -5.8 
percentage points; 95% CI, -17.3 to 5.7). The percentages of patients with detectable viral RNA at various time points 
were similar. Moreover, lopinavir-ritonavir treatment was stopped early in 13 patients (13.8%) because of adverse 
events. The interpretation of these data in the editorial by Baden (NEJM 2020, see below) is also of interest. For 
instance, it highlighted the fact that patients recruited for this study were late in infection and already had considerable 
tissue damage.  
On July 4th, from the analysis of interim data from the trial, the WHO discontinued the lopinavir/ritonavir arm of the 
Solidarity trial  (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-
coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments). 
In the Recovery trial in the UK (NCT04381936), 1616 patients were randomly allocated to receive lopinavir–ritonavir 
and 3424 patients to receive usual care (Recovery collaborative group Lancet 2020: see below). Overall, 374 (23%) 
patients allocated to lopinavir–ritonavir and 767 (22%) patients allocated to usual care died within 28 days (rate ratio 
1·03, 95% CI 0·91–1·17; p=0·60). Results were consistent across all prespecified subgroups of patients. Among patients 
not on invasive mechanical ventilation at baseline, there was no significant difference in the proportion who met the 
composite endpoint of invasive mechanical ventilation or death (risk ratio 1·09, 95% CI 0·99–1·20; p=0·092). In patients 
admitted to hospital with COVID-19, lopinavir–ritonavir was not associated with reductions in 28-day mortality, 
duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.  
Other candidates targeting Mpro 
Zhang (manuscript on bioRxiv: https://www.biorxiv.org/content/10.1101/2020.02.17.952879v1) determined the 
crystal structure of the unliganded Mpro at 1.75 A resolution and used this structure to guide optimization of a series 
of alpha-ketoamide inhibitors. The main goal of the optimization efforts was improvement of the pharmacokinetic 
properties of the compounds.  
Numerous in silico studies aimed at finding Mpro/3CLpro inhibitors. For instance, based on the synergy of virtual 
screening, docking and molecular dynamics techniques, Macchiagodena (on arXiv: https://arxiv.org/abs/2002.09937) 
identified lead compounds for the non-covalent inhibition of Mpro of SARS-CoV-2. Ligands were found to share a 
common binding pattern with aromatic moieties connected by rotatable bonds in a pseudo-linear arrangement. 
Molecular dynamics calculations confirmed the stability in the Mpro binding pocket of most potent binder identified 
by docking, namely a chlorophenyl-pyridyl-carboxamide derivative.  
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Ton (Mol Inf 2020, see below) developed a novel deep learning platform - Deep Docking (DD) which provides fast 
prediction of docking scores of Glide (or any other docking program) and, hence, enables structure-based virtual 
screening of billions of purchasable molecules in a short time. The authors applied DD to all 1.3 billion compounds 
from ZINC15 library to identify top 1000 potential ligands for SARS-CoV-2 Mpro protein. 
Various authors, such as Kandeel (Life Sci 2020, see below), focused on screening FDA-approved drugs. Using this 
approach, ribavirin, anti-hepatitis B virus (telbivudine), two vitamins (vitamin B12 and nicotinamide) and other 
miscellaneous systemically acting drugs were identified as potential blockers of SARS-CoV-2 Mpro. In another example, 
Jin (Nature 2020, see below) assayed over 10 000 compounds including approved drugs, drug candidates in clinical 
trials, and other pharmacologically active compounds as inhibitors of Mpro. Six of these compounds inhibited Mpro 
with IC50 values ranging from 0.67 to 21.4 μM. Ebselen also exhibited promising antiviral activity in cell-based assays. 
To the best of our knowledge, the in vitro, in vivo, and toxicological evaluations of the compounds that have been 
identified by such in silico work has not been documented yet. 
Danoprevir 
A study described by Zhang, Wang, Tu et al (J Med Vir 2020, see below) enrolled 33 COVID-19 patients in Nanchang 
from 27th January to 24th February 2020. Patients were divided into two groups according to different treatment 
plans (danoprevir and lopinavir/ritonavir). COVID-19 patients treated with danoprevir or lopinavir/ritonavir were all 
improved and discharged. Additionally, the authors found that the mean time to achieve both negative nucleic acid 
testing and hospital stays of patients treated with danoprevir were significantly shorter than those of patients with 
lopinavir/ritonavir. 
Other drug candidates 
Nitazoxanide  
Nitazoxanide, a commercial antiprotozoal agent with antiviral potential against a broad range of viruses including 
human and animal coronaviruses, inhibited infection of Vero E6 cells by a clinical isolate of SARS-CoV-2 at a low-
micromolar concentration (EC50 = 2.12 μM; CC50 > 35.53 μM; SI > 16.76). Further in vivo evaluation of this drug 
against SARS-CoV-2 infection was recommended by Wang (Cell Res 2020, see below). 
Ivermectin 
As the epidemic continues to progress, more and more compounds are described as potential therapeutics with 
antiviral activity against SARS-CoV-2. For instance, ivermectin (Caly Antivir Res 2020, see below), a widely-approved 
anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, has been found to inhibit SARS-CoV-
2, with a  single  addition  to  Vero-hSLAM  cells  2  hours  post-infection  with  SARS-CoV-2  inducing a  ~5000-fold  
reduction  in  viral  RNA  at  48  h. Of note, the much higher required dosage for the antiviral as compared to the 
antiparasitic effects of the drug seriously hampers the likelihood of further development of this compound against 
COVID-19. The concentration resulting in IC50 reported being 2 µM was > 35x higher than the maximum plasma 
concentration (Cmax) after oral administration of the approved dose of ivermectin when given in a fasting state 
(reviewed by Elkholy Cureus 2020, see below) . Predicted lung IC50, when given the approved dose of ivermectin, was 
0.0857 µM. Nevertheless, at doses 10x higher than the approved dose, the predicted lung IC50 was 0.817 which 
remains below the IC50 for effective inhibition of viral replication. Nevertheless, a retrospective analysis of 280 
patients with confirmed COVID-19 infection found lower mortality in the ivermectin group (15%) compared to the 
control group (25.2%) (95% CI 0.29 - 0.96, P = .03). After adjustment for the mortality risks between both groups, the 
mortality benefit remained significant (hazard ratio (HR) 0.37, CI 0.19 - 0.71, p = .03). Elkholy (Cureus 2020, see below) 
suggested that inhaled ivermectin should be evaluated as a potential broad-spectrum antiviral against respiratory 
viruses, including COVID-19. 
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Combination therapies 
Numerous reports describe the use of combined drugs as potential COVID-19 therapies. On one hand, synergies have 
been identified in vitro, as exemplified by a combination of remdesivir and emetine (Choy Antivir Res 2020, see below). 
The data suggested that such combinational therapy may help reduce the effective concentration of compounds below 
the therapeutic plasma concentrations and provide better clinical benefits. 
Various drug combinations have also been evaluated (and are still under evaluation) in clinical studies. For instance, 
Hung (Lancet 2020, see below) reported data from an open-label, randomised, phase 2 trial in 127 adults with COVID-
19 that evaluated a combination of lopinavir/ritonavir with ribavirin and interferon β. The trial compared a 14-day 
combination of lopinavir 400 mg and ritonavir 100 mg every 12 h, ribavirin 400 mg every 12 h, and three doses of 8 
million international units of interferon β-1b on alternate days (combination group) or to 14 days of lopinavir 400 mg 
and ritonavir 100 mg every 12 h (control group). 86 were randomly assigned to the combination group and 41 were 
assigned to the control group. The combination group had a significantly shorter median time from start of study 
treatment to negative nasopharyngeal swab (7 days [IQR 5–11]) than the control group (12 days [8–15]; hazard ratio 
4·37 [95% CI 1·86–10·24], p=0·0010). Adverse events included self-limited nausea and diarrhoea with no difference 
between the two groups. No patients died during the study. 
In another example, Chen (manuscript on medRxiv: 
https://www.medrxiv.org/content/10.1101/2020.03.22.20034041v1) reported on the first clinical study using 
danoprevir (Ganovo®), an HCV protease inhibitor marketed in China since 2018, combined with ritonavir 
(NCT04291729), in the presence or absence of α-interferon nebulization. The data from this small study suggested 
that the combination is well tolerated by COVID-19 patients (moderate cases included). After 4 to 12-day treatment, 
all eleven patients enrolled were discharged from the hospital. 
Comparative clinical trials 
A number of small size clinical trials evaluated more than one therapeutic candidate against COVID-19. Shi (J Med Vir 
2020, see below), for instance, reported on a small randomized clinical trial in 184 patients in Shangai, who received 
various treatments. They were divided into 7 groups: the symptomatic treatment group (n=17), arbidol group, 
lopinavir/ritonavir group, arbidol+lopinavir/ritonavir group, interferon group, interferon+lopinavir/ritonavir group, 
and interferon+darunavir group. Treatment duration was 5 days. No significant differences were found among the 
groups in terms of the proportion of patients with pneumonia resolution (P=0.151) after treatment or the length of 
hospital stay (P=0.116).  
However, various statistically well-powered studies have also been reported. Solidarity is an international clinical trial 
to help find an effective treatment for COVID-19, launched by the WHO and partners. It is one of the largest 
international randomized trials for COVID-19 treatments, enrolling almost 12 000 patients in 500 hospital sites in over 
30 countries (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-
coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments). As reported by WHO on October 15 2020, 
interim results from the Solidarity Therapeutics Trial showed that remdesivir, hydroxychloroquine, lopinavir/ritonavir 
and interferon regimens appeared to have little or no effect on 28-day mortality or the in-hospital course of COVID-
19 among hospitalized patients (https://www.who.int/news/item/15-10-2020-solidarity-therapeutics-trial-produces-
conclusive-evidence-on-the-effectiveness-of-repurposed-drugs-for-covid-19-in-record-time). 
As an add-on trial of the Solidarity consortium of trials, DisCoVeRy is a phase III, open-label, adaptive, controlled, 
multicentre clinical trial in which hospitalised patients with COVID-19 in need of oxygen therapy are randomised 
between five arms: (1) a control group managed with standard of care and four therapeutic arms with re-purposed 
antiviral agents: (2) remdesivir + standard of care, (3) lopinavir/ritonavir + standard of care, (4) lopinavir/ritonavir 
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associated with interferon (IFN)-β-1a + standard of care and (5) hydroxychloroquine + standard of care (Ader BMJ 
Open 2020, see below). 
In the UK, the Recovery trial is testing candidate treatments including low-dose dexamethasone  (now only recruiting 
children); azithromycin; tocilizumab; convalescent plasma; REGN-COV2  and aspirin (https://www.recoverytrial.net/) 
Biological response modifiers 
Biological response modifiers (BRM) are substances that interact with and modify the host immune system by acting 
on a therapeutic target considered important in the pathogenic process of the disease (Lacoma Front Imm 2019, see 
below). They are now established as therapies for malignancies, transplant rejection, as well as several immune 
disorders, and can also provide protection against infectious diseases. They include immunostimulatory agents 
capable of enhancing host defence mechanisms, as well as compounds offering protection against the negative 
consequences of immune responses. They include antimicrobial peptides, therapeutic small molecules, therapeutic 
antibodies, cytokines and other immumodulators. Controlling cytokine production and inflammatory response 
appears as a desirable objective, given that they are responsible for the accumulation of cells and fluids. However, as 
pointed out by Li, Fan et al. (J Med Virol 2020, see below), this strategy remains challenging as long as immune 
response parameters that can be inhibited specifically without compromising the beneficial host defence have not 
been identified. For instance, completely blocking a proximal event in the immune response (e.g., activation of 
interferon response-related pattern recognition receptors) seems unwise considering its general role in regulating 
host defence. 
Interferon-α 
During the SARS outbreak in 2003, an animal study revealed that recombinant human IFN-α2b spray can prevent SARS 
CoV infection in Rhesus monkey model by inhibiting virus infection and replication (Shen World J Pediatr 2020, see 
below). Further clinical evaluation revealed that recombinant human IFN-α2b spray can effectively reduce the 
infection rate of respiratory syncytial virus, influenza virus, adenovirus and SARS-CoV. The “Novel Coronavirus 
Infection Pneumonia Diagnosis and Treatment Standards (fourth edition) and Diagnosis, treatment and prevention of 
2019 novel coronavirus infection in children: experts’ consensus statement” of the National Health Commission of 
People’s Republic of China also listed IFN-α atomization as a treatment option for COVID-19 pneumonia. An ongoing 
clinical trial in China evaluates the preventive effect of recombinant human interferon-α nasal drops on SARS-CoV-2 




Corticosteroids were widely used during the outbreaks of SARS and MERS CoVs and are being used in patients with 
COVID-19 in addition to other therapeutics. However, interim guidance from WHO issued on March 13 2020 (Clinical 
management of severe acute respiratory infection when novel coronavirus (COVID-19) infection is suspected: 
https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf) initially advised 
against the use of corticosteroids unless indicated for another reason. The same conclusion was reported by Russell 
(Lancet 2020, see below) who concluded from a literature review that no unique reason exists to expect that patients 
with COVID-19 will benefit from corticosteroids, and that they might be more likely to be harmed with such treatment. 
A subsequent publication by Shang (Lancet 2020, see below) noted that the existing evidence on this topic was 
inconclusive, and even systematic reviews and meta-analyses on this topic reached differing conclusions. The authors 
recommended short courses of corticosteroids at low-to-moderate dose, used prudently, for critically ill patients with 
COVID-19 pneumonia. A similar recommendation was made by Zhou (Signal Transduct Target Ther 2020, see below). 
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Veronese (Front Med 2020, see below) reviewed the use of corticosteroids in COVID-19 pneumonia. Four studies with 
542 Chinese participants were included. The data did not fully support the routine use of corticosteroids in COVID-19, 
but some findings suggested that methylprednisolone could lower the mortality rate in more severe forms of the 
condition. 
In a later review and meta-analysis, Lu (Ann Transl Med 2020, see below) retrieved 23 studies, including one 
randomized controlled trial and 22 cohort studies, with a total of 13,815 patients. The authors concluded that 
glucocorticoid therapy reduced the duration of fever, but not mortality, duration of hospitalization or lung 
inflammation absorption. Long-term use of high-dose glucocorticoids increased the risk of adverse reactions such as 
coinfections. 
However, breakthrough data were obtained from the Randomised Evaluation of COVID-19 therapy (RECOVERY) trial, 
a randomized, controlled, open-label, adaptive, platform trial comparing a range of possible treatments with usual 
care in patients hospitalized with COVID-19. Preliminary results of the study for the comparison of dexamethasone 6 
mg given once daily for up to ten days vs. usual care alone are available (Recovery collaborative group NEJM 2020, see 
below). The primary outcome was 28-day mortality. A total of 2104 patients was randomly allocated to receive 
dexamethasone and compared with 4321 patients concurrently allocated to usual care. Overall, 454 (21.6%) patients 
allocated dexamethasone and 1065 (24.6%) patients allocated usual care died within 28 days. The proportional and 
absolute mortality rate reductions varied significantly depending on level of respiratory support at randomization (test 
for trend p<0.001): dexamethasone reduced deaths by one-third in patients receiving invasive mechanical ventilation 
(29.0% vs. 40.7%, RR 0.65 [95% CI 0.51 to 0.82]; p<0.001), by one-fifth in patients receiving oxygen without invasive 
mechanical ventilation (21.5% vs. 25.0%, RR 0.80 [95% CI 0.70 to 0.92]; p=0.002), but did not reduce mortality in 
patients not receiving respiratory support at randomization (17.0% vs. 13.2%, RR 1.22 [95% CI 0.93 to 1.61]; p=0.14). 
Updated guidance on the use of corticosteroids for COVID-19 was provided by WHO on September 2nd 2020 
(https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1). 
Anti-IL-6 receptor 
IL-6 may play a role in driving the overactive inflammatory response in the lungs of patients who are severely or 
critically ill with COVID-19. A single-arm study of tocilizumab (Actemra), a humanized recombinant monoclonal 
antibody directed against the IL-6 receptor, in 21 Chinese patients with severe pneumonia provided preliminary data 
supporting the role of IL-6 in COVID-19 (https://sfar.org/download/effective-treatment-of-severe-covid-19-patients-
with-tocilizumab/). Another report by Luo (J Med Vir 2020, see below) described a retrospective observational study 
of tocilizumab in 15 patients. Although treatment ameliorated the increased CRP in all patients rapidly, for the 4 
critically ill patients who received only single dose of tocilizumab, 3 of them died and the CRP level in the last patient 
failed to return to normal range with a clinical outcome of disease aggravation. Serum IL-6 level tended to further 
spike first and then decreased after tocilizumab therapy in 10 patients. A persistent and dramatic increase of IL-6 was 
observed in the 4 patients with treatment failure. 
Alzghari (J Clin Virol 2020, see below) reviewed information available from 4 case reports in the U.S., Switzerland, 
France and China, and 2 retrospective studies in respectively 15 and 21 patients in China. The authors highlighted the 
parameters to be monitored upon tocilizumab therapy, and the unknowns of the safety profile. 
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Table 12 Comparison of Major Tocilizumab COVID-19 Studies Reported to Date (from Parr JAMA 2020) 
 
Colaneri (Microorganisms 2020, see below) reported the outcome of a small study, where 21 patients who received 
tocilizumab were matched to 21 patients who received a combination of hydroxychloroquine, azithromycin and 
prophylactic dose of low weight heparin. No adverse event was detected following tocilizumab administration. This 
study found that treatment with tocilizumab did not significantly affect ICU admission (OR 0.11; 95% CI between 0.00 
and 3.38; p = 0.22) or 7-day mortality rate (OR 0.78; 95% CI between 0.06 and 9.34; p = 0.84) when compared with the 
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drug combination. However, in view of the small sample size, this study did not seem to be adequately powered to 
demonstrate differences in efficacy.  
A review by Khiali (J Clin Pharmacol 2020, see below) discussed available evidence regarding the potential therapeutic 
role of tocilizumab and important clinical issues in the treatment of ARDS related to COVID-19. However, randomized 
trials data were released subsequently, which suggested a potential role for tocilizumab in COVID-19 while not 
showing clear evidence of efficacy (Parr JAMA 2020, see below). In contrast to findings from STOP-COVID and a 
growing number of observational studies indeed, none of the tocilizumab randomized trials reported mortality benefit 
at 28 or 30 days, and only 2 of these reported outcomes meeting predefined thresholds for clinical efficacy (Table 12 
above). Double-blinded, randomized, controlled trials of longer-term outcomes remain necessary to ascertain whether 
tocilizumab can reduce the severity of illness and the death rate without higher rates of treatment-related adverse 
events and secondary infections. At least 5 other randomized controlled trials of tocilizumab in COVID-19 have been 
reported (NCT04335071; NCT04356937; NCT04381936; NCT04363736; NCT04409262). 
As reported by Tleyjeh (Clin Microbiol Infect 2020, see below) up to now, randomized controlled trials did not show 
that tocilizumab reduces short-term mortality, but low certainty evidence from cohort studies suggests an association 
between tocilizumab and lower mortality. The authors did not observe a higher risk of infections or adverse events 
with tocilizumab use. This living review will continuously evaluate the role of tocilizumab in COVID-19 treatment. 
Sarilumab (Kevzara) is a fully-human monoclonal antibody that inhibits the IL-6 pathway by binding and blocking the 
IL-6 receptor. An adaptive phase 2/3, randomized, double-blind, placebo-controlled study assessing the efficacy and 
safety of Sarilumab for hospitalized patients with COVID-19 has been conducted in the U.S. (NCT04315298; 1912 
participants). At the time of writing, only preliminary data from the trial have been disclosed 
(https://www.sanofi.com/en/media-room/press-releases/2020/2020-04-27-12-58-00). Additional randomized 
controlled trials have been reported in other countries (e.g. NCT04322773 in Denmark; NCT04357808 in Spain). 
JAK-STAT inhibitors 
Baricitinib is a powerful anti-inflammatory that, as a JAK-STAT signalling inhibitor, is likely to be effective against the 
consequences of the elevated levels of cytokines observed in people with severe COVID-19. Richardson (Lancet Inf Dis 
2020, see below) further acknowledged that that using a JAK1 and JAK2 inhibitor to treat a viral disease might appear 
illogical given that the antiviral effects of interferons are largely mediated by the JAK–STAT signalling pathway. 
However, the authors do not recommend that baricitinib or other JAK inhibitors be given to individuals at an early 
stage of infection. Clinical trials assessing the efficacy of baricitinib to treat COVID-19 are ongoing (NCT04321993) or 
planned (NCT04320277). 
In a pilot uncontrolled trial, baricitinib at 4 mg/day/orally (combined with lopinavir-ritonavir) was given to 12 
pneumonia patients with moderate COVID-19 (Cantini J Infect 2020, see below). No adverse events were recorded, 
after 2 weeks in treated patients. Clinical and respiratory parameters significantly improved at 2 weeks. None of the 
baricitinib-treated patients required admission to ICU. 
Ruxolitinib, a JAK1/2 inhibitor, has also been assessed in COVID-19 patients. Cao reported a prospective, multicenter, 
single-blind, randomized controlled phase II trial involving patients with severe disease (J Allergy Clin Immunol 2020, 
see below). Treatment with ruxolitinib plus standard-of-care was not associated with significantly accelerated clinical 
improvement in patients with severe coronavirus disease, although ruxolitinib recipients had a numerically faster 
clinical improvement. 
Complement inhibitors 
The manifestations of severe COVID-19 such as the ARDS, sepsis and multiorgan failure have an established 
relationship with activation of the complement cascade. Polycarpou (EMBO Mol Med 2020, see below) collected 
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evidence linking severe COVID-19 disease directly with dysfunction of the complement pathways. This information 
lended support for a therapeutic anti-inflammatory strategy against complement, where a number of clinically ready 
potential therapeutic agents are available. 
Preliminary data obtained with anti-complement C5 therapy with eculizumab in 4 COVID-19 patients were reported 
by Diurno (Eur Rev Med Pharmacol Sci 2020, see below). While positive results were obtained, interpretation is 
complicated by the fact that patients received not only eculizumab, but also anticoagulant therapy with Enoxaparin 
4000 IU/day via subcutaneous injection, antiviral therapy with Lopinavir 800 mg/day + Ritonavir 200 mg/day, 
hydroxychloroquine 400 mg/day, ceftriaxone 2 g/day IV, and vitamine C 6 g/day for 4 days. 
Mastaglio (Clin Imm 2020, see below) reported the clinical course of a patient with severe ARDS due to COVID-19 
pneumonia who was successfully treated with the compstatin-based complement C3 inhibitor AMY-101. C3 
interception with compstatin-based inhibitors (such as AMY-101) may offer broader therapeutic coverage than anti-
C5 or anti-C5a agents by blocking simultaneously generation of all downstream proinflammatory mediators involved 
in SARS-CoV-2-induced ARDS and thrombotic microangiopathies. 
Immune checkpoint inhibitors 
Immune checkpoint inhibitors are being considered for their potential to augment the host response in sepsis. PD-1 
and PD-L1 are indeed key mediators in T cell depletion in sepsis patients. Animal models have shown that blocking PD-
1 or PD-L1 can prevent T cell death, regulate cytokine production, reduce organ dysfunction and reduce death in sepsis. 
Previous experience showed the clinical safety of anti-PD-1 antibody in sepsis patients through randomized, placebo-
controlled trials. A phase 2 clinical trial is reported as planned among 120 COVID-19 patients to evaluate anti-PD-1 
antibody treatment vs. thymosin vs. control (NCT04268537, 
https://clinicaltrials.gov/ct2/show/NCT04268537?term=anti-PD-1&cond=COVID-19&draw=2&rank=1). 
BTK inhibitors 
Based on observations in 5 patients on ibrutinib, Treon (Blood 2020, see below) suggested that ibrutinib and possibly 
other BTK-inhibitors may provide protection against lung injury, and even improve pulmonary function in hypoxic 
patients with COVID-19. 
Renin–Angiotensin–Aldosterone System inhibitors 
Placebo-controlled clinical trials of losartan, an  angiotensin-receptor blocker, as a treatment for COVID-19 are being 
conducted among patients who have not previously received treatment with a Renin–Angiotensin–Aldosterone 
System inhibitor and are either hospitalized (NCT04312009) or not hospitalized (NCT04311177) (Vaduganathan NEJM 
2020, see below). 
Other therapeutic antibodies 
Several other antibodies specific for host targets that are developed in the context of lung disease might appear as 
promising for COVID-19 therapy. Some antibodies may indeed have the potential to reduce prolonged damaging 
cellular infiltration during severe lung infections (Elbahesh Front Imm 2019, see below). For instance, angiopoietin-
like 4 (ANGPTL4) is a soluble angiogenic regulating protein. Following proteolytic cleavage, the C-terminal portion 
(cANGPTL4) is involved in integrin-dependent wound repair and can regulate vascular permeability. ANGPTL4 is 
significantly elevated in lung biopsies from influenza virus-induced pneumonia patients. In mouse studies, neutralizing 
anti-ANGPTL4 antibodies reduced pulmonary tissue leakiness, significantly accelerating lung recovery. Vascular 
leakage is a hallmark of many infectious diseases, including those caused by SARS and MERS CoVs (Li Oncotarget 2015, 
see below). The roles of ANGPTL4 in SARS-CoV-2 infection is still unclear, but warrant future investigations.  
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Antimicrobial peptides 
Antimicrobial peptides (AMPs), also termed host defence peptides, can be produced as part of the host’s innate 
immune system during an infection process (Cardoso Int J Mol Sci 2019, see below; Brice Curr Med Chem 2019, see 
below). These peptides belong to a broad group of molecules produced by many tissues and cell types in a variety of 
organisms, including plants, invertebrates, vertebrates, fungi and bacteria. The majority of AMPs are composed of 
relatively small (<10 kDa), cationic and amphipathic molecules, mostly consisting of 6 to 50 amino acid residues. The 
different amino acid compositions lead to structural properties in terms of amphipathicity, net positive charge, shape 
and size, which favour interaction with microbial surfaces, insertion into lipid bilayers and induction of membrane 
damage. It is therefore not surprising that human AMPs display activity against enveloped viruses as well as bacteria 
and fungi (Brice Curr Med Chem 2019, see below). However, these peptides also exhibit activity against a wide range 
of non-enveloped viruses, acting at a number of different steps in viral infection. Recent studies have begun to 
elucidate the antiviral properties of AMPs as well as their role in regulation of inflammation and chemoattraction. 
AMPs have been suggested as promising therapies against viral pathogens (Ahmed Viruses 2019, see below), even 
though experimental data are still needed to support this proposal. 
The antiviral activity of defensins, a class of AMPSs, was first reported in 1986. Since then, defensins have 
demonstrated in vitro effects against HIV, influenza A virus, human adenovirus, human papillomavirus, RSV, herpes 
simplex virus and SARS-CoV. However, few studies in animal models of virus infection have been reported. A murine 
β-defensin 1-deficient mouse model showed that MBD1, the murine counterpart of HBD1, participated in the 
protection of mice from influenza infection via a mechanism other than the inhibition of viral replication (Park 2018). 
Innovation Pharmaceuticals has announced the consideration of its defensin mimetic drug candidate Brilacidin for the 
potential treatment of Covid-19, the disease caused by the coronavirus (https://www.pharmaceutical-
technology.com/news/innovation-pharmaceuticals-covid-19-drug/). Brilacidin is a small molecule in late-phase 
development. The drug is said to have shown antibacterial, anti-inflammatory and immunomodulatory activity in 
different clinical studies. 
Cell-based therapies 
A rapidly increasing number of clinical investigations of cell-based therapy approaches for COVID-19 is reported. These 
utilise a range of different cell sources, doses, dosing strategies, and targeted patient populations. To provide a rational 
strategy to maximise potential therapeutic use, Khoury (Eur Respir J 2020, see below) recommended a good 
understanding of the relevant pre-clinical studies and postulated mechanisms of actions in respiratory virus-induced 
lung injuries.  
Mesenchymal stem cells 
Mesenchymal stem cells (MSCs) have been widely used in cell-based therapy, from basic research to clinical trials. 
Safety and effectiveness have been clearly documented in many clinical trials, especially in the immune-mediated 
inflammatory diseases, such as graft versus-host disease and systemic lupus erythematosus. MSCs play a positive role 
mainly in two ways, namely immunomodulatory effects and differentiation abilities. MSCs can secrete many types of 
cytokines by paracrine secretion or make direct interactions with immune cells, leading to immunomodulation. The 
immunomodulatory effects of MSCs are triggered further by the activation of TLR receptor in MSCs, which is stimulated 
by pathogen-associated molecules such as LPS or double-stranded RNA. Several review papers provide a rationale to 
the use of such therapy in COVID-19 patients (see for instance Yao J Int Med Res 2020, see below).  
In a pilot study (ChiCTR2000029990), MSCs transplantation could cure or improve the functional outcomes of seven 
patients without observed adverse effects (Leng Aging Dis 2020, see below). The pulmonary function and symptoms 
of these patients were significantly improved in 2 days after MSC transplantation. Among them, two common and one 
severe patient were recovered and discharged in 10 days after treatment. After treatment, the peripheral lymphocytes 
were increased, the CRP decreased, and the overactivated cytokine-secreting immune cells CXCR3+CD4+ T cells, 
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CXCR3+CD8+ T cells, and CXCR3+ NK cells disappeared in 3-6 days. In addition, a group of CD14+CD11c+CD11bmid 
regulatory DC cell population dramatically increased. Meanwhile, the level of TNF-α was significantly decreased, while 
IL-10 increased in MSC treatment group compared to the placebo control group. Furthermore, the gene expression 
profile showed MSCs were ACE2- and TMPRSS2- which indicated MSCs are free from COVID-19 infection. Several larger 
trials of this therapy are currently either ongoing or planned in China and other countries (Brazil, Jordan, France). 
Cardiosphere-derived cells 
Cardiosphere-derived cells (CDCs) are stromal/progenitor cells, derived from heart tissue, with a distinctive antigenic 
profile (CD105+, CD45−, CD90low). Since CDCs were first isolated from human endomyocardial biopsies in 2007, these 
cells have been tested in > 200 patients in clinical trials for myocardial infarction, heart failure with reduced and 
preserved ejection fraction, Duchenne muscular dystrophy, pulmonary arterial hypertension, and hypoplastic left 
heart syndrome. These trials, along with extensive preclinical investigation (~ 200 publications from > 55 independent 
laboratories worldwide), have demonstrated immunomodulatory and anti-inflammatory effects of CDCs. Head-to-
head comparisons in preclinical models indicate that CDCs may be more effective than MSCs with regards to paracrine 
factor secretion and myocardial remodeling. Given the safety record of CDCs in humans, and the substantial body of 
evidence confirming relevant disease-modifying bioactivity, applicability to COVID-19 seemed compelling, particularly 
in the hyperinflammatory stage of the illness. Singh (Basic Res Cardiol 2020, see below) evaluated safety and impact 
of administration of allogeneic CDCs, formulated for intravenous infusion as CAP-1002, in 6 critically ill COVID-19 
patients. No patient experienced any complications related to CAP-1002 administration. Patients 1 and 4 received a 
second dose of CAP-1002, after pre-treatment with diphenhydramine, likewise with no complications. All intubated 
patients improved clinically after cell infusion, except patients 4 and 6, who are still in ICU but remain stable. 
High-Dose Intravenous Immunoglobulin  
Cao (Open Forum Infect Dis 2020, see below) reported on the use of high-dose Intravenous Immunoglobulin at 0.3–
0.5 g per kg weight per day for five days in 3 patients with deteriorating condition. None of the 3 patients reported 
any adverse events. All patients were clinically improved shortly after the administration, with their temperature back 
to normal in 1-2 days and breathing difficulties alleviating in 3-5 days. Confounding factors did exist, including the use 




The effectiveness of convalescent plasma for the treatment of SARS, as reviewed by Mair-Jenkins (J Infect Dis 2015, 
see below), was assessed by 8 studies reporting outcomes for 214 patients with SARS in total. The absolute reduction 
in the risk of mortality varied from 7% (95% CI, -2.39 to 18.68) to 23% (95% CI, 5.59–42.02) in 2 studies at medium to 
high risk of bias. Subgroup analyses suggested that early treatment was beneficial. Four non-comparative studies 
found that the case-fatality rate varied from 0% (0/1) to 12.5% (10/80) in treated subjects. Increased antibody levels 
were detected up to day 5 after treatment in 1 study of HCWs (which was at high risk of bias). Experience with 
convalescent plasma infusion has also been obtained in the context of MERS-CoV infections. Ko (Antivir Ther 2018, 
see below), based on experience with 3 patients, suggested that for effective convalescent plasma infusion against 
MERS, donor plasma with a neutralization activity (PRNT titre) ≥1:80 should be used. However, the observation that 
convalescent plasma infusion led to possible transfusion-related acute lung injury (TRALI) in a MERS patient in Korea 
suggests that convalescent plasma therapy should be cautiously approached (Chun Ann Lab Med 2016, see below). 
Zhang and Liu (J Med Vir 2020, see below) identified this approach as a potential treatment for COVID-19. Information 
released in the media soon indicated that the procedure was evaluated clinically in China 
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(https://www.scoop.it/topic/virusworld/p/4115315422/2020/02/14/china-seeks-plasma-from-recovered-patients-
to-treat-virus). A plasma donation program had been launched in Zhejiang Province 
(http://www.xinhuanet.com/english/2020-02/19/c_138799179.htm). The plasma donated by recovered coronavirus 
patients was said to be used for treatment of COVID-19 patients in critical condition. 
Shen (JAMA 2020, see below) reported 5 critically ill patients with laboratory-confirmed COVID-19 and ARDS who 
received convalescent plasma with a SARS-CoV-2–specific antibody (IgG) binding titer greater than 1:1000 and a 
neutralization titer greater than 40 (obtained from patients who recovered from COVID-19). Following plasma 
transfusion, viral loads decreased and became negative within 12 days after the transfusion, and SARS-CoV-2-specific 
ELISA and neutralizing antibody titers increased. ARDS resolved in 4 patients at 12 days after transfusion, and 3 patients 
were weaned from mechanical ventilation within 2 weeks of treatment. Of the 5 patients, 3 have been discharged 
from the hospital, and 2 are in stable condition at 37 days after transfusion. The small sample size of the study 
precludes conclusions in terms of effectiveness, but data from clinical trials are expected in a near future. 
Another pilot study on convalescent plasma therapy (single 200 mL dose with neutralization activity greater than 1:640) 
in severe COVID-19 patients was reported by Duan (PNAS 2020, see below). Data showed no severe adverse events 
and undetectable viral load after transfusion in 7/10 patients. Ye (J Med Vir 2020, see below) reported a positive 
outcome in 6 patients treated with convalescent plasma. Ahn (J Kor Med Sci 2020, see below) reported on 2 additional 
cases treated with convalescent plasma in Korea with positive outcome. 
Liu (Nat Med 2020, see below) reported the outcomes of thirty-nine hospitalized patients with severe to life-
threatening COVID-19 who received convalescent plasma transfusion, and compared them against a cohort of 
retrospectively matched controls. These analyses suggested that convalescent plasma recipients were more likely than 
control patients to remain the same or have improvements in their supplemental oxygen requirements by post-
transfusion day 14, with an odds ratio of 0.86 (95% CI: 0.75~0.98; p=0.028). Plasma recipients also demonstrated 
improved survival, compared to control patients (log-rank test: p=0.039). In a covariates-adjusted Cox model, 
convalescent plasma transfusion improved survival for non-intubated patients (hazard ratio 0.19 (95% CI: 0.05 ~0.72); 
p=0.015), but not for intubated patients (1.24 (0.33~4.67); p=0.752).  
A position paper by Accorsi (Transfus Apher Sci 2020, see below) gave recommendations on biological characteristics 
of a plasma preparation from convalescent donors. The authors support the evaluation of this therapeutic approach 
in more rigorous investigations. 
Multiple randomized controlled clinical trials are ongoing to assess the efficacy and safety of anti-SARS-CoV-2 
convalescent plasma (as reported for instance by Kumar Am J Emerg Med 2020, see below; or NCT04390503, 
NCT04429854, NCT04366245, NCT04411667, NCT04442191, NCT04373460, NCT04390503, NCT04374526, 
NCT04323800). Some of these trials are reported as completed (e.g. NCT04442958, NCT04346446). However, to the 
best of our knowledge, the outcome of these studies has not been disclosed yet. One report described a trial 
conducted in China in a total of 103 participants with either severe or life-threatening laboratory-confirmed COVID-19 
(ChiCTR2000029757). In this trial, use of convalescent plasma was not associated with a statistically significant 
improvement in time to clinical improvement within 28 days (Li JAMA 2020, see below). Daniele (Int J Inf Dis 2020, see 
below) identified the reports of 4 additional randomized controlled studies which have led to inconclusive or negative 
results, potentially due to lack of neutralizing antibody titer assessment in donated units and/or late treatment. More 
encouraging findings have been reported from retrospective or prospective propensity-score-matched studies in the 
USA. For instance, a preprint paper, published on medRxiv on 12 August, examined whether plasma reduced mortality, 
and included 35 322 patients who received transfusions between 4 April and 4 July at one of the 2807 participating US 
centres (https://www.medrxiv.org/content/10.1101/2020.08.12.20169359v1). The study, not peer-reviewed, said, 
“Earlier use of convalescent plasma was associated with lower observed rates of 7-day and 30-day mortality. The use 
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of convalescent plasma with higher antibody levels was associated with reduced 7-day and 30-day mortality.” Experts 
have warned that although these early findings show promise there is not enough evidence to show that it works. 
The US Food and Drug Administration authorized convalescent plasma for treating severe or life-threatening COVID-
19 under individual-patient emergency Investigational New Drug applications in March 2020  (Tanne BMJ 2020, see 
below; Mahase BMJ 2020, see below). On 23 August, convalescent plasma was approved by the FDA for emergency 
use (EUA) in hospital patients with COVID-19. The announcement said they had concluded that plasma from recovered 
patients “may be effective” in treating the virus and that the “potential benefits of the product outweigh the known 
and potential risks.” The move came despite the absence of results from randomised controlled trials. The data that 
were available to support EUA issuance were reviewed by Pau (Ann Int Med 2020, see below). 
Purified immune globulins 
SAB-301 is a fully-human polyclonal IgG immunoglobulin (SAB-301) produced from hyperimmune plasma of 
transchromosomic cattle immunized with purified MERS-CoV spike protein nanoparticles vaccine (Beigel Lancet Inf Dis 
2018, see below). In a phase 1 trial, single infusions of SAB-301 up to 50 mg/kg appear to be safe and well-tolerated 
in healthy participants. However, no published data suggest that SAB-301 purified immune globulin is able to 
neutralize SARS-CoV-2. On March 6 2020, Takeda announced the development of an anti-SARS-CoV-2 polyclonal 




The SARS-CoV and MERS-CoV neutralizing monoclonal antibodies (mAbs) and nanobodies with protective efficacy are 
specific to the S1 subunit of S protein, particularly the receptor-binding domain (RBD) (Jiang Em Micr Inf 2020, see 
below). A range of mAbs were listed by WHO on January 24 2020 as potential candidates against COVID-19 
(https://apps.who.int/iris/bitstream/handle/10665/330680/WHO-HEO-RDBlueprint%28nCoV%29-2020.1-
eng.pdf?ua=1), even though their ability to neutralize SARS-CoV-2 had not been confirmed. However, efforts soon 
shifted to the development of SARS-CoV-2-specific mAbs.  
Lei (Nat Comm 2020, see below) generated 2 fusion proteins, a first one obtained by connecting the extracellular 
domain of human ACE2 to the Fc region of the human immunoglobulin IgG1 and a second one containing an ACE2 
mutant with low catalytic activity. These fusion proteins neutralized virus pseudotyped with SARS-CoV or SARS-CoV-2 
S proteins in vitro. Miersch (manuscript on bioRxiv : https://doi.org/10.1101/2020.06.05.137349) described a panel of 
synthetic monoclonal antibodies, built on a human framework, that bind SARS-CoV-2 S protein, compete for binding 
with ACE2, and potently inhibit infection by SARS-CoV-2. These antibodies were found to have a range of neutralization 
potencies against live virus infection in Vero E6 cells, potently inhibiting authentic SARS-CoV-2 virus at sub-nanomolar 
concentrations.  
Chen (Cell Mol Immunol 2020, see below) reported the cloning of two human blocking mAbs using SARS-CoV-2 RBD-
specific memory B cells isolated from recovered COVID-19 patients. These two mAbs can specifically bind to SARS-
CoV-2 RBD, block the interaction between SARS-CoV- 2 RBD and hACE2 receptor, and lead to efficient neutralization 
of SARS-CoV-2 S protein pseudotyped virus infection. Wang (Nat Commun 2020, see below) also described a human 
monoclonal antibody that neutralizes SARS-CoV-2: 47D11 binds a conserved epitope on the S RBD explaining its ability 
to cross-neutralize SARS-CoV and SARS-CoV-2, using a mechanism that is independent of receptor-binding inhibition. 
Subsequently, Ju (Nature 2020, see below) reported the isolation and characterization of 206 RBD-specific monoclonal 
antibodies derived from single B cells from 8 individuals infected with SARS-CoV-2. The authors identified antibodies 
that potently neutralize SARS-CoV-2; this activity correlated with competition with ACE2 for binding to RBD. 
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Wrapp (Cell 2020, see below) isolated single-domain antibodies (VHHs) from a llama immunized with prefusion-
stabilized coronavirus spikes and neutralizing MERS-CoV or SARS-CoV-1 S pseudotyped viruses, respectively. The 
authors also showed cross-reactivity between the SARS-CoV-1 S-directed VHH and SARS-CoV-2 S and demonstrated 
that this cross-reactive VHH neutralizes SARS-CoV-2 S pseudotyped viruses as a bivalent human IgG Fc-fusion. Similarly, 
Dong (Em Micr Inf 2020, see below) reported the design and evaluation of bi-specific llama VHH-Fc antibody. Data 
showed potent S/ACE2 blocking, with ∼100% blocking at 36.7 nM, and ∼95% blocking at 12.2 nM. 
Of note, a review by Chenoweth (Immunol Cell Biol 2020, see below) addressed the topic of the FcR and antibody 
engineering in the context of monoclonal antibody development against SARS-CoV-2. More recently, an overview of 
neutralizing monoclonal antibodies against SARS-CoV-2 has been made available by Yu (Sign Transd Target Ther 2020, 
see below) (Table 13). 
Table 13 Neutralizing monoclonal antibodies against SARS-CoV-2 (from Yu Sign Transd Target Ther 2020) 
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SARS-CoV-2 monoclonal antibodies under clinical evaluation 
Regeneron is developing REGN-COV2, an antibody cocktail of REGN10933 and REGN10987 being studied both for its 
prophylactic and therapeutic potential against SARS-CoV-2 (https://www.regeneron.com/covid19). Baum (Science 
2020, see below) evaluated the in vivo efficacy of this antibody cocktail in both rhesus macaques, which may model 
mild disease, and golden hamsters, which may model more severe disease. The authors demonstrated that REGN-
COV-2 can greatly reduce virus load in lower and upper airways and decrease virus induced pathological sequelae 
when administered prophylactically or therapeutically in rhesus macaques. Similarly, administration in hamsters 
limited weight loss and decreased lung titers and evidence of pneumonia in the lungs. Clinical trials of REGN-COV2 
began in mid-June. The clinical program involves four separate study populations: two for treatment and two for 
prevention of COVID-19. The first studies evaluated evaluating safety and efficacy in hospitalized and non-hospitalized 
patients with COVID-19 (NCT04425629, NCT04426695). A phase 3, randomized, double-blind, placebo-controlled 
study is currently ongoing to assess the efficacy and safety of the antibody cocktail in preventing SARS-CoV-2 infection 
in household contacts of individuals infected with SARS-CoV-2. The study is to enrol a total of 2000 volunteers 
(https://clinicaltrials.gov/ct2/show/NCT04452318). 
Tychan develops TY027, a monoclonal antibody designed and engineered to SARS-CoV-2 by binding to a specific 
epitope of the S protein found on the surface of the virus (https://www.tychan.com/). A phase 1 first-in-Human, time 
lagged, randomised, placebo controlled, double blind, single ascending dose study of TY027 in healthy adult volunteers 
started on June 12 in Singapore 
(https://clinicaltrials.gov/ct2/show/NCT04429529?term=antibody&recrs=adefh&type=Intr&cond=COVID-
19&draw=2&rank=29). 
Monoclonal antibody LY-CoV555 is developed by Eli Lilly. LY-CoV555 is a potent, neutralizing IgG1 mAb directed against 
the S protein of SARS-CoV-2. LY-CoV555 emerged from a collaboration between Lilly and AbCellera. A randomized, 
double-blind, placebo-controlled, phase 2 study is ongoing to evaluate the efficacy and safety of LY3819253 in 
participants with mild to moderate COVID-19 Illness (https://clinicaltrials.gov/ct2/show/NCT04427501). On August 3, 
2020, Eli Lilly announced the initiation of a Phase 3 trial studying LY-CoV555 for the prevention of SARS-CoV-2 infection 
and COVID-19 in residents and staff at long-term care facilities in the U.S. (skilled nursing facilities, commonly referred 
to as nursing homes, and assisted living facilities) (https://investor.lilly.com/news-releases/news-release-details/lilly-
initiates-phase-3-trial-ly-cov555-prevention-covid-19-long). 
STI-1499 is a monoclonal antibody developed by Sorrento Therapeutics. According to company news, the efficacy of 
the product has been demonstrated in a Syrian Hamster model of SARS-CoV-2 infection 
(https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-releases-preclinical-data-




IP: 157.193.240.2 On: Fri, 04 Jun 2021 12:29:12
Copyright Leuven University Press
 
Authors: Martine Denis, Valerie Vandeweerd, Rein Verbeke, Anne Laudisoit, Tristan Reid, Emma Hobbs, Laure Wynants, Diane 
Van der Vliet  
COVIPENDIUM version: 20 OCT 2020  Transdisciplinary Insights - Living Paper | 194 
Vir Biotechnology and GlaxoSmithKline announced the initiation of a phase 2/3 study with VIR-7831 (also known as 
GSK4182136), a fully human anti-SARS-CoV-2 monoclonal antibody, for the early treatment of COVID-19 in patients 
who are at high risk of hospitalisation. The aim of the COMET-ICE study, which will enrol approximately 1300 patients 
worldwide who have early symptomatic infection, is to assess whether VIR-7831, as a single-dose monoclonal antibody, 
can prevent hospitalisation due to COVID-19 (https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-
and-gsk-start-phase-23-study-of-covid-19-antibody-treatment/). 
Among a few additional trials ongoing in China, a randomized, double-blind, placebo-controlled, phase I clinical study 
sponsored by Shanghai Junshi Bioscience evaluates the tolerability, safety, pharmacokinetic profile and 




Medicinal herbs have proven along history to be a source of multiple cures. A review by Huang (Front Pharmacol 2020, 
see below) showed how exploring prophylactics from herbal medicine is probably a promising and practical strategy 
to contain the pandemic. Several natural compounds were described as potential SARS-CoV-2 viral inhibitor in 
molecular docking studies (Adhikari Phytother Res 2020, see below), and others having anti-inflammatory properties 
that could potentially prevent COVID-19 complications in patients tested positive.  
Eucalyptol (1,8 cineole), an essential oil component from eucalyptus oil, has the potential of inhibiting the main viral 
proteinase (Mpro/3CLpro) that is critical for the SARS-CoV-2 replication (Sharma, manuscript on Preprints: 
https://www.preprints.org/manuscript/202003.0455/v1). The artemisinin class of compounds was found to interact 
with SARS-CoV-2 Protein RBD with an antiviral effect (Sehailia J Biomol Struct Dyn 2020, see below). A clinical study is 
currently conducted in Mexico to evaluate the benefit of artemisia annua and camostat mesylate in preventing COVID-
19 complications in 360 patients with positive testing in mild to moderate disease and high-risk factors (NCT04530617).  
Glycyrrhizin (an active component of licorice roots) has been shown to interfere with the replication and/or 
cytopathogenic effect of many respiratory viruses, including the replication of SARS-associated CoV (Cinatl Lancet 2003, 
see below). The biological function of glycyrrhizin and its multisite mechanisms have been described in vitro and in 
animal experiments (Luo Int J Antimicr Ag 2020, see below), showing potential benefits for COVID-19 including: a) 
Binding ACE2 to prevent SARS-CoV-2 infection. b) Downregulating proinflammatory cytokines. c) Inhibiting the 
accumulation of intracellular ROS. d) Inhibiting thrombin. e) Inhibiting the hyperproduction of airway exudates. f) 
Inducing endogenous interferon to combat the SARS-CoV-2. A clinical study conducted in Egyptian patients with 
COVID-19 is evaluating the potential therapeutic effects of Licorice and Boswellia Serrata Gum as a Complementary 
Medicine. Boswellia serrata, used in Ayurvedic medicine for inflammatory condition of the lung like asthma or allergy, 
has been shown to reduce lung inflammation in BALB/c mice (Soni Curr Drug Discov Technol 2020, see below). 
Originally extracted from colchicum, colchicine is an alcaloid and an anti-inflammatory drug that is usually prescribed 
to treat gout, chronic inflammatory disease like Behcet disease, and pericarditis. As the severe complications of COVID-
19 are largely due to the patient's immune reactions, colchicine would reduce the complications associated with 
COVID-19 (Montealegre-Gómez Reumatol Clin 2020, see below). Several clinical studies are underway to assess the 
effect of colchicine in covid-19 complications as well as its tolerance, among some of them are: the COLCORONA study 
(6000 high risk patients in Canada, NCT04322682), the GRECCO-19 study (180 patients in Greece, NCT04326790), the 
CONVINCE study (420 patients in Switzerland, NCT04516941), and the COLCOVID study (2500 patients in Argentina, 
NCT04328480).  
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A very recent publication reviewed phytopharmaceuticals derived from the traditional herbs that targets entry 
receptor of the host cells to block the interaction and attachment of some pathogenic viruses, and could potentially 
be useful in COVID-19 (Palit Phytomed 2020: 
https://www.sciencedirect.com/science/article/pii/S0944711320302270). Additional researches and clinical studies 
are necessary before utilizing those natural compounds in COVID-19 patient management. 
Traditional Chinese Medicine 
The utilization of Traditional Chinese Medicine (TCM) in managing COVID-19 is substantial in China. All confirmed 
COVID-19 cases in Shanghai started integrative Chinese-Western medicine treatment (Yuan and Qiu. Forty-one 
patients with new coronavirus pneumonia were treated with traditional Chinese medicine. Xinhua Net, Shanghai, 
2020). The Diagnosis and Treatment Protocol issued by the National Health Commission of the People’s Republic of 
China has been updated as additional research evidence and knowledge on COVID-19 have become available. Since 
the release of the first version of the protocol on January 15th, 2020, 7 versions in total have been produced with 8 
updates over a 50-day period (Qiu 2020, see below). The inclusion and elaboration on the use of TCMs in the Diagnosis 
and Treatment Protocol have been gradually improved. This National guideline has recommended herbal formulations 
according to clinical stages and severity of COVID-19.  Although national/provincial/local guidelines could differ in 
terms of treatment strategy, most guidelines defined COVID-19 as endemic, toxic, dampness or warm infectious 
disease (Chan Am J Chin Med 2020, see below). The six most commonly used herbs were Astragali Radix (Huangqi), 
Glycyrrhizae Radix Et Rhizoma (Gancao), Saposhnikoviae Radix (Fangfeng), Atractylodis Macrocephalae Rhizoma 
(Baizhu), Lonicerae Japonicae Flos (Jinyinhua), and Forsythiae Fructus (Lianqiao). Some of them are the core 
components of classical herbal formula: Yupingfeng san (powder), for tonifying qi to protect from external pathogens, 
and Yinqiao san (powder), used to prevent and treat respiratory infectious diseases (Luo Chin J Integr Med 2020, see 
below). During an oral communication at the IDWeek, October 21-25 2020, Dr Gui-Qiang Wang (Department of 
Infection Disease, Peking University First Hospital) presented the most recent COVID-19 patient management in China. 
The Traditional Chinese Medicine treatment is used for the early management of patients with COVID-19 includes oral 
preparations of medicinal herbs, among them: lianhua qingwen capsules, jinhua qiggan granules, and shufeng jiedu 
capsules. 
Clinical trials related to management of patients with COVID-19 19 that include evaluation of TCM were registered on 
the WHO’s International Clinical Trials Registry Platform (ICTRP) (Aronson at https://www.cebm.net/oxford-covid-
19/covid-19-registered-trials-and-analysis/).  
Ayurveda 
Wanjarkhedkar (J Ayurveda Integr Med 2020, see below) reported the outcome of a prospective study conducted with 
a combination of Ayurvedic medications, as an add on, in 101 COVID-19 positive patients with mild to moderate 
symptoms. Patients receiving Dasamoolkaduthrayam Kashaya & Guluchyadi Kwatham in tablet form in addition to 
the standard of care showed a faster recovery from dyspnoea with reduced ageusia. Patients on the treatment group 
could be discharged earlier than those from the control group. However, as pointed out by Pathania (J Famil Med Prim 
Care 2020, see below), studies are still lacking to support the use of Indian systems of medicine like Ayurveda against 
COVID-19. More randomized controlled trials need to be done. Of note, the authors noted that family physicians can 
play a vital role in not only suggesting treatment, but also changes in lifestyle of the patients as well as their family. As 
presented below in the section on Non-vaccine approaches to better host resistance, Ayurveda is largely used as a 
means to increase immunity. 
Host-directed therapies  
An important area of research is focused on host-directed therapies targeting the underlying aberrant immune 
responses leading to pulmonary tissue damage, death, or long-term functional disability in survivors.  
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Therapies targeting acute respiratory distress syndrome 
Acute respiratory distress syndrome is a common cause of respiratory failure in critically ill patients and is defined by 
the acute onset of non-cardiogenic pulmonary oedema, hypoxaemia and the need for mechanical ventilation (Matthay 
Nat Rev Dis Primers 2019, see below). Despite some improvements, it remains associated with a high level of mortality 
(30-40%) in most studies. One approach to improve disease outcome is to identify patients earlier in their clinical 
course, so that supportive care with lung-protective ventilation, prone positioning and a conservative fluid approach 
can be implemented. Up to now, pharmacological agents did not prove very helpful in the management of acute 
respiratory distress syndrome. A review by Lewis (Cochrane Database Syst Rev 2019, see below) found insufficient 
evidence to determine with certainty whether corticosteroids, surfactants, N-acetylcysteine, statins, or beta-agonists 
were effective at reducing mortality, or duration of mechanical ventilation, or at increasing ventilator-free days. The 
list of unsuccessful therapies also includes agents such as prostaglandin E1, activated protein C, anti-oxidants, omega-
3 supplementation, ketoconazole, lisofylline, factor VIIa, IFN-β1α, or granulocyte macrophage-stimulating factor. 
However, it remains possible that the clinical trials that evaluated these products were not designed in the most 
suitable way. 
Shi (Cell Death Diff 2020, see below) suggested the use of intratracheal hyaluronidase to eliminate hyaluronan, known 
to be associated with ARDS. Even though the accumulation of hyaluronan has not been confirmed in COVID-19 cases 
yet, autopsies have concluded that the lungs are filled with clear liquid jelly. Aerosol administration of hyaluronidase 
had been considered before for ARDS (https://www.omicsonline.org/open-access/hyaluronidase-a-potential-new-
treatment-for-acute-respiratory-distresssyndrome-2161-105X-1000407.php?aid=89111). 
Solaimanzadeh (Cureus 2020, see below) analysed clinical data published on COVID-19 in the context of another 
respiratory illness - high altitude pulmonary oedema (HAPE). The similarities between the 2 conditions led to the 
recommendation to evaluate acetazolamide, a drug that potently reduces hypoxic pulmonary vasoconstriction, 
improves minute ventilation and expired vital capacity. Other therapeutics to consider that are also directed towards 
decreased pulmonary pressure include Nifedipine and Phosphodiesterase inhibitors. 
There is evidence in both animals and humans that fibrinolytic therapy in acute lung injury and ARDS improves survival.  
There would be a rationale for such therapeutic approach in patients with ARDS and concomitant diagnoses of 
disseminated intravascular coagulation, as observed in more than 70% of those who die of COVID-19. Wang (J Thromb 
Haemost 2020, see below) reported 3 cases of off-label intravenous administration of tissue plasminogen activator 
(Alteplase) for patients with COVID-19 suffering from ARDS and respiratory failure. In all 3 cases the patients 
demonstrated an initial improvement in their PaO2/FiO2 ratio, with improvements ranging from a 38% improvement 
to a ~100% improvement. However, the observed improvements were transient in all 3 patients. 
Whereas it is reported that plasminogen is dramatically increased in adults with ARDS, Wu (QJM 2020, see below) 
treated 13 clinically moderate, severe or critical COVID-19 patients with atomization inhalation of freeze-dried 
plasminogen. After plasminogen inhalation, conditions of lung lesions in 5 clinically moderate patients quickly 
improved, as shown by the decreased range and density of ‘ground glass’ opacity. Improvements of oxygen saturation 
were observed in 6 clinically severe patients. In the 2 patients with critical conditions, the oxygen levels significantly 
increased from 79-82% to 91% just about 1 hour after the first inhalation. In 8 of 13 patients heart rates slowed down. 
Furthermore, a general relief of chest tightness was observed. Overall, the study suggested that additional 
plasminogen may be effective and efficient in treating lung lesions and hypoxemia during COVID-19 infections. Further 
studies are now needed to confirm this observation. 
Blood purification systems 
A short review by Keith (Crit Care 2020, see below) provided the rationale as well as preliminary data supporting total 
plasma exchange in patients with sepsis and multiple organ failure (not related to COVID-19). To what extent this 
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approach may be successful in the management of patients with the most severe forms of COVID-19 remains to be 
confirmed. 
An artificial-liver blood-purification system is reported to have shown good prognosis in the treatment of severely or 
critically ill COVID-19 patients with cytokine storm (Zhang Engineering 2020, see below). Based on the above-described 
evidence, the Expert Consensus on the Application of Artificial-Liver Blood-Purification System in the Treatment of 
Severe COVID-19 was recently released. This work recommends artificial-liver blood purification for the treatment of 
patients with COVID-19 infection who exhibit cytokine storm and rapid disease progression, as confirmed by lung 
imaging. 
Noting that renal replacement therapy in combination with sequential extracorporeal blood purification therapies 
might support renal function, attenuate systemic inflammation, and prevent or mitigate multiple organ dysfunctions 
in COVID-19, Villa (Crit Care 2020, see below) conducted a preliminary observational prospective study assessing the 
outcome of 37 patients with COVID-19 admitted to the ICU and treated with extracorporeal blood purification 
according to local practice. Extracorporeal blood purification with heparin-coated hemodiafilter featuring cytokine 
adsorption properties (oXiris membrane) showed to be feasible and with no adverse events in patients with COVID-
19. During the treatment, patients experienced serum IL-6 level reduction, attenuation of systemic inflammation, 
multiorgan dysfunction improvement, and reduction in expected ICU mortality rate. 
Another relevant publication on this topic is the report by Akil (Thorac cardiovasc Surg 2020, see below) of a small 
study conducted before the COVID-19 epidemic, where combined high-flow venovenous ECMO and CytoSorb 
hemoadsorption therapy (CytoSorb filter connected to ECMO circuit) were applied in 13 patients with pneumogenic 
sepsis and ARDS. All patients survived in the CytoSorb group, while the 30-day mortality rate reached 57% in the 
control group. After CytoSorb therapy, a significant reduction in procalcitonin and CRP levels was immediately 
observed. CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can 
actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.  
Cell-based therapies 
Meng (Signal Transduct Target Ther 2020, see below) performed a parallel assigned controlled, non-randomized, 
phase 1 clinical trial to evaluate the safety of human umbilical cord-derived mesenchymal stem cells (UC-MSCs) 
infusions in the treatment of patients with moderate and severe COVID-19 pulmonary disease. The study enrolled 18 
hospitalized patients with COVID-19 (n = 9 for each group). The treatment group received three cycles of intravenous 
infusion of UC-MSCs (3 × 107 cells per infusion) on days 0, 3, and 6. Both groups received standard COVID-treatment 
regimens. Adverse events, duration of clinical symptoms, laboratory parameters, length of hospitalization, serial chest 
CT images, the PaO2/FiO2 ratio, dynamics of cytokines, and IgG and IgM anti-SARS-CoV-2 antibodies were analysed. 
No serious UC-MSCs infusion-associated adverse events were observed. Two patients receiving UC-MSCs developed 
transient facial flushing and fever, and one patient developed transient hypoxia at 12 h post UC-MSCs transfusion. 
Mechanical ventilation was required in one patient in the treatment group compared with four in the control group. 
All patients recovered and were discharged. These data suggest that intravenous UC-MSCs infusion in patients with 
moderate and severe COVID-19 is safe and well tolerated, but phase 2/3 randomized, controlled, double-blinded trials 
with long-term follow-up are needed to evaluate the therapeutic use of UC-MSCs in patients with serious COVID-19. 
Ozone therapy 
A review by Martínez-Sánchez (Antioxidants 2020, see below) suggested that systemic ozone therapy could be 
potentially useful in the clinical management of several complications secondary to SARS-CoV-2 infection. Ozone 
therapy usually consists of an ex vivo procedure called autohemotherapy. For instance, 100mL of blood is drawn from 
the patient into a sterile glass bottle with anticoagulant. A corresponding volume of gas with an ozone concentration 
of 10-20 µg/mL is immediately added and continuously mixed. Reinfusion is then performed within about 15-20 
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minutes. The procedure is repeated two or three times a week. The rationale and mechanism of action of ozone 
therapy has been previously studied in other viral infections and shown effective at decreasing organ damage 
mediated by inflammation and oxidative stress.  
Tascini (Intern Emerg Med 2020, see below) used auto-hemotherapy treated with an oxygen/ozone (O2/O3) gaseous 
mixture as adjuvant therapy for COVID-19 in Udine University Hospital (Italy). The authors reported a case-control 
study involving 60 hospitalized adult patients with confirmed COVID-19 with mild to moderate pneumonia. The study 
data suggested that O2/O3 therapy as adjuvant therapy could be useful in mild to moderate pneumonia due to SARS-
CoV-2. Several clinical evaluations of ozone have been reported as ongoing, targeting either COVID-19 therapy (e.g. 
NCT04366089, NCT04388514) or prophylaxis (NCT04400006, in 71 participants only). 
Local disinfection 
The nose and the mouth represent entry portals for SARS-CoV-2. Nasal irrigations can reduce the viral load in the nasal 
cavities. Oral rinse with antimicrobial agents is efficacious in reducing the viral load in oral fluids (Casale Int J 
Immunopathol Pharmacol 2020, see below). Various authors advocate the inclusion of nasal irrigations and oral rinses 
as additional measures to current public health measures, to prevent and control the transmission of any respiratory 
infectious disease, including COVID-19. 
Oral hygiene 
Pattanshetty (Oral Dis 2020, see below) suggested oral hygiene as a quite novel approach to reduce COVID-19 
transmission. The proposal is based on several previous reports suggesting for instance that povidone-iodine (PVP-I) 
products in the form of mouthwashes and throat sprays had a prophylactic effect on SARS-CoV transmission. The 
importance of oral hygiene interventions, including gel/mouthwash, standard oral care and professional oral hygiene 
protocols in reducing the risk of pneumonia had been documented long before the COVID-19 epidemic. And a more 
recent line of evidence was obtained from post-hoc secondary analysis of data from the Edinburgh and Lothians Viral 
Intervention Study (ELVIS) pilot randomised controlled trial indicated that hypertonic saline nasal irrigation and 
gargling reduced the duration of coronavirus upper respiratory tract infection by an average of two-and-a-half days 
(Ramalingam J Glob Health 2020, see below). The authors suggested that it may offer a potentially safe, effective and 
scalable intervention in those with COVID-19. 
It has been suggested that the measures for controlling SARS-CoV-2 cross-infection during dental practice should 
include a preprocedural mouth rinse containing oxidative agents such as 1% hydrogen peroxide and 0.2% PVP-I. This 
protocol, with small variations, has been accepted by the main professional dental associations worldwide. 
Considering that there is no reason to limit this approach to the dental clinic setting,  Martínez Lamas (Oral Dis 2020, 
see below) suggested a routine administration of such mouth rinses to the entire population to prevent community 
transmission of SARS-CoV-2.  
From a literature search, Herrera (Clin Oral Investig. 2020, see below) even suggested that antiseptic mouth rinses, 
such as those containing cetylpyridinium chloride or povidone-iodine, may be able to decrease the severity of COVID-
19 by reducing oral viral load in infected subjects. Nevertheless, well-designed clinical and preclinical research must 
be conducted to support these hypotheses. 
Meister examined the in vitro virucidal activity of 8 commercially available oral rinses using a quantitative suspension 
test with 3 different SARS-CoV-2 isolates mixed with an interfering substance mimicking a respiratory secretion (J Inf 
Dis 2020, see below). The different SARS-CoV-2 strains were highly susceptible to various oral rinses. Three of the 8 
formulations significantly reduced viral infectivity to up to 3 orders of magnitude to background levels. Also, for the 
other products containing different active compounds, virucidal activities could be observed with log reduction factors 
ranging between 0.3 to 1.78.  
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Martínez Lamas (Oral Dis 2020, see below) analysed the impact of a mouthwash with PVP-I on the salivary virus load 
in 4 patients with COVID-19. A significant drop in salivary viral load, which remained for at least 3 hr, was observed in 
2/4 patients. Of note, the PCR of the nasopharyngeal exudate of these 2 patients was negative at baseline. These 
preliminary findings remain insufficient to draw any conclusion as to the clinical efficacy of an antiseptic mouthwash 
to control the transmission of SARS-CoV-2. The likely impact of a daily use of mouth rinses containing antiseptics for 
limited periods of time (e.g., when being a carrier of the virus) on the viral transmissivity remains to be better explored. 
From a search on June 1st 2020, Burton (Cochrane Database Syst Rev 2020, see below) found no completed studies to 
include in their Cochrane review. The authors identified 16 ongoing studies (including 14 RCTs), which aim to enrol 
nearly 1250 participants. The interventions included in these trials are ArtemiC (artemisinin, curcumin, frankincense 
and vitamin C), Citrox (a bioflavonoid), cetylpyridinium chloride, chlorhexidine, chlorine dioxide, essential oils, 
hydrogen peroxide, hypertonic saline, Kerecis spray (omega 3 viruxide - containing neem oil and St John's wort), neem 
extract, nitric oxide releasing solution, povidone iodine and saline with baby shampoo. The authors were concerned 
that few of the ongoing studies specifically stated that they will evaluate adverse events such as changes in the sense 
of smell or to the oral and nasal microbiota, and any consequences thereof. If a positive treatment effect is 
demonstrated, it may indeed not be large. In these circumstances the authors consider that it may be a challenge to 
weigh up the benefits against the harms if the latter are of uncertain frequency and severity. 
Nasal wash 
The technique of nasopharyngeal wash to prevent virus from inhabiting and replicating in the nasal and pharyngeal 
mucosa has been suggested to be useful in reducing symptoms, transmission, and viral shedding in cases of acute 
respiratory tract infections. In a rapid systematic review, Singh (Lung India 2020, see below) found studies showing 
some improvement in prevention and treatment of upper respiratory tract infections. The authors postulated that 
hypertonic saline gargles and nasal wash may be useful in prevention and for care of patients with COVID-19. The 
present evidence emphasizes the need of randomized controlled trials to evaluate the role and mechanism of 
nasopharyngeal wash in COVID-19. 
Inhalation of acetic acid 
Pianta (Eur Arch Otorhinolaryngol. 2020, see below) indicated that inhalation of a water-based acetic acid solution to 
treat the symptoms of the common cold is a common folk remedy in Italy. Indeed, the anti-bacterial and anti-viral 
activities of acetic acid are documented in the literature. Acetic acid causes inactivation and dis-aggregation of 
haemagglutinin glycoproteins (found on the surface of influenza viruses) by generating a low pH-dependent 
conformational change of those glycoproteins and it destroys the viral envelope and inhibits viral transmission. 
Therefore, the authors explored the use of this historical therapy in a small group of patients with early-stage COVID-
19. In this exploratory study, patients treated with acetic acid that experienced improvement in individual symptoms 
was double that of the other group of patients, although numbers were too small for robust statistical analysis. 
Vaccine development  
Overview 
Vaccines in development  
Within two months of the COVID-19 outbreak, at least 37 biopharmaceutical companies or academic sectors were 
reported to be in the race to develop a prophylactic vaccine by using several platforms including mRNA, DNA, 
adenoviral vector and recombinant protein (Prompetchara Asia Pac J All Imm 2020, see below). However, the number 
of vaccine projects soon increased. A draft landscape of the candidate SARS-CoV-2 vaccines under development has 
been provided by WHO (last updated on October 19 2020): https://www.who.int/who-documents-detail/draft-
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landscape-of-covid-19-candidate-vaccines. As of October 19 2020, the dashboard of the London School of Hygiene and 
Tropical Medicine (https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/) described a total of 248 vaccine 
candidates, including 49 candidates in clinical trial testing phase. As presented in Table 14, numerous vaccine 
candidates have reached phase 1 or 1/2 clinical trial testing stage of development, and phase 3 is ongoing for a total 
of eleven candidates (2 RNA, 1 subunit, 4 non-replicating viral vectors, and 4 inactivated vaccines).  
Table 14 Vaccine candidates in clinical development as of October 6 2020* 



















mRNA-1273 (Moderna) NCT04283461 Phase 1 120 
 NCT04405076 Phase 2 600 








LNP-nCoVsaRNA (Imperial College) ISRCTN17072692 Phase 1 320 
ARCT-021 (Arcturus) NCT04480957 Phase 1/2 92 
DNA 
INO-4800 (Inovio) NCT04336410 Phase 1 120 
 NCT04447781 Phase 1/2 160 
GX-19 (Genexine) NCT04445389 Phase 1/2 210 
ZyCoV-D (Zydus Cadila) CTRI/2020/07/026352 Phase 1/2 1048 



















CoVLP (Medicago) NCT04450004 Phase 1 180 
(SpyBiotech/Serum Institute of India) ACTRN12620000817943 Phase 1/2 280 
Covax-19 (Vaxine/Medytox) NCT04453852 Phase 1 40 
SCB-2019 (Clover) NCT04405908 Phase 1 150 
V451 (University of Queensland/CSL/Seqirus) 
ACTRN12620000674932p 
(NCT04495933) 
Phase 1 216 
AdimrSC-2f (AdImmune) NCT04522089 Phase 1 70 
EpiVacCorona (Federal Budgetary Research Institution State 
Research Center of Virology and Biotechnology "Vector") 
NCT04527575 Phase 1/2 100 
(Sanofi Pasteur, GSK) NCT04537208 Phase 1/2 440 
UB-612 (Covaxx/Uni Nebraska) NCT04545749 Phase 1 60 
(Finlay Institute) IFV/COR/04 Phase 1/2 676 


































Adenovirus Type 5 Vector (CanSino) 
NCT04313127 
(ChiCTR2000030906) 
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Ad5-nCoV (Institute of Biotechnology, Academy of Military Medical 
Sciences, PLA of China) 
NCT04552366 Phase 1 144 
VXA-CoV2-1 (Vaxart) NCT04563702 Phase 1 48 
























GRAd-COV2 (ReiThera/Leukocare/Univercells NCT04528641 Phase 1 90 







 Sinovac/Butantan NCT04352608 Phase 1/2 744 












 Beijing Institute of 
Biological 
Products/Sinopharm 







 Wuhan Institute of 
Biological 
Products/Sinopharm 

















 Institute of Medical Biology, Chinese Academy of 
Medical Sciences 
NCT04412538 Phase 1 942 
NCT04470609 Phase 1/2 471 
QazCovid-in (inactivated, Research Institute for Biological Safety 
Problems) 
NCT04530357 Phase 1/2 244 
Cell-based  
aAPC (Shenzhen Geno-Immune Medical Institute) NCT04299724 Phase 1 100 
LV-SMENP-DC (Shenzhen Geno-Immune Medical Institute) NCT04276896 Phase 1 100 
* All studies included in this table have recruited or are recruiting participants 
Another overview of the various COVID-19 vaccines under development (including planned vaccine manufacturing 
capacity and key business information) can be found at https://racap.com/covid-19 (last accessed on October 19 2020). 
A Target Product Profile (TPP), issued by WHO in April 2020, described the preferred and minimally acceptable profiles 
for human vaccines for long term protection of persons at high ongoing risk of COVID-19 such as healthcare workers 
as well as for reactive use in outbreak settings with rapid onset of immunity 
(https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccines). 
Full-length S or S1 which contains receptor binding domain (RDB) have been considered as a candidate vaccine 
antigens as they induce neutralizing antibodies preventing host cell attachment and infection. The S antigen has been 
included in different types of vaccines against infections by CoVs (Yu Micr Inf 2020, see below). Conserved B cell and 
T cell epitopes between SARS-CoV and SARS-CoV-2 were also found in the viral nucleocapsid (N) protein (Ahmed 
Viruses 2020 see below, Grifoni Cell Host & Microbe 2020, see below).  
An illustrative landscape on the development of coronavirus vaccines has been provided in a Nature’s news feature 
by Callaway (Nature 2020, see below).  However, the review is by Poland (Mayo Clin Proc 2020, see below) on this 
topic is more up-to-date. 
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Probability of success 
Lu (Emerg Microbes Inf 2020, see below) described both the reasons why a COVID-19 vaccine is needed, and the 
challenges to be faced. Likewise, Amanat and Krammer gave their perspective on the development of SARS-CoV-2 
vaccines and its challenges (Immunity 2020, see below).  
Building on experience from the past, various authors have highlighted a list of criteria that can help predict the 
likelihood of success of research towards vaccines against novel infectious diseases. Satterfield (Vaccine 2016, see 
below) for instance, identified a set of criteria while discussing the biological feasibility of a vaccine against Nipah. 
Additional criteria can be identified from the decision guide provided by the Medical Research Council in the U.K. 
(http://vaccinedevelopment.org.uk/decision-guide.html). 
- Complexity and size of pathogen 
- Little genetic (antigenic) diversity, low mutation rate 
- The pathogen can be cultured in vitro 
- Vaccine available against a closely related pathogen 
- Incubation period of the disease of at least 5-7 days  
- Reported cases of natural immunity, both durable and protective 
- Passive transfer of neutralizing antibodies known to be protective 
- Available animal models, including human challenge models 
More recently, in considering the “certainty of success” in development of SARS-CoV-2 vaccines, Kaslow (NPJ Vaccines 
2020, see below) proposed a third, related critical parameter - the infectious inoculum intensity, at an individual-level, 
and force of infection, at a population-level. Reducing the infectious inoculum intensity (and force of infection, at a 
population-level) is indeed predicted to lengthen the incubation period, which in turn is predicted to reduce the 
severity of illness, and increase the opportunity for an anamnestic response upon exposure to the circulating virus. 
Similarly, successfully implementing individual- and population-based behaviours that reduce the infectious inoculum 
intensity and force of infection, respectively, while testing and deploying COVID-19 vaccines is predicted to increase 
the “certainty of success” of demonstrating vaccine efficacy and controlling SARS-CoV-2 infection and the pandemic 
itself. 
Of note, all of these success criteria focused on vaccine efficacy/effectiveness. Vaccine safety upon large scale 
utilization is obviously of utmost importance in the case of COVID-19, even though the criteria that could help predict 
such safety seem more difficult to identify. Su (Nature Rev Microb 2020, see below) provided an important perspective 
on this topic by summarizing examples of vaccine-associated disease enhancement in the history of developing 
vaccines against respiratory syncytial virus, dengue virus, SARS-CoV and MERS-CoV, highlighting the importance of a 
robust safety and efficacy profile. 
RNA vaccines 
Moderna, Inc. and the Coalition for Epidemic Preparedness Innovations (CEPI) announced a new collaboration to 
develop an mRNA vaccine against COVID-19 (https://investors.modernatx.com/news-releases/news-release-
details/moderna-announces-funding-award-cepi-accelerate-development). Under the terms of the agreement, 
Moderna will manufacture an mRNA vaccine, which will be funded by CEPI. The Vaccine Research Center (VRC) of the 
National Institute of Allergy and Infectious Diseases (NIAID) collaborated with Moderna to design the vaccine. The 
mRNA-1273 vaccine candidate encodes the S-2P antigen, consisting of the SARS-CoV-2 glycoprotein with a 
transmembrane anchor and an intact S1–S2 cleavage site (Jackson NEJM 2020, see below). S-2P is stabilized in its 
prefusion conformation by two consecutive proline substitutions at amino acid positions 986 and 987, at the top of 
the central helix in the S2 subunit. 
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Corbett (manuscript on medRxiv, see https://www.biorxiv.org/content/10.1101/2020.06.11.145920v1) presented 
data indicating that mRNA-1273 induces both potent neutralizing antibody and CD8 T cell responses in mice. As 
highlighted by Vabret (Nature Rev Imm 2020, see below), two doses of the candidate vaccine given in prime-boost 
combination (2 x 1 µg/mouse) protected mice against infection of the nasal mucosa and lungs after challenge with 
mouse-adapted SARS-CoV-2. Importantly, there was no indication of enhanced immunopathology in animals that 
received sub-protective doses. 
Moderna announced the initiation of the phase 1 trial of the mRNA-1273 vaccine on March 16 
(https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-first-participant-dosed-
nih-led-phase-1-study; study NCT04283461). The vaccine candidate mRNA-1273 consists of lipid nanoparticles 
packaged with nucleoside-modified mRNA that encodes a prefusion-stabilized form of the SARS-CoV-2 S protein. Three 
dose levels of mRNA-1273 (25, 100, 250 μg) were administered on a two-dose vaccination schedule, given 28 days 
apart. A total of 45 healthy adults were enrolled in the study. Participants are to be followed through 12 months after 
the second vaccination. Preliminary results from the trial were disclosed by Jackson (NEJM 2020, see below). Solicited 
adverse events that occurred in more than half the participants included fatigue, chills, headache, myalgia, and pain 
at the injection site. Systemic adverse events were more common after the second vaccination, particularly with the 
highest dose, and three participants (21%) in the 250-μg dose group reported one or more severe adverse events. 
After the first vaccination, antibody responses were higher with higher dose (day 29 enzyme-linked immunosorbent 
assay anti–S-2P antibody geometric mean titer [GMT], 40 227 in the 25-μg group, 109 209 in the 100-μg group, and 
213 526 in the 250-μg group). After the second vaccination, the titers increased (day 57 GMT, 299 751, 782 719, and 
1 192 154, respectively). After the second vaccination, serum-neutralizing activity was detected by two methods in all 
participants evaluated, with values generally similar to those in the upper half of the distribution of a panel of control 
convalescent serum specimens.  Data obtained from 40 additional participants of older age were reported by Anderson 
(NEJM 2020, see below). Binding- and neutralizing-antibody responses appeared to be similar to those previously 
reported among vaccine recipients between the ages of 18 and 55 years and were above the median of a panel of 
controls who had donated convalescent serum. The vaccine elicited a strong CD4 cytokine response involving type 1 
helper T cells. 
A phase 2 clinical trial is ongoing, which compares vaccine doses of 50 and 100 µg in young vs. older adults (total size 
of 600 study participants) (https://clinicaltrials.gov/ct2/show/NCT04405076?term=mRNA-1273&draw=2&rank=1). A 
phase 3 efficacy trial was initiated on July 27th (https://www.nih.gov/news-events/news-releases/phase-3-clinical-
trial-investigational-vaccine-covid-19-begins). 
Curevac and CEPI also announced a collaboration to develop a vaccine against COVID-19 based on CureVac’s 
technology and mRNA platform  (https://www.curevac.com/news/curevac-and-cepi-extend-their-cooperation-to-
develop-a-vaccine-against-coronavirus-ncov-2019#). CureVac indicated that their mRNA platform using lipid 
nanoparticles in phase 1 study for the prevention of rabies was capable of providing protective virus-neutralizing 
antibody titers after two vaccination with dose of 1µg mRNA vaccine (https://www.curevac.com/news/curevac-
announces-positive-results-in-low-dose-1-%C2%B5g-rabies-vaccine-clinical-phase-1-study). The company received 
regulatory approval from the German and Belgian authorities in June 2020 to initiate Phase 1 clinical trial of its SARS-
CoV-2 vaccine candidate (https://www.curevac.com/en/2020/06/17/curevac-receives-regulatory-approval-from-
german-and-belgian-authorities-to-initiate-phase-1-clinical-trial-of-its-sars-cov-2-vaccine-candidate/l). A phase 2 trial 
is currently recruiting participants in Panama and Peru (NCT04515147). 
BioNTech and Pfizer collaborate on the development of a mRNA-based vaccine candidate aimed at preventing COVID-
19 (https://investors.biontech.de/news-releases/news-release-details/pfizer-and-biontech-co-develop-potential-
covid-19-vaccine), building on a joined programme initiated by BioNTech and Pfizer in 2018 for the development of an 
influenza mRNA vaccine. The BNT162 program is evaluating at least four experimental vaccine candidates, each of 
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which represents a unique combination of mRNA format and target antigen. On May 5, Pfizer Inc. and BioNTech SE 
announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial of BNT162.  This Phase 
1/2 study was designed to determine the safety, immunogenicity and optimal dose level of the four mRNA vaccine 
candidates. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S. was to enroll up to 360 healthy 
subjects into two age cohorts (18-55 and 65-85 years of age) (https://www.pfizer.com/news/press-release/press-
release-
detail/pfizer_and_biontech_dose_first_participants_in_the_u_s_as_part_of_global_covid_19_mrna_vaccine_develo
pment_program). Data from 45 healthy adults, 18 to 55 years of age, randomized to receive 2 doses of 10 µg, 30 µg, 
or 100 µg of BNT162b1, have been reported by Mulligan (Nature 2020, see below).  Local reactions and systemic 
events were dose-dependent, generally mild to moderate, and transient. A second vaccination with 100 µg was not 
administered due to increased reactogenicity and a lack of meaningfully increased immunogenicity after a single dose 
compared to the 30 μg dose. RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titers in sera increased with 
dose level and after a second dose. Geometric mean neutralizing titers reached 1.9- to 4.6-fold that of a panel of 
COVID-19 convalescent human sera at least 14 days after a positive SARS-CoV-2 PCR. Sahin (Nature 2020, see below) 
presented antibody and T-cell responses after BNT162b1 vaccination from a second, non-randomized open-label 
phase 1/2 trial in healthy adults, 18-55 years of age. Two doses of 1 to 50 µg of BNT162b1 elicited robust CD4+ and 
CD8+ T-cell responses and strong antibody responses, with RBD-binding IgG concentrations clearly above those in a 
COVID-19 human convalescent sample panel. Day 43 SARS-CoV-2 serum neutralising geometric mean titers were 0.7-
fold (1 µg) to 3.5-fold (50 µg) those of the convalescent panel. Immune sera broadly neutralised pseudoviruses with 
diverse SARS-CoV-2 spike variants. Most participants had T helper type 1 skewed T cell immune responses with RBD-
specific CD8+ and CD4+ T-cell expansion. IFNγ was produced by a high fraction of RBD-specific CD8+ and CD4+ T cells. 
Pfizer and BioNTech have chosen to advance the BNT162b2 vaccine candidate into the Phase 2/3 study, at a 30 µg 
dose level in a 2 dose regimen. Enrolment of a planned cohort of 32 000 volunteers is currently ongoing 
(https://clinicaltrials.gov/ct2/show/NCT04368728). BNT162b2 received U.S. FDA Fast Track designation 
(https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-granted-fda-fast-track-
designation-two). BioNTech also initiated an alliance with Fosun Pharma to conduct clinical trials in China.  
A phase 1 clinical trial of a RNA vaccine candidate has been announced by Walvax Biotechnology, a Chinese company 
(https://www.yicaiglobal.com/news/china-gives-go-ahead-for-first-covid-19-mrna-vaccine-trial-; 
http://www.chictr.org.cn/showprojen.aspx?proj=55524). 
Translate Bio also announced a collaboration with Sanofi Pasteur on a new mRNA COVID-19 vaccine 
(https://investors.translate.bio/news-releases/news-release-details/sanofi-pasteur-and-translate-bio-collaborate-
develop-novel-mrna). On August 25 2020, a company presentation indicated that two injections of the mRNA/LNP 
vaccine candidate induced neutralizing antibodies and a TH1-biased T-cell responses 
(https://www.sec.gov/Archives/edgar/data/1693415/000119312520229383/d904716dex991.htm). 
Self-amplifying RNA vaccines 
A type of mRNA that has shown extraordinary properties to induce immune responses is the so-called self-amplifying 
RNA (saRNA). saRNA is derived from the genome of certain viruses like alphaviruses and flaviviruses and has the 
capacity of self-amplification due to the fact that it expresses a viral replicase (Rep), while the genes coding for the 
viral structural proteins have been substituted by the transgene of interest. As reviewed by Ballesteros-Briones (Curr 
Opin Virol 2020, see below), most saRNAs used in vaccination studies derive from alphaviruses, including Venezuelan 
equine encephalitis virus, Semliki Forest virus, and Sindbis virus. 
The Imperial College in London works on a mRNA COVID-19 vaccine candidate based on Venezuelan equine 
encephalitis virus self-amplifying RNA (saRNA) encapsulated in lipid nanoparticles. Encoding a pre-fusion stabilized 
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SARS-CoV-2 S protein, this self-amplifying mRNA vaccine was capable to elicit cellular responses and robust antibody 
responses in mice, showing neutralizing capacity of a pseudotyped SARS-CoV-2 virus (McKay Nature Comm 2020, see 
below). A phase 1 trial of the candidate is reported as ongoing in the U.K. (http://www.isrctn.com/ISRCTN17072692). 
Another self-replicating (replicon) mRNA that encodes for the prefusion S protein of SARS-CoV-2 was formulated in a 
lipid nanoparticle (Arcturus Therapeutics). De Alwis  reported the positive outcome of immunogenicity experiments 
conducted in mice, with 100% of the animals developing a robust serological response after single dose vaccination 
and a dominance of TH1 response (manuscript on bioRxiv : 
https://www.biorxiv.org/content/10.1101/2020.09.03.280446v1). The investigational vaccine, ARCT-021, is 
undergoing phase 1/2 clinical evaluation 
(https://clinicaltrials.gov/ct2/show/NCT04480957?term=vaccine&cond=covid-19&draw=10).  
A third candidate based on Venezuelan equine encephalitis virus saRNA expressing SARS-CoV-2 S encapsulated with 
Lipid InOrganic Nanoparticles (LION) has been developed by the University of Washington in partnership with HDT Bio 
Corp. This vaccine was able to induce neutralizing antibodies in old mice, as well as in nonhuman primates that lasted 
for at least 70 days (Erasmus Sci Transl Med 2020, see below). According to HDT Bio communication, HDT-301 vaccine 
for COVID-19 is now preparing for IND filing (https://www.hdt.bio/news). 
Pfizer in partnership with BioNtech has also developed a saRNA prototype vaccine, although the details of this 
vector/formulation have not been disclosed yet.  
DNA vaccines 
A study by Yu (Science 2020, see below) provided encouraging data supporting the feasibility of a DNA vaccine against 
COVID-19 as early as in May 2020. The authors developed a series of DNA vaccine candidates expressing different 
forms of the SARS-CoV-2 S protein and evaluated them in 35 rhesus macaques. Vaccinated animals developed humoral 
and cellular immune responses, including neutralizing antibody titres comparable to those found in convalescent 
humans and macaques infected with SARS-CoV-2. Following vaccination, all animals were challenged with SARS-CoV-
2, and the vaccine encoding the full-length S protein resulted in >3.1 and >3.7 log10 reductions in median viral loads 
in bronchoalveolar lavage and nasal mucosa, respectively, as compared with sham controls. Protection was likely not 
sterilizing but instead appeared to be mediated by rapid immunologic control following challenge. Vaccine-elicited 
neutralizing antibody titers correlated with protective efficacy, suggesting an immune correlate of protection. Several 
DNA vaccine candidates are currently undergoing clinical evaluation. 
Inovio Pharmaceuticals, Inc. announced that it is developing INO-4800, a vaccine against COVID-19 based on the 
company’s DNA platform with the support of CEPI (http://ir.inovio.com/news-and-media/news/press-release-
details/2020/Inovio-Collaborating-With-Beijing-Advaccine-To-Advance-INO-4800-Vaccine-Against-New-Coronavirus-
In-China/default.aspx). The Phase 1 study of INO-4800, reported to have started on April 3rd, enrolled 120 healthy 
adult volunteers to receive 1 or 2 injections per visit of INO-4800 administered intradermally followed by 
electroporation using CELLECTRA® 2000 device, on day 0 and week 4 
(https://clinicaltrials.gov/ct2/show/NCT04336410). An ongoing phase 1/2 trial started on July 15. Of note, Inovio 
announced that the U.S. FDA has notified the company it has additional questions about the company's planned Phase 
2/3 trial of INO-4800, including the CELLECTRA® 2000 delivery device to be used in the trial. Until the FDA's questions 
have been satisfactorily addressed, INOVIO's Investigational New Drug Application for the Phase 2/3 trial is on partial 
clinical hold (http://ir.inovio.com/news-releases/news-releases-details/2020/INOVIO-Reports-FDA-Partial-Clinical-
Hold-for-Planned-Phase-2--3-Trial-of-COVID-19-Vaccine-Candidate-INO-4800/default.aspx). The company also 
announced that it is collaborating with Beijing Advaccine Biotechnology Co. to advance the vaccine candidate 
development in China. The goal of this collaboration is to leverage Advaccine's expertise to run a Phase 1 trial in China 
in parallel with Inovio's clinical development efforts in the U.S. Inovio and Advaccine will also work together to attract 
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additional grant funding and further collaborations with larger vaccine companies in China to increase the speed of 
future testing of INO-4800.  
Another candidate under clinical evaluation is GX-19, the DNA vaccine candidate developed by Genexine, Inc 
(http://www.genexine.com/m62_view.php?idx=157&cate=1&year=). A phase 1/2 study is ongoing in a total of 210 
subjects. The phase 2a part of the trial has a randomized, double-blind, placebo controlled design 
(https://clinicaltrials.gov/ct2/show/NCT04445389?term=antibody&recrs=adefh&type=Intr&cond=COVID-
19&draw=1&rank=61). 
On August 6 2020, India’s Zydus Cadila said its COVID-19 vaccine candidate (ZyCoV-D) was found to be safe and well-
tolerated in an early-stage human trial (https://zyduscadila.com/public/pdf/pressrelease/Press-Release-ZyCoV-D.pdf). 
Enrollment in a phase 2 study followed in over 1000 healthy adult volunteers as part of the adaptive phase I/II dose 
escalation, multicentric, randomized, double-blind placebo controlled study of the company (CTRI/2020/07/026352). 
Subunit vaccines 
Virus-like particles (nanoparticles) 
On March 12 2020, Medicago announced the successful production of Virus-Like Particle (VLPs) of SARS-CoV-2 
(https://www.medicago.com/en/covid-19-programs/). Preclinical studies were to be initiated in a very short 
timeframe. A partnership with Glaxo SmithKline allowed combination of the VLPs with an adjuvant 
(https://www.gsk.com/en-gb/media/press-releases/gsk-and-medicago-announce-collaboration-to-develop-a-novel-
adjuvanted-covid-19-candidate-vaccine/). The vaccine candidate is currently being evaluated in a phase 1 staggered 
dose-escalation clinical trial (https://clinicaltrials.gov/ct2/show/NCT04450004?term=medicago&cond=COVID-
19&draw=2&rank=1). 
Novavax previously developed vaccine candidates against SARS-CoV and MERS-CoV (see for instance, Coleman 
Vaccine 2014, see below). Purified full-length MERS and SARS S proteins formed ~25 nm diameter particles consisting 
of multiple S protein molecules. The antigens were combined with Matrix M1 adjuvant and evaluated in mice. On May 
11, the company announced that CEPI will invest up to $384 million of additional funding, on top of $4 million invested 
in March, to advance clinical development of NVX-CoV2373, Novavax’ coronavirus vaccine candidate against SARS-
CoV-2. The additional funding from CEPI will also support rapid scale-up of the NVX-CoV2373 vaccine antigen, as well 
as Novavax’ proprietary Matrix-M™ adjuvant, which is expected to enhance immune responses by stimulating high 
levels of neutralizing antibodies (http://ir.novavax.com/news-releases/news-release-details/novavax-receive-388-
million-funding-cepi-covid-19-vaccine). The vaccine candidate is now undergoing phase 1/2 clinical testing in 1419 
volunteers in Australia (https://clinicaltrials.gov/ct2/show/NCT04368988?term=covid-
19+vaccine&recrs=abdf&draw=2). According to company communication, in the Phase 1 portion of the Phase 1/2 
clinical trial, NVX-CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior 
to that seen in human convalescent sera (https://ir.novavax.com/news-releases/news-release-details/novavax-
initiates-efficacy-trial-covid-19-vaccine-south-africa). A phase 2b as well as a phase 3 trial are now ongoing. 
Fusion protein-based approach 
Viral fusion proteins undergo structural rearrangements from a metastable pre-fusion conformation to a highly stable 
post-fusion conformation (https://www.pharmalicensing.com/detail.php?uid=66499). Traditional approaches to 
recombinant expression of these proteins typically result in premature triggering and a conformational shift to the 
structurally more stable post-fusion form. The “molecular clamp” approach developed by the University of Queensland, 
Australia, uses a polypeptide moiety and has been shown to display increased stability over alternate stabilizing 
trimerization domains (https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018176103). This technique has 
already been used to produce chimeric polypeptides that mimic the pre-fusion conformations of HIV, respiratory 
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syncytial virus, influenza, measles and Ebola viruses. The University of Queensland has been requested to use this 
technology to develop a vaccine candidate against COVID-19 (https://www.uq.edu.au/news/article/2020/01/race-
develop-coronavirus-vaccine). A partnership with CSL’s influenza vaccines company, Seqirus, supports the rapid 
development and large-scale manufacture of the vaccine candidate (V451). V451 (formulated with MF59 adjuvant) is 
currently undergoing phase 1 evaluation (https://clinicaltrials.gov/ct2/show/NCT04495933).  
Other subunit candidates 
Dai (Cell 2020, see below) described a dimeric form of MERS-CoV RBD that significantly increased neutralizing antibody 
responses compared to conventional monomeric form and protected mice against MERS-CoV infection. Crystal 
structure showed RBD-dimer fully exposed dual receptor-binding motifs, the major target for neutralizing antibodies. 
Structure-guided design further yielded a stable version of RBD-dimer as a tandem repeat single-chain (RBD-sc-dimer) 
which retained the vaccine potency. This strategy was used to design a vaccine candidate against COVID-19. RBD-sc-
dimers in pilot scale production yielded high yields, supporting their scalability. A phase 1 trial evaluates this vaccine 
candidate in 50 volunteers in China (https://clinicaltrials.gov/ct2/show/NCT04445194). 
A team from Flinders University, Oracle Cloud technology and Vaxine Pty Ltd, is developing another subunit vaccine 
candidate against SARS-CoV-2 (https://news.flinders.edu.au/blog/2020/04/03/flinders-targets-covid-19-vaccine/). 
The candidate, made of S antigen (25µg) combined to 15 mg Advax-2 adjuvant, is undergoing phase 1 clinical testing 
in Australia (https://clinicaltrials.gov/ct2/show/NCT04453852?term=vaxine&cond=COVID-19&draw=2&rank=1). 
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. also has clinical trials ongoing to evaluate a non-adjuvanted subunit 
vaccine produced in CHO cells (see for instance, 
https://clinicaltrials.gov/ct2/show/NCT04445194?term=longcom&draw=2&rank=2). 
Adjuvanted vaccines 
As indicated above (see Fusion protein-based approach), the University of Queensland created a subunit vaccine, 
which has been formulated with MF59. 
Sanofi Pasteur’s (formerly Protein Sciences) vaccine candidate is produced by baculovirus expression platform, which 
was initially developed to manufacture large quantities of pandemic influenza vaccines. A collaboration with GSK 
allowed for the evaluation in a phase 1/2 clinical trial of 2 different adjuvant formulations of the vaccine candidate 
(NCT04537208). 
Another adjuvanted vaccine candidate is based on the S-trimer subunit vaccine candidate of Clover 
Biopharmaceuticals Inc (SCB-2019) (https://www.gsk.com/en-gb/media/press-releases/clover-and-gsk-announce-
research-collaboration-to-evaluate-coronavirus-covid-19-vaccine-candidate-with-pandemic-adjuvant-system/). A 
randomized, double blind, placebo controlled, first-in-human study is currently ongoing to assess safety, 
reactogenicity, and immunogenicity of SCB-2019 either administered alone or with AS03 adjuvant or with CpG 1018 





The Ad5-nCoV vaccine of CanSino Biologics is a replication-defective adenovirus type 5 vector expressing SARS-CoV-2 
S protein. Phase 1 and 2 clinical trials were initiated respectively in March and April 2020. The phase 1 trial was a 
single-centre, open and dose-escalation trial, testing safety and tolerance of Ad5-nCoV in healthy adults, aged 18 to 
60 years. The low-, middle- and high-dosage groups sequentially enrolled 36 patients each, who received either 
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5 × 1010, 1 × 1011 or 1.5 × 1011 viral particles of Ad5-nCoV 
(https://clinicaltrials.gov/ct2/show/NCT04313127?term=cansino&cond=covid-19&draw=2&rank=1; 
http://www.chictr.org.cn/showprojen.aspx?proj=51154). As reported by Zhu (Lancet 2020, see below), at least one 
adverse reaction within the first 7 days after vaccination was reported in 30 (83%) participants in the low dose group, 
30 (83%) participants in the middle dose group, and 27 (75%) participants in the high dose group. The most common 
injection site adverse reaction was pain, which was reported in 58 (54%) vaccine recipients, and the most commonly 
reported systematic adverse reactions were fever (50 [46%]), fatigue (47 [44%]), headache (42 [39%]), and muscle pain 
(18 [17%]. Most adverse reactions that were reported in all dose groups were mild or moderate in severity. No serious 
adverse event was noted within 28 days post-vaccination. ELISA antibodies and neutralising antibodies increased 
significantly at day 14, and peaked 28 days post-vaccination. Specific T-cell response were found to peak at day 14 
post-vaccination. The phase 2 trial, conducted in a total of 508 volunteers, evaluated only the 2 lower doses of the 
candidate (Zhu, Guan et al. Lancet 2020, see below). In the 1 × 1011 and 5 × 1010 viral particles dose groups, the RBD-
specific ELISA antibodies peaked at 656·5 (95% CI 575·2–749·2) and 571·0 (467·6–697·3), with seroconversion rates at 
96% (95% CI 93–98) and 97% (92–99), respectively, at day 28. Both doses of the vaccine induced significant neutralising 
antibody responses to live SARS-CoV-2, with GMTs of 19·5 (95% CI 16·8–22·7) and 18·3 (14·4–23·3) in participants 
receiving 1 × 1011 and 5 × 1010 viral particles, respectively. Specific IFN-γ enzyme-linked immunospot assay responses 
post vaccination were observed in 227 (90%, 95% CI 85–93) of 253 and 113 (88%, 81–92) of 129 participants in the 
1 × 1011 and 5 × 1010 viral particles dose groups, respectively. Solicited adverse reactions were reported by 183 (72%) 
of 253 and 96 (74%) of 129 participants in the 1 × 1011 and 5 × 1010 viral particles dose groups, respectively. Severe 
adverse reactions were reported by 24 (9%) participants in the 1 × 1011 viral particles dose group and one (1%) 
participant in the 5 × 1010 viral particles dose group. No serious adverse reactions were documented. On June 25th, 
China's Central Military Commission approved the use of the vaccine (for military purposes) for one year 
(https://medicalxpress.com/news/2020-06-chinese-coronavirus-vaccine-military.html).  
The Jenner Institute developed a ChAdOx1 COVID-19 candidate, AZD1222, based on the non-replicating chimpanzee 
adenovirus platform, previously used for a vaccine against MERS which was tested in phase 1 trials in UK and KSA 
(http://www.ox.ac.uk/news/2020-02-07-oxford-team-begin-novel-coronavirus-vaccine-research#). The vaccine 
candidate was designed to encode a codon-optimised full-length S protein of SARS-CoV-2 (YP_009724390.1) with a 
human tPA leader sequence. A partnership with Advent in Italy allowed for the manufacturing of clinical batches and 
initiation of a phase 1/2 study. On April 30, Oxford University announced a partnership with AstraZeneca for the 
development and potential large-scale distribution of the vaccine candidate (http://www.ox.ac.uk/news/2020-04-30-
oxford-university-announces-landmark-partnership-astrazeneca-development-and). Preclinical immunogenicity data 
following single vaccination with ChAdOx1 nCoV-19by were presented by Van Doremalen (Nature 2020, see below). 
In rhesus macaques, the vaccine candidate was found to significantly reduce viral load in bronchoalveolar lavage fluid 
and respiratory tract tissue upon challenge with SARS-CoV-2. However, no difference in viral load in nose swabs was 
found on any days between vaccinated and control animals. Folegatti reported the outcome of the phase 1/2, single-
blind, randomised controlled trial of the vaccine candidate (Lancet 2020, see below). A total of 1077 participants were 
enrolled and assigned to receive either ChAdOx1 nCoV-19 (n=543) or MenACWY (n=534), ten of whom were enrolled 
in a non-randomised ChAdOx1 nCoV-19 prime-boost group. Local and systemic reactions were more common in the 
ChAdOx1 nCoV-19 group and many were reduced by use of prophylactic paracetamol, including pain, feeling feverish, 
chills, muscle ache, headache, and malaise (all p<0·05). There were no serious adverse events related to ChAdOx1 
nCoV-19. In the ChAdOx1 nCoV-19 group, S-specific T-cell responses peaked on day 14 (median 856 spot-forming cells 
per million peripheral blood mononuclear cells, IQR 493–1802; n=43). Anti-S IgG responses rose by day 28 (median 
157 ELISA units [EU], 96–317; n=127), and were boosted following a second dose (639 EU, 360–792; n=10). Neutralising 
antibody responses against SARS-CoV-2 were detected in 32 (91%) of 35 participants after a single dose or in 35 (100%) 
participants depending on the method used. After a booster dose, all participants had neutralising activity. Neutralising 
antibody responses correlated strongly with antibody levels measured by ELISA. Phase 2/3 and phase 3 trials of the 
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candidate vaccine are ongoing (https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001228-32/GB and 
http://www.isrctn.com/ISRCTN89951424). On September 9 2020, the company announced a voluntary pause of 
vaccination across all trials to allow for a review of the safety data following a single event of an unexplained illness 
that occurred in the UK Phase 3 trial (https://www.astrazeneca.com/media-centre/press-releases/2020/statement-
on-astrazeneca-oxford-sars-cov-2-vaccine-azd1222-covid-19-vaccine-trials-temporary-pause.html). The trials 
resumed in the UK on September 12 (https://www.astrazeneca.com/content/astraz/media-centre/press-
releases/2020/covid-19-vaccine-azd1222-clinical-trials-resumed-in-the-uk.html), and globally in the following weeks 
(https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/fda-authorises-restart-of-the-
covid-19-azd1222-vaccine-us-phase-iii-trial.html). On October 1st, the EMA announced that the committee has started 
a rolling review of the product, whereby a first batch of non-clinical data on the vaccine is already being reviewed 
(https://www.ema.europa.eu/en/news/ema-starts-first-rolling-review-covid-19-vaccine-eu). 
Russia also conducted a national clinical trial of 2 vaccine candidates developed at the Gamaleya Research Institute. 
The candidates are recombinant adenovirus vectors based on either the human adenovirus type 26 or type 5 virus, 
containing the SARS-CoV-2 S protein gene (https://www.trialsitenews.com/gamaleya-research-institute-developed-
covid-19-vaccine-clinical-trial-commences-across-russia/). Two open trials that enrolled 38 study participants were 
reported by Logunov (Lancet 2020, see below). All participants produced antibodies to SARS-CoV-2 glycoprotein.  
Surprisingly, Russia’s president Vladimir Putin announced on 11 August that the country’s health regulator had become 
the world’s first to approve a CoV vaccine for widespread use. As Russia hadn’t completed large trials to test the safety 
and efficacy of the vaccine, scientists worldwide have condemned the decision as dangerously rushed (Callaway 
Nature 2020, see below). A large- scale phase 3 trial is now ongoing (NCT04530396). 
As early as by the end of January 2020, Johnson & Johnson (Janssen Vaccines & Prevention ) announced that it has 
initiated efforts to develop a vaccine candidate against COVID-19 (https://www.jnj.com/johnson-johnson-launches-
multi-pronged-response-to-coronavirus-global-public-health-threat). The vaccine program is leveraging Janssen’s 
AdVac® and PER.C6® technologies that provide the ability to rapidly upscale production of the optimal vaccine 
candidate. These are the same technologies that were used in the development and manufacturing of an 
investigational Ebola adenovirus type 26 vector vaccine, which is currently deployed in the Democratic Republic of the 
Congo and Rwanda. They were also used to construct the Company’s Zika, respiratory syncytial virus and HIV vaccine 
candidates. A randomized, double-blind, placebo-controlled phase 1/2a study in 1045 volunteers to evaluate the 
safety, reactogenicity, and immunogenicity of the Ad26COVS1 vaccine candidate in adults aged 18 to 55 years inclusive 
and adults aged 65 years and older (NCT04436276). A pivotal phase 3 trial is currently ongoing in 60000 participants 
(ENSEMBLE). On October 23 2020, the company announced that it is preparing to resume recruitment in this phase 3 
trial after a temporary pause. After a thorough evaluation of a serious medical event experienced by one study 
participant, no clear cause has been identified. Based on the information gathered and the input of independent 
experts, the Company found no evidence that the vaccine candidate caused the event (https://www.jnj.com/our-
company/johnson-johnson-prepares-to-resume-phase-3-ensemble-trial-of-its-janssen-covid-19-vaccine-candidate-
in-the-us). 
On April 23 2020, ReiThera, Leukocare and Univercells announced a strategic collaboration for the development and 
large-scale manufacturing of a novel adenovirus vector-based vaccine against COVID-19 
(https://www.reithera.com/2020/04/23/reithera-leukocare-and-univercells-announce-pan-european-consortium-
for-the-fast-track-development-of-a-single-dose-adenovirus-based-covid-19-vaccine/). The Replication defective 
Simian Adenovirus (GRAd) encoding S candidate is used as a single dose vaccine. A phase 1 clinical trial is currently 
reported as ongoing (EudraCT 2020-002835-31). 
According to company communication, Altimmune develops a single-dose intranasal COVID-19 vaccine candidate, 
based on the technology used for their influenza vaccine candidate, NasoVAX, which is known to induce mucosal 
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immunity as well as cell and IgG responses (https://ir.altimmune.com/static-files/f9e406df-9cc0-4fb7-9d9c-
52d780679780). The candidate is a replication-deficient adenovirus 5 vector expressing SARS-CoV-2 S protein. 
Modified Vaccinia Ankara vector 
GeoVax Labs, Inc., together with BravoVax, a vaccine developer in Wuhan, China, today announced the signing of a 
Letter of Intent to jointly develop a vaccine against COVID-19. Under the collaboration, GeoVax will use its MVA-VLP 
vaccine platform and expertise to design and construct the vaccine candidate using genetic sequences from the 
ongoing coronavirus outbreak. BravoVax will provide further development, including testing and manufacturing 




Tonix Pharmaceuticals announced a strategic collaboration with Southern Research to support the development of a 




Several inactivated vaccine candidates have been described and are currently evaluated in clinical trials. 
Sinovac Biotech used a similar strategy as selected for a SARS vaccine tested in a clinical trial 16 years ago (Cohen 
Science 2020, see below). The SARS-CoV-2 vaccine candidate (PiCoVacc) is made by chemically inactivating whole virus 
particles and combination to Alum adjuvant. As reported by Gao, Bao et al. (Science 2020, see below) the vaccine 
induced potent neutralizing responses in various animal models. Immunization with two different doses (3 μg or 6 μg 
per dose) provided partial or complete protection in rhesus macaques against SARS-CoV-2 challenge. A publication by 
Risson (Nat Rev Imm 2020, see below) commenting these data highlighted the expected scalability of the inactivation 
method (β-propiolactone). The vaccine entered phase 3 clinical evaluation in July 
(https://clinicaltrials.gov/ct2/show/NCT04456595). 
Clinical development of other inactivated vaccine candidates produced in Vero cells, led by the Beijing and Wuhan 
Institutes of Biological Products and Sinopharm, have also been reported as reaching phase 3 
(http://www.chictr.org.cn/showprojen.aspx?proj=56651). Wang, Zhang, Huang et al. (Cell 2020, see below) reported 
the pilot-scale production of this inactivated SARS-CoV-2 vaccine candidate (BBIBP-CorV) that induces high levels of 
neutralizing antibodies titers in mice, rats, guinea pigs, rabbits, and nonhuman primates (cynomolgus monkeys and 
rhesus macaques). Two-dose immunizations using 2 mg/dose were shown to provide highly efficient protection 
against SARS-CoV-2 intratracheal challenge in rhesus macaques. Xia subsequently presented an interim analysis of a 
randomized phase 1/2 placebo-controlled trials of the vaccine (ChiCTR2000031809, JAMA 2020, see below). In 96 
healthy adults randomized to aluminum hydroxide (alum) only and low, medium, and high vaccine doses on days 0, 
28, and 56, 7-day adverse reactions occurred in 12.5%, 20.8%, 16.7%, and 25.0%, respectively; geometric mean titers 
of neutralizing antibodies at day 14 after the third injection were 316, 206 and 297 in the low-, medium-, and high-
dose groups, respectively. In 224 healthy adults randomized to the medium dose, 7-day adverse reactions occurred in 
6.0% and 14.3% of the participants who received injections on days 0 and 14 vs alum only, and 19.0% and 17.9% who 
received injections on days 0 and 21 vs alum only, respectively; geometric mean titers of neutralizing antibodies in the 
vaccine groups at day 14 after the second injection were 121 vs 247, respectively. 
COVAXIN (or BBV152), a COVID-19 vaccine candidate by Bharat Biotech is developed in collaboration with the Indian 
Council of Medical Research (ICMR) - National Institute of Virology (NIV). This vaccine received approval for Phase 1 
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and 2 human clinical trials and the trials commenced in July, 2020. After successful completion of the interim analysis 
from these clinical trials, Bharat Biotech received DCGI approval for Phase 3 clinical trials in 26 000 participants in over 
25 centres across India (https://www.bharatbiotech.com/covaxin.html). 
Live-attenuated vaccines 
Codagenix announced a collaboration with the Serum Institute of India to rapidly co-develop a live-attenuated vaccine 
against COVID-19 (https://www.prnewswire.com/news-releases/codagenix-and-serum-institute-of-india-initiate-co-
development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19-301004654.html). 
Codagenix uses viral deoptimization to synthesize "rationally designed," live-attenuated vaccines. According to 
another announcement of the company dated September 22 2020, Serum Institute of India has initiated 




Symvivo’s bacTRL platform is an orally administered, genetically modified probiotic bacteria which colonizes the gut, 
binds directly to intestinal epithelial cells and constitutively replicates, secretes and delivers plasmid DNA molecules 
encoding antigenic transgenes and neutralizing nanobodies (https://www.symvivo.com/covid-19). A phase 1 clinical 
trial is ongoing to evaluate bacTRL-Spike administered orally (NCT04334980). The S protein has also been combined 
to N protein and M glycoprotein for a trivalent vaccine called bacTRL-Tri. 
The Shenzhen Geno-immune Medical Institute reported 2 phase 1 clinical trials evaluating cell-based approaches of 
vaccination against COVID-19. The first one investigated a lentiviral vector system (NHP/TYF) to express viral proteins 
and immune modulatory genes to modify dendritic cells (DCs) and thereby activate T cells. The vaccine candidate (LV-
SMENP) uses a COVID-19 minigene engineered based on multiple viral genes 
(https://clinicaltrials.gov/ct2/show/NCT04276896?term=covid-19+vaccine&recrs=adf&draw=2&rank=6). The second 
trial investigates artificial antigen presenting cells (aAPC) modified by the lentiviral vector system to express viral 
proteins (minigene based on conserved domains of the viral structural proteins and a polyprotein protease) and 
immune modulatory genes (https://clinicaltrials.gov/ct2/show/NCT04299724?term=covid-
19+vaccine&recrs=adf&draw=2&rank=4). 
Aivita Biomedical, Inc also plans an adaptive phase 1b/2 randomized clinical trial of a preventive vaccine candidate 
(AV-COVID-19) made of autologous DCs loaded with SARS-CoV-2 antigens, with or without GM-CSF. The trial is to enrol 
a total of 180 study participants (https://clinicaltrials.gov/ct2/show/NCT04386252). 
A therapeutic vaccine approach has been proposed by Immunitor. The V-SARS candidate said to be made from heat-
inactivated plasma from COVID-19 donors, and administered once-daily as an oral pill 
(https://clinicaltrials.gov/ct2/show/NCT04380532?term=covid-19+vaccine&recrs=abdf&draw=2&rank=16). However, 
while technical details have not been disclosed, it is unclear that this candidate can be considered as a real vaccine. A 
phase 1/2 clinical trial is reported as currently ongoing in 20 patients. 
Planning vaccine access 
To break the current epidemic, epidemiologists have suggested that 70% of the population may need to develop 
immunity.  As of today, only a minor fraction of the population has been found to display antibodies against SARS-
CoV-2 (see Seroepidemiology). Vaccines are therefore perceived as the best way of rapidly inducing herd immunity. 
However, as reported by Cornwall, polls have found as few as 50% of people in the United States are committed to 
receiving a vaccine, with another quarter wavering (https://www.sciencemag.org/news/2020/06/just-50-americans-
plan-get-covid-19-vaccine-here-s-how-win-over-rest). Some of the communities most at risk from the virus are also 
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the most leery: among Black people, who account for nearly one-quarter of U.S. COVID-19 deaths, 40% said they 
wouldn’t get a vaccine in a mid-May poll by the Associated Press and the University of Chicago. In France, according 
to Cornwall, 26% said they wouldn’t get a coronavirus vaccine. However, a European survey by Neumann-Böhme (Eur 
J Health Eco, see below) rather suggested that France has the largest group of people who are unsure about getting 
vaccinated (28%) while 10% are opposed to a COVID-19 vaccination. Overall, 73.9% of the 7664 participants from 
Denmark, France, Germany, Italy, Portugal, the Netherlands, and the UK stated that they would be willing to get 
vaccinated against COVID-19 if a vaccine would be available. A further 18.9% of respondents stated that they were not 
sure, and 7.2% stated that they do not want to get vaccinated.  
Nevertheless, a number of high income countries (such as the UK and the US) have pre-ordered vast amounts of 
candidate COVID-19 vaccines ahead of their regulatory approval (see for instance Torjesen BMJ 2020: 
https://www.bmj.com/content/370/bmj.m3226). 
However, new vaccines will initially be supply-constrained, requiring a sequential allocation as supply increases to 
achieve the best public health impact. WHO indicated that equitable distribution is particularly important in the area 
of vaccines. Therefore, WHO advises that once a vaccine is shown to be safe and effective, and authorized for use, all 
countries receive doses in proportion to their population size, albeit initially in reduced quantities. This will enable 
every country to start by immunizing the highest priority populations. 
(https://www.who.int/publications/m/item/fair-allocation-mechanism-for-covid-19-vaccines-through-the-covax-
facility). The selection of target groups according to strategy and policy recommendations is considered of cardinal 
importance. For example, if the goal is to reduce mortality, those at the highest risk of dying should be prioritized for 
vaccination, and therapeutics may be reserved for potentially severe cases of illness. Similarly, rapid diagnostic tests 
and vaccines may be prioritized for essential workers in a scenario where the preservation of essential services is 
critical. 
Seventy-five countries have submitted expressions of interest to the COVAX Facility, a mechanism designed to 
guarantee rapid, fair and equitable access to COVID-19 vaccines worldwide (https://www.who.int/news-
room/detail/15-07-2020-more-than-150-countries-engaged-in-covid-19-vaccine-global-access-facility). The goal of 
COVAX is by the end of 2021 to deliver two billion doses of safe, effective vaccines that have passed regulatory 
approval and/or WHO prequalification. These vaccines will be delivered equally to all participating countries, 
proportional to their populations, initially prioritising healthcare workers then expanding to cover 20% of the 
population of participating countries. The 75 countries, which would finance the vaccines from their own public finance 
budgets, partner with up to 90 lower-income countries that could be supported through voluntary donations to Gavi’s 
COVAX Advance Market Commitment (AMC).  
Non-vaccine approaches to better host resistance 
Host resistance to viral infections can be increased in multiple ways. While more data are still required in the context 
of COVID-19, there is already sufficient evidence available to support further investigations in this area. 
Traditional Chinese Medicine 
In China, the use of Traditional Chinese Medicine (TCM) to prevent epidemics of infectious diseases was traced back 
to ancient Chinese practice cited in Huangdi's Internal Classic (Huang Di Nei Jing), which was written about 2000 years 
ago (Luo Chin J Integr Med 2020, see below). It suggested two aspects which should be employed to prevent the 
spread of epidemics. One was to maintain and improve the healthy qi (energy) in the body by taking preventive 
medicine (Xiaojin dan, the first recommended formula of TCM to prevent pestilence), healthy diet care, exercise and 
so on, so as to resist the invasion of external pathogen, and the other was to avoid the source of infection. These two 
principles of epidemic disease prevention have been followed by TCM practitioners until now.  
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Chinese medical classics also described the basic nature of the current pandemic disease millennia ago. The Yellow 
Emperor’s Classic states:  ”When two types of deficiency encounter each other they will pathologically effect the body”. 
One is the external type, corresponding to abnormal climate conditions create the external terrain for the 
development of an epidemic. The climate was unusual in Wuhan with its continuous rain and abnormal warmth during 
the winter, which affect the body with dampness and impaired qi, especially in the lung and the spleen (Sun J Chin 
Med 2020, see below). Dampness is at the core of COVID-19, characterized by a sticky coating on the tongue and a 
slippery pulse corresponding to turbid damp obstructing the lung. Besides, if the body presents some internal 
deficiency that impairs its ability to defend itself, this external condition could favour manifestations of the disease. In 
addition to these two deficiency factors, the Classic speaks about “invasion into the body”, by an epidemic toxin (yidu) 
as another prerequisite for epidemic development. The epidemic toxins (SARS-Cov2) can only invade the body when 
its defences have become compromised. Besides, a patient’s emotional state influences the onset and development 
of the disease. The Chinese medical classics say that the Heart is the sovereign of the organ systems, and “When the 
sovereign is clear and bright, all below is at peace; when the sovereign is not clear and bright, all of the other organs 
are at peril.” Most diseases invade the body layers by layers, from the surface of the body (the three yang channels) 
and then progress deeper inside (the three yin channels). SARS-CoV-2 typically invades several channels 
simultaneously, and right from the start. This is the reason why many patients exhibit symptoms from different organ 
systems (respiratory symptoms, digestive problems or neurological symptoms). Acupuncture and medicinal herbs 
must evade epidemic toxins from the affected yang channels, then it won’t be able to go any deeper into the yin 
channels, and then won’t impair vital organs (e.g. kidney) (Liu, Report from the Front Line in Wuhan, Classical Chinese 
Medicine, available at https://classicalchinesemedicine.org/report-from-front-line-
wuhan/?fbclid=IwAR2vXVOkJpL5kOlUmKrkEQGAEMFJSzsbQgydh9ScfB6IGnBg8X-BA8LJYpE). Several stages of COVID-
19 were described according to invaded channels with corresponding impaired organs. For each stage, specific 
medicinal herbs and acupuncture protocols are described (Wang, Expert Consensus Statement on the Prevention, 




Ayurveda, a traditional system of medicine, originated in India more than 3,000 years ago. The term Ayurveda is 
derived from the Sanskrit words ayur (life) and veda (science or knowledge) (Golechha Brain Behav Imm 2020, see 
below). The classic Ayurveda text Charaka Samhita, mentioned about epidemic management and defines immunity as 
the ability to prevent and arrest the progression of disease for maintaining homeostasis. The Ayurveda pays larger 
emphasis on building strength of mind and body to cope with various stressors, including infection. Similar to innate 
and acquired immunity, the Ayurveda concept of immunity (Bala or strength) is classified as natural (Sahaja), 
chronobiologic (Kalaja), and acquired (Yuktikrut). In Ayurveda several treatment options are available for enhancing 
immunity against respiratory illnesses, these include certain immunomodulators (known as Rasayana), local and 
systemic interventions. Local prophylaxis measures such as herbal decoctions, consumptions of hot water, gargling 
with medicated water, and steam inhalation are described in Ayurveda for respiratory illnesses.  
In India, several initiatives have been taken to utilise the vast potential of Ayurveda in this pandemic. The Ministry of 
Ayush, a nodal Ministry of Complementary and Alternative Medicine, has released a set of guidelines for boosting 
immunity and measures for self-care by using Ayurvedic principles. Gujarat, one of the western states of India, has 
initiated a study, in which Ayush treatment will be administered to asymptomatic patients of COVID-19 and the state 
government has also distributed ayurvedic medicines to millions of citizens for boosting their immunity against COVID-
19. The Kerala, southern Indian state, also started use of Ayurveda in mitigating the spread of COVID-19. The 
government has categorised the population in seven categories based on the possible spread of the virus, and 
Ayurvedic treatment has been advised accordingly. 
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Psychoneuroimmunity aspects 
A view point by Kim (Brain Behav Imm 2020, see below) provided a reminder of the impact of a healthy lifestyle, 
regular exercise, balanced nutrition, quality sleep and a strong connection with people on resistance to infections. 
Although the psychological impact of COVID-19 remains unclear, infected patients may experience anxiety, depression, 
guilt, stigma, and anger. Such emotional issues may reduce immunity and compromise recovery. Current prevention 
efforts are largely focused on social distancing. The authors suggested that all forms of psychological support should 
be routinely implemented not only for psychological resilience, but also to enhance immunity against COVID-19. A 
letter to the Editor by Lazzari (Brain Behav Imm 2020, see below) further advised in favor of a large-scale integration 
of medicine and psychology. 
Of interest, Burtscher (Scand J Med Sci Sports 2020, see below) noted that isolation of individuals in combination with 
fear of contagion, quarantine and stigma, as well as with potential (mis)information overload causes chronic stress 
and is associated with a burden on mental health, posing risk factors for anxiety and depression. It is well understood 
that chronic stress is a major modulator of immunity and thus directly influences the probability of infection. 
BCG vaccination 
The BCG vaccine has beneficial nonspecific (off-target) effects on the immune system that protect against a wide range 
of other infections. O’Neill (Nat Rev Immunol 2020, see below) discussed the non-specific beneficial effects of BCG 
against viral infections and provided a background to support the contention that vaccine may afford protection to 
COVID-19. Curtis (Lancet 2020, see below) indicated that randomised controlled trials are underway in the 
Netherlands and Australia to assess whether prophylactic administration of BCG-Danish reduces the incidence and 
severity of COVID-19 in health-care workers, and the effect this has on time away from work (respectively, 
NCT04328441 in 1500 volunteers and NCT04327206 in 10 078 volunteers). By October 20 2020, 8 additional trials of 
BCG vaccination to assess protection against COVID-19 were reported as ongoing in the Netherlands (NCT04417335, 
N=2014 volunteers from 60 years of age ; NCT04537663, N=5200), U.S.A. (NCT04348370, N=1800), South Africa 
(NCT04379336, N=500), Greece (NCT04414267, N=900), France (NCT04384549, N=1120), India (NCT04475302, 
N=2175) and Mexico (NCT04461379, N=908). Additional phase 3 clinical trials evaluate the VPN1002 tuberculosis 
vaccine candidate for its efficacy at preventing COVID-19 (NCT04387409, NCT04435379 and NCT04439045). VPN1002 
is a recombinant BCG which expresses listeriolysin from Listeria monocytogenes and is devoid of urease C (Kaufmann 
Front Imm 2020, see below). Development of this tuberculosis vaccine candidate started in the 1990s and is still 
ongoing. BCG vaccination is also evaluated in a therapeutic approach (NCT04369794 in Brazil). 
As reviewed by Kamat (Front Pharm, see below), some statistical data depicted a higher death rate of COVID-19 in 
non-BCG vaccinated countries than in BCG-vaccinated nations. However, in view of the high death rate for patients 
over 70 years of age, and given the fact that BCG vaccination is typically given early in life, Wassenaar (Lett Appl Microb 
2020, see below) compared countries that had introduced BCG in the 1950s with those that had not. No effect on 
COVID-19 case fatality rate or number of deaths per population could be demonstrated.  
In conclusion, BCG vaccines provide trained and heterologous immunity against multiple diseases by eliciting non-
specific innate and adaptive immunities. However, it is too early to conclude on a role of BCG vaccination on COVID-
19 without randomized clinical trials data and further scientific research. As of today, the WHO does not recommend 
BCG vaccination for COVID-19 prevention. 
Manipulating the commensal microbiota 
A plethora of evidence suggests that the commensal microbiota regulates and is in turn regulated by invading viruses 
through diverse mechanisms, thereby having stimulatory or suppressive roles in viral infections (reviewed by Li Front 
Imm 2019, see below; Baud Front Publ Health 2020, see below). Such knowledge could help design alternative 
approaches to the control of a number of viral infections, including COVID-19. A trial investigating the underlying 
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mechanism of development of lower respiratory tract infection (LRTI) after viral infection showed for instance that 
patients with a higher abundance of butyrate-producing bacteria in their faecal samples had a 5-fold lower possibility 
of developing viral LRTI. Considering that butyrate-producing bacteria are favoured by a diet rich in fibers, similar 
studies on COVID-19 appear useful to undertake. 
A particular strain of Streptococcus salivarius, known as K12, has been clinically demonstrated to help create a stable 
upper respiratory tract microbiota capable of protecting the host from pathogenic bacteria, fungi and viruses (Di Pierro 
Minerva Med 2020, see below). The proposed antiviral effect has been attributed to an adaptive immune response as 
revealed by detection of enhanced levels of IFN-γ in human saliva 10 hours after oral administration, with values at 24 
hours between 22 and 139 pg/ml. IFN-γ release occurs without modifying either IL-1β or TNF-α levels, and substantially 
lowering IL-8 release, therefore occurring without evoking an inflammatory response. Moreover, Streptococcus 
salivarius K12 is capable of suppressing bronchial inflammatory responses by inhibiting NF-κB pathways and other 
important human immune cell functions. Interestingly, the authors noted that a significant difference in the lung 
microbiota composition has previously been reported between patients with SARS-CoV-2 pneumonia and healthy 
subjects (Shen Clin Inf Dis 2020, see below). Among 8 subjects with SARS-CoV-2 pneumonia, 6 had a pathogen-
enriched microbiota, and the other two had a commensal-enriched microbiota. 
d'Ettorre (Front Med 2020, see below) reported the outcome of a clinical study in 70 patients positive for COVID-19, 
where a specific bacterial formulation showed a significant ameliorating impact on the clinical conditions of patients. 
Forty-two patients received hydroxychloroquine, antibiotics, and tocilizumab, alone or in combination. A second group 
of 28 subjects received the same therapy added with oral bacteriotherapy, using a multistrain formulation. The 
formulation administered in this study, Sivomixx® (SivoBiome® in USA), contained: Streptococcus thermophilus DSM 
32345, L.acidophilus DSM 32241, L. helveticus DSM 32242, L.  paracasei DSM 32243, L. plantarum DSM 32244, L. brevis 
DSM 27961, B. lactis DSM 32246, B. lactis DSM 32247. The oral bacteriotherapy involved the use of 2400 billion 
bacteria per day. The two cohorts of patients were comparable for age, sex, laboratory values, concomitant 
pathologies, and the modality of oxygen support. Within 72 h, nearly all patients treated with bacteriotherapy showed 
remission of diarrhoea and other symptoms as compared to less than half of the not supplemented group. The 
estimated risk of developing respiratory failure was eight-fold lower in patients receiving oral bacteriotherapy. Both 
the prevalence of patients transferred to ICU and mortality were higher among the patients not treated with oral 
bacteriotherapy. 
Vitamins and nutrition 
Calder (Nutrients 2020, see below) noted that a wealth of mechanistic and clinical data show that vitamins, including 
vitamins A, B6, B12, C, D, E, and folate; trace elements, including zinc, iron, selenium, magnesium, and copper; and 
the omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid play important and complementary roles in 
supporting the immune system. Inadequate intake and status of these nutrients are widespread, leading to a decrease 
in resistance to infections. The authors encourage public health officials to include nutritional strategies in their 
recommendations to improve public health. The authors did not indicate if any research is ongoing on the impact of 
diet on COVID-19, but a review by Briguglio (Front Med 2020, see below) noted that a greater understanding of the 
link between nutrition and SARS-CoV-2 is needed. 
Shi (Cell Death Diff 2020, see below)  indicated that vitamin B3 has a protective role on lung tissue damage, and 
suggested its use as soon as cough is observed. 
Grant (Nutrients 2020, see below) presented evidence that vitamin D supplementation could reduce the risk of COVID-
19 infections and deaths. This evidence includes that the outbreak occurred in winter, a time when 25-hydroxyvitamin 
D (25(OH)D) concentrations are lowest; that the number of cases in the Southern Hemisphere near the end of summer 
were low; that vitamin D deficiency has been found to contribute to acute respiratory distress syndrome; and that 
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case-fatality rates increase with age and with chronic disease comorbidity, both of which are associated with lower 
25(OH)D concentration. D’Avolio (Nutrients 2020, see below) retrospectively investigated the 25(OH)D concentrations 
in plasma obtained from a cohort of patients from Switzerland. In this cohort, significantly lower 25(OH)D levels (p = 
0.004) were found in PCR-positive for SARS-CoV-2 (median value 11.1 ng/mL) patients compared with negative 
patients (24.6 ng/mL); this was also confirmed by stratifying patients according to age >70 years. A recommendation 
in favour of vitamin D supplementation was also made by McCartney (Ir Med J. 2020, see below). On October 14 2020, 
a search on Clintrials.gov identified several ongoing studies evaluating vitamin D supplementation used either 
prophylactically (e.g. NCT04482673, NCT04535791) or therapeutically (e.g. NCT04449718, NCT04552951, 
NCT04411446). 
Curcumin 
Curcumin is considered as the major active compound in the rhizome of turmeric (Curcuma longa). Curcumin has been 
used extensively in Ayurveda, Siddha medicine and traditional Chinese medicine for centuries, as it has been 
associated with a variety of therapeutic properties including antioxidant, analgesic, anti-inflammatory, antiseptic 
activity, and anti-carcinogenic activity (reviewed by Mathew J Funct Foods 2018, see below). Curcumin’s antiviral 
effects were observed against numerous viruses including parainfluenza virus type 3, vesicular stomatitis virus (VSV), 
herpes simplex virus, and RSV. Curcumin also appeared as a potent inhibitor when tested for its in vitro activity against 
SARS-CoV on Vero E6 cells (Wen J Med Chem 2007, see below).  
A study using an in silico approach involving docking and stimulation, demonstrated the dual binding affinity of 
polyphenolic compounds in which both the viral S protein and ACE2 binds to curcumin (Manoharan Ind J Clin Bioch 
2020, see below). Binding of curcumin to receptor-binding domain (RBD) site of viral S protein and also to the viral 
attachment sites of ACE2 receptor, demonstrated that curcumin can act as potential inhibitory agent antagonizing the 
entry of SARS-CoV2 viral protein. Moreover, emulsion form of topical application of curcumin may effectively prevent 
the SARS-CoV2 infection in humans, as the viral entry site of ACE2 receptor is predominantly distributed at the nasal 
cells, mucosal surface of respiratory tract and eyes. 
Further, curcumin has been extensively studied for its role in the regulation of RAAS (renin-angiotensin-aldosterone 
system) components through which it is known to exert anti-oxidant, anti-inflammatory and antihypertensive effects. 
Animal studies have implicated the role of curcumin in the downregulation of ACE and AT1R receptor expression in 
brain tissue and vascular smooth muscle cells, respectively resulting inhibition of Angiotensin II-AT1R mediated effects 
of hypertension and oxidative stress in animals. Previous studies revealed high level of AT2R and ACE2 expression in 
myocardial cells treated with curcumin thus exhibiting the protective mechanism of curcumin via modulation of effects 
mediated by Angiotensin II receptors AT1R and AT2R. Upregulation of AT2R induces suppression of AT1R expression 
leading to Angiotensin II-AT2R mediated anti-inflammatory effects involving an inhibition of NF-κB activity and 
oxidative stress. Hence, treatment with curcumin attenuated the proinflammatory effects induced by Angiotensin II-
AT1R axis leading to significant decrease in the level of proinfammatory cytokines TNF-α, IL-6 and reactive oxygen 
species. 
Various clinical trials provided promising results suggesting a low toxicity of curcumin. However, many questions and 
challenges still exist. Curcumin has been reported as an unstable, reactive, non-bioavailable compound (Nelson J Med 
Chem 2017, see below), and the lack of placebo-controlled trials to support its efficacy in humans has been pointed 
out (Nelson ACS Med Chem Lett 2017, see below). The distinction between turmeric (the plant), curcuminoids 
(contained in turmeric and in extracts of turmeric) and curcumin also needs to be highlighted. Curcuminoids, as 
typically available commercially, contain not only curcumin but three primary components and approximately 15% of 
oleoresins and essential oil.  
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Nevertheless, various authors have suggested the use of curcumin as a preventive measure in the inhibition of 
transmission of SARS-COV2 infection among humans (Gupta Clin Exp Derm, see below; Manoharan Ind J Clin Bioch 
2020, see below). An ongoing clinical trial evaluates a spray preparation of ArtemiC, comprising Artemisinin, Curcumin, 
Boswellia, and Vitamin C in a nanoparticular formulation for COVID-19 therapy 
(https://clinicaltrials.gov/ct2/show/NCT04382040?term=curcumin&cond=COVID-19&draw=2&rank=1). 
Vector control and disease control in animals 
Available evidence on SARS-CoV-2 and previous experience with other coronavirus (MERS-CoV and SARS-CoV) and 
other respiratory viruses (e.g., avian influenza) suggest that there may be zoonotic transmission associated with SARS-
CoV-2. The following recommendations were therefore issued by WHO on March 26 2020 
(https://www.who.int/health-topics/coronavirus/who-recommendations-to-reduce-risk-of-transmission-of-
emerging-pathogens-from-animals-to-humans-in-live-animal-markets). These recommendations may appear as very 
general, as the animal species that may be involved in such transmission remained largely unknown at that time.  
As a general precaution, general hygiene measures are recommended to anyone visiting live animal markets, wet 
markets or animal product markets. These include regular hand washing with soap and potable water after touching 
animals and animal products, avoiding touching eyes, nose or mouth with hands, and avoiding contact with sick 
animals or spoiled animal products. It is also recommended to avoid contact with other animals possibly living in the 
market (e.g., stray cats and dogs) and with potentially contaminated animal waste or fluids on the soil or structures of 
shops and market facilities. A last recommendation is to avoid consumption of raw or undercooked animal products.  
People with underlying medical conditions are considered at higher risk of severe disease. Therefore, individuals with 
these underlying medical conditions are recommended to avoid contact with live animal markets, stray animals and 
wild animals, and should not eat animal raw meat.  
Good personal hygiene is specifically recommended to slaughterhouse workers, veterinarians in charge of animal and 
food inspection in markets, market workers, and those handling live animals and animal products. Use of protective 
gowns, gloves, masks as well as frequent disinfection of equipment and working stations, is also recommended.  
Social interventions 
Psychological intervention for affected people 
It has been claimed that the mental health needs of patients with confirmed COVID-19, patients with suspected 
infection, quarantined family members, and medical personnel have been poorly handled in China, and that the 
organisation and management models for psychological interventions must be improved (Duan Lancet Psych 2020, 
see below). With disease progression, clinical symptoms become severe and psychological problems in infected 
patients change; therefore, psychological intervention measures should be targeted and adapted as appropriate. 
Studies have confirmed that individuals who have experienced public health emergencies still have varying degrees of 
stress disorders, even after the event is over, or they have been cured and discharged from hospital, indicating these 
individuals should not be ignored. It is recommended that interventions are based on a comprehensive assessment of 
risk factors leading to psychological issues, including poor mental health before a crisis, bereavement, injury to self or 
family members, life-threatening circumstances, panic, separation from family and low household income. 
Numerous studies assessed the impact of social isolation and loneliness on the mental health of previously healthy 
people. A review by Brooks (Lancet 2020, see below) reported negative psychological effects of quarantine, including 
post-traumatic stress symptoms, confusion, and anger. Stressors included longer quarantine duration, infection fears, 
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frustration, boredom, inadequate supplies, inadequate information, financial loss, and stigma. In situations where 
quarantine is deemed necessary, the author recommended officials to quarantine individuals for no longer than 
required, provide clear rationale for quarantine and information about protocols, and ensure sufficient supplies are 
provided. Appeals to altruism by reminding the public about the benefits of quarantine to wider society are presented 
as favourable. 
Fitzpatrick (Psychol Trauma 2020, see https://psycnet.apa.org/fulltext/2020-38568-001.html) reported data from a 
nationally representative sample of 10 368 U.S. adults surveyed during the week of March 23, 2020. Respondents 
were fearful, averaging a score of nearly 7 on a scale of 10 when asked how fearful they were of COVID-19. Preliminary 
analysis suggested clear spatial diffusion of COVID-19 fear. Fear appeared to be concentrated in regions with the 
highest reported COVID-19 cases. Significant differences across several U.S. census regions were noted (p < .01). 
Additionally, significant bivariate relationships were found between socially vulnerable respondents (female, Asians, 
Hispanic, foreign-born, families with children) and fear, as well as with mental health consequences (anxiety and 
depressive symptoms). 
A rapid review by Loades (J Am Acad Child Adolesc Psychiatry 2020, see below) showed that children and adolescents 
are probably more likely to experience high rates of depression and probably anxiety during and after enforced 
isolation ends. This may increase as enforced isolation continues. The authors concluded that clinical services should 
offer preventative support and early intervention where possible and be prepared for an increase in mental health 
problems. 
Interestingly, a review by Bzdok (Trends Cognitive Sci 2020: see below) noted that we never experienced social 
isolation before on such a massive scale as we have in response to COVID-19. However, the authors showed that from 
babies to the elderly, psychosocial embedding in interpersonal relationships is critical for survival. They highlighted 
the neurocognitive basis of social isolation and its deep consequences not only for mental, but also for physical health. 
Social media and information to the general public 
Using data collected during the 2015 Middle East Respiratory Syndrome coronavirus (MERS-CoV) outbreak in South 
Korea, a study reported by Oh (Health Comm 2020, see below) explored the relationships among social media use, 
risk perception, and preventive behaviours by examining the mediating role of two self-relevant emotions: fear and 
anger. The findings demonstrate that social media use is positively related to both of these emotions, which are also 
positively related to the public's risk perception. The findings also indicate that social media use can significantly 
increase preventive behaviours via the two self-relevant emotions and the public's risk perception. 
In China, the government strives to improve the public's awareness of prevention and intervention strategies by 
providing daily updates about surveillance and active cases on websites and social media (Bao Lancet 2020, see below). 
Increasingly, psychologists and psychiatrists use the internet and social media (e.g., WeChat, Weibo, etc) to share 
strategies for dealing with psychological stress. For example, experts from Peking University Sixth Hospital made six 
suggestions for the public to cope with mental stress. These included assessing the accuracy of information disclosed, 
enhancing social support systems (e.g., families and friends), eliminating stigma associated with the epidemic, 
maintaining a normal life under safe conditions, and using the psychosocial service system, particularly telephone-
based and internet-based counselling for health-care staff, patients, family members, and the public. Liu (Lancet Psych 
2020, see below) even reported that several artificial intelligence (AI) programmes have been put in use as 
interventions for psychological crises during the epidemic. For example, individuals at risk of suicide can be recognised 
by the AI programme Tree Holes Rescue,5 by monitoring and analysing messages posted on Weibo, and alerting 
designated volunteers to act accordingly. 
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Outside China, at the start of the epidemic, the emergence of misinformation and racism against patients and Chinese 
visitors has been reported (Shimizu Lancet 2020, see below). Excess demand for surgical masks among the general 
public also became a serious concern, as it lowered provision for medical facilities including emergency and critical 
care centres. It has been recommended that mass media take responsibility for providing correct information and 
creating comprehension among citizens. Effective communication may contribute to lessening the risk for 
inappropriate behaviour, such as unnecessary visits to health-care facilities, as well as help eliminate fake news and 
discrimination against patients and Chinese visitors. 
However, just as the coronavirus itself, misinformation has spread far and wide, drowning out credible sources of 
information (Mian BMC Med 2020, see below). Over the last couple of months, posts from the WHO and the US CDC 
have cumulatively only achieved several hundred thousand engagements, considerably eclipsed by hoax and 
conspiracy theory sites, which have amassed over 52 million. This serves to emphasise the popularity of unverified 
sources of information. 
Gonçalves-Sá (Nat Med 2020, see below) also highlighted the staggering amount of misinformation propagating online 
on the topic of COVID-19, including the most concerning conspiracy theory circulating online related to the factitious 
claim that the virus was engineered by the Chinese, with political or economic goals. The author noted that the 
decision to delete this misinformation publicly might reinforce conspiracy theories. As an alternative, it was suggested 
that social-media platforms could attempt to implement simple nudges: asking people whether they are sure they 
want to share something could activate their best judgment and reduce over-confidence; and introducing time delays 
on the publication of dubious information, while it is being checked, could slow the spreading process and eventually 
prevent its publication.  
Mian (BMC Med 2020, see below) noted that the disconnect between scientific consensus and members of the public 
has progressively worsened as society has become further divided in the political climate of today. On February 19 
2020, Calisher (Lancet 2020, see https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30418-
9/fulltext) published a statement of solidarity to fight against COVID-19 and to promote scientific evidence and unity 
over misinformation and conjecture.  
In February 2020, the Finnish Institute for Health and Welfare started collecting weekly qualitative data on COVID-19 
risk perception. The process is based on thematic analysis of emails and social media messages from the public and 
identifies factors linked to appraisal of risk magnitude, which are developed into risk communication 
recommendations together with health and communication experts (Lohiniva EuroSurv 2020, see below). The findings 
were related to five risk perception domains: catastrophic potential (e.g. emotional response, anticipation of growth 
of the epidemic), probability of dying (death perceived as likely), reasons for exposure (e.g. contact with infected 
persons, people coming from abroad or foreign nationals), the belief of being in control of the situation (a lack of the 
belief that a person can individually control the spread of the epidemic and instead a strong belief that authorities can 
do that), and trust towards authorities (distrust of information provided and actions taken by the authorities). This 
process helped develop context-specific risk communication messages. 
Mental support for health care workers  
Several reports described the importance of maintaining staff mental health when dealing with the epidemic. For 
instance, Tan (Ann Int Med 2020, see below) reported the outcome of a study where, from 19 February to 13 March 
2020, health care workers who were caring for patients with COVID-19 at 2 major tertiary institutions in Singapore 
answered a self-administered questionnaire. Sixty-eight (14.5%) participants screened positive for anxiety, 42 (8.9%) 
for depression, 31 (6.6%) for stress, and 36 (7.7%) for clinical concern of posttraumatic stress disorder. The prevalence 
of anxiety was higher among nonmedical health care workers than medical personnel (20.7% versus 10.8%; adjusted 
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prevalence ratio, 1.85 [95% CI, 1.15 to 2.99]; P = 0.011), after adjustment for age, sex, ethnicity, marital status, survey 
completion date, and presence of comorbid conditions.  
Various measures of psychological intervention were reported (see for instance Chen Lancet Psych 2020, see below). 
First, the hospital provided a place for rest where staff could temporarily isolate themselves from their family. The 
hospital also guaranteed food and daily living supplies, and helped staff to video record their routines in the hospital 
to share with their families and alleviate family members' concerns. Second, in addition to disease knowledge and 
protective measures, pre-job training was arranged to address identification of and responses to psychological 
problems in patients with COVID-19, and hospital security staff were available to be sent to help deal with 
uncooperative patients. Third, the hospital developed detailed rules on the use and management of protective 
equipment to reduce worry. Fourth, leisure activities and training on how to relax were properly arranged to help staff 
reduce stress. Finally, psychological counsellors regularly visited the rest area to listen to difficulties or stories 
encountered by staff at work, and provide support accordingly.  
A role for religion 
The April 27/May 4, 2020 “Finding Hope” special issue of Time Magazine provided the following words of the Dalai 
Lama: “This crisis shows that we must all take responsibility where we can. We must combine the courage doctors and 
nurses are showing with empirical science to begin to turn this situation around and protect our future from more such 
threats. … As a Buddhist, I believe in the principle of impermanence. Eventually, this virus will pass, as I have seen wars 
and other terrible threats pass in my lifetime, and we will have the opportunity to rebuild our global community as we 
have done many times before”. Modell (J Relig Health 2020, see below) described three major ways that religious faith 
helped to sustain people’s health and welfare in the midst of the broad social challenges posed by COVID-19 in Detroit, 
U.S.A., i.e.  through church-based health programs (e.g. educational sessions), by providing hope, and providing social 
services (e.g. free grocery delivery to unemployed workers or student laptop loans). 
Vulnerable groups 
Elderly people  
The outbreak of COVID-19 has raised great challenges for mental health services for older adults in the community in 
China. Yang (Lancet Psych 2020, see below) noted that older adults have limited access to internet services and smart 
phones, and as such only a small fraction of older adults can benefit from such service provision. In addition, in most 
areas of China, clinically stable older adults with psychiatric disorders or their guardians usually need to visit psychiatric 
outpatient clinics monthly to obtain the maintenance medications. The mass quarantines and restrictions to public 
transport have inevitably become a major barrier to access maintenance treatments for this group.  
Armitage (Lancet Public Health 2020, see below) also predicted that self-isolation will disproportionately affect elderly 
individuals whose only social contact is out of the home, such as at day-care venues, community centres, and places 
of worship. Those who do not have close family or friends, and rely on the support of voluntary services or social care, 
could be placed at additional risk, along with those who are already lonely, isolated, or secluded. Dichter (Int 
Psychogeriatr 2020, see below) noted that in spite of the restrictive infection control measures, the principles of 
person-centred care must be implemented in nursing home care. Infection management and person-centred care 
should be weighed carefully in order to maintain the residents’ social participation, mental health and quality of life. 
International migrant workers 
Regardless of their communities' self-reliance and resilience, Liem (Lancet Psych 2020, see below) noted that 
addressing the health needs of international migrant workers should be made an urgent public health priority. 
Compared with other international migrants, migrant workers encounter more barriers in accessing health services in 
host countries. Under normal conditions, they have a high burden of common mental disorders (e.g., depression) and 
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a lower quality of life than local populations. This situation could worsen during the COVID-19 epidemic due to the 
potential and fear of governmental-imposed quarantine and lost income. In the absence of reliable information in 
their own language, international migrant workers may not recognise the seriousness of the epidemic or receive 
accurate information on how to protect themselves from infection. However, most international migrant workers have 
smartphones, which can be a useful aid in providing informational and social support during the epidemic. For instance, 
WeChat (a Chinese social network platform) is used by international migrant workers in Hong Kong and Macau for 
sharing key health messages and official information to the community and providing one another with emotional 
support. It can, however, also spread inaccurate information and panic that could lead to IMWs delaying visits to 
health centres due to stigmatisation of those who are infected. 
Homeless people 
Tsai (Lancet Resp Med 2020, see below) described various issues, which are unique to people experiencing 
homelessness, with regards to the COVID-19 epidemic. For instance, when cities impose a lockdown to prevent COVID-
19 transmission, it is unclear whether shelter is provided for the large number of people experiencing homelessness, 
especially when considering that closures of shelters and other high-density communal settings (eg, drop-in centres 
and soup kitchens) are possible. 
Implications of the COVID-19 pandemic 
The impacts of the COVID-19 pandemic across the globe have been dramatic. COVID-19 is both a global health crisis 
and an international economic threat. Numerous publications have described how people’s life have been affected. A 
few examples are provided below. 
Impacts on healthcare systems 
As a consequence of the pandemic, healthcare systems face various “collateral” issues. The physical and mental 
exhaustion of the healthcare workforce has been described. In addition, containment (and progressive de-
confinement) measures, compounded by the economic recession, have been reported to affect mental health (e.g., 
anxiety, depression) as well as physical health (e.g., weight gain, unbalanced nutrition). Another important area under 
study relates to the delays of healthcare procedures unrelated to COVID-19. Cancer centres, for instance, have indeed 
postponed monitoring consultations and operations considered to be non-urgent. Maringe (Lancet Oncol 2020, see 
below) estimated the impact of diagnostic delays over a 12-month period from the commencement of physical 
distancing measures in the UK up to 1, 3, and 5 years after diagnosis. The authors concluded that substantial increases 
in the number of avoidable cancer deaths are to be expected as a result of diagnostic delays due to the COVID-19 
pandemic in the UK. They underscored the need to manage the backlog within routine diagnostic services to mitigate 
the expected impact of the COVID-19 pandemic on patients with cancer. 
Impacts on the rest of society 
Kniffin (Am Psychol 2020, see below) reviewed the implications of the pandemic for employees, teams, and work 
organizations. The authors focused on emergent changes in work practices (e.g., working from home, virtual 
teamwork), emergent changes for workers (social distancing and loneliness; health and well-being; unemployment 
and inequality), as well as the importance of moderating factors (demographic characteristics; individual differences; 
organizational norms). They found obvious that COVID-19 will be recognized for changing the ways people work in 
fundamental ways.  
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